This Supplement Contains: 
AKB-6548-CI-0017 (Study Registry ID: [REMOVED]; Eu draCT Number:  
2016-001360-11)
1.Original Protocol 
2.Final Protocol
3.Rationale for Change for Protocol Amendments AKB-6548-CI-0017
Date:  26 Feb 2019 
Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 1 of 78  
 
 
CLINICAL PROTOCOL  
 
PHASE 3 , RANDOMIZED, OPEN -LABEL, ACTIVE- CONTROLLED STUDY 
EVALUATING  THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR  THE 
MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS  WITH 
DIALYSIS -DEPENDENT CHRONIC KIDNEY DISEASE (DD- CKD)  (INNO 2VATE – 
CONVERSION)  
 
Compound:  Vadadustat (AKB -6548)  
Protocol Number:  AKB -6548 -CI-0017 
US IND Number:  102,465  
EudraCT Number  2016 -001360 -11 
Phase:  Phase 3  
Status/ Date:  Final,  Version 1.0  
Sponsor:  Akebia Therapeutics, Inc.  
245 First Street 
Suite 1100 Cambridge, MA 02142 
United States of America  
 
  
This document contains information that is confidential and proprietary to the Sponsor, Akebia Therapeutics, Inc .  
This information is being provided to you solely for the purpose of evaluating and/or conducting a clinical study  
for the Sponsor .  You may disclose the contents of this document only to study personnel under your supervision, 
the Institutional Review Board, the United States Food and Drug Administration, or duly authorized 
representatives of regulatory agencies for this purpose under the condition that they maintain confidentiality .  The 
contents of this document may not be used in any other clinical study , disclosed to any other person or entity, 
and/or published without the prior written permission of the Sponsor .  The foregoing shall not apply to disclosure 
required by any regulations; however, you will give prompt notice to the Sponsor of any such discl osure.  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 2 of 78 1 SIGNATURE PAGES 
1.1 Protocol Approval  
 
  
           
Akebia Therapeutics, Inc.  
 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 3 of 78 1.2 Investigator Agreement  
I confirm that I have read and that I understand this protocol, the Investigator B rochure, and other 
product  information provided by the S ponsor .  I agree to conduct this study in accordance with the 
requirements of this protocol and also protect the rights, safety, privacy, and well -being of study 
subjects in accordance with the following: 
• The ethical principles that have their origin in the Declaration of Helsinki.  
• International Council for Harmonisation Guidance for Industry, Good Clinical Practice E6. 
• All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations. 
• Regula tory requirements for reporting serious adverse events defined in this protocol. 
• Terms outlined in the Clinical Study Site Agreement.  
 
  
Signature of Investigator  Date  
  
Investigator Name (print or type)   
  
Investigator’s Title   
  
Phone Number   
  
Full Address   
  
  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 4 of 78  
TABLE  OF CONTENTS 
1 SIGNATURE PAGES  .................................................................................................. 2 
1.1 Protocol Approval .................................................................................................... 2 
1.2 Investigator Agreement  ............................................................................................ 3 
2 PROTOCOL SYNOPSIS  .............................................................................................. 9 
3 LIST OF ABBREVIATION S ..................................................................................... 19 
4 BACKGROUND INFORMATI ON ........................................................................... 21 
4.1 Hypoxia-Inducible Factor Prolyl- Hydroxylase Inhibitors  ..................................... 23 
4.2 Summary of Clinical Experience  ........................................................................... 23 
4.3 Potential Benefits and Risks ................................................................................... 24 
5 STUDY OBJECTIVES AND ENDPOI NTS  .............................................................. 24 
5.1 Primary Objective  .................................................................................................. 24 
5.2 Primary Efficacy Endpoint ..................................................................................... 24 
5.3 Secondary Efficacy Endpoints ............................................................................... 25 
5.4 Safety Endpoints  .................................................................................................... 25 
6 STUDY DESIGN  ........................................................................................................ 25 
6.1 Study Design  .......................................................................................................... 25 
6.2 Rationale for Study Design  .................................................................................... 27 
6.3 Dose Justification  ................................................................................................... 28 
6.4 Independent Data Monitoring Committee .............................................................. 29 
6.5 Endpoint Adjudication Committee ......................................................................... 29 
7 SELECTION AND WITHDRAWAL OF SUBJECTS  .............................................. 29 
7.1 General Criteria  ...................................................................................................... 29 
7.2 Inclusion Criteria  .................................................................................................... 29 
7.3 Exclusion Criteria  ................................................................................................... 30 
7.4 Retesting and Rescreening  ..................................................................................... 31 
7.4.1  Retesting  ............................................................................................................ 31 
7.4.2  Rescreening  ....................................................................................................... 31 
7.5 Study Completion, Subject Completion, Study Discontinuation, and Withdraw al of 
Subjects  .................................................................................................................. 31 
7.5.1  Study Completion  .............................................................................................. 31 
7.5.2  Subject Completion  ........................................................................................... 31 
7.5.3  Entire Study Termination  .................................................................................. 32 
7.5.4  Individual Study Site Termination  .................................................................... 32 
7.5.5  Individual Subject Discontinuation ................................................................... 32 
7.5.5.1  Temporary Interruption of Study Medication ............................................... 33 
7.5.5.2  Permanent Discontinuation of Study Medication ......................................... 33 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 5 of 78 7.5.5.3  Complete Withdrawal from Further Study Visits/Assessments  ................... 33 
7.5.5.4  Procedures to Encourage Continued Study Participation ............................. 33 
7.5.5.5  Procedures to Prevent “Lost to Follow-up” .................................................. 34 
8 STUDY PRODUCT AND TR EATMENT OF SUBJECTS  ....................................... 35 
8.1 Study Product, Supplies, and Storage .................................................................... 35 
8.1.1  Vadadustat  ......................................................................................................... 35 
8.1.2  Darbepoetin Alfa  ............................................................................................... 35 
8.2 Dispensing Procedures ........................................................................................... 35 
8.2.1  Dispensing of Vadadustat .................................................................................. 35 
8.2.2  Dispensing of Darbepoetin Alfa ........................................................................ 36 
8.3 Product Accountability and Destruction ................................................................ 36 
8.4 Treatment of Subjects  ............................................................................................. 37 
8.4.1  Treatment Group Assignments  .......................................................................... 37 
8.4.2  Randomization ................................................................................................... 37 
8.4.3  Blinding ............................................................................................................. 37 
8.4.4  Dosing and Dose Adjustment Guidelines .......................................................... 38 
8.4.4.1  Vadadustat Dosing and Dose Adjustment Guidelines .................................. 38 
8.4.4.2  Darbepoetin Alfa Dosing and Dose Adjustment Guidelines  ........................ 39 
8.4.5  Late or Missed Doses  ........................................................................................ 40 
8.4.6  Iron Supplementation ........................................................................................ 40 
8.4.7  Rescue Therapy  ................................................................................................. 40 
8.4.7.1  Red Blood Cell Transfusion ......................................................................... 41 
8.4.7.2  Erythropoiesis- stimulating Agent Rescue (Optional)  ................................... 41 
8.4.8  Phlebotomy ........................................................................................................ 41 
8.4.9  Treatment Compliance  ...................................................................................... 42 
8.4.10  Continuation of Treatment ................................................................................ 42 
8.5 Prior and Concomitant Therapy ............................................................................. 42 
8.5.1  General  .............................................................................................................. 42 
8.5.2  Erythropoiesis- stimulating Agents  .................................................................... 42 
8.5.3  Transfusions ...................................................................................................... 42 
8.5.4  Dialysis Treatment and Renal Replacement Therapy  ....................................... 42 
8.5.5  Investigational Medications ............................................................................... 42 
9 STUDY PROCEDURES AND SCHEDULE OF ACTIVITI ES ................................ 43 
9.1 Administrativ e Procedures  ..................................................................................... 43 
9.1.1  Informed Consent .............................................................................................. 43 
9.1.2  Documentation of Scre en Failures  .................................................................... 43 
9.1.3  Contraception and Pregnancy Avoidance Measures ......................................... 44 
9.1.4  Laboratory Accreditation and Reference Ranges  .............................................. 44 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 6 of 78 9.2 Study Procedures and Evaluations ......................................................................... 45 
9.2.1  Clinical Evaluations ........................................................................................... 45 
9.2.2  Laboratory Evaluations ..................................................................................... 46 
9.3 Schedule of Activ ities ............................................................................................ 49 
9.3.1  Prescreening Visit  .............................................................................................. 49 
9.3.2  Screening Visits  ................................................................................................. 49 
9.3.2.1  Screening Visit 1 (SV1)  ................................................................................ 49 
9.3.2.2  Screening Visit 2 (SV2)  ................................................................................ 50 
9.3.2.3  Subject Retesting  .......................................................................................... 50 
9.3.3  Subject Rescreening  .......................................................................................... 50 
9.3.4  Baseline Visit (Day 1)  ....................................................................................... 50 
9.3.5  Year 1 Treatment Period Visits (Day 2 through Week 52) ............................... 51 
9.3.6  Year 2 Treatment Period Vis its (Weeks 53 through 104) ................................. 52 
9.3.7  Year 3/4 Treatment Period Visits (Weeks 116 through 208) ............................ 53 
9.3.8  End of Treatment Visit ...................................................................................... 54 
9.3.9  Follow-up Visit .................................................................................................. 54 
10 ADVERSE EVENTS  .................................................................................................. 55 
10.1  Definitions  .............................................................................................................. 55 
10.1.1  Adverse Events  .................................................................................................. 55 
10.1.2  Serious Adverse Events ..................................................................................... 57 
10.2  Eliciting Adverse Event Information  ..................................................................... 58 
10.3  Reporting ................................................................................................................ 58 
10.3.1  Reporting Period ................................................................................................ 58 
10.3.2  Reporting AEs ................................................................................................... 58 
10.3.3  Reporting SAEs ................................................................................................. 58 
10.3.4  Reporting Study Endpoints ................................................................................ 59 
10.3.5  Relationship to Study Medication  ..................................................................... 59 
10.3.6  Severity  .............................................................................................................. 60 
10.3.7  Follow-up of Unresolved Events ....................................................................... 60 
10.4  Exposure In Utero .................................................................................................. 60 
10.5  Special Situations  ................................................................................................... 61 
11 DATA ANALYSIS  ..................................................................................................... 61 
11.1  Sample Size Determination  .................................................................................... 62 
11.1.1  Sample Size for the Primary Efficacy Endpoint ................................................ 62 
11.1.2  Sample Size for the Primary Safety Endpoint ................................................... 62 
11.2  Study Analysis Populations .................................................................................... 63 
11.3  Analysis of Demographic and Pretreatment Variables  .......................................... 63 
11.4  Disposition of Subjects ........................................................................................... 63 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 7 of 78 11.5  Missing Data  .......................................................................................................... 64 
11.6  Efficacy Analyses  ................................................................................................... 64 
11.6.1  Analysis of Primary Efficacy Endpoint ............................................................. 64 
11.6.1.1  Primary Analysis of Primary Efficacy Endpoint  .......................................... 65 
11.6.1.2  Sensitivity Analyses of Primary Efficacy Endpoint ..................................... 65 
11.6.2  Analysis of Key Secondary Efficacy Endpoints ............................................... 65 
11.6.2.1  Analysis of Mean Change in Hb Value between Baseline (Mean Pretreatment 
Hb) and the Secondary Evaluation Period (Weeks 40 to 52) ....................... 66 
11.6.2.2  Analysis of Proportion of Subjects with Mean Hb within the Target Range during the Primary Evaluation Period (Weeks 24 to 36) .............................. 66
 
11.6.2.3  Analysis of Mean Weekly Dose of Iron: Baseline to Week  52 .................... 66 
11.6.2.4  Analysis of Proportion of Subjects who Receive RBC Transfusion(s ): 
Baseline to Week  52 ..................................................................................... 66 
11.6.3  Analysis of Additional Secondary Efficacy Endpoints ..................................... 66 
11.7  Safety Analyses  ...................................................................................................... 66 
11.7.1  Analysis of MACE  ............................................................................................ 66 
11.7.2  Analysis of Adverse Events ............................................................................... 67 
11.7.3  Remaining Safety Endpoints ............................................................................. 67 
11.8  Additional Assessments  ......................................................................................... 68 
11.8.1  Concomitant Medications .................................................................................. 68 
11.8.2  Biomarkers  ........................................................................................................ 68 
11.8.3  Pharmacokinetics  ............................................................................................... 68 
12 DATA HANDLING AND RECORD KEEPING  ...................................................... 68 
12.1  Case Report Forms/Electronic Data Capture  ......................................................... 68 
12.2  Record Retention  .................................................................................................... 69 
13 QUALITY CONTROL AND QUALITY ASSURANCE  .......................................... 69 
13.1  Investigative Site Monitoring Visits  ...................................................................... 69 
13.2  Protocol Deviations ................................................................................................ 70 
14 STUDY DISCONTINUATION/INVESTIGATIVE SITE  TER MINATION  ............ 70 
14.1  Criteria for Premature Termination or Suspension of the Study ............................ 70 
14.2  Criteria for Premature Termination or Suspension of Investigational Study Sites 70 
14.3  Procedures for Premature Termination or Suspension of the Study or 
Investigational Sites  ............................................................................................... 70 
15 ETHICS  ....................................................................................................................... 71 
15.1  Ethical Conduct of the Study ................................................................................. 71 
15.2  Institutional Review Board/Independent Ethics Committee  .................................. 71 
15.3  Subject Information and Consent  ........................................................................... 71 
15.4  Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP .... 71 
15.5  Subject Co nfidentiality  ........................................................................................... 72 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 8 of 78 16 PUBLICATION OF STUDY RESULTS  ................................................................... 72 
17 REFERENCES  ............................................................................................................ 73 
APPENDIX A: SCHEDULE  OF ACTIVITIES  .................................................................... 75 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 9 of 78 2 PROTOCOL SYNOPSIS  
Study Title  Phase 3, Randomized, Open -Label, Active -Controlled Study Evaluating the Efficacy 
and Safety of Oral Vadadustat for the Maintenance T reatment of Anemia in Subjects 
with Dialysis -Dependent Chronic Kidney Disease (DD -CKD)  (INNO 2VATE – 
CONVERSION)  
Protocol Number  AKB -6548 -CI-0017 
Study Phase  Phase 3  
Investigational 
Product  Vadadustat ; 150 mg tablets  
Reference Medicinal 
Product  Darbepoetin  alfa; Amgen, Inc.  
Study Population  The study population will consist of subjects ≥18 years of age  receiving chronic 
outpatient dialysis ( either  peritoneal dialysis or hemodialysis), with hemoglobin ( Hb) 
between 8.0  g/dL and 11.0 g/dL (inclusive) in the United States (US) and  betw een 9.0 
and 12.0 g/dL (inclusive)  outside of the US, and who are currently treated with an 
erythropoiesis -stimulating agent (ESA) for anemia.  
Investigative Sites  Approximately 300 investigative sites  in North America, Latin America, Europe, and 
Asia Pacific . 
Planned Number of 
Subjects  Approximately 2200 subjects . 
Primary Objective  To d emonstrate the efficacy and safety of vadadustat  compared to darbepoetin  alfa for 
the maintenance treatment of anemia in subjects with DD -CKD after conversion from 
current ESA therapy . 
Study Design 
Overview  Phase 3, randomized, open -label, active -controlled study of vadadustat vs darbepoetin  
alfa for the maintenance treatment of anemia af ter conversion from ESA therapy.  
Following a Screening period of up to 28 days , subjects who meet all inclusion and 
none of the  exclusion criteria will be randomized 1:1 to vadadustat or darbepoetin  alfa. 
Randomization will be stratified by:  
• Geographic region (United States [US] versus E uropean Union [EU] versus 
Rest of World [ROW]) . 
• New York Heart Association congestive heart failure (CHF) Class 0 or I 
versus II or III . 
• Study entry Hb (<10.0 versus ≥10.0  g/dL) . 
Following randomization, there will be 3 periods during the study:  
• Conversion and Maintenance Period (Weeks 0 to 52): conversion to  study 
medication for maintaining Hb (Weeks 0 -23), primary  efficacy evaluation  
(Weeks 24 -36), and secondary efficacy evaluation  (Weeks 40 -52). 
• Long -term Treatment Period (Weeks 53 to End of Tr eatment [EOT]): 
continued study medication to assess long -term safety . 
• Follow -up (EOT  + 4 weeks):  post-treatment visit (either in person or via 
telephone) for safety . 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 10 of 78 Study Duration  Estimated time to full enrollment of approximately 2200 randomized subjects is 
20 months, and average follow -up duration is expected to be 1.8 years.   
The study will be considered completed (end of trial) when 631 major adverse 
cardiovascular events (MACE) have accrued over the 2 DD -CKD studies (Studies 
AKB -6548- CI-0016 and AKB -6548- CI-0017). All subjects will remain in the study 
until the end of trial, at which time subjects will be scheduled for a final visit and the 
study will close.  Sites will be notified of the global study end date approximately 
3 months prior to study closure (based on accrual of MACE across the 2 studies) and 
will inform active s ubjects of the global study end date thereafter.  
Inclusion Criteria  Subjects  must meet  the following inclusion  criteria:  
1. ≥18 years of age.  
2. Receiving  chronic maintenance dialysis (either peritoneal or hemodialysis) for 
end-stage kidney disease for at least  12 weeks prior to Screening . 
3. Currently maintained on ESA therapy, with  the last dose received within 
8 weeks prior to Screening  
4. Mean screening Hb between 8.0 and 11.0 g/dL (inclusive) in the US and 
between 9.0 and 12.0 g/dL (inclusive ) outside of the US , as determined by the 
average of 2  Hb values measured by the central laboratory during Screening.  
5. Serum ferritin ≥100 ng/mL and transferrin saturation (TSAT) ≥20% during 
Screening.  
6. Folate and vitamin B 12 measurements  ≥ lower limit of normal during  
Screening . 
7. Understands the procedures and requirements of the study and provides 
written informed consent and authorization for protected health information disclosure.  
Exclusion Criteria  Subjects must meet  none of the  following exclusion criteria : 
1. Anemia due to a cause other than CKD or subjects with  active bleeding or 
recent blood loss.  
2. History of  sickle cell disease, myelodysplastic syndromes, bone marrow 
fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell ap lasia. 
3. Red blood cell (RBC) transfusion within 4 weeks prior to or during the 
Screening  period. 
4. Anticipated to recover adequate kidney function to no longer require dialysis.  
5. Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic pyruvic 
transaminase (SGPT), or total bilirubin >2.0  x upper limit of normal (ULN) 
during  Screening.  Subjects with a history of Gilbert’s syndrome are not 
excluded. 
6. Uncontrolled hypertension (defined as confirmed predialysis systolic blood pressure [BP] >190  mmHg or diastolic BP >110  mmHg at rest) during  
Screening.  
7. Severe heart failure (HF) during Screening (New York Heart Association 
Class IV).  
8. Acute coronary syndrome (hospitalization for unstable angina or m yocardial 
infarction),  surgical or percutaneous intervention for coronary, 
cerebrovascular or peripheral artery disease (aortic or lower extremity) , 
surgical or percutaneous valvular replacement or repair, sustained ventricular 
tachycardia, hospitalizatio n for HF, or stroke within 12 weeks prior to or 
during Screening . 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 11 of 78 9. History of active malignancy within 2 years prior to or during Screening, 
except for treated  basal cell carcinoma of skin, curatively resected squamous 
cell carcinoma of skin, cervical carcinoma in situ, or resected benign colonic 
polyps.  
10. History of deep vein thrombosis (DVT) or pulmonary embolism (PE) requiring active treatment within 8 weeks prior to or during Screening.  
11. History of hemosiderosis or hemochromatosis.  
12. History of prior organ tr ansplantation or scheduled organ transplant (subjects 
on the kidney transplant wait -list or with a history of failed kidney transplant 
are not excluded), or prior hematopoietic stem cell or bone marrow transplant 
(corneal transplants and stem cell therapy for knee arthritis are not excluded). 
13. Hypersensitivity to vadadustat, darbepoetin alfa, or any of their excipients.  
14. Use of an investigational medication or participation in an investigational study within 30 days or 5 half -lives of the investigational medication 
(whichever is longer), prior to  Screening.  
15. Previous participation in this study  or previous participation in a study with 
another hypoxia -inducible factor prolyl -hydroxylase inhibitor (HIF -PHI)  
other than vadadustat . 
16. Females who are pregnant or breastfeeding.  Women of child bearing potential 
who are unable or unwilling to use an acceptable method of contraception . 
17. Non-vasectomized male subjects who are unable or unwilling to use an 
acceptable method of contraception.  
18. Any other reaso n, which in the opinion of the I nvestigator, would make the 
subject not suitable for participation in the study.  
Retesting/ Rescreening  Subjects who initially fail to qualify for the study based on laboratory test results may 
be retested once within the 28 -day Screeni ng period, per Investigator discretion.  
Subjects who fail to meet the qualifying criteria for Hb during a Screening period may 
be considered for rescreening at the discretion of the Investigator if it is felt that the subject’s status has progressed and t hat the subject may now qualify for the study.  
Additionally, subjects who fail to qualify for the study based on low TSAT, ferritin, 
folate, or B
12 values may be considered for rescreening after receiving replacement 
therapy.  Screening is limited to 3 at tempts (initial Screening and 2  additional 
rescreening attempts).  
Efficacy Endpoints  Primary : 
• Mean change in Hb between Baseline (mean pretreatment Hb) and the 
primary evaluation period (mean Hb from Weeks  24 to 36). 
Key Secondary : 
• Mean change in Hb value between Baseline (mean pretreatment Hb) and the 
secondary evaluation period (Weeks  40 to 52). 
• Proportion of  subjects with mean Hb within the target range during the 
primary evaluation period (Weeks 24  to 36). 
• Mean weekly dose of intravenous ( IV) elemental iron administered from 
Baseline to Week  52. 
• Proportion of subjects receiving RBC transfusion(s) from Baseline to 
Week  52. 
Other Secondary : 
• Proportion of Hb values within the target range during the Maintenance 
period (Weeks 24 to 52). 
• Confirmed Hb values <10.0 or >12.0 g/dL . 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 12 of 78 • ESA rescue.  
• Dose adjustments.  
• Maintenance of iron sufficiency (defined as fer ritin ≥100 ng/mL and TSAT 
≥20%).  
• Receiving IV iron therapy . 
Safety Endpoints  • MACE, defined as all -cause mortality, non -fatal myocardial infarction, or 
non-fatal stroke . 
• Individual components of MACE:  
o All-cause mortality  
o Non-fatal myocardial infarction  
o Non-fatal stroke .  
• Thromboembolic events: arterial thrombosis, DVT, PE, or vascular access 
thrombosis . 
• Hospitalization for HF 
• Hb >12.0 g/dL, >13.0 g/dL, or >14.0 g/dL.  
• Hb increase >1.0 g/dL within any 2 -week interval or >2.0 g/dL within any 4 -
week interval.  
• Adverse events (AEs) and serious AEs (SAEs) . 
• Vital sign measurements and clinical laboratory values . 
Dosage and Regimens  Subjects will be randomized 1:1 to either:  
Vadadustat starting dose :  2 tablets once daily (300 mg/day)  
Darbepoetin alfa:  initial dose as follows  
• For subjects already on darbepoetin, the initial dosing regimen in the study 
should be based on the prior dosing regimen.  
• For subjects taking other ESAs, the initial dose of darbepoetin should be 
based on the approved local product label  for adult patients with CKD on 
dialysis.  
For all subjects, it is recommended that no additional ESA doses be administered after Screening visit 2 (SV2) and prior to the Randomization visit.  
Dose Adjustment Guidelines – All Treatment Groups  
Dosing will be initiated at the Baseline visit, and the first dose of study medication (vadadustat or darbepoetin  alfa) will be administered at the clinic/investigative site 
after other Baseline procedures have been completed.  For all subjects, it is 
recommended that no additional ESA doses be administered after SV2 and prior to the Randomization visit.  
Hemoglobin will be monitored via HemoCue
® point of car e device throughout the 
study to determine if the dose of study medication (vadadustat or darbepoetin  alfa) 
should be adjusted or interrupted.  From Weeks  0 to 12, Hb will be measured via 
HemoCue every 2  weeks for monitoring for dose adjustment s.  From Wee k 12 to Week 
52, Hb via HemoCue will be monitored every 4  weeks  unless more frequent 
monitoring is clinically indicated or warranted based on dosing changes .  From Week 
53 through the end of the study, Hb will continue to be monitored via HemoCue to 
determ ine if the dose of study medication should be adjusted or interrupted.  
Hemoglobin will be assessed with a complete blood count (CBC) through the central laboratory for efficacy and safety evaluations; however, dose adjustments should be based on the local  HemoCue Hb value.  
The aim is to maintain a Hb level of 10.0  to 11.0 g/dL  in the US and 10.0  to 12.0 g/dL 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 13 of 78 outside the US throughout the study.  
Adjustments to doses will be guided by an interactive web response (IWR) system 
based on Hb concentration and pro grammed Dose Adjustment Algorithms.  The 
programmed Dose Adjustment Algorithm for vadadustat will follow the Dose Adjustment Guidelines (see below).  The programmed Dose Adjustment Algorithm for 
darbepoetin  alfa will be based on the approved local product label  for adult patients 
with CKD on dialysis . 
When adjusting therapy, the Investigator will consider Hb  rate of rise, rate of decline, 
ESA responsiveness and variability , as well as the subject’s clinical condition (eg, 
recent illness, volu me depletion, volume overload, etc.).  In cases of extenuating 
clinical circumstances, the Investigator may elect to dose outside the IWR system dosing recommendation for initial darbepoetin alfa dose, dosing frequency, and dose 
adjustment to maintain the Hb within the target range.  In such cases, the clinical 
circumstances must be documented in the subject’s record  and IWR system . 
Vadadustat  
Vadadustat  should be dosed according to the following Dose Adjustment Guidelines.  
US 
• Do not increase the dose more frequently than once every 4 weeks.   Decreases 
in dose can occur more frequently.  Avoid frequent dose adjustments.  
• If a dose adjustment is required to maintain Hb at the desired level, the 
vadadustat dose is adjusted by 1  tablet ( minimum dose of vadadustat is 
150 mg/day [1  tablet]; maxi mum dose of vadadustat is 600 mg/day [4 
tablets]).  
• If the Hb rises rapidly (eg, >1.0 g/dL in any 2 -week period), reduce the dose 
of vadadustat by 1  tablet.  
• If the Hb falls below 10.0  g/dL, increase t he dose of vadadustat by 1 tablet.  
• If the Hb exceeds 11.0  g/dL, interrupt vadadustat until Hb decreases to 
11.0 g/dL or less, then resume dosing of vadadustat with 1 fewer tablet.  
 Non-US
 
• Do not increase the dose more frequently than once every 4  weeks.  Decreases 
in dose can occur more frequently.  Avoid frequent dose adjustments.  
• If a dose adjustment is required to maintain Hb at the desired level, the 
vadadustat dose is adjusted by 1 tablet ( minimum dose of vadadustat is 
150 mg/day [1  tablet]; maximum d ose of vadadustat is 600 mg/day [4 
tablets]).  
• If the Hb rises rapidly (eg, > 1 g/dL in any 2 -week period), reduce the dose of 
vadadustat  by 1 tablet.  
• If the Hb falls below 10.0  g/dL, increase the dose of vadadustat by 1  tablet.  
• If the Hb exceeds 12.0  g/dL, reduce the dose of vadadustat by 1  tablet.  If the 
Hb exceeds 13.0  g/dL, interrupt vadadustat until the Hb decreases to 
12.5 g/dL or below, then resume dosing of vadadustat with 1 fewer tablet.  
 
Darbepoetin  alfa 
For subjects randomized to darbepoetin alfa, the initial dose will be determined as 
follows:  
• For subjects already on darbepoetin, the initial dosing regimen in the study should be based on the prior dosing regimen.  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 14 of 78 • For subjects taking other ESAs, the initial dose of darbepoetin s hould be 
based on the approved local product label  for adult patients with CKD on 
dialysis.  
Following dose conversion, darbepoetin  alfa will be dosed IV or SC, with dose 
adjustments guided by an IWR system implementing a Dose Adjustment Algorithm  
based on the approved darbepoetin  alfa local product label.  Subsequent  administration 
of darbepoetin  alfa may occur at the clinic/investigative site or may be self -
administered at home per regional standard of care and/or based on dialysis modality 
(hemodialysis o r peritoneal dialysis).  Darbepoetin  alfa dosing is independent of the 
study visit schedule, and the dosing schedule may shift per local standard of care, the 
patient’s dialysis schedule,  and country -specific darbepoetin  alfa dosing guidelines.  
Dosing Instructions  Vadadustat  
All subjects will start with 2 tablets daily (300  mg/day).  Dose levels of vadadustat 
include 150, 300, 450, and 600 mg (available tablet strength is 150  mg).  Each  subject 
will take his/her first dose of vadadustat at the investigative site at the Baseline visit.  Thereafter, vadadustat will be taken once daily on an outpatient basis.  Subj ects may 
take vadadustat with or without food.  The dose should be taken at approximately the same time each  day, preferably between 7 AM and 2 PM.  The subject should be 
instructed to take any oral iron supplements at least 2  hours before or 2 hours after the 
dose of vadadustat.
 
Darbepoetin  alfa 
Darbepoetin  alfa will be administered, stored, and dispensed based on  the approved 
local product label.  
Iron Supplementation  Investigators should prescribe iron supplementation  (IV, oral, or intradialytic)  as 
needed during the study to maintain ferritin ≥100 ng/mL and TSAT ≥20%.  Subjects 
already receiving oral iron supplementation as part of their treatment plan may 
continue their current treatment regimen.  For subjects  who are on peritoneal dialysis, 
oral iron supplementation is allowed as per local guidelines and routine practice.    
Important : Because of the potential for oral iron to reduce the bioavailability of 
vadadustat, the study medication should not be administered concurrently with an oral 
iron supplement (including multivitamins containing iron).  The subject should be  
instructed to take any oral iron supplements at least 2 hours before or 2 hours after the dose of vadadustat.  
Rescue Therapy 
Guidelines  To ensure the safety of study subjects and to standardize the use of rescue in the study, rescue therapy guidelines are provided.  
 
1. Red Blood Cell (RBC) Transfusion:  Investigators should use their local 
institution’s transfusion guidelines when determin ing whether to transfuse a study 
subject.  In general, in the event of an acute or severe loss of blood, a RBC 
transfusion should be administered as clinically indicated.  In less severe instances but where there may be worsening of anemia or moderate to severe symptoms of anemia, RBC transfusions are perm itted at the discretion of the I nvestigator given 
medical necessity.  Study medication ( vadadustat or darbepoetin  alfa) may be 
continued during the transfusion period. 
2. ESA Rescue:  Starting at Week 6, s ubjects in both treatment arms will be allowed 
(although will not be required) to have their Hb rescued with ESA therapy.  When 
possible, a subject on vadadustat should be on maximum dose of vadadustat for 
2 weeks prior to ESA rescue.  A subject on darbepo etin alfa may be rescued with 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 15 of 78 another ESA per the standard of care.  To qualify for ESA rescue, a subject must 
fulfill ALL of the following:  
• The subject has experienced a clinically significant worsening of their anemia 
or symptoms of anemia (eg, fatigue, weakness, shortness of breath, chest pain, 
confusion, or dizziness) compared to Baseline  
• The subject’s Hb is <9.0 g/dL  
The ESA rescue therapy should be administered using an approved local product and 
dosing as per the local institution’s guidelines and per the approved local product label.  
While receiving ESA rescue therapy, subjects must temporarily interrupt study 
medication (vadadustat or darbepoetin  alfa).  Hemoglobin will be monitored 
throughout the study at scheduled visits using a HemoCue point of care device, and ESA rescue treatment should be stopped when Hb is ≥9 .0 g/dL.  A minimum interval 
must be observed prior to restarting vadadustat after the la st dose of rescue medication, 
and treatment may be resumed after the following intervals:
 
• 2 days after last dose of epoetin  rescue.  
• 7 days after last dose of darbepoetin  alfa. 
• 14 days after last dose of methoxy polyethylene glycol -epoetin beta rescue.  
Following ESA rescue, the study medication should be resumed and adjusted 
according to the Dose Adjustment Guidelines.  
Phlebotomy  If a subject’s Hb exceeds 14.0 g/dL or the rate of rise of Hb raises concern to the 
Investigator, the subject may be phlebotomized based on the Investigator’s clinical judgment.  The method of phlebotomy will be in accordance with the investigative site’s standard clinical practice
. 
Study Completion, 
Subject Completion, 
Premature 
Termination of Study Medication, or Withdrawal from the Study  Study Completion  
The study will be considered completed (end of trial) when 631 MACE events have 
accrued over the 2 DD -CKD studies (Studie s AKB -6548- CI-0016 and 
AKB -6548- CI-0017).  
Subject Completion 
A subject will be considered as having completed the study, regardless of whether the 
subject is on or off study medication, if the subject is followed until global study  
completion (end of trial) .  Subjects who continue on the study medication up to the 
global study end date will continue receiving vadadustat or darbepoetin  alfa until the 
EOT visit.  A post -treatment follow -up either in person or via telephone will occur 
approximately 4 weeks after the EOT visit.  The need for rescue therapy or the 
occurrence of safety endpoint do not constitute study completion and are not criteria for subject withdrawal from the study or permanent discontinuation of study medication (vadadustat or darbepoetin  alfa). 
Discontinuation of Study Medi cation Treatment  
During the course of this long -term study, it is anticipated that subjects may 
temporarily interrupt or permanently discontinue study medication (vadadustat or darbepoetin  alfa) for any of the following reasons:  
• Unacceptable toxicity or drug intolerability  
• Investigator discretion  
• Subject withdrawal of consent  
• Subject becomes pregnant  
• Receipt of  kidney transplant  
• Other reasons  
Subjects who either temporarily interrupt or permanently discontinue study 
medication (vadadustat or darbepoetin  alfa) after randomization and prior to 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 16 of 78 completion of the study should continue with study visits and safety assessments 
through Week 52 and sho uld be followed for safety assessments a fter Week  52 
(see “Procedures to Avoid Withdrawal or Loss to Follow -up” below).    
Unless contraindicated, treatment should be resumed wherever possible and routinely 
considered at every visit following study medication interruption . 
Receipt of rescue therapy is not a reason for permanent study medication 
discontinuation.  While receiving ESA rescue, subjects must temporarily discontinue 
study medication,  but should resume study medication following the end of rescue 
therapy.  
Complete Withdrawal from Study Visits/Assessments  
Subjects may request to be withdrawn or may be withdrawn from the study prior to completion for the following reasons only:  
• Death  
• Withdrawal of informed consent (complete withdrawal of consent requi res a 
subject’s refusal of ALL methods of follow -up noted  in the informed consent 
form: procedures, participation in reduced procedures/study visits, telephone 
contact only or alternative contact only, source document or designated alternative contact, or access to medical records from alternative sources)  
• Lost to follow -up (detailed procedures to prevent subjects from becoming 
“lost to follow -up” are provided below, and these procedures must be 
followed by the Investigators, their staff, and all designated  trial personnel) . 
Procedures to Avoid 
Withdrawal or Los t to 
Follow -up Avoiding Study Discontinuation  
As part of the informed consent process, only subjects who fully understand and agree to full participation and long -term follow -up should be consented to participate.  
In all cases on impending study drug discontinuation or subject request for withdrawal from study visits or consent withdrawal, the Investigator should discuss with the 
subject his/her options of continuing in the trial.  
The Investigator should ensure understanding and documentation of the reasons for a subject’s desire to stop study procedures or stop study drug.  
Minimizing Loss to Follow -up 
The I nvestigator must make every effort to contact subjects who fail to return for 
scheduled visits so that they will not be declared “lost to follow -up.”  The actions must 
include, but are not limited to, the following:  
• Contact all telephone numbers for the subject and his/her listed contacts (to be collected in the source at the subject’s entry into the study).  This includes making phone calls after normal business hours or on holidays or weekends.  
• Contact the subject’s primary care physician, referring specialist, pharmacist, or other healthcare professional, as applicable.  
• Send email, text, and postal mail with certified letters to all the subject’s addresses and contacts, as applicable.  
• Review ava ilable medical records/notes for details of hospitalizations, clinic 
visits, or other procedures that may indicate the status of the subject, as applicable. 
• Utilize the internet to search for additional contact information, as applicable.  
• Check local, regional, and national public records to locate the subject or search for mortality status as allowed by law, as applicable.  
Once all these actions have been exhausted and documented, then the S ponsor or 
Sponsor representative should be contacted for additional guidance.  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 17 of 78 Study Termination/  
Individual Study Site 
Termination  The entire trial may be suspended or terminated by the Sponsor for safety or other 
unanticipated reasons or upon request of regulatory agencies.  If this occurs, prompt 
notification will be given to Investigators, Institutional Review Boards (IRBs)/Institutional Ethics Committees (IECs), and regulatory authorities in accordance with regulatory requirements.  
The Investigator must notify the Sponsor if the trial is terminated by the Investigato r or 
the IRB/IEC at the site.  If the Investigator, IRB/IEC, or Sponsor decides to terminate 
or suspend the trial conduct at a particular investigative site for safety, non -enrollment, 
non-compliance with the protocol, or other unanticipated reasons, the above parties 
will be promptly notified.  
Statistical 
Considerations  Primary Efficacy Endpoint Analysis  
The primary efficacy endpoint is defined as the mean Hb change from Baseline (mean 
pretreatment Hb) to the mean Hb from Weeks 24 to 36 (inclusive ). 
The primary analysis will use an analysis of variance (ANOVA), stratified by the 
randomization strata with strata weighted by the stratum size.  
A 2-sided, 95% confidence interval (CI) will be calculated for the difference between 
the vadadustat group and control group.  Noninferiority of vadadustat will be 
established if the lower limit of this CI is ≥-0.5 g/dL.  
MACE Analysis  
The MACE endpoint (adjudicated result) will be analyzed as the time from  first dose 
of study medication  to first MACE.  Subjects who have  not experienced an adjudicated 
MACE by study closure will be censored as of their last assessment time.  
Major adverse cardiovascular events will be analyzed using a stratified Cox proportional hazards model with a model containing treatment group.  The randomization strata will be used in this analysis.  The primary MACE analysis will 
take place at study conclusion and will be based upon all subjects in the Safety population.  The hazard ratio (vadadustat/control) will be estimated, together with its 95% CI.  As this individual study has not been powered to provide a stand -alone 
estimate of the hazard ratio for MACE, this interval will be considered as descriptive.  Time to first MACE will also be graphically presented using Kaplan -Meier curves. 
The primary  analysis for MACE will be performed using the Safety population.  These 
analyses will be repeated with censoring occurring 4 weeks following early discontinuation of study medication.  
An independent statistical analysis center will perform analyses in sup port of the 
Independent Data Monitoring Committee (IDMC). 
Sample Size 
Estimation  For the primary efficacy analysis, it will be assumed that the difference in mean change 
in Hb for vadadustat will be the same as the active control, darbepoetin , and the 
common standard deviation for the mean change will be assumed to be 1.5 g/dL.  The noninferiority margin of -0.5 g/dL will be used  (for vadadustat minus darbepoetin  
alfa).  With these assumptions and approximately 1100 subjects per treatment grou p, 
the noninferiority test will have > 99% power.  
The primary MACE analysis will be based upon all events that accrue over the 
2 DD-CKD studies (Studies AKB -6548- CI-0016 and AKB -6548- CI-0017).  It has been 
calculated that 631 events will be required overall  to have 80% power to establish 
noninferiority with a margin of 1.25, and 90% to establish noninferiority with a margin of 1.3 evaluated with a 2 -sided 95% confidence interval assuming no difference 
between the treatments .  With 631 events, the power is >90% to establish 
noninferiority with a margin of 1.25 if the hazard ratio is 0.95 favoring vadadustat.    
A MACE rate of 12% annually is anticipated in both treatment arms based on a comprehensive review of available epidemiology and prospective clinical tri als in the 
field.  With approximately 1100 subjects per treatment group enrolled in this study, 
20 months for accrual and 36 months of maximum follow -up, approximately 85% of 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 18 of 78 the needed MACE events ( 536) would be captured.  
Independent Data 
Monitoring 
Committee  (IDMC)  An IDMC will be established to review and discuss the available study data as subjects 
are enrolled and followed.  The team will meet approximately twice per year throughout the course of the study.  The IDMC will be unblinded and will inc lude, at a 
minimum, a nephrologist, a cardiologist, and a biostatistician.  The discussions of the IDMC will include a review of key safety  data (ie, AEs, vital sign measurements, 
electrocardiograms, and  laboratory assessments). 
Endpoint 
Adjudication Comm ittee (EAC)  An independent safety EAC, blinded to treatment assignment, will be formed prior to 
study commencement to adjudicate the components of the primary safety endpoints (eg, death, myocardial infarction, and stroke).  Thromboembolic events and 
hospi talization for HF will also be adjudicated by the EAC.  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 19 of 78 3 LIST OF ABBREVIATIONS 
AE adverse event  
ALT  alanine aminotransferase (SGPT)  
ANOVA  analysis of variance  
AST  aspartate aminotransferase (SGOT)  
BUN  blood urea nitrogen 
CBC  complete blood count 
CHF  congestive heart failure  
CKD chronic kidney disease 
CMH  Cochran -Mantel -Haenszel  
CPK  creatine phosphokinase 
CRF  case report form  
CRO  contract research organization  
CV cardiovascular  
CVD cardiovascular disease  
DD-CKD  dialysis dependent chronic kidney disease 
dL deciliter  
DNA deoxyribonucleic acid  
DVT  deep venous thrombosis 
EAC  Endpoint Adjudication Committee 
ECG  electrocardiogram  
EDC  electronic data capture  
EOT  end of treatment 
EPO  erythropoietin  
ESA  erythropoiesis- stimulating agent  
ESRD  end-stage renal disease  
EU European Union 
FDA  Food and Drug Administration 
g gram  
GCP  Good C linical Practice  
HAs Health A uthorities  
HDL  high-density lipoprotein 
HF heart failure  
Hb hemoglobin 
HIF hypoxia-inducible factor 
HIFPH  hypoxia-inducible factor prolyl- hydroxylase  
HIF-PHI hypoxia-inducible factor prolyl-hydroxylase inhibitor 
IC50 50% inhibitory concentration 
ICH International Council for Harmonis ation  
IDMC  Independent D ata Monitoring C ommittee  
IEC independent ethics committee 
INR international normalized ratio  
IRB institutional review board 
IV intravenous (ly) 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 20 of 78 IWR  interactive web response  
JSDT  Japanese Society for Dialysis Therapy  
JSN Japanese Society of Nephrology  
KDIGO  Kidney Disease: Improving Global Outcomes 
kg kilogram 
LDH  lactate dehydrogenase  
LDL  low-density lipoprotein 
LLN  lower limit of normal 
MACE  major adverse cardiovascular events 
MCH  mean corpuscular (cell) hemoglobin  
MCHC  mean corpuscular (cell) hemoglobin concentration  
MCV  mean corpuscular ( cell) volume  
MedDRA  Medical Dicti onary for Regulatory Activiti es 
µM micromolar  
mg milligram 
mL milliliter  
mRNA messenger ribonucleic acid   
ng nanogram 
PD pharmacodynamics(s)  
PHD prolyl 4- hydroxylase domain  
PK pharmacokinetic (s) 
PP per protocol 
PT prothrombin time 
PTT partial thromboplastin time  
RBC  red blood cell 
RDW  red cell distribution width  
ROW  rest of world  
SAE  serious adverse event  
SAP Statistical Analysis Plan 
SC subcutaneous (ly) 
SGOT  serum glutamic oxaloacetic transaminase  (AST)  
SGPT  serum glutamic pyruvic transaminase (ALT)  
SmPC  summary of product characteristics  
SV Screening visit  
TIBC  total iron binding capacity 
TREAT Trial to Reduce Cardiovascular Events with Aranesp Therapy 
TSAT  transferrin saturation  
ULN  upper limit of normal 
US United States  
VEGF  vascular endothelial growth factor  
WBC  white blood cell 
WHO World Health Organization  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 21 of 78 4 BACKGROUND INFORMATI ON 
Chronic kidney disease (CKD), defined as the presence of kidney damage or a decreased level of 
kidney function, is a major public health problem worldwide.  Globally, CKD is estimated to affect between 8 % to 16% of the population ( Jha et al.  2013; KDIGO 2013 ).  At the most 
advanced stages of CKD, end- stage renal disease (ESRD), patients require chronic dialysis or 
kidney transplantation to sustain life.  Chronic kidney disease is not only a cause of ESRD, but is also a significant risk factor for cardiovascular disease (CVD), infection, cancer, and mortality (Iseki and Kohagura 2007). 
Renal anemia often develops during the progression of CKD and is present in almost all patients with ESR D.  Anemia is defined as a decrease in circulating red blood cell (RBC) mass that is 
usually detected by low hemoglobin ( Hb) concentration.  The causes of anemia in CKD include 
blood loss, shortened RBC lifespan, iron deficiency, erythropoietin (EPO) defic iency, and 
inflammation ( Nurko 2006).  Although many factors contribute to anemia in CKD, it occurs 
primarily due to an inadequate synthesis of EPO by the kidneys, leading to a deficiency in the 
production of RBC progenitor cells by the bone marrow.  Also contributing to anemia in CKD are impaired iron homeostasis and iron loss, which often necessitate iron supplementation (Nurko 2006).  Anemia in CKD patients usually occurs when the glomerular filtration rate 
(GFR) falls below 60 mL/min/1.73 m
2, and is present in >90% of the patients undergoing 
dialysis (CKD Stage  5) (Goodkin et al. 2011). 
The main impact of anemia on organ function is reduced oxygen delivery to tissues leading to a constellation of symptoms including fatigue, shortness of breath, and exerc ise intolerance 
(Stauffer  and Fan  2014) .  In patients with anemia related to CKD, compensatory changes occur 
in cardiac structure and function, including an increase in cardiac output, the development of left ventricular hypertrophy, and, eventually, the development of heart failure ( Metivier  et al.  2000).  
Risk of stroke also increases with anemia, which may be an underlying mechanism leading to stroke in CKD ( Abramson et al., 2003;  Iseki and Kohagura 2007 ).  Other consequences from 
anemia in CKD patients include impaired cognitive function, sleep disorders, and depressed immune function, which can impact the quality of life in these patients (Iseki and 
Kohagura 2007; NICE  2011).  Overall, anemia contributes to a poorer prognosis in patients with 
CKD (Nurko 2006; Iseki and Kohagura 2007). 
Erythropoiesis- stimulating agents (ESAs) administered either intravenously (IV) or 
subcutaneously (SC), along with oral or IV iron therapy, are currently the cornerstones f or 
treating anemia in patients with CKD.  Treatment with exogenous recombinant ESAs can raise Hb levels, relieve symptoms, and reduce the complications of anemia, including RBC 
transfusions which carry the risks of infection, iron overload, and impact candidacy for kidney transplantation. 
Clinical practice guidelines and prescribing information for approved ESAs and guidelines 
provided by the United States (US) Food and Drug Administration (FDA), the European Union (EU), the Japanese Society of Nephrology, and the Japanese Society for Dialysis Therapy Guideline Committee differ slightly in their recommendations for treatment of renal anemia, as summarized in  Table 1. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 22 of 78 Table 1 Treatment Guidelines and Prescribing I nformation for Renal Anemia in 
DD-CKD  
KDIGO guidelines  Treatment should be given when  Hb is between 9.0 -10.0 g/dL (Kidney Disease: 
Improving Global Outcomes [KDIGO] 2012).   ESAs should not be used to maintain ESAs 
above 11.5 g/dL  
US darbepoetin alfa 
label  Initiate treatment when the Hgb level is less than 10 g/dL.  I f Hb approaches or exceeds 
11.0 g/dL in adults on dialysis, the dose of ESA should be reduced or interrupted 
(darbepoetin alfa  [Aranesp®) US Package Insert  2015). 
EU practice 
guidelines  Individualize dosing to achieve and maintain hemoglobin levels within the range of 100 to 
120 g/L  (10.0 – 12.0 g/dL) .  Hemoglobin levels should not exceed 120 g/L  (12.0 g/dL) .  
(Aranesp EU Label ). Detailed information on darbepoetin alfa in the EU is available on 
the European Medicines Agency web site.  
Japan practice 
guidelines  JSDT recommends that ESA treatment be initiated when Hb is below 11.0  g/dL following 
a diagnosis of renal anemia in DD -CKD.  JSN 2013 does not provide a clear 
recommendation or maintenance range for Hb.  Both guidelines recommend that if the Hb 
exceeds 13.0  g/dL, the dose of ESA should be reduced or interrupte d.  In patients with 
CVD or complications, ESA treatment should be reduced or interrupted if the Hb exceeds 
12.0 g/dL ( Tsubakihara  2010; Japanese Society of Nephrology  2014).  
Abbreviations: CVD  = cardiovascular disease; DD-CKD  = dialysis dependent chronic  kidney disease;  ESA  = erythropoietin 
stimulating agent; EU  = European Union; Hb = hemoglobin; JSDT  = Japanese Society for Dialysis Therapy; JSN  = Japanese 
Society of Nephrology; KDIGO  = Kidney Disease Improving Global Outcomes; US  = United States.  
 
The m ajority of patients with ESRD  currently receive interventional therapy in the form of iron 
therapy and an ESA if their  Hb levels fall below 10.0 to 11.0 g/dL, dependent upon local clinical 
practice guidelines.  
A number of large, prospective, randomized controlled trials in CKD (Stages 3 to 5) have 
explored the potential benefit of ESAs in patients with CKD with respect to overall mortality, cardiovascular (CV) events, and progression of CKD with higher Hb  target s (≥13.0 g/dL) 
(Besarab  et al.  1998; Drüeke et al.  2006; Singh  et al.  2006; Pfeffer et al.  2009a ; Pfeffer 
et al. 2009b) .  These trials did not demonstrate the expected beneficial effects of correcting 
anemia on these outcomes, but suggested an increased risk of death and CV events when targeting higher Hb levels (Besarab  et al.  1998; Drüeke et al.  2006; Singh  et al.  2006; Pfeffer et 
al. 2009a ; Pfeffer  et al.  2009b) .  Additional analyses from these trials suggest that the risk of 
death or CV events appears t o be highest in CKD patients who fail to respond to ESAs, as 
indicated by lower achieved Hb levels and higher average ESA dose requirements ( Szczech  
et al. 2008; Solomon et al.  2010).  This suggests that in some subjects the ESAs themselves, and 
not the Hb  level, may be causative of the increase in events.  This is supported by studies in 
CKD patients on dialysis with naturally high Hb  levels and no increase in CV events (Goodkin et 
al. 2011). 
The risks identified with ESAs from these trials have led to cha nges in prescribing information 
and practice guidelines in the US, the EU, and Japan that guide clinicians toward more cautious use of ESAs and targeting lower Hb  levels.  In the US, the mortality and CV risks associated 
with ESAs are outlined in a black-box warning in the prescribing information of ESAs with a recommendation to use the lowest dose possible to avoid transfusions.  While no similar major warnings exist in the EU Summary of Product Characteristics (SmPC) or on the approved labeling for ESAs in Japan, the EU SmPCs for ESAs do suggest caution with the use of these 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 23 of 78 drugs, with a recommendation to keep Hb  levels below  12.0 g/dL, while the Japanese practice 
guidelines recommend ESA treatment be reduced or interrupted if the Hb exceeds 12 .0 g/dL in 
patients with CVD or complications.  Further, recent EU clinical practice guidelines (Locatelli  et 
al. 2013) recommend that risk factors for stroke (including a past history of stroke) and the 
presence of active malignancy or a past history of malignancy s hould be taken into account when 
making decisions to use ESAs for the treatment of anemia. 
The risks associated with ESAs, including an increased risk of death and CV events, highlight 
the need for additional therapies that might minimize or avoid these risks when compared to currently available recombinant protein -based ESAs.  Therefore, the unmet medical need for the 
treatment of anemia in dialysis dependent CKD (DD- CKD) patients remains high, especially 
from a CV safety perspective.  To fulfill this unme t need, the vadadustat clinical program is 
focused on developing an orally active therapeutic for the treatment of anemia in patients with CKD.  
4.1 Hypoxia -Inducible Factor Prolyl -Hydroxylase Inhibitors  
Please see the vadadustat Investigator ’s Brochure for additional discussion and information for 
the following section . 
Vadadustat is a novel, synthetic, orally bioavailable, small molecule being developed as an inhibitor of hypoxia-inducible factor prolyl- hydroxylases (HIF -PHs) for the treatment of anemia 
associ ated with CKD.  Hypoxia-inducible factor prolyl- hydroxylase enzymes are also referred to 
as prolyl 4-hydroxylase domains (PHDs), of which the 2 most commonly expressed are PHD2 and PHD3.  Vadadustat is a slightly more potent inhibitor of PHD3 (50% inhibitory concentration [IC
50] = 0.08 µM) than of PHD2 (IC 50 = 0.19 µM).  The inhibition of PHD3 and 
PHD2 stabilizes hypoxia -inducible factor (HIF)-2α and HIF-1α, which in turn stimulates the 
production of EPO.  In vivo animal efficacy and messenger ribonucleic acid (mRNA) data 
indicate that vadadustat induces the production of EPO from both renal and extra- renal sites 
(liver and brain), and this increase in EPO results in an increase in RBC production in the bone marrow.  In clinical trials, vadadustat has been shown to facilitate iron homeostasis by decreasing hepcidin and increasing transferrin levels in healthy adult male volunteers and male and female CKD patients.  This enables iron transport mechanisms that should enhance the terminal steps of erythropoiesis.  Vadadustat offers the potential of flexible oral dosing that provides a more gradual and reliable means of titration than injectable hormones.  Therefore, vadadustat is being developed as an alternative to the existing protein hormone ESAs. 
4.2 Summary of Clinical Experience  
Please see the vadadustat Investigator ’s Brochure for additional discussion and information for 
the following section . 
To date, the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of 
vadadustat have been characterized in approximately 450 unique subjects having received 
vadadustat, including more than 165 healthy volunteers and more than 250 subjects with CKD.  
Overall, vadadustat has been well -tolerated and has demonstrated consistent, dose proportional 
PK and PD.  Vadadustat has demonstrated the desired and anticipated effects of raising EPO 
concentrations in a dose-dependent manner in Phase 1 and Phase 2a studies.  The changes in 
EPO have been accompanied by dose responsive increases in iron mobilization ( increased total 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 24 of 78 iron binding capacity [TIBC] and transferrin and decreased hepcidin and ferritin).  Together, 
these effects have stimulated an increase in reticulocytes and Hb.  Vadadustat has generally been 
well-tolerated with limited adverse events (AEs)  and serious AE s (SAEs) observed to date.  
Vadadustat is eliminated by dual routes of elimination (both urinary and fecal).  Given the dual routes of elimination, vadadustat is not expected to accumulate in patients with CKD.  
Based on the Phase 1 and Phase 2 study results, vadadustat is  a suitable candidate for continued 
development as a treatment for anemia in patients with CKD.  
4.3 Potential Benefits and Risks  
Please see the vadadustat Investigator ’s Brochure for additional discussion and information for 
the following section . 
Vadadustat offers the potential of flexible oral dosing that is easier to titrate than injectable hormone ESAs.  This alternate therapeutic approach may avoid the overshoots and fluctuations in Hb  levels seen with currently available inj ectable ESAs and provide for a controlled, steady 
rise in Hb concentration.  This less aggressive approach to modifying the Hb  concentration may 
be of benefit based on the FDA’s suggestion that fluctuations in Hb  concentrations, rapidly 
increasing Hb level s, and overshoots of the target level are associated with an increased risk of 
CV events ( Unger  2007; Unger et al.  2010 ). 
In addition, since HIFs downregulate the iron absorption regulator hepcidin, and upregulate the iron-mobilizing regulators ferroportin  and transferrin (and its receptor) ( Peyssonnaux et al. 
2007), vadadustat will likely enhance iron metabolism and transport, thereby enhancing EPO responsiveness.  In the Phase 1b multiple -ascending -dose  study, a prominent effect on iron 
metabolism was noted with the dosing of vadadustat, including a rapid increase in iron uptake, a dose responsive increase in TIBC, decreases in hepcidin and ferritin, and an increase in transferrin.  A similar pattern was observed in the Phase 2a and Phase 2b studies, with dose 
responsive increases in TIBC and decreases in ferritin and hepcidin.  
To date, all of the acute findings observed at doses less than the maximum tolerated dose (MTD) in animals have been shown to be reversible and dose-related.  In addition, most of the findings have followed a pattern that would have been predicted based on the known HIF and HIFPH biochemistry, pharmacology, and human genetic variations ( eg, Chuvash polycythemia, etc.).  In 
the completed clinical studies, vadadustat has been generally well -tolerated.  
5 STUDY OBJECTIVES AND ENDPOINTS  
5.1 Primary Objective  
The primary objective of this study is to demonstrate the efficacy and safety of vadadustat 
compared with darbepoetin alfa for the maintenance treatment of anemia in subjects with DD -
CKD. 
5.2 Primary Efficacy Endpoint  
The primary endpoint used to assess the efficacy  objective will be the mean change in Hb 
between Baseline (mean pretreatment Hb) and the primary evaluation period (mean Hb  from 
Weeks  24 to  36). 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 25 of 78 5.3 Secondary Efficacy  Endpoints  
Key secondary efficacy endpoints include the following: 
• Mean change in Hb value between Baseline (mean pretreatment Hb) and the secondary 
evaluation period (Weeks 40 to  52) 
• Proportion of subjects with mean Hb  within the target range  during the primary 
evaluation period (Weeks 24  to 36) 
• Mean weekly  dose of IV elemental iron administered from Baseline to Week  52 
• Proportion of subjects receiving RBC  transfusion(s) from Baseline to Week  52. 
Other secondary efficacy endpoints include: 
• Proportion of Hb  values within the target range  during t he Maintenance P eriod 
(Weeks  24 to  52) 
• Confirmed Hb  values <10.0 or >12.0 g/dL 
• ESA rescue  
• Dose adjustments 
• Maintenance of iron sufficiency (defin ed as ferritin ≥100 ng/mL and t ransferrin 
saturation  [TSAT ] ≥20%) 
• Receiving IV iron therapy 
5.4 Safety Endpoints  
Safety endpoints in this study include the following:  
• Major adverse cardiovascular events (MACE) , defi ned as all -cause mortality, non- fatal 
myocardial i nfarction, or non- fatal stroke  
• Individual components of MACE: 
• All-cause mortality  
• Non- fatal myocardial infarction  
• Non- fatal stroke  
• Thromboembolic events: arterial thrombosis, deep vein  thrombosis (DVT), pulmonary 
embolism (PE), or vascular access thrombosis 
• Hospitalization for heart failure  (HF)  
• Hb >12.0 g/dL, >13.0 g/dL, or >14.0 g/dL  
• Hb increase >1.0  g/dL wit hin any 2-week interval or >2.0 g/dL within any 4 -week 
interval  
• AEs and SAEs  
• Vital signs and clinical laboratory values . 
6 STUDY DESIGN  
6.1 Study Design 
This is a P hase 3, randomized, open- label, active -controlled study of vadadustat versus 
darbepoetin alfa for the maintenance treatment of anemia in subjects with DD -CKD ( either  
peritoneal dialysis or hemodialysis) after conversion from  erythropoiesis- stimulating agent 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 26 of 78 (ESA) therapy .  Target enrollment in this study is approx imately  2200 subjects at approximately 
300 investigative sites in North America, Latin America, Europe, and Asia Pacific.  
Subjects will be randomized  at the Baseline visit using an Interactive Web Response (IWR)  
system to receive either vadadustat  at a starting dose of two 150 mg tablets once daily 
(300 mg/day) or darbepoetin alfa (based on the approved local product label for adult patients 
with CKD on dialysis).  
Randomization will be stratified by geographic re gion (US versus EU  versus rest of world 
[ROW]), by New York Heart Association  congestive heart failure (CHF) Class 0 or I versus II or 
III, and by s tudy entry Hb (<10.0 versus ≥10.0 g/dL) . 
Following randomization, there will be 3 periods during the study: 
• Conversion and Maintenance Period (Weeks 0 to 52): conversion to study medication for 
maintaining Hb (Weeks 0 -23), primary efficacy evaluation  (Weeks 24 -36), and secondary 
efficacy evaluation  (Weeks 40-52)  
• Long -term Treatment Period (Week 5 3 to EOT ): continued study medicat ion to assess 
long- term safety  
• Follow-up P eriod  (EOT + 4 weeks): post- treatment visit for safety (either in per son or via 
telephone) 
A HemoCue® point of care device will be used throughout the study to monitor Hb  to determine 
if the dose of study medication (vadadustat or darbepoetin alfa) will be adjusted  or interrupted.  
From Weeks  0 to 12, HemoCue will be used to monitor Hb  every 2  weeks for dose adjustment.  
From Week  12 to Week  52, Hb  will be monitored via HemoCue every 4 weeks  unless more 
frequent monitoring is clinically indicated or warranted based on dosing changes.  From 
Week  53 through the end of study, Hb  will continue to be monitored via HemoCue to determine 
if the dose of study medication will be adjusted or suspended.  Hemoglobin will also be assessed with a complete blood count (CBC) through the central laboratory for efficacy and safety evaluations; however, dose adjustments should be based on the HemoCue Hb  value.  
The aim of the dosing strategy is to maintain Hb  levels of 10.0 g/dL to 11.0 g/dL in the US 
and 10.0 g/dL to 12.0 g/dL outside of the US throughout the study.  
Subjects assigned to vadadustat will initiate dosing at 2  tablets once daily at the Baseline visit.   
Adjustments to doses for vadadustat will be guided by an IWR system based on Hb  
concentration and a programmed Dose Adjustment Algorithm ( Section  8.4.4.1, Vadadustat 
Dosing and Dose Adjustment Guidelines ).  Dosing will be suspended if Hb  rises to > 11.0 g/dL 
(US investigative sites) or >13.0  g/dL (non- US investigative sites) , and will not be restarted until 
Hb levels are reduced to ≤ 11.0 g/dL (US investigative sites) or ≤12.5 g/dL (non- US investigative 
sites) (see Section  8.4.4.1 , Vadadustat Dosing and Dose Adjustment Guidelines  for details 
regarding dose suspension). 
For subjects randomized to darbepoetin alfa, the initial dose will be determined as follows: 
• For subjects already on darbepoetin, the initial dosing regimen in the study should be 
based on the prior dosing regimen. 
• For subjects taking other ESAs, the initial dose of darbepoetin should be based on the approved local product label. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 27 of 78 Following dose conversion, darbepoetin alfa will be dosed IV/SC with dose adjustments guided 
by an IWR system implementing a Dose Adjustment Algorithm based on the approved local 
product label for adult patients with CKD on dialysis ( Section  8.4.4.2, Darbepoetin  Alfa Dosing 
and Dose Adjustment Guidelines ).  Darbepoetin  alfa dosing is independent of the visit schedule, 
and the dosing schedule may shift per local standard of care and country- specific dosing 
guidelines. 
Investigators should prescribe iron supplementation ( IV, oral, or intradialytic ) as needed during 
the study to maintain ferritin ≥100 ng/mL and TSAT ≥20% ( see Section  8.4.6, Iron 
Supplementation for details regarding iron supplementation during the study).  Subjects already 
receiving oral iron supplementation as part of their treatment plan may continue their current 
treatment regimen.  For patients who are on peritoneal dialysis, oral iron supplementation is allowed as per local guidelines and routine practice.  
Clinical and safety assessment s (including laboratory assays, P K evaluations  [both vadadustat 
parent compound and metabolites], MACE endpoint data, vital sign measurements, and AE s) 
will be perform ed as indicated at Screening, during the Conversion and Maintenance Period 
(Baseline [Week 0], Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52), during 
the Long- term Treatment Period  (visits approximately every 3 months, Weeks  53 to  EOT) , and 
during the Follow-up Period (4 weeks after the EOT).   Refer to Section  9, Study Procedures and 
Schedule of Activities  and Appendix A : Schedule of Activities  for additional details.  
The study will be considered completed (end of trial) when 631 major adverse  cardiovascular 
events (MACE) have accrued over  the 2  DD-CKD studies (Studies AKB-6548- CI-0016 and 
AKB -6548- CI-0017).  All subjects will remain in the study until the end of trial , at which time  
subjects will be scheduled for a final visit and the study wi ll close (see Section  11.1.2, Sample 
Size for the Primary Safety Endpoint ). 
6.2 Rationale for Study Design  
During prior clinical trials, vadadustat has been well-tolerated, and has demonstrated consistent, dose proportional PK and PD.  Vadadustat has demonstrated the desired and anticipated effects of raising EPO concentrations in a dose-dependent manner in Phase 1 and Phase 2 studies.  The changes in EPO have been accompanied by dose responsive increases in iron mobilization 
(increased TIBC and transferrin and decreased hepcidin and ferritin).  Together, these effects have stimulated an increase in reticulocytes and Hb.  Vadadustat has generally been 
well-tolerated with limited AEs.  In a clinical study conducted to evaluate the effect of 
hemodialysis on the exposures to vadadustat, the hemodialysis procedure did not impact the exposures of vadadustat or its metabolites.  Vadadustat is eliminated from the body by dual routes of elimination, both renal and fecal.  Given the dual routes of elimination, vadadustat is not ex pected to accumulate in patients with CKD.  Based on the Phase 1 and Phase 2 study 
results, continued development of vadadustat as a treatment for anemia in patients with CKD is warranted.  
In this study, darbepoetin  alfa was chosen as an active comparator  as it is marketed and available 
globally and has an extensive safety profile.  This is particularly relevant  in the current medical 
and regulatory climate given the accumulating trial findings that resulted in the FDA revising the prescribing information for the currently marketed ESAs.  These trial results indicate an increased risk of death and adverse CV events, such as stroke and heart failure, particularly when 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 28 of 78 using ESAs to achieve a higher Hb concentration.  In the US, the mortality and CV risks 
associated with ESAs are outlined in a black -box warning in the prescribing information of 
ESAs, with a recommendation to use the lowest dose possible to avoid transfusions.  While no 
similar major warnings exist in the EU SmPC or on the approved labeling for ESAs in Japan, the EU SmPCs for ESAs do suggest caution with the use of these drugs, with a recommendation to keep Hb levels below 12 .0 g/dL.  Recent clinical practice guidelines ( Locatelli et al.  2013) 
recommend that risk factors for stroke and malignancy should also be taken into account when making treatment decisions to use ESAs for the treatment of anemia.  
Given the concerns associated with marketed ESAs, a goal of this study will be to evaluate the CV events during the treatment of anemia with vadadustat.  The inclusion of a MACE endpoint in this study will allow for a statistical comparison of the rates of  CV events between vadadustat 
and darbepoetin  alfa treatment groups when used to treat anemia associated with DD -CKD.  
While the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)  (Pfeffer  et 
al 2009b) compared different Hb  targets, the pre sent study will have similar Hb targets between 
treatment arms.  Importantly, the Hb goals for this study are lower than those used in TREAT 
and are consistent with practice guidelines and prescribing information for approved ESAs. 
This study will be perfo rmed as an open -label study.  Because Hb values are objective and will 
be measured via a central laboratory for all efficacy endpoints, efficacy assessments are not 
considered to be subject to bias with an open-label design.  Blinding of this study present ed 
inherent practical problems, including potential dosing errors, inappropriate dose adjustments, and delays in dosing, which may also increase the safety risk to study participants.  Given the differing dosing regimens and routes for vadadustat (oral) and darbepoetin  alfa ( IV/SC 
injection), a double-dummy design would have been required, which also created ethical concerns and required extensive coordination to maintain the blind.  To minimize bias, the Sponsor and contract research organization (CRO) study teams will remain blinded to the randomization codes.  In addition, the study will involve blinded adjudication of MACE, the use of an independent data monitoring committee (IDMC), and an identical schedule of visits, procedures, and assessments for both treatment groups in order to reduce the potential for bias.  However, certain personnel directly involved in medical oversight of the study, regulatory reporting of safety information, and on- site monitoring activities may become unblinded to the 
treatme nt assignments of individual subjects during the course of the study.  In addition, to 
reduce subjectivity of dose adjustment, adjustments to doses for vadadustat and darbepoetin alfa will be guided by an IWR system based on Hb  concentration and programmed  Dose Adjustment 
Algorithms . 
6.3 Dose Justification  
The starting dose and the proposed dosing algorithm in this study are designed to maintain Hb  in 
a predictable and controlled manner while minimizing abrupt increases or excessive rises in Hb  
levels.  Based on plasma concentrations and PD measures from previously conducted clinical studies with vadadustat, a population PK/PD model was developed.  Using this model and the proposed dosing algorithm, simulations were carried out to evaluate the e ffects of different 
starting doses and the resulting Hb  responses to support the dosing rationale.  Results of the 
simulations indicated that a starting dose regimen of 300  mg once daily along with the proposed 
dosing algorithm are optimal to maintain Hb levels of 10.0 to 11.0 g/dL in the US and 10.0 to 
12.0 g/dL outside of the US while minimizing excessive rises.  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 29 of 78 6.4 Independent Data Monitoring Committee  
An IDMC will be established to review and discuss study safety data as subjects are enrolled and 
followed.  The team will meet approximately twice per year throughout the course of the study.  The IDMC will be unblinded and will include, at a minimum, a nephrologist, a cardiologist, and a biostatistician.  The discussions of the IDMC will include a review of ke y safety data (ie, AEs, 
vital signs, and laboratory assessments).  Written records of the IDMC meetings, the materials reviewed, and the decisions made will be maintained.  Details on the roles and responsibilities of the IDMC and guidelines for monitoring study safety data will be described further in the IDMC charter.  
6.5 Endpoint Adjudication Committee  
An independent safety endpoint adjudication committee (EAC) will be formed prior to study commencement to adjudicate the primary safety endpoints (death, myocardial infarction, and stroke).  Thromboembolic events and hospitalization for HF  will also be adjudicated by the EAC.  
The committee will be blinded throughout the course of the study.  The EAC will be composed of independent experts with experience and training appropriate for adjudication of MACE, thromboembolic events, and hospitalization for HF .  Details on the responsibilities of the EAC 
will be described further in the EAC charter.  
7 SELECTION AND WITHDRAWAL OF SUBJECTS  
7.1 General Criteria  
To be eligible for this study, a subject or their legally acceptable representative must provide 
valid informed consent and must meet all of the following criteria .  No study procedures 
(including s creening  tests) may be performed until after the informed consent has been legally 
signed. 
An optional Pres creen visit can be used to perform initial testing of the Hb level using a local 
point of care devi ce to evaluate whether a subject should progress to full s creening procedures.  
A separate Prescreen informed consent (distinct from the full protocol informed consent) will be implemented for the Pre screen visit.  To be eligible for the Pres creen Hb measurement, a study 
subject or their legally acceptable representative must provide valid informed consent prior to the Prescreen procedure.  For a better understanding of the Pres creening visit, please see 
Section  9.3.1, Pre screening Visit. 
7.2 Inclusion Criteria  
Subjects must meet all of the following inclusion criteria to be eligible:  
1. ≥18 years of age . 
2. Receiving  chronic maintenance dialysis (either peritoneal or hemodialysis) for end- stage 
kidney disease for at least 12  weeks prior to Screening . 
3. Currently maintained on ESA therapy, with the last dose received within 8 weeks prior to Screening.  
4. Mean screening Hb between 8.0 and 11.0 g/dL (inclusive) in the US and between 9.0 and 
12.0 g/dL (inclusive) outside of the US, as determined by the average of 2  Hb values 
measured by the central laboratory during Screening . 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 30 of 78 5. Serum ferritin ≥100 ng/mL and  transferrin saturation  (TSAT) ≥20% during S creening . 
6. Folate and vitamin B 12 measurement s ≥ lower limit of normal (LLN) during S creening . 
7. Understands the procedures and requirements of the study and provides written informed 
consent and authorization for protected health information disclosure. 
7.3 Exclusion Criteria  
Subjects presenting with any  of the following will not qualify for entry into the study:  
1. Anemia due to a cause other than CKD or subjects with  active bleeding or recent blood loss. 
2. History of sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia. 
3. Red blood cell transfusion within 4 weeks prior to or during the Screening  period. 
4. Anticipated to recover adequate kidney function to no longer require dialysis. 
5. Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT), or total bilirubin >2.0 x upper l imit of normal (ULN) during Screening.  Subjects with a history of Gilbert’s 
syndrome are not excluded. 
6. Uncontrolled hypertension (defined as confirmed predialysis systolic blood pressure [BP] >190 mmHg or dia stolic BP >110 mmHg at rest)  during S creening . 
7. Severe heart failure during Screening (New York Heart Association Class IV) . 
8. Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular or peripheral artery disease (aortic or lower extremity) , surgical or percutaneous valvular replacement or repair, 
sustained ventricular tachycardia, hospitalization for HF, or stroke within 12 weeks prior to or during Screening. 
9. History of active malignancy within 2 years prior to or during Screening, except for treated  
basal cell carcinoma of skin, curatively resected squamous cell carcinoma of skin, cervical 
carcinoma in situ, or resected benign colonic polyps. 
10. History of deep vein thrombosis (DVT) or pulmonary embolism (PE) requiring active treatment within 8 weeks prior to  or during S creening . 
11. History of hemosiderosis or hemochromatosis. 
12. History of prior organ transplantation or scheduled organ transplant (subjects on the kidne y 
transplant wait-list or with a history of failed kidney transplant are not excluded), or prior hematopoietic stem cell or bone marrow transplant (corneal transplants and stem cell therapy 
for knee arthritis are not excluded) . 
13. Hypersensitivity to vadadustat, darbepoetin alfa, or any of their excipients.  
14. Use of an investigational medication or participation in an investigational study within 30 days or 5 half- lives of the investigational medication (whichever is longer ), prior to 
Screening . 
15. Previous participation in this study or previous participation in a study with another hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF- PHI)  other than vadadustat . 
16. Females who are pregnant or breastfeeding.  Wo men of childbearing potential who are 
unable or unw illing to use an acceptable method of co ntraception (r efer to Section  9.1.3, 
Contraception and Pregnancy Avoidance Measures ). 
17. Non-vasectomized male subjects who are unable or unwilling to use an acceptable method of 
contraception (r efer to Section  9.1.3, Contraception and Pregnancy Avoidance Measures ). 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 31 of 78 18. Any other reaso n, which in the opinion of the Investigator, would make the subject not 
suitable for participation in the study.  
7.4 Retesting and Rescreening  
Subjects who fail to qualify for the study based on certain laboratory parameters may be retested 
and/or rescreened at the discretion  of the Investigator. 
7.4.1 Retesting  
Subjects who initially fail to qualify for the study based on laboratory test results may have their laboratory value retested 1 time within the 28 -day Screening period at the discretion of the 
Investigator.  Retesting within the 28-day Screening period does not constitute rescreening; however, if retesting falls outside of the 28-day Screening period, it should be considered a rescreen.  All screening laboratories, including any repeat measurements, must be performed 
within the 28-day Screening window with a minimum of 4 days between the last qualifying 
repeat measurement and the Baseline visit.  
For eligibility purposes, if Hb  at SV1 is 11.1 to 11.5 g/dL in the US or 12.1 to 12.5 g/dL outside 
of the US, 1 retest CBC should be performed prior to SV2.  If retest Hb  is ≥11.0 g/dL in the US 
or >12.0 g/dL outside the US, the subject should not proceed with SV2.  If the Hb  at SV1 is 
>11.5 g/dL in the US or >12.5 g/dL outside of the US, the subject should not proceed with any further Screening at this time.  
7.4.2 Rescreening  
Subjects who fail to meet the qualifying criteria for Hb during a Screening period may be 
considered for rescreening at the discretion of the Investigator if it is felt that the subject’s status has progressed and that the subject may now qualify for the study.  Additionally, subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B
12 values may be considered 
for rescreening after receiving rep lacement therapy.  
Screening is limited to 3 attempts (initial Screening and 2 additional rescreening attempts).   
Subjects who fail to qualify for the study at the initial Screening visit will receive a new subject number for each rescreening attempt.  If rescreened, the subject will also sign a new informed consent form and will repeat all s creening procedures for each rescreening attempt.  
7.5 Study Completion, Subject Completion, Study Discontinuation, and Withdrawal of Subjects  
7.5.1 Study Completion  
The study will be considered completed (end of trial) when 631 MACE events have accrued over the 2 DD- CKD studies (Studies AKB -6548- CI-0016 and AKB-6548- CI-0017). 
7.5.2 Subject Completion  
A subject will be considered as having completed the study, regardless of whether they are on or off study medication (vadadustat or darbepoetin  alfa), if the subject is followed until the global 
study completion (end date of trial) .  A post- treatment follow -up either in person or via telephone 
should occur approximately 4 weeks after the EOT visit.  The need for rescue therapy does not 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 32 of 78 constitute study completion and is not a criterion for subject withdrawal from the study.  Also, 
the occurrence of a safety endpoint also does not constitute study completion and is not a 
criterion for subj ect withdrawal from the study or study medication (vadadustat or darbepoetin  
alfa).  
7.5.3 Entire Study Termination  
The entire study may be suspended or terminated by the Sponsor for safety or other 
unanticipated reasons or upon request of regulatory agencies.  C riteria for premature study 
termination or suspension are detailed in Section  14.1, Criteria for Premature Ter mination or 
Suspension of the Study . 
7.5.4 Individual Study Site Termination  
Study participation may be suspended or terminated at an individual investigational site for various reasons.  Criteria and procedures for premature termination or suspension of an investigational site are detailed in Section  14.2, Criteria for Premature Termination or 
Suspension of Investigational Study Sites  and Section  14.3, Procedures for Premature 
Termination or Suspension of the Study or Investigati onal Sites . 
7.5.5 Individual Subject Discontinuation 
During the course of this long- term study, it is anticipated that subjects may temporarily interrupt 
or permanently discontinue study medication (vadadustat or darbepoetin  alfa) or study 
participation for any of the following reasons: 
• Unacceptable toxicity or drug intolerability  
• Investigator discretion  
• Subject withdrawal of consent 
• Subject becomes pregnant  
• Receipt of a kidney transplant  
• Other reasons. 
Subjects who either temporarily interrupt or permanently discontinue study medication 
(vadadustat or darbepoetin  alfa) early or are withdrawn from the study prior to Week 52 should 
continue with the Schedule of Activities and safety assessments through Week  52 and should be 
followed for safety assessments  only after Week  52.  Subjects who stop study medication after 
Week  52 should be followed for safety assessments only for the remainder of the study (See 
Section  7.5.5.1, Temporary Interruption of Study Medication and Section 7.5.5.2, Permanent 
Discontinuatio n of Study Medication, and  Appendix A : Schedule of Activities ). 
Receipt of rescue therapy is not a reason for permanent study medication discontinuation.  While receiving ESA rescue, subjects must temporarily discontinue study medication (vadadustat or darbepoetin alfa), but should resume study medication once rescue therapy has ended, as detailed in Section  8.4.7, Rescue Therapy . 
As part of the informed consent process, only subjects who fully understand and agree to full participation and long- term follow -up should be consented to participate. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 33 of 78 7.5.5.1 Temporary Interruption of Study Medication 
Subjects who temporarily interrupt study medication (vadadustat or darbepoetin alfa) treatment 
after the first dose and prior to completion of the study will continue with study visits and assessments.  Unless contraindicated, treatment should be resumed wherever possible and 
routinely considered at every visit following study medication discontinuation.  If a subject does 
not return for a scheduled visit, every effort should be made to contact the subject. 
7.5.5.2 Perm anent Discontinuation of Study Medication 
If a subject wishes to discontinue study medication (vadadustat or darbepoetin  alfa) or withdraw 
from the study, the Investigator should encourage continued study participation, as described in Section  7.5.5.4, Procedures to Encourage Continued Study Participation.  A subject who 
permanently discontinues treatment will be recorded as a discontinuation on the case report form (CRF) , and the Investigator must document the primary reason for the discontinuation. 
Subjects who permanently discontinue study medication early or are withdrawn from the study 
prior to Week 52 should continue with the Schedule of Activities and safety assessments through 
Week  52 and should be followed for safety assessments only after Week 52.  Subjects who stop 
study medication after Week  52 should be followed for safety assessments only for the 
remainder of the study  (See Appendix A : Schedule of Activities ). 
For subjects who permanently discontinue study medication, the Investigator should resume standard of care treatment, including ESAs and iron therapy, as deemed appropriate.  
7.5.5.3 Complete Withdrawal from Further Study Visits/Assessments  
Subjects may request to be withdrawn from the study or may be withdrawn prior to completion only for the following reasons of: 
• Death  
• Withdrawal of informed consent (complete withdrawal of consent requires a subjec t’s 
refusal of ALL methods of follow-up noted in the informed consent form: procedures, participation in reduced procedures/study visits, telephone contact only or alternative 
contact only, source document or designated alternative contact, or access to me dical 
records from alternative sources)  
• Lost to follow-up (detailed procedures to prevent subjects from becoming lost to 
follow-up are provided in Section  7.5.5.5, Procedures to Prevent “Lost to Follow-up” , 
and these procedures must be followed by the Investigators, their staff, and all designated study personnel). 
7.5.5.4 Procedures to Encourage Continued Study Participation 
In all cases of impending study drug discontinuation or subject request for withdrawal, the Investigator should discuss with the subject their options of continuing in the study.  If a subject wishes to discontinue study medication (vadadustat or darbepoetin  alfa) or to withdraw from the 
study, the following procedures should take place: 
1. The Investigator should understand the subject’s motivation to discontinue or withdraw ( eg, 
study vi sit fatigue, study medication intolerability, etc .) and wherever possible make 
accommodations to prevent treatment discontinuation or complete withdrawal of consent and 
to maintain the fullest compliance with the protocol assessments (eg, provide necessary 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 34 of 78 travel reimbursement, in -home visits, alternate visit scheduling, including during weekends).  
If the subject’s wish is to discontinue study medication only, proceed to Step 2. 
2. Ask the subject, “Would you be willing to continue if your dose of medication was 
lowered?”  If the answer is “Yes”, titrate the subject’s dose down 1 level for vadadustat or reduce the dose or dosing frequency for darbepoetin  alfa.  Repeat this step if the subject 
continues to request withdrawal of consent.  If the answer is “No” or if, once the lowest dose is reached, the subject continues to request discontinuation from study medication, proceed to Step 3. 
3. Ask the subject, “If we temporarily interrupt your study medication would you be willing to later resume medication and contin ue with all visits and sample collections?”  If the answer 
is “Yes”, interrupt study medication but continue to follow all other study procedures for the subject until they restart treatment.  If the answer is “No”, proceed to Step 4.  
4. Ask the subject, “If we discontinue your study medication permanently, would you continue with all visits and sample collections?”  If the answer is “Yes”, discontinue study medication, continue with all other assessments until Week  52, and  then continue with safety assessment s 
only for the remainder of the study after Week  52.  If the answer is “No”, proceed to Step 5. 
5. If further study support, interruption, or permanent discontinuation of study medication does not resolve the subject’s issues, further accommodations such as less frequent visits or blood draws may be used, so long as adequate safety monitoring can be ensured for those continuing study medication treatments.  Less frequent visits or procedures should be offered only if they are required to maintain access to the subject’s medical information and/or to encourage the subject to continue in the study.  For subjects who are no longer on study medication after Week 52, study visits can be reduced to every 24 weeks for safety assessments only either in person or via telephone. 
7.5.5.5 Procedures to Prevent “Lost to Follow-up” 
The Investigator must make every effort to contact subjects who fail to return for scheduled 
visits so that they will not be declared “lost to follow -up.”  These actions must include, but are 
not limited to, the following: 
1. Contact all numbers for the subject and their listed contacts (to be collected in source at the 
subject’s entry into the study), as applicable.  This includes making calls after normal business hours or on holidays and weekends. 
2. Contact the subject’s primary care physician, referring specialist, pharmacist, and/or other 
healthcare professional (using the contacts provided by the subject at entry into the study), as applicable. 
3. Send a text, email, and postal mail with certified (return -receipt requested) letters to the 
subject’s addresses and all contacts, as applicable. 
4. Review available medical records/notes for details of hospitalizations, clinic visits, or other procedures which may indicate the status of the subject (as allowed through release of 
medical reco rd forms to be completed by the subject at study entry), as applicable. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 35 of 78 5. Utilize the internet to search for additional contact information (eg, reverse directory for 
phone numbers or new address information, Facebook, LinkedIn, or other social media for status updates), as applicable. 
6. Check local, regional, and national public records to locate the subject or search for mortality status as allowed by law, as applicable. 
Once these actions have been exhausted and documented, the Sponsor or the Sponsor ’s 
representative should be contacted for additional guidance. 
8 STUDY PRODUCT AND TREATMENT OF SUBJECTS  
8.1 Study Product, Supplies, and Storage  
Vadadustat for oral administration and darbepoetin  alfa for injection will be provided and 
shipped by the Sponsor or its designated supplier/distributor.  Both vadadustat and darbepoetin  
alfa will be supplied as open -label supplies.  All study medication supplies must be kept in a 
temperature-controlled, locked facility, accessible only to authorized study personnel.  
The Investigator or designated study personnel will be responsible for preparing study medication for dispensing to the subject ( Section  8.2, Dispensing Procedures ) and for study 
medication supply accountability ( Section  8.3, Product Accountability and Destruction).  
8.1.1 Vadadustat  
Vadadustat will be provided as 150 mg white to off-white, round, bi-convex film- coated tablets 
for oral administration.  The tablets will be packaged in high- density polyethylene bottles with 
child -resistant closures, polypropylene liner, and induction seal.  Labeling will be in accordance 
with curr ent Good Manufacturing Practices (GMP) and local regulatory requirements.  
Dose levels utilized in this study will include: 150  mg (1 tablet), 300 mg  (2 tablets), 450 mg 
(3 tablets), and 600 mg  (4 tablets) per  day.  
Vadadustat should be stored at a controlled room temperature of 15°C to  30°C (59°F to  86°F). 
8.1.2 Darbepoetin  Alfa  
Darbepoetin  alfa will be provided in its commercially -approved primary packaging and stored 
per the approved local product label. 
See the approved darbepoetin alfa local product label for further description and detail. 
8.2 Dispensing Procedures  
The Investigator will maintain  record of all vadadustat tablets and darbepoetin  alfa injections 
dispensed to and returned from each subject during the study.  Subjects will receive either 
vadadustat or darbepoetin alfa according to the randomization assignments provided via the IWR system (see Section  8.4.2 , Randomization).  
8.2.1 Dispensing of Vadadustat 
Subjects will be provided with a supply of vadadustat at the Baseline visit according to the IWR system assignment.  Resupply of additional vadadustat at subsequent visits will be managed via the IWR system and will be dependent on the current dose level of vadadustat and the num ber of 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 36 of 78 tablets remaining in the subject’s current vadadustat supply at a given study visit 
(Section  8.4.4.1, Vadadustat Dosing and Dose Adjustment Guidelines ).  Subject s will be 
instru cted to finish 1 bottle before opening a new bottle. 
At the Baseline visit, study subjects will be provided with 1  bottle of vadadustat.  Each bottle of 
vadadustat will contain 100 tablets of vadadustat (150 mg /tablet).  
Subjects should be instructed to bring unused vadadustat and empty bottles to each study visit for 
product accountability.  Empty bottles will be collected at these study visits.  Previously dispensed bottles (whether opened or unopened) with remaining tablets may be redispensed to the subject during the dosing phase of the study. 
8.2.2 Dispensing of Darbepoetin  Alfa  
The initial darbepoetin alfa dose will be  dispensed accordi ng to the IWR system assignment.  
Dispensing of additional darbepoetin alfa at subsequent dosing visits will be managed by the 
IWR sy stem ( Section  8.4.4.2, Darbepoetin  Alfa Dosing and Dose Adjustment Guidelines ). 
8.3 Product Accountability and Destruction  
Product accountability should be an ongoing process throughout the study.  All study medication (vadadustat and darbepoetin  alfa) must be accounted for and any discrepancies explained.  The 
Investigator or designated study personnel are respons ible for keeping accurate records of the 
clinical supplies received from the Sponsor, all supplies retained in inventory at the investigative site, and study medication dispensed to or returned from each subject.  Records will be maintained that accurately  reflect the drug accountability of vadadustat and darbepoetin alfa at 
all times.  
Proper drug accountability includes, but is not limited to: 
• Continuously monitoring expiration dates if expiry date or retest date is provided to the 
Investigator 
• Frequently verifying that actual inventory matches documented inventory 
• Verifying that the log is completed for all drug received and that all required fields are complete, accurate, and legible.  
If any dispensing errors or discrepancies are discovered, the Sponsor must be notified 
immediately.  
During the study, the Investigator will be notified of any expiry dates or retest date extensions of clinical study material.  If an expiry date notification is received during the study, the investigative site must complete all instructions outlined in the notification, including segregation of expired clinical study material for return to the Sponsor or its designee for destruction. 
Prior to investigative site closure and at appropriate intervals during the study, a representa tive 
from the Sponsor will perform clinical study material accountability and reconciliation.  
At the end of the study, the Investigator will retain all original documentation regarding clinical 
study material accountability, return, and/or destruction, and copies will be sent to the Sponsor. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 37 of 78 All unused and/or partially used vadadustat or darbepoetin alfa should be returned to the Sponsor 
or destroyed at the investigational site, as specified by the Sponsor.  Appropriate records of the disposal will be documented and maintained.  No unused vadadustat or darbepoetin  alfa may be 
disposed of until fully accounted for by the Sponsor’s monitor (or designee).  Empty containers may be disposed of according to local procedures. 
8.4 Treatment of Subjects  
8.4.1 Treatment  Group A ssignments  
Subjects will be randomized in a 1:1 ratio via the IWR system to either: 
• Vadadustat (starting dose of 2 tablets once daily [300 mg/day])  
• Darbepoetin  alfa:  initial dose as follows  
o For subjects already on darbepoetin, the initial dosing regimen in the study should 
be based on the prior dosing regimen. 
o For subjects taking other ESAs, the initial dose of darbepoetin should be based on the approved local product label (for adult patients with CKD on dialysis). 
Target enrollment for each treatment group is approximately 1100 subjects.  
8.4.2 Randomization 
This study will be open to approximately 2200 subjects with DD -CKD with Hb  between 8.0 and 
11.0 g/dL (inclusive) in the US and between 9.0 and 12.0 g/dL  (inclusive ) outside of the US. 
Using an IWR system, eligible subjects will be assigned using permuted block randomization and a 1:1 ratio to either vadadustat or darbepoetin alfa during their Baseline visit.  
To maintain balance between vadadustat -treated and darbepoetin  alfa-treated  subjects, 
randomization will be stratified with respect to: 1) geographic region (US v ersus EU v ersus 
ROW);  2) New York Heart Association CHF Class (0 or I versu s II or III ); and 3) s tudy entry Hb 
(<10.0 versus ≥10.0 g/dL). 
8.4.3 Blinding 
This will be an open-label study.  Treatment assignment will be done through the IWR system 
and the Investigator will not be aware of which treatment will be assigned next.  Treatments will 
be administered in an open-label fashion; however, the Sponsor and CRO study teams will be blinded to the randomization codes.  Because Hb values are objective and will be measured via a 
central laboratory for all efficacy endpoints, efficacy assessments are not considered to be subject to bias with an open- label design.   In addition, the study will involve blinded 
adjudication of MACE, the use of an IDMC, and an identical schedule of visits, procedures, and assessments for both treatment groups in order to reduce the potential for bias.  However, certain personnel directly involved in medical oversight of the study, regulatory reporting of safety information, and on- site monitoring activities may become unblinded to the treatment 
assignments of individual subjects during the course of the study.  In addition, in order to reduce subjectivity of dose adjustment, adjustments to doses for vadadustat and darbepoetin alfa will be guided by an IWR system based on Hb  concentration and programmed Dose Adjustment 
Algorithms.  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 38 of 78 In geographies where regulatory approval does not require a formal analysis of MACE, efficacy  
and safety  analyses may be performed upon the completion of 52 weeks of post-randomization 
follow-up in a sufficient number of subjects to support registration in that geography.  The 
unblinding of the treatment assignme nts for this analysis will be detailed in the Statistical 
Analysis Plan (SAP).  The EAC will remain blinded throughout the full course of the study. 
8.4.4 Dosing and Dose Adjustment Guidelines 
Dosing will be initiated at the Baseline visit, and the first dose of  study medication (vadadustat 
or darbepoetin  alfa) will be administered at the investigative site after other Baseline visit 
procedures have been completed . 
Hemoglobin will be monitored via HemoCue throughout the study to determine if the dose of 
study med ication (vadadustat or darbepoetin  alfa) will be adjusted  or interrupted.  From Weeks 0 
to 12, Hb  will be obtained via HemoCue every 2 weeks for monitoring for dose adjustment.  
From Week  12 to Week 52, Hb  will be monitored every 4 weeks via HemoCue unless more 
frequent monitoring is clinically indicated or warranted based on dosing changes.  From 
Week  53 through the study end, Hb will continue to be monitored via HemoCue to determine if 
the dose of study medication will be adjusted or suspended.  He moglobin will also be assessed 
with a CBC through the central laboratory for efficacy and safety evaluations; however, dose adjustments should be based on the HemoCue Hb  value.  
The aim is to maintain a Hb level of 10.0 g/dL to 11.0 g/dL in the US and 10.0 g/dL to 12.0 g/dL 
outside of the US throughout the study. 
Adjustments to doses for vadadustat and darbepoetin alfa will be guided by an IWR system based on Hb  concentration and programmed Dose Adjustment Algorithms.  The programmed 
Dose Adjustment Algorithm for vadadustat will follow the Dose Adjustment Guidelines ( see 
Section  8.4.4.1, Vadadustat Dosing and Dose Adjustment Guidelines ).  The programmed Dose 
Adjustment Algorithm for darbepoetin  alfa will be based on the approved local product label  for 
adult patients with CKD on dialysis . 
When adjusting therapy, the Investigator will consider Hb  rate of rise, rate of decline, ESA 
responsiveness, and variability, as well as the subject’s clinical condition ( eg, recent illness, 
volume depletion, volume overload, etc.).   
In cases of extenuati ng clinical circumstances, the Investigator may elect to dose outside the 
IWR system dosing recommendation to maintain the Hb within the target range.  In such cases, 
the clinical circumstances must be documented in the subject’s record and IWR system.  
8.4.4.1 Vadadustat Dosing and Dose Adjustment Guidelines 
Subjects assigned to vadadustat will initiate dosing at 2 tablets taken orally once daily 
(300 mg/day).  Dose levels of vadadustat utilized in this study include 150, 300, 450, and 600 mg (available tablet strength is 150 mg).  
Dosing will be initiated at the Baseline visit and the first dose of vadadustat will be administered at the investigative site after other Baseline visit procedures have been completed.  Thereafter, vadadustat will be taken once daily on an outpatient basis.  Subjects may take vadadustat with or without food and should be instructed to swallow the tablet(s) whole, without chewing.  Subjects 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 39 of 78 should be instructed to take vadadustat at roughly the same time each day, preferably between 
7 AM an d 2 PM.  
During the study, vadadustat should be dosed according to the following Dose Adjustment Guidelines: 
For subjects enrolled in a US investigative site , the following guidelines should be followed: 
• Do not increase the dose more frequently than once every 4  weeks.  Decreases in dose 
can occur more frequently.  Avoid frequent dose adjustments. 
• If a dose adjustment is required to maintain Hb  at the desired level, the vadadustat dose is 
adjusted by 1 t ablet ( minimum dose of vadadustat is 150 mg/day [1 tabl et]; maximum 
dose of vadadustat is 600 mg/day [4 tablets])
. 
• If the Hb rises rapidly (eg, > 1.0 g/dL  in any 2 -week period), reduce the dose of 
vadadustat by 1 tablet.  
• If the Hb falls below 10.0 g/dL , increase the dose of vadadustat by 1 tablet.  
• If the Hb exceeds 11.0 g/dL , interrupt vadadustat until the Hb  decreases to 11.0 g/dL or 
less then resume dosing of vadadustat with 1 fewer tablet. 
For subjects enrolled in investigative sites outside of the US  (non-US), the following guidelines 
should be followed: 
• Do not increase the dose more frequently than once every 4 weeks.  Decreases in dose 
can occur more frequently.  Avoid frequent dose adjustments. 
• If a dose adjustment is required to maintain Hb  at the desired level, the vadadustat dose is 
adjusted by 1 tablet (minimum dose of vadadustat is 150 mg/day [1  tablet]; maximum 
dose of vadadustat is 600 mg/day [4  tablets]).  
• If the Hb rises rapidly (eg, > 1.0 g/dL  in any 2 -week period), reduce the dose of 
vadadustat by 1 tablet.  
• If the Hb falls below 10.0 g/dL , increase the dose of vadadustat by 1 tablet.  
• If the Hb exceeds 12.0 g/dL , reduce the dose of vadadusta t by 1  tablet.  If the Hb exceeds 
13.0 g/dL , interrupt vadadustat until the Hb  decreases to 12.5 g/dL or less then resume 
dosing of vadadustat with 1 fewer ta blet. 
8.4.4.2 Darbepoetin  Alfa Dosing and Dose Adjustment Guidelines 
For subjects randomized to darbepoetin alfa, the initial dose will be determined as follows: 
• For subjects already on darbepoetin, the initial dosing regimen in the study should be 
based on the prior dosing regimen. 
• For subjects taking other ESAs, the initial dose of darbepoetin should be based on the 
approved local product label for adult patients with CKD on dialysis. 
When adjusting therapy, the Investigator will consider Hb  rate of rise, rate of decline, ESA 
responsiveness, and variability, as well as the subject’s clinical condition (eg, recent illness, 
volume depletion, volume overload, etc.).  In cases of extenuating clinical circumstances, the Investigator may elect to dose outside the IWR system dosing recommendation for initial 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 40 of 78 darbepoetin alfa dose, dosing frequency, and dose adjustment to maintain the Hb  within the 
target range.  In such cases, the clinical circumstances must be documented in the subject’s  
record and IWR system.  
In gener al, darbepoetin  alfa will be dosed intravenously for subjects on chronic hemodialysis and 
SC for subjects receiving peritoneal dialysis and in accordance with the approved local product 
label.  Each subject will receive their first dose of darbepoetin alfa at the Baseline visit.  
Following dose conversion, darbepoetin alfa will be dosed IV or SC, with dose adjustments guided by an IWR system implementing a Dose Adjustment Algorithm based on the approved darbepoetin alfa local product label.  Subsequent admi nistration of darbepoetin  alfa may occur at 
the clinic/investigative site  or may be self -administered at home per regional standard of care 
and/or based on dialysis modality (hemodialysis or peritoneal dialysis).  Darbepoetin alfa dosing is independent of the study visit schedule, and the dosing schedule may shift per local standard of care, the patient’s dialysis schedule, and country specific darbepoetin alfa dosing guidelines. 
8.4.5 Late or Missed Doses  
Subjects on vadadustat should be instructed to take the study medication at roughly the same 
time each  day, preferably between 7  AM and 2 PM.  If a dose is forgotten, subjects should be 
instructed to take the dose as soon as they remember during the same day.  If a forgotten dose is not remembered on the same day, the subject should skip the dose and resume the normal dosing 
schedule the following day.  Subjects should not double-up on missed doses. 
Subjects on darbepoetin alfa should be instructed to take the study medication, including 
handling of late or missed dosed, as described in the approved local product label. 
Subjects should be questioned regarding dosing compliance and whether they have questions or 
have experienced any problems related to the dosing of study medication (vadadustat or darbepoetin alfa) . 
8.4.6 Iron Supplementation 
Investigators should prescribe iron supplementation ( IV, oral, or intradialytic ) as needed during 
the study to maintain ferritin ≥100 ng/mL and TSAT ≥20%.  The use of iron-based phosphate binders (eg, ferric citrate) is permitted. However, the duration, dosage, and frequency of 
intradialytic iron should be documented in CRF. 
Subjects already receiving oral iron supplementation as part of their treatment plan may continue 
their current treatment regimen.  For subjects who are on peritoneal dialysis, oral iron supplementation is allowed per local guidelines and routine practice.   
Important : Because of the potential for iron to reduce the bioavailability of vadadustat, the 
study medication should not  be administered concurrently with an oral iron supplement 
(including multivitamins containing iron).  The subject should be instructed to take any oral iron supplement at least 2 hours before or 2 hours after the dose of vadadustat . 
8.4.7 Rescue Therapy  
To ensure the safety of study subjects and to standardize the use of rescue in the study, rescue therapy guidelines are provided. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 41 of 78 8.4.7.1 Red Blood Cell Transfusion 
Investigators should use their local institution’s transfusion guidelines when determining whether 
to transfuse a study subject.  In general, in the event of an acute or severe loss of blood, an RBC transfusion should be administered as clinically indicated.  In less severe instances but where there may be worsening of anemia or moderate to severe symptoms of anemia, RBC transfusions are permitted at the discretion of the Investigator given the medical necessity.  Study medication 
(vadadustat or darbepoetin  alfa) may be continued during the RBC transfusion period. 
8.4.7.2 Erythropoiesis- stimulating Agent Rescue (Optional)  
Starting at Week  6, subjects in both treatment arms will be allowed (although will not be 
required) to have their Hb rescued with ESA therapy.  Drug product and supplies for ESA rescue 
will not be provided by the Sponsor. 
If possible, a subject on vadadustat should be on a maximum dose of vadadustat for 2 weeks 
prior to ESA rescue.  A subject on darbepoetin  alfa may rescue with another ESA per the 
standard of care.  To qualify for ESA rescue, a subject must fulfill ALL of the following: 
• The subject has experienced a clinically significant  worsening of their anemia or 
symptoms of anemia (eg, fatigue, weakness, shortness of breath, chest pain, confusion, or dizziness) compared with Baseline  
• The subject’s Hb is <9.0 g/dL  
The ESA rescue therapy should be administered  using an approved local product and dosing as 
per the local institution’s guidelines and per the approved local product label.  While receiving 
ESA rescue therapy, subjects must temporarily discontinue taking study medication (vadadustat 
or darbepoetin  alfa) .  Hemoglobin will be mo nitored throughout the study at scheduled visits as 
defined in the Schedule of Activities ( See Appendix A : Schedule of Activities ) using HemoCue, 
and ESA rescue treatment should be stopped when Hb  is ≥9.0 g/dL.  A minimum interval must 
be observed prior to restarting vadadustat after the last dose of rescue medication, and treatment may be resumed after the following intervals: 
• 2 days after last dose of epoetin alfa rescue. 
• 7 days after last dose of darbepoetin  alfa rescue. 
• 14 days after last dose of methoxy polyethylene glycol- epoetin beta rescue.  
Following ESA rescue, the study medication should be resumed at the same dose as previously used and adjusted according to the Dose Adjustment Guidelines ( Section  8.4.4, Dosing and Dose 
Adjustment Guidelines ). 
8.4.8 Phlebotomy 
If a subject’s Hb exceeds 14.0  g/dL or the rate of rise of Hb raises concern to the Investigator, 
the subject may be phlebotomized based on the Investigator’s judgment.  The method of phlebotomy will be in accordance with the local institution’s guidelines and standard clinical practice.  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 42 of 78 8.4.9 Treatment Compliance  
Subjects will be questioned regarding dosing compliance and whether they have questions or 
have experienced any problems related to the dosing of study medication (vadadustat or darbepoetin alfa).  The Investigator will also maintain drug accountability logs itemizing all study medications dispensed to and returned from each subject during the study.  Treatment compliance will be determined from these forms along with the  subject questioning and the study 
medication dispensing CRFs. 
Subjects who miss doses will be counseled on the importance of compliance. 
Subjects will also be questioned regarding the timing of their last dose of vadadustat prior to the 
PK samples at the Week 4, 12, 28, and 52 study visits.  The date and time of these doses will be recorded on the CRF. 
8.4.10 Continuation of Treatment 
Subjects may receive study medication (vadadustat or darbepoetin  alfa) up until the EOT visit.  
8.5 Prior and Concomitant Therapy  
8.5.1 General  
All medications  (except those routinely administered as part of the dialysis procedure or flus hes 
used for routine catheter maintenance) taken within 30 days prior to the start of study medication 
and during the study should be recorded on the appropriate CRF.  In addi tion, the ESA , blood 
transfusion, and iron treatment regimen prior to randomization and the date of last dose will be 
recorded.  
8.5.2 Erythropoiesis- stimulating Agents  
For all subjects, it is recommended that no additional ESA doses be administered after Screening visit 2 (SV2) and prior to the Randomization visit.  Non-protocol ESAs are prohibited from  
Randomization until the end of the study, unless the subject is  receiv ing ESA rescue therapy  or 
will permanently discontinue study treatment.   
8.5.3 Transfusions 
Documen tation of transfusions will be collected.  The receipt of any transfusions for 4 weeks 
prior to Screening will be recorded. 
8.5.4 Dialysis Treatment and Renal Replacement Therapy  
Information on dialysis treatment including dialysis vascular access type, dialysis  adequacy , and 
history of and changes in renal replacement therapies will be collected as described in  Section  9, 
Study Procedures and Schedule of Activities  and Appendix A : Schedule of Activities . 
8.5.5 Investigational Medications 
Study subjects should not have received any investigational medications or participated in an 
investigational study within 30 da ys or 5  half-lives of the investigational medication, whichever 
is longer, prior to the Screening visit.   In addition, subjects should not have participated in a 
study with another HIF- PHI. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 43 of 78 Additionally, subjects should not take another investigational medication while participating in 
this study.  
9 STUDY PROCEDURES AND SCHEDULE OF ACTIVITI ES 
Please see Appendix A : Schedule of Activities  for a detailed table of the Schedule of Activities.  
This study includes the following visits: 
• Optional P rescreening  
• Two Screening visits (SV1 and SV2) 
• Baseline/Randomization  visit ( Week 0/ Day 1) 
• Year 1 Treatment Period Study Visits/Evaluations while receiving study medication: 
Weeks 2, 4, 6, 8, 10, 12, (± 3 days ) and every 4 weeks thereafter until Week 52  (± 5 days) 
• Year 2 Treatment Period Study Visits/Evaluations while receiving study medication: 
Weeks 64, 76, 88, and 104 (± 10 days) 
• Year 3 Treatment Period Study Visits/Evaluations while receiving study medication: 
Weeks 116, 128, 140, and 156 (± 10 days) 
• Year 4 Treatment Period Study Visits/Evaluations while receiving study medication: 
Weeks 168, 180, 192, and 208 (± 10 days) 
• EOT visit (± 7 days) 
• Follow- up visit: 4 weeks after the EOT  (± 7 days). 
The following sections describe the procedures to be completed during the study.  Subjects are to be assessed by the same Investigator or investigative site personnel whenever possible. 
9.1 Administrative Procedures  
9.1.1 Informed Consent 
Informed consent must be obtained prior to the subject entering into the study and before any protocol-directed procedures are performed (including Screening activities).  Subj ects 
participating in the optional Pre screening visit must sign an abbreviated consent form or full 
consent form prior to Pres creening and, if eligible, may proceed with the Screening visit after 
full consent has been obtained (see Section  9.3.1, Prescreening Visit and Section  15.3, Subject 
Information and Consent  for additional details).  Additionally, subjects may be asked to provide 
a separate, optional consent to obtain and store a blood sample(s) for future genetic analyses. 
9.1.2 Documentation of Screen Failures  
Investigators will maintain documentation of prescreening  activities, to include information on 
potential study candidates evaluated and reasons that subjects  considered for the study did not 
qualify. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 44 of 78 Investigators must account for all subjects who sign informed consent and will maintain a log of 
subjects screened and indicate who was randomized or excluded .  If the subject is found not to be 
eligible for randomization, the reason(s) for ineligibility must be documented by the Investigator. 
Screening numbers assigned to subjects who fail Screening will not be re-used. 
9.1.3 Contraception and Pregnancy Avoidance Measures 
In nonclinical animal embryo -fetal development and fertility studies, there was no evidence of 
teratogenicity, no skeletal or visceral malformations, and no changes in male or female 
reproductive and fertility indices, or in sperm parameters.  In rats, decreased fetal body weight and reduced skeletal ossification were noted at the highest dose tested of 160 mg/kg/day.  Peri-postnatal development studies have not yet been conducted with vadadustat, and the re are 
no data on the transmission of vadadustat in breast milk or the effect of vadadustat on infants. 
Although the potential risk of vadadustat on the developing fetus is limited based on studies to 
date, the study requires that all subjects must agree t o use adequate contraception throughout the 
study and for 30 days after the last dose of study medication. 
Adequate contraception is defined as follows: 
• Female subjects must be surgically sterile, postmenopausal (no menses for at least one year), 
or have negative pregnancy test results at Screening (serum).  
• Female subjects not surgically sterile or postmenopausal (no menses for at least one year) 
and non- vasectomized male subjects must practice at least 1 of the following methods of 
birth control: 
• Total abs tinence from sexual intercourse (minimum one complete menstrual cycle prior 
to Screening visit, throughout the study, and for 30  days after the last dose of study 
medication)  
• A vasectomized partner  
• Hormonal contraceptives (oral, parenteral, or transdermal) for at least 3  months prior to 
study drug administration or intrauterine contraception/device, throughout the study, and 
for 30 days after the last dose of study medication 
• Double-barrier method (such as male condom, female condom, diaphragm, sponge, or 
cervical cap together with  spermicidal foam/gel/film/suppository)  starting at Screening 
Visit 1, throughout the study, and for 30 days after the last dose of study medication. 
9.1.4 Laboratory Accreditation and Reference Ranges  
The Investigator and the Sponsor will maintain a copy of the laboratory accreditation and the 
reference ranges for the central laboratory used for clinical laboratory evaluations.  Additionally, other accreditation(s) will be collected as required.  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 45 of 78 9.2 Study Procedures and Evaluations  
9.2.1 Clinica l Evaluations 
The following clinical evaluations will be conducted during the course of the study.  If the 
evaluations will occur on a hemodialysis day, the clinical evaluations should be completed 
before dialysis, if applicable. 
• Medical History, Demographics, and Physical E xamination: Medical history, 
demographic information, and physical examination (including height) will be collected 
at SV2.  Relevant medical history (with particular emphasis on previous medical 
conditions that may lead to exclusion) and significant ongoing medical conditions or diseases should be documented.  After SV2, an abbreviated, symptom- directed physical 
examination should be performed at the discretion of the Investigator, as clinically 
indicated.  
• Dialysis A dequacy :  Dialysis adequacy, as available from local collection, will be 
recorded in the CRF.  
• Dialysis Treatment : Hemodialysis vascular access type use and any changes at baseline 
and monthly; and changes in renal replacement therapy (from hemodialysis to peritoneal dialysis  or from in -center to home dialysis) 
• Vital S ign Measurement s: Vital signs will include  heart  rate and blood pressure.  Heart  
rate and blood pressure should be assessed in the seated position after 5  minutes of rest.  
Vital signs will be collected at SV1, S V2, Baseline, during study visits, and EOT and 
should be taken prior to blood draws when possible. 
• Weight : Dry weight will be collected for all subjects at SV2, at Weeks 12, 24, 36, and 52, 
yearly thereafter , and at the EOT visit.  For subjects on darbepoe tin alfa, subject s will be 
weighed for dosing as per the local standard of care. 
• 12-Lead E lectrocardiogram (ECG): A standard 12- lead ECG will be performed at 
Baseline.  The ECG should be obtained after the subject has been resting comfortably in a supine position for approximately 5 minutes and should be taken prior to vital sign assessments and blood draws when possible.  With the subject in a supine position, obtain the 12- lead tracing.  All ECGs will be r eviewed by the Investigator for the presence of 
rhythms of potential clinical concern.  A record of the tracing(s) will be made and retained with other source documents. 
• Completion of MACE Endpoint Questionnaire : At each post-randomization study visit, 
the subject must specifically be questioned regarding the occurrence of any potential MACE endpoint event since the last study visit.  IMPORTANT: The endpoint 
questionnaire electronic CRF must be completed in full at each visit even if no 
potential MACE endpo ints have occurred.   If a potential endpoint event is reported, 
the date of the event should be recorded and the appropriate source documents should be 
collected according to the endpoint packet checklist.  
• AE Assessments: Beginning with the first dose of study medication (vadadustat or 
darbepoetin alfa) and  through global study end (Follow-up visit), the Investigator and 
study personnel will review each  subject’s laboratory and clinical evaluation findings and 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 46 of 78 query the subject directly regarding AEs (see Section  10, Adverse Events ).  Subjects 
must be followed for AEs until the final required protocol visit (global study end date) or 
until all drug- related toxicities and SAEs have resolved (or are considered 
chronic/sta ble), whichever is later.  
• Concomitant Medication Recording : All medications (both prescription and 
non-prescription, and including vitamins, herbals, topicals, inhaled, and intranasal), taken within 30 days prior to the start of study medication (vadadusta t or darbepoetin  alfa) and 
ending at the final protocol required visit, should be recorded on the appropriate CRF.  At specified time  points, subjects will be asked whether they have started or discontinued 
any medication.   Changes in dosage and frequency will not be captured except for iron 
supplementation and ESA administration.  Routine m edications  and treatments used 
during each hemodialysis  session , such as heparin injections or saline flushes, are not 
required to be recorded  unless relevant for an AE or SAE .  In addition, the ESA, blood 
transfusion, and iron treatment regimen  prior to randomization and date of last dose will 
be recorded.  
9.2.2 Laboratory Evaluations 
Samples for laboratory assays will be sent to a central laboratory  for analysis.  Detailed 
instructions for the collection, processing, and shipment of laboratory samples will be provided by the Sponsor and the central laboratory.  If blood is collected on a hemo dialysis day, blood 
draws should be done prior to dialysis, if applicable .  The Investigator is responsible for 
reviewing laboratory results for clinical significance.  
The following laboratory evaluations will be conducted during the course of the study: 
• Pregnancy Test : A serum pregnancy test will be performed at SV2 for females of 
childbearing potential.  Additional serum or local urine (if possible) pregnancy tests may 
be conducted throughout the study in sufficient number, as determined by the Investigator or required by local regulations, to establish the absence of pregnancy during 
the study.  The SV2 results must be available and must be negative before the subject 
takes the first dose of study medication.  
• Complete Blood Count : A CBC with differential will be performed at Baseline and twice 
annually at Weeks  28, 52, 76, 104, 128, 156, 180, and 208.  At all other noted visits in 
Appendix A : Schedule of Activities , including SV1 and SV2, a CBC without differe ntial 
will be performed.  The CBC w ith differential will include: Hb, hematocrit, RBCs, mean 
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), and platelets. 
Hemoglobin assessed by central laboratory CBC will be used for evaluations of efficacy 
and safety, but should not be used for dose adjustments.  Rather, Hb  levels assessed by 
HemoCue should be used for dose adjustments, as described in Section  8.4.4, Dosing and 
Dose Adjustment Guidelines . 
If the Hb at SV1 is 11.1 to 11.5 g/dL in the US or 12.1 to 12.5 g/dL outside of the US, 1 retest CBC should be performed prior to SV2.  If the retest Hb is ≥11.0 g/dL in the US 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 47 of 78 or >12.0 g/dL outside the US, the subject should not proceed with SV2.  If the Hb at SV1 
is >11.5 g/dL in the US or >12.5 g/dL outside of the US, the subject should not proceed with any further Screening at this time.   Refer to Section  7.4.1, Retesting  and Section 
7.4.2, Rescreening  for further details regarding repeating laboratory measurements during 
the Screening period. 
• Point of C are Hb: Using HemoCue, Hb  will be monitored throughout the study to 
determine if the dose of study medication (vadadustat or darbepoetin  alfa) will be 
adjusted or suspended as described in Section  8.4.4, Dosing and Dose Adjustment 
Guidelines . 
• Reticulocyte C ount: An automated reticulocyte count (both absolute and percent) will be 
performed at Baseline and at Weeks 4, 12, 28, and 52. 
• Coagulation T ests: Blood samples will be drawn at Baseline to assess the prothrombin 
time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR).  
• Folate and Vitamin B 12: A blood sample will be drawn at SV2 t o assess the folate and 
Vitamin  B12 levels.  
• C-reactive Protein : A blood sample for C- reactive protein will be collected at the 
Baseline visit.  
• Serum Chemistry: Blood samples to assess serum chemistry will be collect ed at SV2, 
Baseline, and twice annually at Weeks 28, 52, 76, 104, 128, 156, 180, and 208, and EOT.  The serum chemistry will include the following assays: sodium, potassium, bicarbonate, chloride, calcium, magnesium, phosphorus, glucose, creatinine, blood urea nitrogen 
(BUN), creatine phosphokinase (CPK), uric acid, albumin, and total protein. 
• Liver Function Tests : Blood samples to assess liver function will be collected at SV2, 
Baseline, every 4  weeks through Week 28, every 8 weeks from Week 28 to Week 52, and 
twice annually  from Week 53 through the end of the study.  Blood samples will also be 
collected at the EOT visit.  Liver function tests will include: total bilirubin, alkaline phosphatase, ALT/SGPT, AST/SGOT, and lactate dehydrogenase (LDH). 
• Iron I ndices : Blood samples to assess the iron indices will be collected at SV1, Baseline, 
every 4  weeks through Week 12, every 8 weeks from Week 12 to Week 52, and every 
12 weeks from Week 53 through the end of the study.  Blood samples will also be collected at the EOT visit.  Assessments will include the following indices: ferritin, iron, 
TIBC, and TSAT. 
• Lipid Profile: Blood samples will be collected at the Baseline, Week 28, and Week 52 
visits to assess the cholesterol levels and will be tested for the follow ing types of lipids: 
total cholesterol, low -density lipoprotein (LDL), high-density lipoprotein (HDL), and 
triglycerides.  
• Biomarkers (hepcidin, vascular endothelial growth factor [VEGF]) : Samples for 
biomarker analysis will be drawn at the Baseline, Week 1 2, Week 28, and EOT visits. 
• Erythropoietin : Blood samples for EPO analysis will be obtained at Baseline and at 
Weeks 4, 12, 28, and 52. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 48 of 78 • PK Evaluations (samples to be drawn only for subjects randomized to vadadustat) : 
Plasma samples for PK evaluation will b e collected to analyze for both the parent 
compound (vadadustat) and its metabolites.  Collection time points for PK will include 
Study Day 1 ( Baseline), Weeks 4, 12, 28, and 52. 
The modality of dialysis (hemodialysis vs peritoneal dialysis) that the subject is receiving 
will determine the timing of the PK samples . 
For subjects receiving hemodialysis : 
Study Day 1 (Baseline visit): 
Ideally, vadadustat will be administered on Study Day 1 after the Baseline 
procedures, and the PK sample will be collected between 15 minutes to  1.0 hour 
after vadadustat  administration , but prior to start of the hemodialysis session.   
If it is not possible to administer vadadustat prior to start of the hemodialysis session, then the next preferred time would be to administer vadadustat just after completion of the hemodialysis session with the PK sample collected  between 
15 minutes to  1.0 hour after vadadustat administration .   
Otherwise, the first dose of vadadustat may be administered during the hemodialysis session and the PK sample  will be collected  between 15 minutes to 1.0 hour after 
vadadustat administration .  The times of the vadadustat dose, the PK sample, and the 
start and stop of the hemodialysis session will be documented. 
Weeks 4, 12, 28, and 52: Pharmacokinetic samples  will be collected pre- dialysis at the same time as the other 
study laboratory samples at the  Weeks 4, 12, 28, and 52 study visits.  T he date and 
time of the last dose of vadadustat prior to the PK sampling, as well as the timing of 
the PK sample collection,  will be documented. 
For subjects receiving peritoneal dialysis  (or subjects receiving in -home hemodialysis 
whose study visits are independent of their dialysis sessions): 
Study Day 1 (Baseline visit): Vadadustat will be administered on Study Da y 1 in the clinic after the Baseline 
procedures, and the PK sample will be collected between 15 minutes to  1.0 hour 
after vadadustat  administration .  The times of the vadadustat dose and the PK sample 
will be documented. Weeks 4, 12, 28, and 52: 
Pharmacokinetic sampling will be collected along with the other study laboratory 
samples at  the Weeks 4, 12, 28, and 52 study visits .  The date and times of 
vadadustat administration and PK sampling will be documented. 
• Exploratory Samples : Additional blood and urine samples will be collected at Baseline 
and Week  28 which may be used for exploratory measurement of biomarkers (eg, factors 
relating to the activation of the HIF pathway).  Subjects will also be asked to provide 
optional consent to obtain and store a blood sample for future genetic analyses (eg, DNA and mRNA).  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 49 of 78 9.3 Schedule of Activities  
The Schedule of Activities  (see Appendix A : Schedule of Activities ) shows the timing of 
planned study procedures.  Every effort should be made to adhere to this procedure schedule and 
all assessments should be completed at each study visit.  Where possible, study visits  should be 
performed and scheduled as part of a patients regularly scheduled dialysis  session. 
9.3.1 Prescreening Visit 
To minimize screen failures, there will be an optional Pres creening visit which will enable the 
subject to have a HemoCue Hb prior to proceedi ng with full Screening.  Subjects will need to 
sign an abbreviated Prescreening informed consent form or full consent form prior to Prescreening.  If the Pres creen HemoCue Hb is <10.0 g/dL  (inclusive) , the investigative site may 
proceed with SV1, which pre ferably will occur on the same day as Prescreening.  
9.3.2 Screening Visit s 
Subjects will need to sign a full consent form prior to Screening.  The Screening period is a maximum of 28 days in duration.  Two Screening visits (SV1 and SV2) must be performed within 28 days prior to d osing (Baseline visit/Day 1).  There must be a minimum of 4 days 
between the 2 Screening visits and a minimum of 4 days between SV2 and the Baseline visit. 
The Investigator will maintain a log of  subjects (both Pres creened and Screened) and indicate 
who of the pres creened  subj ects were brought in for informed consent and Screening and who of 
the Screened  subj ects were enrolled or excluded and the reason for exclusion. 
After obtaining informed consent and receiving a unique subject identification number, subjects 
will undergo a number of s creening activities.  
9.3.2.1 Screening Visit 1 (SV1)  
At SV1, the following activities/procedures will be performed:  
• Informed consent (including an additional optional consent for blood samples for future 
genetic analyses ). 
• Review of eligibility criteria  
• Vital signs including heart  rate and blood pressure (assessed in seated position after 
5 minutes of rest and prior to blood draws) 
• Laboratory procedures:  
o CBC (without differential)  
o Iron indices. 
If the Hb at SV1 is 11.1-11.5 g/dL in the US or 12.1-12.5 g/dL outside of the US, 1 retest CBC 
should be performed prior to SV2.  If the retest Hb  is ≥11.0 g/dL in the US or >12.0 g/dL outside 
the US, the subject should not proceed with SV2.  If the Hb  at SV1 is >1 1.5 g/dL in the US or 
>12.5 g/dL outside of the US, the subject should not proceed with any further Screening at this 
time.   Refer to Section  7.4.1, Retesting  and Section 7.4.2, Rescreening  for further details 
regarding repeating laboratory measurements during the Screening period. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 50 of 78 9.3.2.2 Screening Visit 2 (SV2)  
At SV2, the following activities/procedures will be performed:  
• Review of eligibility criteria  
• Physical examination  
• Demographics and medical history 
• Vital signs including heart rate and blood pressure (assessed in seated position after 
5 minutes of rest and prior to blood draws), as well as height and dry  weight 
• Laboratory procedures:  
o Folate and vitamin B 12 levels  
o CBC (without differential)  
o Serum chemistry  
o Liver function tests 
o Serum pregnancy test for females of childbearing potential (eligible  subjects will 
be advised to use an adequate contraceptive method)  
• Prior and current medication use. 
The mean of 2 Hb values from the central laboratory must be between 8.0 and 11.0 g/dL 
(inclusive) in the US or between 9.0 and 12.0 g/dL (inclusive) outside the US to qualify for 
inclusion into the trial.  If the subject’s Hb does not qualify after SV1 and/or SV2 ± 1 retest Hb, 
the subject should be considered a Screen failure.  
9.3.2.3 Subject Retesting  
Subjects who initially fail to qualify for the study based on laboratory test results may be retested once within the 28-day Screening period, per Investigator discretion ( Section  7.4.1, Retesting ). 
9.3.3 Subject Rescreen ing 
Subjects who fail to meet the qualifying criteria for Hb during the Screening period may be 
considered for rescreening at the discretion of the Investigator if it is felt that the subject’s status has progressed and that the subject may now qualify for the study.  Additionally, subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B
12 values may be considered 
for rescreening after receiving re placement therapy.  Screening is limited to 3  attempts (initial 
Screening and 2 additional rescreening attempts) ( Section  7.4.2, Rescreening ) and the Inclusion 
Criteria for initiating  chronic maintenance dialysis within 16 weeks prior to Screening must 
continue to be met based on the date of the Rescreening visit. 
9.3.4 Baseline Visit ( Day 1)  
The Baseline visit must be performed within 28  days of the 2 Screening visits (SV1 and SV2) 
and a minimum of 4 days must elapse between the last Screening visit (SV2) and the Baseline 
visit.  
At the Baseline visit, the following activities/procedures  will be performed: 
• Randomization 
• 12-lead ECG (prior to vital sign assessments and blood draws) 
• Vital signs including heart rate and blood pressure (assessed in seated position after 
5 minutes of rest and prior to blood draws) 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 51 of 78 • Laboratory Procedures:  
o Coagulation Tests 
o C-reactive protein  
o CBC (including differential)  
o Reticulocyte count  
o Serum chemistry   
o Liver function tests 
o Iron indices 
o Lipid profile 
o EPO  
o Biomarkers (hepcidin, VEGF) 
o PK (see Section 9.2.2, Laboratory Evaluations; samples to be drawn only for 
subjects randomized to vadadustat) 
o Exploratory samples 
• Review of medical history for new conditions since Screening visit 
• Medication use since Screening visit  
• Study medication assessments and procedures:  
o Subject will take their first dose of study medication at the investigative site during the Baseline visit 
o Hb by HemoCue
 for dose initiation  
o Assess:  
• Hemodialysis vascular access type use changes  
• Renal replacement therapy changes  
o Dialysis adequacy, as available from local collection  
o Vadadustat dispensing 
o Darbepoetin  alfa dispensing (per approved local product label)  
o Iron supplementation as needed to maintain ferritin ≥100 ng/mL and TSAT ≥20% (per local product label; see Section  8.4.6, Iron Supplementation) 
o Visit registration in IWR  
• Safety assessments:  
o AE assessment as needed (after receiving the first dose of study medication). 
9.3.5 Year 1 Treatment Period Visits  (Day 2 through Week 52) 
During the Year  1 Treatment Period v isits at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 
44, 48, and 52, the following activities/procedures will be performed: 
• Vital signs including heart rate and blood pressure (assessed in seated position after 
5 minutes of rest and prior to blood draws) 
• Dry weight (Weeks 12, 24, 36, and 52) 
• Laboratory procedures:  
o CBC (Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52; 
differential at Weeks 28 and 52) 
o Reticulocyte count (Weeks 4, 12, 28, and 52) 
o Serum chemistry (Weeks 28 and 52) 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 52 of 78 o Liver function tests (Weeks 4, 8, 12, 16, 20, 24, 28, 36, 44, and 52) 
o Iron indices (Weeks 4, 8, 12, 20, 28, 36, 44, and 52) 
o Lipid profile (Weeks 28 and 52) 
o EPO (Weeks 4, 12, 28, and 52) 
o Biomarkers (Weeks 12 and 28) 
o PK (Weeks 4, 12, 28, and 52; see Section  9.2.2, Laboratory Evaluations ; samples 
to be drawn only for subjects randomized to vadadustat) 
o Exploratory samples (Week 28) 
• Record date and time of subject’s last dose of vadadustat prior to the PK sample 
(Weeks  4, 12, 28, and 52) 
• Safety assessments:  
o AE assessment  
o RBC transfusions and ESA rescue collection  
o Therapeutic phlebotomy collection 
o MACE endpoint questionnaire 
• Medication assessments and procedures:  
o Review of concomitant medications  
o Hb by HemoCue for dose adjustment 
o Assess:  
 Hemodialysis vascular access type use changes  
 Renal replacement therapy changes  
o Dialysis adequacy, as available from local collection  
o Drug reconciliation: Study medication (vadadustat or darbepoetin  alfa) 
reconciliation will be conducted per the pharmacy manual instructions. 
o Visit registration in IWR  
o Vadadustat dispensing as needed per Section  8.2.1 , Dispensing of Vadadustat  
o Darbepoetin  alfa dispensing (per  approved local product label) 
o Iron supplementation as needed to maintain ferritin ≥100 ng/mL and TSAT ≥20% 
(per local product label; see Section  8.4.6, Iron Supplementation) 
o Question subject regarding dosing compliance and whether they have questions or have experienced any problems related to the dosing of study medication (vadadustat or darbepoetin  alfa) . 
9.3.6 Year 2 Treatment Period Visits  (Weeks 53 through 104) 
During the Year 2 Treatment Period v isits at Weeks 64, 76, 88, and 104, the following 
activities/procedures will be performed:  
• Vital signs including heart rate and blood pressure (assessed in seated position after 
5 minutes of rest and prior to blood draws)  
• Dry weight (Week 104) 
• Laboratory Procedures: 
o CBC (Weeks 64, 76, 88, and 104; differential at Weeks 76 and 104) 
o Serum chemistry (Weeks 76 and 104) 
o Liver function tests (Weeks 76 and 104) 
o Iron indices (Weeks 64, 76, 88, and 104) 
• Safety assessments:  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 53 of 78 o AE assessment  
o RBC transfusions and ESA rescue c ollection  
o Therapeutic phlebotomy collection 
o MACE endpoint questionnaire 
• Medication assessments and procedures:  
o Review of concomitant medications  
o Hb by HemoCue for dose adjustment 
o Assess:  
 Hemodialysis vascular access type use changes  
 Renal replacement therapy changes  
o Dialysis adequacy, as available from local collection  
o Drug reconciliation: Study medication (vadadustat or darbepoetin  alfa) 
reconciliation will be conducted per the pharmacy manual instructions. 
o Visit registration in IWR  
o Vadadustat dispensing as needed per Section  8.2.1 , Dispensing of Vadadustat  
o Darbepoetin  alfa dispensing (per approved local product label) 
o Iron supplementation to maintain ferritin ≥100 ng/mL and TSAT ≥ 20% (per local 
product label; see Section  8.4.6, Iron Supplementation) 
o Question subject regarding dosing compliance and whether they have questions or 
have experienced any problems related to the dosing of study medication (vadadustat or darbepoetin  alfa) . 
9.3.7 Year  3/4 Treatment Period Visits  (Weeks 116 through 208) 
During the Year 3/4 Treatment Period visits  at Weeks 116, 128, 140, 156, 168, 180, 192, 
and 208, the following activities/procedures will be performed: 
• Vital signs including heart rate and blood pressure (assessed in seated position after 5 minutes of rest and prior to blood draws) 
• Dry weight (Weeks 156 and 208) 
• Laboratory Procedures:  
o CBC (Weeks 116, 128, 140, 156, 168, 180, 192, and 208; differential at Weeks  128, 156, 180, and 208) 
o Serum chemistry (Week s 128, 156, 180, and 208) 
o Liver function tests (Weeks 128, 156, 180, and 208) 
o Iron indices (Weeks 116, 128, 140, 156, 168, 180, 192, and 208) 
• Safety assessments:  
o AE assessment  
o RBC transfusions and ESA rescue collection  
o Therapeutic phlebotomy collection 
o MACE endpoint questionnaire 
• Medication assessments and procedures:  
o Review of concomitant medications  
o Hb by HemoCue for dose adjustment 
o Assess:  
 Hemodialysis vascular access type use changes  
 Renal replacement therapy changes  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 54 of 78 o Dialysis adequacy, as available from local collection  
o Drug reconciliation: Study medication (vadadustat or darbepoetin  alfa) 
reconciliation will be conducted per the pharmacy manual instructions. 
o Visit registration in IWR  
o Vadadustat dispensing as needed per Section  8.2.1 , Dispensing of Vadadustat  
o Darbepoetin  alfa dispensing (per approved local product label)  
o Iron supplementation to maintain ferritin ≥ 100 ng/mL and TSAT ≥ 20% (per local 
product label; see Section  8.4.6, Iron Supplementation) 
o Question subject regarding dosing compliance and whether they have questions or 
have experienced any problems related to the dosing of study medication (vadadustat or darbepoetin  alfa) . 
9.3.8 End of T reatment  Visit 
End of treatment  evaluations will be performed when the study is ended.  Subjects who 
prematurely discontinue study medication for any reason should attend all subsequent protocol-defined study visits and be continually monitored according to the Schedule of Activities for the duration of the study  (See Appendix A : Schedule of Activities ). 
At the EOT visit, the following activities/procedures will be performed:  
• Vital signs including heart rate and blood pressure (assessed in seated position after 
5 minutes of rest and prior to blood draws), as well as dry weight  
• Laboratory Procedures:  
o CBC (without differential)  
o Serum  chemistry  
o Liver function tests 
o Iron indices 
o Biomarkers (hepcidin, VEGF) 
• Safety assessments:  
o AE assessment  
o RBC transfusions and ESA rescue collection  
o Therapeutic phlebotomy collection 
o MACE endpoint questionnaire 
• Recording of concomitant medications 
• Assess:  
o Hemodialysis vascular access type use changes  
o Renal replacement therapy changes  
• Dialysis adequacy, as available from local collection  
• Drug reconciliation: Study medication (vadadustat or darbepoetin  alfa) reconciliation will 
be conducted per the pharmacy manual instructions. 
• Visit registration in I WR 
• Question subject regarding dosing compliance and whether they have experienced any 
problems related to the dosing of study medication (vadadustat or darbepoetin  alfa) . 
9.3.9 Follow-up Visit 
The F ollow-up visit will be conducted in person or via the telephone 4 weeks after the EOT visit.  
The following activities/procedures will be performed: 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 55 of 78 • AE assessment  
• RBC transfusions and ESA rescue collection  
• Therapeutic phlebotomy collection 
• MACE endpoint questionnaire 
• Recording of concomitant medications 
• Dialysis adequacy, as available from local collection  
10 ADVERSE EVENTS 
10.1 Definitions  
10.1.1 Adverse Events  
For the purposes of this study, an AE is any untoward medical occurrence (including an 
abnormal laboratory finding) that occurs in the protocol-specified AE reporting period; the event does not necessarily have a causal relationship with that treatment or usage.  
An AE includes medical conditions, signs, and symptoms not previously observed in the subject 
that emerge du ring the protocol-specified AE reporting period, including signs or symptoms 
associated with pre -existing underlying conditions that were not present prior to the AE reporting 
period. 
Adverse events therefore include the following:  
• All AEs, whether suspected to be causally related to study drug or otherwise 
• All AEs secondary to any medication overdose, medication error, abuse, withdrawal, 
sensitivity, or toxicity  
• Illnesses apparently unrelated to study drug, including the worsening of a pre- existing 
illnes s (see paragraph below on Pre-existing Conditions) 
• Injury or accidents.  Note that if a medical condition is known to have caused the injury 
or accident (eg, a fall secondary to dizziness), the medical condition (dizziness) and the 
accident (fall) should be reported as 2 separate AEs . 
• Abnormalities in physiological testing or physical examination findings that require 
clinical intervention or further investigation (beyond ordering a repeat [confirmatory] 
test) 
• Laboratory abnormalities that require clinical intervention or further investigation 
(beyond ordering a repeat [confirmatory] test) unless they are associated with an already reported clinical event.  Laboratory abnormalities associated with a clinical event reported as an AE (eg, elevated liver enzymes in a subject with jaundice) should be described under ‘ Comments ’ on the report of the clinical event rather than reported as 
separate AEs.  
The following guidelines are to be used when reporting AEs for this study: 
Medical Diagnoses  – Whenever possible, a medical diagnosis term should be used to report AEs 
instead of signs and symptoms due to a common etiology, as determined by qualified medical 
study staff.  For example, pneumonia should be the reported AE term, instead of fever and  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 56 of 78 dyspnea, when the diagnosis has been established.  Signs and symptoms should be reported as 
event terms only when the medical diagnosis remains unknown, and revised to a medical diagnosis term once it has been established. 
Procedures  – Diagnostic and therapeutic non-invasive and invasive procedures, such as surgery, 
should not be reported as AEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an AE.  For example, an acute appendicitis that begins during the AE reporting period should be reported as the AE and the resulting appendectomy noted under ‘ Comments ’. 
Pre-planned therapeutic procedures not associated with a new medical condition or worsening 
pre-existing condition should not be reported as AEs. 
Pre-existing Conditions  – In this study, a pre-existing condition (ie, a disorder present before 
the AE reporting period started and noted on the pretreatment medical history/physical examination form) should not be reported as an AE unless the condition worsens or episodes increase in frequency during the AE reporting period. 
Abnormal Test Findings – All laboratory test results will be reviewed by the Investigator.  The 
Investigator will utilize his/her  judgment in determining if out-of-range laboratory va lues are 
clinically significant and will denote this using the abbreviation “CS” on the laboratory report for 
source documentation.  Laboratory tests that are labeled as clinically significant  should be 
reported as AEs, either separately or as part of a description of a symptomatic AE.  If there are significant changes in a laboratory report from a previous visit that are determined to be clinically significant, these should also be reported as AEs.  Any abnormal laboratory value which requires treatment or  further diagnostic testing and/or results in discontinuation from study 
should be reported as an AE .  An expected laboratory abnormality from a condition that is part of 
the medical history is not considered clinically significant for the purposes of the study unless it represents a worsening of the condition. 
Abnormalities in ALT, AST , and Total Bilirubin  – Abnormalities in ALT, AST , and total 
bilirubin should be reported to the Sponsor’s Medical Monitor or CRO designee within 24 hours 
of awareness as an SAE with ‘other medically important event’ criteria selected, if the following 
conditions are met: 
• New elevation in ALT or AST >3 times ULN, with or without an eleva tion of total serum 
bilirubin > 2 times ULN, AND  
• No other reason was identified that explains the increased ALT/AST with or without an 
increased bilirubin (eg, viral hepatitis, acute liver disease).  
If new elevations in ALT or AST >3 times ULN, with or without an elevation of total serum 
bilirubin > 2 times ULN are identified, the following steps are to be taken:  
• Temporary discontinuation of study medication ; 
• Repeat testing of ALT, AST, ALP , and total bilirubin, to be completed within 48 to 72 hours 
to confirm the abnormalities and to determine trend; 
• Study medication  should not be resumed until monitoring indicates abnormalities have 
resolved  or are stable. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 57 of 78 Worsening of Anemia – In this study, it is possible that some subjects may experience a 
worsening of anemia.  As the primary endpoint of this study assesses Hb  response, worsening of 
anemia is captured as part of this efficacy parameter.  Worsening of anemia should not be 
considered an AE unless the worsening of anemia is associated with a cause other than the 
subject’s CKD.  
Transplantation – During this long- term study, it is anticipated  that some subjects may receive 
a kidney transplant.  These events will not be recorded as AEs.  Subjects who discontinue study 
medication for receipt of a kidney transplant should continue with the Schedule of Activities and 
safety assessments as described  in Section 7.5.5.2, Permanent Discontinuation of Study 
Medication . 
10.1.2 Serious Adverse Events 
Each AE is to be classified by the Investigator as SERIOUS or NONSERIOUS.  An AE that meets 1 or more of the following criteria/outcomes is classified as serious:  
• Death  
• Life-threatening (see paragraph below on life-threatening) 
• In-patient hospitalization or prolongation of existing hospitalization (see paragraph below 
on hospitalization) 
• Persistent or significant disability/incapacity (see paragraph below on disability)  
• Congenital anomaly/birth defect 
• Is cons idered a medically important event not meeting the above criteria, but which may 
jeopardize a subject, or may require medical or surgical intervention to prevent one of the criteria listed in this definition.  
Serious also includes any other event that the Investigator or Sponsor judges to be serious.  If there is any doubt whether the information constitutes an AE or SAE, the information is to be treated as an SAE.  
Life-threatening – Any event in which the subject was at risk of de ath at the time of the event; 
‘life-threatening’ does not refer to an event which hypothetically might have caus ed death if it 
were more severe.  For example, drug-induced hepatitis that resolved without evidence of hepatic failure would not be considered life threatening, even though drug-induced hepatitis of a more severe nature can be fatal.  
Hospitalization – Hospitalization is defined as an overnight admission with observation of a 
minimum of 24 hours.  A hospitalization planned before the start of the study for a pre -existing 
condition that has not worsened during the AE reporting period does not constitute an SAE unless an untoward event occurs related to the procedure (eg, elective hospitalization for a total 
knee replacement due to a preexisting cond ition of osteoarthritis of the knee that has not 
worsened during the course of the study). 
Disability  – Defined as a substantial disruption in a person’s ability to conduct normal life 
functions. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 58 of 78 10.2 Eliciting Adverse Event Information 
The Investigator is to report all directly observed AEs and all AEs spontaneously reported by the 
study subject.  In addition, each study subject will be questioned about AEs at each visit following the initiation of treatment.  
10.3 Reporting 
Each AE is to be classified by the Invest igator as SERIOUS or NONSERIOUS.  
All AEs that occur in study  subjects during the AE reporting period specified in this protocol 
must be reported, whether or not the event is considered related to study medication (vadadustat or darbepoetin  alfa).  
10.3.1 Reporting Period  
The AE reporting period for this study begins upon receiving the first dose of study medication (vadadustat or darbepoetin  alfa) and ends at the final protocol-required visit. 
In addition, any AE that occurs subsequent to the AE reporting period that the Investigator assesses as related to the study medication should also be reported as an AE.  
10.3.2 Reporting AEs 
NONSERIOUS AEs are to be reported on the AE CRFs.  
10.3.3 Reporting SAEs 
Any SAE, regardless of causal relationship, must be reported to the Sponsor’s Medical Monitor or CRO designee within 24 hours after the Investigator becomes aware of the SAE.  Compliance with this time requirement is essential so that the Sponsor may comply with its regulatory obligations. 
The initial SAE report should be completed as fully as possible but should contain, at a minimum:  
• Subject number/ID, sex, and age/date of birth 
• The date of report 
• Name of the reporter  
• Name of the suspected medicinal product  
• A description of the event , including event term(s), seriousness criteria, and a clinical 
summary of the event  
• Causality assessment . 
Information about all SAEs (either initial or follow -up information) should be collected and 
recorded in English on the electronic SAE Report Form within the electronic data capture (EDC) 
system.  T he Investigator must assess the relationship to each specific component of the study 
treatment.  If the event meets serious criteria and it is not possible to access the EDC  system , a 
paper SAE Report Form should be sent to the CRO via email or fax, or the Investigator should call the CRO SAE hotline within 24 hours of being made aware of the SAE (reference the site manual for contact information).  When the EDC system becomes available, the SAE information must be entered within 24 hours of the system becoming available.  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 59 of 78 The Investigator must report follow-up information relating to an SAE to the Sponsor’s Medical 
Monitor or CRO designee within 24 hours of awareness  updating the electronic CRF with the 
new information or by submitting a paper SAE Report For m in the event that the EDC is not 
available.  When the EDC system becomes available, the SAE information must be entered within 24 hours.  The subject should be observed and monitored carefully until the condition resolves or stabilizes.  
All deaths are to  be thoroughly investigated and reported.  Autopsy reports and death certificates 
are to be obtained, if possible. 
The Sponsor and/or its designee are responsible for reporting SAEs to all applicable regulatory 
agencies and the central ethics committees wi thin the required timeline.  
The Investigators are responsible for submitting required safety information to their local Institutional Review Board (IRB) or Independent Ethics Committee (IEC) as per local 
regulations.  This information includes, but is not limited to, any safety alert letter received from the Sponsor and any SAEs occurring at their investigative site. 
10.3.4 Reporting Study Endpoints 
Investigators will be counseled to report any event that they assess as potentially being a study 
endpoint requiring adjudication (death, myocardial infarction, stroke, thromboembolic events, and hospitalization for HF ).  All study endpoint events will be submitted in a blinded fashion to 
the EAC for adjudication.  To protect the integrity of the trial, already  adjudicated events will not 
be unblinded or reported to either Health Authorities (HAs) or Investigator s as safety reports 
unless otherwise requested by HAs or Ethics Committees.  After study completion, these events will be included in the final analysis which will be unblinded and submitted to HAs with the study report.  
10.3.5 Relationship to Study Medication  
The causal relationship of the AE to study medication (vadadustat or darbepoetin alfa) will be assessed by both the Investigator and the Sponsor.   
The assessment of causal relationship to study drug should be evidence-based, and not based on 
the premise that all AEs are possibly causally related to study drug until proven otherwise.   
Examples of evidence that would suggest a causal relationship betw een the study drug and the 
AE include the occurrence of an AE that is uncommon and known to be strongly associated with drug exposure (eg, angioedema, hepatic injury, and Stevens -Johnson syndrome) or an AE that is 
uncommon in the population exposed to the drug. 
The causal relationship of the AE is assessed using a binary system, and AEs are classified as 
either ‘related’ or ‘unrelated;  
Related : There is ‘reasonable possibility’ that the drug caused the AE. The AE follows a 
reasonable temporal sequence from the time of drug administration. There is supportive evidence 
(facts) to suggest a possible causal relationship, irrespective of the degree of certainty between the observed AE and the drug. 
Unrelated : An AE does not follow a reasonable temporal sequence f rom administration of the 
product and/or there is no reasonable possibility that the drug caused the AE. This assessment 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 60 of 78 includes situations where the AE is related to other factors such as the subject’s clinical state, 
other therapeutic interventions, or concomitant drugs administered to the subject. 
Default assessments using the ‘related ’ category without supportive evidence for a causal 
relationship to study drug  are generally uninformative and do not contribute meaningfully to the 
development of the safety profile of the drug or to subject protection. Investigators are encouraged to choose the most plausible cause for the event(s) from the 
following list: medical history, lack of efficacy/worsening of treated condition, study treatment, other treatment ( concomitant, or previous), withdrawal of study treatment, administration error, 
protocol-related procedure, others (specify). 
10.3.6 Severity  
The Investigator will assess each AE as either MILD, MODERATE, or SEVERE using the 
following guidelines to describe the maximum severity of the AE:  
MILD: Does not interfere with subject's usual function 
MODERATE: Interferes to some extent with subject's usual function 
SEVERE:  Interferes significantly with subject's usual function 
Note that a severe AE is not necessarily a serious  AE.  For example, a headache may be severe 
in intensity, but would not be class ified as serious unless it met 1  of the criteria for serious events 
listed above. 
10.3.7 Follow-up of Unresolved Events 
All AEs should be followed until they are resolved or the Investigator assesses them as chronic 
or stable or the subject’s participation in the trial ends (ie, until a fin al report is completed for 
that subject).  
In addition, all SAEs and those nonserious events assessed by the Investigator as related to the 
study medication should continue to be followed even after the subject's participation in the trial 
is over.  Such events should be followed until they resolve or until the Investigator assesses them as “chronic” or “stable”.  Resolution of such events is to be documented on the appropriate CRF. 
10.4 Exposure In Utero  
A pregnancy in a female subject must be confirmed by a positive serum β human chorionic 
gonadotropin (β -HCG)  test.  
The study medication should be immediately discontinued once the pregnancy of a femal e study 
participant has been confirmed. 
If any study  participant becomes or is found to be pregnant while receiving a study medication 
(vadadustat or darbepoetin  alfa) or within 30 days of discontinuing the study medication, the 
pregnancy must be recorded on the Pregnancy Reporting Form/Exposure in Utero Form in EDC 
within 24 hours of awareness of the pregnancy or the Investigator should call the CRO SAE hotline within 24 hours of being made aware of the pregnancy. 
Pregnancy during this time frame of the fe male partner of a male subject should also be reported. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 61 of 78 The Pregnancy Reporting Form/Exposure in Utero Form must be completed with all known 
information regarding the pregnancy at the time of reporting.  Investigative site personnel will update the form with additional information regarding the pregnancy and the outcome of the pregnancy as it becomes available until the outcome of the pregnancy is reported. 
The Investigator will follow the subject (or female partner of a male subject) until completion of 
the pregnancy.  If the outcome of the pregnancy meets the criteria for classification as an SAE 
(ie, spontaneous abortion, stillbirth, neonatal death within 1 month of birth, or congenital anomaly [including that in an aborted fetus]), the Investigator should also follow the procedures for reporting a n SAE within 24 hours of awareness.  A pregnancy in and of itself is not 
considered an AE; however, unexpected complications are considered AEs. 
Additional information about pregnancy outcomes follows: 
• Note that “spontaneous abortion” includes miscarriage and missed abortion. 
• All neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality, as SAEs.  In addition, any infant death after 1 month that the Investigator assesses as related  or unrelated  to the in utero exposure to the study medication should 
also be reported. 
• In the case of a live birth, the “normality” of the newborn can be assessed at time of birth. 
• The “normality” of an aborted fetus can be assessed by gross visual inspection unless 
there are pre-abortion laboratory findings suggestive of a congenital anomaly. 
10.5 Special Situations  
Certain safety events, called ‘Special Situations’, that occur in association with study medication(s) may require reporting.  These Special Situations include, but are not limited to, the following: 
• Overdose of the medicinal product 
• Suspected abuse/misuse of the medicinal product 
• Inadvertent or accidental exposure to the medicinal product 
• Medication error involving the medicinal product (with or without subject exposure to the Sponsor ’s medicinal product [eg, name confusion]) 
• Drug -drug interaction . 
Special situations should be reported on the Special Situations CRF whether they result in an AE/SAE or not.  Special situations with associated AE/SAE should also be reported on the corresponding AE/SAE forms, following applicable AE or SAE process. 
11 DATA ANALYSIS  
Data collected throughout the study will be summarized using descriptive statistics and listed in 
by-subject listings.  Continuous variables will be summarized using number of subjects with 
data, mean, standard deviation, median, minimum, and maximum.  For categorical variables, the number and percentage of subjects in each category will be tabulated.  Summaries will be 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 62 of 78 provided by treatment group within appropriate analysis populations (as defined in Section  11.2, 
Study Analysis Populations ) and by time poi nt/time period , as appropriate.  
For Hb, Baseline will be defined as the mean of all qualifying Hb values collected prior to the 
first dose of study medication (vadadustat or darbepoetin  alfa).  For subjects rescreened, only 
values for the last Screening period will be used for establishing the Baseline.  For other 
parameters, unless otherwise specified, Baseline will be defined as the last available value prior to the first dose of study medication. 
Hemoglobin values as assessed through the central laboratory will be used for efficacy and safety 
evaluations; local HemoCue Hb values will be used only for dose adjustments. 
In geographies where regulatory approval does not require a formal analysis of MA CE, efficacy 
and safety analyses may be performed upon the completion of 52 weeks of post-randomization follow-up in a sufficient number of subjects to support registration in that geography.  Such analysis will be documented in a geography -specific SAP.  
11.1 Sample Size Determination  
The goal of this study is to demonstrate the efficacy and safety of vadadustat compared with darbepoetin alfa for the maintenance treatment  of anemia in subjects with DD -CKD.   The sample 
size is calculated to ensure sufficient power for testing both efficacy in this trial and the primary 
safety endpoints as part of a pooled analysis. 
11.1.1 Sample Size for the Primary Efficacy Endpoint 
The primary efficacy endpoint is defined as the mean change in Hb from Baseline (mean 
pretreatment Hb) to the average Hb over the primary evaluation period (mean Hb  from Weeks 24 
to 36, inclusive ).
 
The primary efficacy objective of this study is to show that vadadustat is noninferior to 
darbepoetin alfa within the noninferiority margin.  Noninferiority will be established based on a margin of -0.5 g/dL (for vadadustat minus darbepoetin  alfa).  
For the primary efficacy analysis in this study, it is assumed that the mean change from Baseline 
in Hb  for vadadustat will be the same as for darbepoetin alfa, and the common standard deviation 
for the mean change from Baseline is  assumed to be 1.5 g/dL.  Noninferiority will be established 
based on a 2-sided 95% confidence interval (CI) for the difference betwe en the vadadustat group 
and darbepoetin  alfa and using a noninferiority margin of -0.5 g/dL.  With these assumptions and 
approximately 1100 subjects per treatment group for the primary efficacy analysis, the 
noninferiority assessment will have > 99% power.  
11.1.2 Sample Size for the Primary Safety Endpoint 
The primary safety endpoint is the time from first dose of study medication  to the first 
(adjudicated) MACE (defined as all -cause mortality, non-fatal myocardial infarction, or non- fatal 
stroke). 
The primary safety analysis will be based upon all events that accrue over the 2 DD- CKD studies 
(Studies AKB -6548- CI-0016 and AKB -6548- CI-0017).  The sample size with respect to the 
MACE endpoint has been determined based on the number of events needed to demonstrate 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 63 of 78 noninferiority of the 2 -sided 95% CI  for the hazard ratio (vadadustat/darbepoetin alfa).  It has 
been calculated that 631  events will be required overall to have 80% power to establish 
noninferiority with a margin of 1.25, and 90% to establish noninferiority with a margin of 1.3 
evaluated with a 2 -sided 95% CI  assuming no difference between the treatments .  The power is 
>90% to establish a noninferiority margin of 1.25 if the hazard ratio is 0.95 favoring vadadustat.  A MACE rate of 12% annually is anticipated in both treatment arms based on a comprehensive review of available epidemiology and prospective clinical studies in the field.  With 1100 subjects per treatment group enrolled in this study, approximately 20 months for accrual, and up to 36 months of follow-up, approximate ly 85% of the needed MACE events ( 536) would 
be captured , assuming the dropout rate is negligible.  The remaining 15% of the needed MACE 
would be captured in Study AKB-6548- CI-0016. 
11.2 Study Analysis Populations  
The following analysis populations will be used in this study: 
• Randomized population: defined as all randomized subjects 
• Full analysis population: defined as randomized subjects receiving 1 or more doses of 
therapy  
• Per protocol (PP) population: defined as all randomized subjects who received study 
medication  (vadadustat or darbepoetin  alfa)  during the primary evaluation period, had at 
least 2 Hb assessments during the primary evaluation period , and received no rescue 
therapy in the 8  weeks  prior to the evaluation period 
• Safety population: defined as all subjects who received at least 1 dose of study medication  
Efficacy analyses will utilize the ra ndomized, full analysis, and PP populations while safety 
analyses will utilize the safety population.  
11.3 Analysis of Demographic and Pretreatment Variables  
Descriptive statistics will be generated for demographic and pretreatment variables  for each 
analysis p opulation defined in Section  11.2, Study Analysis Populations . 
Medical history terms will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) and summarized by System Organ Class and Preferred Term for each treatment group based on the safety population. 
11.4 Disposition of Subjects  
The number and percentage of subjects randomized and included in each analysis population will 
be summa rized by treatment and overall.  Reasons for excluding subjects from the analysis 
populations will be presented in a by- subject listing.  
The number of randomized subjects who completed each period of study medication treatment (Conversion and Maintenance, and Long -term T reatment), discontinued from study medication 
early, and completed or discontinued from the study and reasons for discontinuation will be 
summarized by treatment group and overall. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 64 of 78 11.5 Missing Data  
Subjects who stop study medication  treatment after randomization and prior to completion of the 
study should continue with planned study visits and assessments  unless they withdraw consent 
for participation in the study.  Similarly, subj ects will continue with study medication  and study 
procedures following the initiation of rescue therapy , with the exception that the subjects must 
discontinue taking study medication while receiving an ESA rescue therapy.  Treatment with 
study medication should be resumed after an appropriate interval  following the ESA rescue 
therapy as described in Section  8.4.7, Rescue Therapy .  Data will continue to be collected 
following initiation of the rescue therapy as per the study Schedule of Activities  (See Appendix 
A: Schedule of Acti vities ). 
All data collected during the study, including at any point after the initiation of rescue therapy as 
well as after early discontinuation of study medication treatment, will be us ed for the primary 
analysis as well as main analyses of all efficacy endpoints.  Sensitivity analyses, as described below, will be performed to assess an impact of rescue therapy on study conclusions. 
In the primary analysis of the primary efficacy endpoint, all available qualifying Hb 
measurements during the pretreatment period and during the primary evaluation period 
(Weeks  24 to  36) will be used to calculate an average Hb during each period respectively.  For 
any subj ect with no available Hb  measurements  during the primary evaluation period, the value 
(central laboratory data only) closest in time to the evaluation period will be used for the change 
from Baseline.  Given the design of this study where the subjects will continue to be assessed 
after early study medication discontinuation, i t is expected that only a minimal amount of 
missing data will be present and the primary analysis should not be substantially affected by the imputation.  
All data pertaining to the MACE endpoint collected at any point during the study, both during study medication treatment and post-study medication treatment discontinuation, and regardless of the rescue therapy, will be used for the primary analysis of the MACE endpoint and its individual components. 
Unless stated otherwise, missing data for all other secondary efficacy and safety endpoints will 
not be imputed and the analysis will be based on observed data.  For certain responder- type 
binary endpoints, subjects with no available data will be classified into one of the categories as 
described in the relevant sections below. 
11.6 Efficacy Analyses  
The primary efficacy endpoint as well as all key and other secondary endpoints will be 
summarized using descriptive statistics by treatment group, as well as by study visit and/or analysis period as appropriate.  Mean values of Hb as well as selected other  efficacy parameters 
will be plotted across study visits/periods by treatment group. 
11.6.1 Analysis of Primary Efficacy Endpoint  
The primary efficacy endpoint is defined as the mean Hb  change from Baseline (mean 
pretreatment Hb) to the mean  Hb from Weeks 24 to  36 (inclusive). 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 65 of 78 11.6.1.1 Primary Analysis of Primary Efficacy Endpoint  
The primary analysis will use an analysis of variance ( ANOVA ) stratified by the randomization 
strata .  Within this model the strata -specific differences between the treatments will be combined 
using weights proportionate to the stratum size.  A 2-sided 95% CI  for the difference between the 
vadadustat group and the darbepoetin alfa group will be obtained from this model. 
Noninferiority of vadadustat  to darbepoetin al fa will be established by comparing the lower limit 
of the 95% CI  for the difference between treatment groups ( vadadustat minus darbepoetin al fa) 
obtained from this model to the noninferiority margin of -0.5 g/dL . 
The primary analysis will be performed using the randomized population and the assigned 
treatment as described in Section  11.2, Study Analysis Populations .  All data collected during the 
study for subjects included in the randomized population at the time of analysis, including data 
collected at any point after the initiation of rescue therapy as well as after early discontinuati on 
of study medication treatment, will be used for the primary analysis.  Mis sing data will be 
handled by using the prior Hb data closest to the evaluation period, as described in Section  11.5, 
Missing Data . 
In geographies where regulatory approval does not require a formal analysis of MACE, efficacy and safety analyses may be perform ed upon the completion of 52 weeks of post-randomization 
follow-up in a sufficient number of subjects to support registration in that geography.  Details will be provided in a geography- specific SAP.  
11.6.1.2 Sensitivity Analyses of Primary Efficacy Endpoint 
The fo llowing sensitivity analyses will be conducted to investigate the impact of missing data 
and rescue treatment.  
• Primary analysis will be repeated with change from Baseline to the primary evaluation 
period in Hb  based upon the last Hb  value before rescue for subjects receiving any form 
of rescue (transfusion or ESA) prior to the primary evaluation period (ie, during the 
Conversion P eriod Weeks 0  to 23). 
• Primary analysis will be repeated using the full analysis population. 
• Primary analysis will be repeated using only subjects with available Hb data during the 
primary evaluation period, ie, excluding subjects with no available data during the primary evaluation period. 
• Primary analysis will be repeated using the PP population with the actual treatment 
received.  
11.6.2 Analysis of Key Secondary Efficacy Endpoints  
Secondary efficacy endpoints analyses will be performed using the randomized and full analysis 
populations and the assigned treatment as described in Section  11.2, Study Analysis Populations .  
Analysis for the key secondary efficacy endpoints will be repeated using the PP population with the actual treatment received.  
In order to control the overall Type I error rate, hierarchical testing procedures will be applied to the primary and secondary efficacy endpoints, and details will be provided in the SAP. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 66 of 78 11.6.2.1  Analysis of Mean Change in Hb  Value between Baseline (Mean Pretreatment Hb) and 
the Secondary Evaluation Period (Weeks 40 to 52) 
This endpoint will be analyzed using the same methodology as specified for the primary efficacy 
endpoint, including the same method of imputation in absence of any measurements during the secondary evaluation period (Weeks 40 to  52). 
Sensitivity analyses similar to those of the primary efficacy endpoint will be performed and details will be provided in the SAP. 
11.6.2.2 Analysis of Proportion of Subjects with Mean Hb  within the Target Range during the 
Primary Evaluation Period (Weeks 24  to 36) 
Each subject will be classified using a binary variable (“yes”/”no”) for the analysis of this endpoint.  A cl assification of “yes” will be assigned to any subject with a mean Hb within the 
target range during the primary evaluation period (Weeks 24 to  36).  All other subjects, including 
those with no available values during the primary evaluation period, will be classified to the “no” category.  The between -treatment difference will be summarized with a confidence interval 
which uses Cochran- Mantel -Haenszel (CMH) weighting.  
11.6.2.3 Analysis of Mean Weekly Dose of Iron: Baseline to Week  52 
For each subject, a mean weekly d ose (mg) of IV elemental iron administered at any time 
starting on Day 1 through Week 52 will be calculated based upon observed data.  It will be calculated as a total cumulative dose (mg) of IV elemental iron administered from Day  1 through 
Week  52 divided by the number of weeks the subject remained in the study up to the Week 52 
visit.  The between -treatment difference will be summarized with a confidence interval similar to 
those used for the primary endpoint. 
11.6.2.4 Analysis of Proportion of Subjects who R eceive RBC Transfusion(s) : Baseline to 
Week  52 
Each subject will be classified using a binary variable (“yes”/”no”) for the analysis of this 
endpoint.  A classification of “yes” will be assigned to any  subject receiving RBC transfusion(s) 
at any time starting on Day 1 through Week 52.  All other subjects will be classified to the “no” 
category.  The between -treatment difference will be summarized with a confidence interval 
which uses CMH weighting.  Time to first RBC transfusion will also be summarized.  
11.6.3 Analysis of Additional Secondary Efficacy Endpoints 
Descriptive summaries of all secondary efficacy endpoints will be presented using observed data without imputation.  Analyses will consist of the presentation of descriptive statistics by treatment group along with the presentation of 2-sided 95% CI s for the treatment differences.  
The descriptive summaries of the secondary endpoints will be made without stratification.  
11.7 Safety Analyses 
11.7.1 Analysis of MACE  
The primary safety endpoint, time to the first adjudic ated MACE, will be analyzed as [date of the 
first MACE – the date of first dose of study medication].  A MACE is defined as all- cause 
mortality, non-fatal myocardial infarction, or non-fatal stroke.  Subjects who have not 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 67 of 78 experienced a MACE by study closure will be censored on the date of their last study 
assessment.  The hazard ratio (vadadustat/ darbepoetin alfa) and its 95% CI  will be obtained from 
a stratified Cox proportional hazards model.  As this study has not been designed to provide a stand -alone assessment of MACE, this analysis will be considered a descriptive analysis.  A 
similar analysis as described for the primary analysis of the MACE endpoint will be performed with censoring of subjects 4 weeks following discontinuation of study treatment if they did not have a MACE prior to that time.  
The primary MACE analysis will be based upon all events that accrue over the 2 DD- CKD 
studies (Studies AKB-6548- CI-0016 and AKB-6548- CI-0017) (see Section  11.1.2, Sample Size 
for the Primary Safety Endpoint ). 
11.7.2 Analysis of Adverse Events 
Adverse even ts will be summarized using the number and percentage of subjects with AEs for 
all subjects in the safety population. 
All AEs will be coded using MedDRA.  Treatment-emergent and post- treatment AEs will be 
summarized by System Organ Class and Preferred Term  for each treatment group.  Adverse 
events will also be summarized by their maximum severity.  
Summaries will also be provided for the following types of AEs: 
• SAEs  
• Related AEs (including all categories for relationship to study medication other than “Unrelated”, as determined by the Investigator)  
• AEs leading to early discontinuation of study medication. 
11.7.3 Remaining Safety Endpoints 
The following safety endpoints will be analyzed using time to event methods: 
1) Individual components (death, myocardial infarction, or stroke) of MACE  
2) Thromboembolic events (defined as arterial thrombosis, DVT, PE, or vascular access 
thrombosis ). 
3) Hospitalization for heart failure  
For these endpoints the incidence ("yes"/"no") of the endpoint will be presented for each treatment arm.  K aplan -Meier curves will be presented for each endpoint as the time of endpoint 
free survival (ie, time until endpoint or death). 
The analysis of proportion of subjects with Hb >12.0 g/dL, >13.0 g/dL, or >14.0 g/dL 
post- Baseline will classify a  subject as a “yes” if:  
• Any value Hb >12.0 g/dL at any time after  Day 1  
• Any confirmed value Hb >12.0 g/dL at any time after  Day 1  
• Any value Hb >13.0 g/dL at any time after  Day 1  
• Any confirmed value Hb >13.0 g/dL at any time after  Day 1  
• Any value Hb >14.0 g/dL at any time after  Day 1  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 68 of 78 • Any confirmed value Hb >14.0 g/dL at any time after  Day 1 . 
A Hb  value above a set threshold will be considered as confirmed if there are 2 consecutive 
values above that threshold.  The second of the 2 consecutive assessments should be done at 
most 12 weeks after the first assessment.  Subjects with no available data post -Baseline will be 
excluded from this analysis.  All other subjects will be classified to the “no” category.  
The analysis of proportion of subjects with any Hb increase >1.0  g/dL within any 2 -week 
interval or >2.0 g/dL within any 4 -week interval post- Baseline will classify a  subject as a “yes” 
if at least 1 of the following criteria at any point after  Day 1 is met:  
• Hb increase >1.0 g/dL within any 2 -week interval  
• Hb increase >2.0  g/dL within any 4 -week interval . 
Subjects with no available data post- Baseline will be excluded from this analysis.  All 
other subjects will be classified to the “no” category.  
Observed values of continuous and categorical parameters and changes from Baseline for continuous parameters to each study visit will be summarized descriptively for vital signs and clinical laboratory results.  Graphical displays of selected laboratory parameters will also be provided. 
11.8 Additional Assessments 
11.8.1 Concomitant Medications 
Prior and concomitant medications will be coded using World Health Organization (WHO) Drug 
dictionary. 
Prior medications will be defined as any medications that were taken before the date of the first 
dose of study medication.  Concomitant medications will be defined as any medications taken at any time from the date of the first dose of study medication through the date of the last dose of the study medication.  
The total number of transfusions, ESA rescue therapies, and therapeutic phlebotomy collections will be summarized by period as well as post- Baseline overall.  
11.8.2 Biomarkers  
Biomarkers (hepcidin and VEGF) will be summarized descriptively at Baseline and by visit post- Baseline.  
11.8.3 Pharmacokinetics  
Descriptive and graphical summaries will be generated for PK measurements.  
12 DATA HANDLING AND RECORD KEEPING  
12.1 Case Report Forms /Electronic Data Capture 
This study will utilize an EDC system to manage data collection during this trial.  The system is fully C ode of Fe deral Regulations 21 part 11 compliant.  An EDC system contains certain 
functionality including, but not limited to, a graphical user interface to help facilitate data entry, 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 69 of 78 a data validation element to check user data, and a reporting function to assist with the review 
and analysis of data.  Case report forms available through this system are required and should be completed for each randomized subject.  
Any form of data from the electronic system are the sole property of the Sponsor and should not be made available in any form to third parties, except for authorized representatives of the Sponsor or appropriate regulatory authorities, without written permission from the Sponsor. 
The Investigator has ultimate responsibility for the accuracy, authenticity, a nd timely collection 
and reporting of all clinical, safety, and laboratory data entered in the EDC or any other data 
collection forms.  The CRFs must be signed electronically by the Investigator to attest that the data contained on the CRFs is true. 
In most cases, the source documents are contained in the subject’s chart at the hospital or the 
physician's office.  In these cases, data collected on the CRFs must match the data in those 
charts.  
12.2 Record Retention  
To enable evaluations and/or audits from regulatory authorities or the Sponsor, the Investigator agrees to keep records, including the identity of all participating subjects (sufficient information to link records, eg, CRFs and hospital records), all original signed informed consent forms, copies of all CRFs, SAE forms, source documents, detailed records of drug disposition, and adequate documentation of relevant correspondence (eg, letters, meeting minutes, and telephone 
calls reports).  The records should be retained by the Investigator according to the International Council for Harmonis ation  (ICH), local regulations, or as specified in the Clinical Study 
Agreement, whichever is longer. 
If the Investigator becomes unable for any reason to continue to retain study records for the 
required period (eg, retirement and  relocation), the Sponsor should be prospectively notified.  
The study records must be transferred to a designee acceptable to the Sponsor, such as another Investigator, another institution, or to the Sponsor.  The Investigator must obtain Sponsor’s written permission before disposing of any records, even if retention requirements have been met. 
13 QUALITY CONTROL AND QUALITY ASSURANCE  
13.1 Investigative Site Monitoring Visits  
During study conduct, the Sponsor or its agent will conduct periodic monitoring visits to ensure that the protocol and Good C linical Practice (GCP) are being followed.  The monitors will 
review source documents to confirm that the data recorded on the CRFs is accurate.  The Investigator/institution will allow the Sponsor’s monitors or designees and appropriate regulatory authorities direct access to source documents to perform this verification. 
The investigative site may also be  subject to Q uality Assurance audits performed by the Sponsor 
or companies working with or on behalf of the Sponsor, and/or review by the IRB/IEC, and/or to 
inspection by appropriate regulatory authorities. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 70 of 78 It is important that the Investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the process.  
13.2 Protocol Deviations  
The Investigator should not deviate from the protocol, except where necessary to eliminate an immediate hazard to  study subjects.  Should other unexpected circumstances arise that will 
require deviation from protocol-specified procedures, the Investigator should consult with the Sponsor or designee (and IRB or IEC, as required) to determine the appropriate course of action.  
The investigative site should document all protocol deviations in the subject’s source documents.  In the event of a significant deviation, the investigative site should notify the Sponsor or its designee (and IRB or IEC, as required).  Significant deviations include, but are not limited to, those that involve fraud or misconduct, increase the health risk to the subject, or confound interpretation of primary study assessments.  
14 STUDY DISCONTINUATION/INVESTIGATIVE SITE  TERMINATION 
The Sponsor reserves the right to discontinue the study prior to inclusion of the intended number of subjects, but intends only to exercise this right for valid scientific or administrative reasons.  After such a decision, the Investigator must contact all participating subjects within a time period specified by the Sponsor to inform them of the decision to discontinue the study. 
14.1 Criteria for Premature Termination or Suspension of the Study  
The following criteria may result in either temporary suspension or early termination o f the 
study:  
• New information regarding the safety or efficacy of the study medication that indicates a 
change in the known risk/benefit profile for the compound, such that the risk/benefit is no longer acceptable for  subj ects participating in the study  
• Significant violation of GCP that compromises the ability to achieve the primary study objectives or compromises subj ect safety.  
The Sponsor reserves the right to discontinue the study for other valid administrative reasons. 
14.2 Criteria for Premature Termination  or Suspension of Investigational Study 
Sites  
A study site may be terminated prematurely or suspended if the study site (including the 
Investigator) is found to be in significant violation of GCP, protocol, contractual agreement, or is unable to ensure ade quate performance of the study.  
14.3 Procedures for Premature Termination or Suspension of the Study or Investigational Site s 
In the event that the Sponsor elects to terminate or suspend the study or the participation of an investigational study site, a study -specific procedure for early termination or suspension will be 
provided by the Sponsor; the procedure will be followed by applicable investigational study sites during the course of termination or study suspension. 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 71 of 78 15 ETHICS  
15.1 Ethical Conduct of the Study  
The study will be conducted in accordance with the Declaration of Helsinki on Ethical Principles 
for Medical Research Involving Human  Subjects, adopted by the General Assembly of the World 
Medical Association ( 2013).  
In addition, the study will be conducted in accordance with the protocol, the ICH E6 guideline on 
GCP, and applicable local regulatory requirements and laws. 
15.2 Institutional Review Board/ Independent Ethics Committee  
It is the responsibility of the Investigator to have prospective approval of the study protocol, 
protocol amendments, informed consent forms, and other relevant documents, (eg, recruitment advertisements, if applicable) from the IRB/IEC.  All correspondence with the IRB/IEC should be retained in the Investigator File.  Copies of IRB/IEC approvals should be forwarded to the Sponsor or its designee. 
In case of substantial protocol amendment, the sponsor will obtain approval from responsible 
Regulatory Authorities before implementation.  
The only circumstance in which an amendment may be initiated prior to IRB/IEC approval is where the change is necessary to eliminate apparent immediate hazards to the subjects.  In that event, the Investigator must notify the IRB/IEC and the Sponsor in writing immediately after the implementation.  
15.3 Subject Information and Consent  
It is the responsibility of the Investigator to give each  subject (or the subject’s acceptable 
representative), prior to inclusion in the study, full and adequate verbal and written information regarding the objective and procedures of the study and the possible risks involved.  The subjects must be informed about their right to withdraw from the study at any time.  
Furthermore, it is the responsibility of the Investigator, or a person designated by the Investigator, to obtain signed inform ed consent from each  subject or the subject’s legally 
acceptable representative prior to inclusion in the study.  The Investigator will retain the original of each  subject's signed consent form. 
The informed consent forms will be in compliance with ICH GCP, local regulatory requirements, and legal requirements.  The informed consent forms used in this study, and any changes made during the course of the study, must be prospectively approved by both the IRB/IEC and the Sponsor before use. 
15.4 Reporting of Safety  Issues and Serious Breaches of the Protocol or ICH GCP  
In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable 
Competent Authority, or if the Investigator is aware of any new information which might influence the evaluation of the benefits and risks of the investigational product, the Sponsor should be informed immediately. 
In addition, the Investigator will inform the Sponsor immediately of any urgent safety measures 
taken by the Investigator to protect the study subjec ts against any immediate hazard, and of any 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 72 of 78 serious breaches of this protocol or of ICH GCP, defined as a breach that will likely affect the 
safety or physical or mental integrity of subjects or the scientific value of the trial, that comes to the attentio n of the Investigator. 
15.5 Subject Confidentiality  
All parties will ensure protection of  subject personal data and will not include subject names on 
any Sponsor forms, reports, publications, or in any other disclosures, except where required by law.  In case o f data transfer, the Sponsor will maintain high standards of confidentiality and 
protection of subject personal data. 
The Sponsor and designees affirm and uphold the principle of the subject’s right to protection 
against invasion of privacy.  Throughout this study, a subject’s source data will only be linked to the Sponsor’s clinical study database or documentation via a unique identification number.  As permitted by all applicable laws and regulations, limited  subject attributes, such as sex, age, or 
date of birth, and subject initials may be used to verify the  subject and accuracy of the subject’s 
unique identification number. 
To comply with ICH guidelines for GCP and to verify compliance with this protocol, the 
Sponsor requires the Investigator to permit its monitor or designee’s monitor, representatives from any regulatory authority (eg, FDA), the Sponsor’s designated auditors, and the appropriate IRBs and IECs to review the subject’s original medical records (source data or documents), including, but not limited to, laboratory test result reports, ECG reports, admission and discharge summaries for hospital admissions occurring during a subject’s study participation, and autopsy reports.  Access to a subject’s original medical records requires the specific  authorization of 
the subject as part of the informed consent process. 
Copies of any subject source documents that are provided to the Sponsor must have certain 
personally identifiable information removed (i e, subject name, address, and other identifier fi elds 
not collected on the subject’s CRF).  
16 PUBLICATION OF STUDY  RESULTS  
No publication or disclosure of study results will be permitted, except under the terms and conditions of a separate, written agreement between Sponsor and the Investigator and/or the Investigator’s institution.  The Sponsor must have the opportunity to review and approve all proposed abstracts, manuscripts, or presentations regarding this study prior to submission for publication/presentation.  Any information identified by the Sponsor as confidential must be deleted prior to submission. 
For all publications relating to the study, the institution will comply with recognized ethical 
standards concerning publicati ons and authorship, including: Section II - “Ethical Considerations 
in the Conduct and Reporting of Research” of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, established by 
the International Committee of Medical Journal Editors.  
 
 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 73 of 78 17 REFERENCES  
Abramson JL, Jurkovitz CT, Vaccarino V et al. Chronic kidney disease, anemia, and incident 
stroke in a middle- aged, community -based population: the ARIC study.  Kidney Int (2003) 
64(2): 610-615. 
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al.  The effects 
of normal as compared with low hematocrit values in patients with cardiac disease who are 
receiving hemodialysis and epoetin.  N Engl J Med (1998) 339(9):584-590. 
Darbepoetin alfa: Information on darbepoetin alfa in the US is available in the package insert for 
Aranesp ( Amgen, Thousand Oaks, CA; 2015. http://www.amgen.co); and d etailed information 
on darbepoetin alfa in the EU is available on the Eur opean Medicines Agency website 
(http://www.ema.europa.eu; Accessed 29March2015). 
Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al.  Normalization 
of hemoglobin level in patients with chronic kidney disease and anemia.  N Engl J Med (2006) 
355(20):2071-2084. 
Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, et al.  Naturally 
occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients.  J Am Soc Nephrol (2011) 22(2):358-365. 
Iseki K and Kohagura K.  Anemia as a risk factor for chronic kidney disease.  Kidney Int (2007) 
Suppl 72:S4 -9. 
Japanese Society of Nephrology.  Evidence- based clinical practice guideline for CKD 2013. Clin 
Exp Nephrol (2014) 18(3):346-423. 
Jha V, Garcia- Garcia G, Iseki K , et al. Chronic kidney disease: global dimension and 
perspectives. Lancet (2013) 382(9888): 260-272.  KDIGO CKD Working Group. KDIGO clinical practice guideline for the evaluation and 
management of chronic kidney disease. Kidney Int Suppl (2013) 3(1): 1-150. 
KDIGO.  KDIGO clinical practice guideline for anemia in chronic kidney disease.  Kidney Int 
(2012) 2(4):1-64.  Available at: http://www2.kidney.org/professionals/kdoqi/guidelines_ckd/p4_class_g1.htm 
Levey AS, Stevens LA, Schmid CH, et al.  A new equati on to estimate glomerular filtration rate.  
Ann Intern Med (2009) 150(9): 604-612. 
Locatelli F, B árány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al.  Kidney 
Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney 
disease: a European Renal Best Practice position statement.  Nephrol Dial Transplant (2013) 
28(6):1346-1359. 
Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM.  Pathophysiology of anaemia: 
focus on the heart and blood vessels.  Nephrol Dial Transplant (2000) 15 Suppl 3: 14-18. 
National Institute for Health and Care Excellence (NICE).  Chronic kidney disease: managing 
anaemia. NICE clinical guideline. Published: 3 June 2015. http://nice.org.uk/guidance/ng8  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 74 of 78 Nurko S.  Anemia in chronic kidney di sease: causes, diagnosis, treatment.  Cleve Clin J Med 
(2006) 73(3):289-297. 
Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, and 
Johnson RS.  Regulation of iron homeostasis by the hypoxia-inducible transcription factor s 
(HIFs).  J Clin Invest (2007) 117(7):1926-1932. 
Pfeffer MA, Burdmann EA, Chen CY, et al.  A trial of darbepoetin alfa in type 2 diabetes and 
chronic kidney disease.  N E ngl J Med (2009a) 361(21):2019-2032. 
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al.  Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).  Am J Kidney Dis (2009b) 54(1):59-69. 
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al.  Correction of anemia 
with epoetin alfa in chronic kidney disease.  N Engl J Med (2006) 355(20):2085-2098. 
Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al.  Erythropoietic 
response and outcomes in kidney disease and type 2 diabetes.  N Engl J Med (2010) 363( 12): 
1146-1155. 
Stauffer ME  and Fan T.  Prevalence of anemia in chronic kidney disease in the United States.  
PLoS One (2014) 9(1): e84943. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al.  Secondary analysis 
of the CHOIR trial epoet in-alpha dose and achieved hemoglobin outcomes.  Kidney Int (2008) 
74(6):791-798. 
Tsubakihara Y, Nishi S, Akiba T, et al.  2008 Japanese Society for Dialysis Therapy:  Guidelines 
for renal anemia in chronic kidney disease.  Ther Apher and Dial (2010) 14(3):240-275. 
Unger EF.  FDA perspectives on erythropoiesis- stimulating agents (ESAs) for anemia of chronic 
renal failure: Hemoglobin target and dose optimization (Slide presentation from the Sep 11, 2007 
Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety 
and Risk Management Advisory Committee).  Retrieved from http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4315s1-10- FDA-Unger.ppt. 
Unger EF, Thompson AM, Blank MJ, and Temple R.  Erythropoiesis- stimulating agents - Time 
for a reevaluation.  N Engl J Med  (2010) 362(3):189-92. 
 

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 75 of 78 APPENDIX A : SCHEDULE OF ACTIVI TIES  
Study Period  Optional  
Pre-
screen  Screening Treatment Period  
Post  
Treatment BL/ 
rand.  
[a] Year 1 Year 2 Year 3/Year 4 
Visit  PS SV1 SV2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22/ 
26 23/ 
27 24/ 
28 25/ 
29 End of 
Trtmt Follow -
up [b]  
Week   -4 to 0  0 2 4 6 8 10 12 16 20 24 28 32 36 40 44 48 52 64 76 88 104 116/ 
168 128/ 
180 140/ 
192 156/ 
208 EOT [c ] EOT 
+4 
wks 
Visit Window (Days)     ±3 ±3 ±3 ±3 ±3 ±3 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±7 ±7 
Procedures/Assessments  
Informed Consent  X [d] X [d]                             
Prescreening Local Hb 
[e] X                              
I/E Criteria [f ] X X X                            
Vital Signs [g ]  X X X X X X X X X X X X X X X X X X X X X X X X X X X X  
Demographics, Med ical 
History    X                            
Physical Exam [h ]   X                            
12-Lead ECG [i ]    X                           
Randomization     X                           
Laboratory Procedures  
Pregnancy Test [j ]   X                            
Folate and Vitamin B 12   X [k]                            
Coagulation Tests [l ]    X                           
C-Reactive Protein    X                           
CBC [m, n ] with 
periodic diff   X [k] X [k] X X X X X X X X X X X X X X X X X X X X X X X X X X  
Iron Indices [o ]  X [k]  X  X  X  X  X  X  X  X  X X X X X X X X X X  
Serum Chemistry [p ]   X [k] X          X      X  X  X  X  X X  
Liver Function Tests [q ]   X [k] X  X  X  X X X X X  X  X  X  X  X  X  X X  
Lipid Panel [r ]    X          X      X           
Biomarkers [s ]    X      X    X               X  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 76 of 78 Study Period  Optional  
Pre-
screen  Screening Treatment Period  
Post  
Treatment BL/ 
rand.  
[a] Year 1 Year 2 Year  3/Year 4 
Visit  PS SV1 SV2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22/ 
26 23/ 
27 24/ 
28 25/ 
29 End of 
Trtmt Follow -
up [b]  
Week   -4 to 0  0 2 4 6 8 10 12 16 20 24 28 32 36 40 44 48 52 64 76 88 104 116/ 
168 128/ 
180 140/ 
192 156/ 
208 EOT [c ] EOT 
+4 
wks 
Visit Window (Days)     ±3 ±3 ±3 ±3 ±3 ±3 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±7 ±7 
Reticulocyte Count     X  X    X    X      X           
Erythropoietin     X  X    X    X      X           
PK [t]     X  X    X    X      X           
Dialysis adequacy     To be reported every 3 months during Year 1  To be reported every 6 months until end of study  
Dialysis Treatment 
Type and Prescription     X  X  X  X X X X X X X X X X X X X X X X X X X X  
Exploratory Samples 
[u]    X          X                 
Safety Assessments  
MACE Endpoint 
Questionnaire [v ]     X X X X X X X X X X X X X X X X X X X X X X X X X X 
AE Assessment [w ]    X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Transfusions and ESA 
Rescue C ollection      X X X X X X X X X X X X X X X X X X X X X X X X X X 
Therapeutic 
Phlebotomy Collection      X X X X X X X X X X X X X X X X X X X X X X X X X X 
Medication  Assessment s and Procedures  
Concomitant Medicine 
Review [x ]   X X X X Only changes in medication (started or discontinued) will be recorded X X 
Vadadustat Medication 
Dispensing [y ]    X X X X X X X X X X X X X X X X X X X X X X X X X   
Drug Reconciliation      X X X X X X X X X X X X X X X X X X X X X X X X X  
Visit Registration in 
IWR    X X X X X X X X X X X X X X X X X X X X X X X X X X  
Hb via HemoCue® for 
Dose Adjustment [ z]    X X X X X X X X X X X X X X X X X X X X X X X X X   
Darbepoetin alfa     Dosing per approved local product label  [aa]   

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 77 of 78 Vadadustat  Dose 
Adjustments [ bb]    Start at 300 mg once daily, then adjust dose as per  Dose Adjustment Guidelines    
Iron Supplementation 
[cc]    As needed to maintain ferritin ≥100 ng/mL and TSAT ≥20%    
Abbreviations: AE = adverse event; ALT/SGPT  = alanine transaminase/serum glutamic- pyruvic transaminase; AST/SGOT  = aspartate aminotransaminase/serum glutamic oxaloacetic transaminase; 
BL = baseline; BUN = blood urea nitrogen; CBC = complete blood count; CPK = creatine phosphokinase; diff = differential; ECG = electrocardiogram; EOT = end of treatment; ESA = erythropoiesis -
stimulating agent; HDL = high density lipoprotein; Hb = hemoglobin;  HIF = hypoxia inducible factor;  ICF = informed consent form;  I/E = inclusion/exclusion; INR = internatio nal normalized ratio; 
IWR  = interactive web response; LDH  = lactate dehydrogenase; LDL  = low density lipoprotein; MACE  = major adverse cardiovascular event; MCH  = mean corpuscular hemoglobin; MCHC  = mean 
corpuscular hemoglobin concentration; MCV  = mean cor puscular volume; med = medicati on; PK  = pharmacokinetic; PS  = Prescreening; PT  = prothrombin time; PTT  = partial thromboplastin time; 
RBC  = red blood cell; RDW  = red cell distribution width; SV1  = Screening visit 1; SV2  = Screening visit 2; TIBC  = total ir on binding capacity; Trtmt = treatment; TSAT = transferrin saturation; 
VEGF  = vascular endothelial growth factor; WBC  = white blood cell; wks = weeks.  
[a] The Screening period is a maximum of 28 days in duration.  The Baseline visit must be performed withi n 28 days of the 2 Screening visits and a minimum of 4  days must elapse between the 
2 Screening visits (SV1 and SV2) and between SV2 and the Baseline visit.  
[b] The Follow -up visit can be performed either in person OR via the telephone.  
[c] The EOT assessm ents will be performed when the study is ended.  Subjects who prematurely discontinue study medication (vadadustat or darbepoetin alfa) for any reason should attend all 
subsequent study visits and be continually monitored according to the Schedule of Activitie s for the duration of the study.  
[d] An abbrev iated ICF will be used for Prescreening.  If the subject is eligible for Screening, a separate full ICF will be used.   An additional optional consent form for collection of blood samples for 
future gen etic analysis will be provided at SV1.  
[e] If the Pre -Screen HemoCue® Hb is between 8.0 and 11.0  g/dL (inclusive) within the US or between 9.0 and 12.0  g/dL (inclusive) outside of the US , the investigative site may proceed with 
Screening Visit 1 (SV1), pre ferably on the same day as Pre -Screening. 
[f] Inclusion/Exclusion criter ia will be reviewed at the Pres creening and Screening visits (SV1 and SV2).  Final eligibility determination will occur following the Screening visits when all data are 
available.  
[g] Vital  sign measurements : Heart  rate and blood pressure to be assessed in the seated position after 5 minutes of rest.  Height (SV2 only) and dry  weight (SV2, Weeks 12, 24, 36, and 52, and yearly 
thereafter) will also be measured.  For hemodialysis patients , the clinical evaluations should be completed before dialysis, if applicable.  
[h] Physical exam: a physical exam ination is required at SV2 as outlined in the protocol.  Thereafter, an abbreviated symptom -directed physical exam should be performed at the di scretion of the 
Investigator as clinically indicated.  
[i] An ECG should be performed prior to blood draws when possible and obtained after the  subject has been resting comfortably in a supine position for approximately 5 minutes.   For hemodialysis 
patients , the clinical evaluations should be completed before dialysis, if applicable.  
[j]  Serum pregnancy will be tested in women of childbearing potential at SV2.  (Eligible  subjects will be advised to use an adequate contraceptive method.)  Additional serum or  local urine pregnancy 
tests should be conducted throughout the study in sufficient number, as determined by the Investigator or required by local regulations, to establish the absence of pregnancy during the study.  If 
positive at SV2, the  subject is not eligible to enter the study.  If a subject becomes pregnant during the study, the subject must permanently discontinue study medication and should  attend all 
subsequent study visits and be continually monitored  according to the Schedule of Activitie s for t he duration of the study.  
[k] Subjects may be retested and/or rescreened.  
[l]  Coagulation  tests: prothrombin time , partial thromboplastin time, and international normalized ratio.  
[m] If Hb at SV1 is 11.1  to 11.5 g/dL in the US or 12.1  to 12.5 g/dL outside of the US, 1 retest CBC should be performed prior to SV2.  If retest Hb is ≥11.0 g/dL in the US or >12.0  g/dL outside the 
US, the subject should not proceed with SV2.  If the Hb at SV1 is >11.5  g/dL in the US or >12.5  g/dL outside of the US, the subject should not proceed with any further Screening at this time.   
[n] A CBC with differential will be performed at Baseline and twice annually at Weeks 28, 52, 76, 104, 128, 156, 180, 208.  At al l other noted visits, a CBC without differential will be performed.  
CBC:  hemoglobin, hematocrit, red blood cells (RBC), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concen tration (MCHC), red cell 
distribution width (RDW), white blood cell (WBC) count with  differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), and platelets.  
[o] Iron indices: ferritin, iron, total iron binding capacity (TIBC), and transferrin saturation (TSAT).  Blood samples to assess the iron indices will be collected at SV1, Baseline, every 4 weeks through  
Week 12, every 8 weeks from Week 12 to Week 52, and every 12 weeks from Week 53 through the end of the study.  Blood samples will also be collected at the EOT visit. 
[p] A full serum chemistry panel will be performed  at SV2, Baseline and twice annually at Weeks 28, 52, 76, 104, 128, 156, 180, 208, and EOT.  If blood is collected  on a hemodialysis day, the blood 
draw  should be completed before dialysis, if applicable.   Serum chemistry : sodium, potassium, bicarbonate, c hloride, calcium, magnesium, phosphorus, glucose, creatinine , blood urea nitrogen 
(BUN)/urea, creatine phosphokinase (CPK), uric acid, albumin, and total protein.  
[q] Liver function tests: total bilirubin, alkaline phosphatase, alanine aminotransaminase (A LT/SGPT), aspartate aminotransferase (AST/SGOT), and lactate dehydrogenase (LDH).  
[r] Lipids: total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), and triglycerides.  
[s] Hepcidin and vascular endothelial growth factor (VEGF) wi ll be analyzed at Baseline and at Weeks 12, 28, and EOT.  
[t]  PK samples are to be drawn only for subjects randomized to vadadustat.  Subjects will be questioned regarding the timing of their last dose of vadadustat. Refer to protocol for specified timing of 
PK samples.  

Protocol No.  AKB -6548- CI-0017   
 
 
Akebia  — Company Confidential  
Page 78 of 78 [u]  Additional blood and urine samples will be collected at Baseline and Week 28 which may be used for exploratory measurement of  biomarkers (eg, factors relating to the activation of the HIF 
pathway).  Subjects will also be asked to provid e optional consent to obtain and store a blood sample for future genetic analyses (DNA  and mRNA).  
[v]  At each study visit, the subject must specifically be questioned regarding the occurrence of any potential MACE endpoint even ts since the last study visi t.  If a potential endpoint event is reported, 
the date of the event should be recorded and the appropriate source documents should be collected according to the endpoint p acket checklist. 
[w] Adverse events should be documented and recorded at each visit.   The AE reporting period for this study begins upon receiving the first dose of study medication (vadadustat or darbepoetin  alfa) 
and ends at the final protocol -required visit .  All adverse events (serious and non -serious, and related and non -related) will be documented and recorded through the follow -up visit.  Subjects must 
be followed for adverse events until the final required protocol visit or until all drug- related toxicities and serious adverse events have resolved (or are considered chronic/stab le). 
[x] Concomitant medications should be collected and recorded at each visit as noted.  All concomitant medications received up to and including 30  days prior to the start of study medication through to 
the final protocol visit will be recorded.  
[y] Subjects will be provided w ith a supply of vadadustat  at the Baseline visit and will be resupplied at subsequent visits as needed.  Subjects will be instructed to complete 1 bottl e prior to opening the 
next bottle.  The dose should be taken at approximately t he same time each  day, preferably between 7 AM and 2 PM.  
[z] Hemoglobin will be monitored via local HemoCue throughout the study to determine if the dose of study medication will be adjusted or suspended.  
[aa]   Refer to the approved local product label.  Vital signs and dry weight should be obtained prior to dosing per the local product label.  
[bb] The dose will be adjus ted in accordance with the Dose Adjustment Guidelines.  Changes to dose will be accomplished by changing the number of tablets to be taken  per day. 
[cc] Iron supplementation (IV, oral, or intradialytic) should be prescribed as needed during the study to maintain ferritin ≥100  ng/mL and TSAT ≥20%.  Vadadustat  should not be administered 
concurrently with oral iron supplement (including multivi tamins containing iron).  Oral iron supplement should be taken at least 2 hours before or 2 hours after the dose of study med ication.  
 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 1 of 98  
 
 
CLINICAL PROTOCOL 
 
PHASE 3 , RANDOMIZED, OPEN -LABEL, ACTIVE- CONTROLLED STUDY 
EVALUATING  THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR  THE 
MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS  WITH 
DIALYSIS -DEPENDENT CHRONIC KIDNEY DISEASE (DD- CKD)  (INNO 2VATE – 
CONVERSION)  
 
Compound:  Vadadustat (AKB -6548)  
Protocol Number:  AKB -6548 -CI-0017 
US IND Number:  102,465  
EudraCT Number  2016 -001360 -11 
Phase:  Phase 3  
Status/ Date:  Amendment 5 ( Version 6.0 ) 
Amendment 4 (Version 5.0 ) 
Amendment 3 (Version 4.0 ) 
Amendment 2 (Version 3.0 ) 
Amendment 1 ( Version 2.0 ) 
Final,  Version 1.0  
 
Sponsor:   
Akebia Therapeutics, Inc. 
245 First Street Cambridge, MA 02142 
United States of America  
 
This document contains information that is confidential and proprietary to the Sponsor, Akebia Therapeutics, Inc .  
This information is being provided to you solely for the purpose of evaluating and/or conducting a clinical study  
for the Sponsor .  You may disclose the contents of this document only to study personnel under your supervision, 
the Institutional Review Boar d, the United States Food and Drug Administration, or duly authorized 
representatives of regulatory agencies for this purpose under the condition that they maintain confidentiality .  The 
contents of this document may not be used in any other clinical study , disclosed to any other person or entity, 

Protocol No. AKB-6548-CI-OO 17 
Amendment 5 (Version 6)  
and/or published without the prior written permission of the Sponsor. The foregoing shall not apply to disclosure 
re uired b anv re ations; howev er, ou will ive rom t notice to the S onsor of an such disclosure. 
1 SIGNATURE PAGES 
1.1 Protocol Approval 
Signature 
, Clinical Development 
Signature 
 
, Drug Safety and Pharmacovigilence 
Signature 
 
, Clinical Date 
Date 
Date 
Date 
Akebia -Company Confidential 
Page 2 of98 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 3 of 98 1.2 Investigator Agreement  
I confirm that I have read and that I understand this protocol, the Investigator B rochure, and other 
product information provided by the S ponsor .  I agree to conduct  this study in accordance with the 
requirements of this protocol and also protect the rights, safety, privacy, and well -being of study 
subjects in accordance with the following: 
• The ethical principles that have their origin in the Declaration of Helsinki.  
• International Council for Harmonisation Guidance for Industry, Good Clinical Practice E6. 
• All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations. 
• Regulatory requirements for reporting serious adverse events defined in this protocol. 
• Terms outlined in the Clinical Study Site Agreement.  
 
  
Signature of Investigator  Date  
  
Investigator Name (print or type)   
  
Investigator’s Title   
  
Phone Number   
  
Full Address   
  
  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 4 of 98 TABLE OF  CONTENTS  
1 SIGNATURE PAGES  .................................................................................................. 2 
1.1 Protocol Approval .................................................................................................... 2 
1.2 Investigator Agreement  ............................................................................................ 3 
TABLE OF CONTENTS  ......................................................................................................... 4 
2 PROTOCOL SYNOPSIS  .............................................................................................. 9 
3 LIST OF ABBREVIATIONS ..................................................................................... 21 
4 BACKGROUND INFORMATION  ........................................................................... 24 
4.1 Hypoxia- Inducible Factor Prolyl -Hydroxylase Inhibitors  ..................................... 26 
4.2 Summary of Clinical Experience  ........................................................................... 26 
4.3 Potential Benefits and Risks ................................................................................... 27 
5 STUDY OBJECTIVES AND ENDPOINTS  .............................................................. 28 
5.1 Primary Objective  .................................................................................................. 28 
5.2 Primary Efficacy Endpoint ..................................................................................... 28 
5.3 Secondary Efficacy Endpoints ............................................................................... 28 
5.4 Safety Endpoints .................................................................................................... 29 
5.5 Exploratory Endpoints  ............................................................................................ 29 
6 STUDY DESIGN  ........................................................................................................ 30 
6.1 Study Design .......................................................................................................... 30 
6.2 Rationale for Study Design .................................................................................... 31 
6.3 Dose Justification  ................................................................................................... 32 
6.4 Executive Steering Committee and Independent Data Monitoring Committee ..... 33 
6.4.1  Executive Steering Committee  .......................................................................... 33 
6.4.2  Independent Data Monitoring Committee ......................................................... 33 
6.5 Endpoint Adjudication Committee  ......................................................................... 33 
7 SELECTION AND WITHDR AWAL OF SUBJECTS  .............................................. 33 
7.1 General Criteria  ...................................................................................................... 33 
7.2 Inclusion Criteria  .................................................................................................... 34 
7.3 Exclusion Criteria  ................................................................................................... 34 
7.4 Retesting and Rescreening  ..................................................................................... 35 
7.4.1  Retesting  ............................................................................................................ 35 
7.4.2  Rescreening  ....................................................................................................... 35 
7.5 Study Completion, Subject Completion, Study Discontinuation, and 
Withdrawal of Subjects  .......................................................................................... 36 
7.5.1  Study Completion .............................................................................................. 36 
7.5.2  Subject Completion  ........................................................................................... 36 
7.5.3  Entire Study Termination  .................................................................................. 37 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 5 of 98 7.5.4  Individual Study Site Termination  .................................................................... 37 
7.5.5  Individual Subject Discontinuation ................................................................... 37 
7.5.5.1  Temporary Interruption of Study Medication ............................................... 38 
7.5.5.2  Permanent Discontinuation of Study Medication ......................................... 38 
7.5.5.3  Complete Withdrawal from Further Study Visits/Assessments ................... 39 
7.5.5.4  Procedures to Support Continued Study Participation ................................. 39 
7.5.5.5  Procedures to Prevent “Lost to Follow-up” .................................................. 40 
8 STUDY PRODUCT AND TR EATMENT OF SUBJECTS  ....................................... 41 
8.1 Study Product, Supplies, and Storage .................................................................... 41 
8.1.1  Vadadustat  ......................................................................................................... 41 
8.1.2  Darbepoetin Alfa ............................................................................................... 41 
8.2 Dispensing Procedures  ........................................................................................... 41 
8.2.1  Dispensing of Vadadustat  .................................................................................. 41 
8.2.2  Dispensing of Darbepoetin Alfa ........................................................................ 42 
8.3 Product Accountability and Destruction ................................................................ 42 
8.4 Treatment of Subjects  ............................................................................................. 43 
8.4.1  Treatment Group Assignments .......................................................................... 43 
8.4.2  Randomization ................................................................................................... 43 
8.4.3  Blinding ............................................................................................................. 43 
8.4.4  Dosing and Dose Adjustment Guidelines .......................................................... 44 
8.4.4.1  Vadadustat Dosing and Dose Adjustment Algorithms ................................. 45 
8.4.4.2  Darbepoetin Alfa Dosing and Dose Adjustment Algorithms ....................... 45 
8.4.5  Late or Missed Doses ........................................................................................ 46 
8.4.6  Iron Supplementation ........................................................................................ 46 
8.4.7  Rescue Therapy  ................................................................................................. 46 
8.4.7.1  Red Blood Cell Transfusion (Optional) ........................................................ 46 
8.4.7.2  Erythropoiesis -stimulating Agent Rescue (Optional) ................................... 47 
8.4.8  Phlebotomy (Optional)  ...................................................................................... 47 
8.4.9  Treatment Compliance  ...................................................................................... 47 
8.4.10  Continuation of Treatment ................................................................................ 48 
8.5 Prior and Concomitant Therapy ............................................................................. 48 
8.5.1  General  .............................................................................................................. 48 
8.5.2  Erythropoiesis -stimulating Agents  .................................................................... 48 
8.5.3  Transfusions ...................................................................................................... 49 
8.5.4  Dialysis Treatment and Renal Replacement Therapy  ....................................... 49 
8.5.5  Investigational Medications ............................................................................... 49 
8.5.6  HMG- CoA Reductase Inhibitors (Statins)  ........................................................ 49 
8.5.7  Sulfasalazine and Other BCRP Substrates  ........................................................ 50 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 6 of 98 9 STU DY PROCEDURES AND SC HEDULE OF ACTIVITIES ................................ 50 
9.1 Administrative Procedures  ..................................................................................... 51 
9.1.1  Informed Consent  .............................................................................................. 51 
9.1.2  Documentation of Screen Failures .................................................................... 51 
9.1.3  Contraception and Pregnancy Avoidance Measures  ......................................... 51 
9.1.4  Laboratory Accreditation and Reference Ranges  .............................................. 52 
9.2 Study Procedures and Evaluations ......................................................................... 52 
9.2.1  Clinical Evaluations  ........................................................................................... 52 
9.2.2  Laboratory Evaluations  ..................................................................................... 53 
9.3 Schedule of Activities ............................................................................................ 56 
9.3.1  Prescreening Visit  .............................................................................................. 56 
9.3.2  Screening Visits  ................................................................................................. 56 
9.3.2.1  Screening Visit 1 (SV1)  ................................................................................ 56 
9.3.2.2  Screening Visit 2 (SV2)  ................................................................................ 57 
9.3.2.3  Subject Retesting  .......................................................................................... 57 
9.3.2.4  Subject Rescreening  ...................................................................................... 57 
9.3.3  Baseline Visit (Day 1)  ....................................................................................... 58 
9.3.4  Year 1 Treatment Period Visits (Day 2 through Week 52) ............................... 58 
9.3.5  Year 2 -4 Monthly Hb Monitoring ..................................................................... 59 
9.3.6  Year 2 Treatment Period Visits (Weeks 53 through 104) ................................. 60 
9.3.7  Year 3/4 Treatment Period Visits (Weeks 116 through 208) ............................ 60 
9.3.8  End of Treatment (EOT) Visit  ........................................................................... 61 
9.3.9  Follow- up Visit  .................................................................................................. 62 
9.3.10  Unscheduled Visits ............................................................................................ 62 
9.3.11  End of Study Subject Status .............................................................................. 62 
9.4 Study Medication Stopping Rules .......................................................................... 63 
10 ADVERSE EVENTS  .................................................................................................. 64 
10.1  Definitions  .............................................................................................................. 64 
10.1.1  Adverse Events .................................................................................................. 64 
10.1.2  Serious Adverse Events  ..................................................................................... 66 
10.2  Eliciting Adverse Event Information  ..................................................................... 67 
10.3  Reporting ................................................................................................................ 67 
10.3.1  Reporting Period ................................................................................................ 67 
10.3.2  Reporting AEs ................................................................................................... 67 
10.3.3  Reporting SAEs ................................................................................................. 67 
10.3.4  Reporting Study Endpoints ................................................................................ 68 
10.3.5  Relationship to Study Medication  ..................................................................... 69 
10.3.6  Severity  .............................................................................................................. 69 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 7 of 98 10.3.7  Follow-up of Unresolved Events ....................................................................... 70 
10.4  Exposure In Utero  .................................................................................................. 70 
10.5  Special Situations  ................................................................................................... 71 
11 DATA ANALYSIS  ..................................................................................................... 71 
11.1  Sample Size Determination  .................................................................................... 72 
11.1.1  Sample Size for the Primary Efficacy Endpoint ................................................ 72 
11.1.2  Sample Size for the Primary Safety Endpoint ................................................... 72 
11.2  Study Analysis Populations .................................................................................... 73 
11.3  Analysis of Demographic and Pretreatment Variables  .......................................... 73 
11.4  Disposition of  Subjects ........................................................................................... 73 
11.5  Missing Data .......................................................................................................... 73 
11.6  Efficacy Analyses  ................................................................................................... 74 
11.6.1  Analysis of Primary Efficacy Endpoint ............................................................. 74 
11.6.1.1  Primary Analysis  of Primary Efficacy Endpoint .......................................... 74 
11.6.1.2  Sensitivity Analyses of Primary Efficacy Endpoint ..................................... 75 
11.6.2  Secondary Efficacy Analyses  ............................................................................ 75 
11.6.2.1  Key Secondary Efficacy Analyses  ................................................................ 75 
11.6.3  Subgroups .......................................................................................................... 75 
11.7  Safety Analyses  ...................................................................................................... 76 
11.7.1  Analysis of MACE and Expanded MACE Components ................................... 76 
11.7.2  Analysis of Adverse Events ............................................................................... 77 
11.7.3  Remaining Safety Endpoints ............................................................................. 77 
11.8  Additional Assessments ......................................................................................... 78 
11.8.1  Concomitant Medications .................................................................................. 78 
11.8.2  Biomarkers  ........................................................................................................ 78 
11.8.3  Pharmacokinetics ............................................................................................... 78 
12 DATA HANDLING AND RE CORD KEEPING....................................................... 78 
12.1  Case Report Forms/Electronic Data Capture  ......................................................... 78 
12.2  Record Retention .................................................................................................... 79 
13 QUALITY CONTROL AND QUALITY ASSURANCE  .......................................... 79 
13.1  Investigative Site Monitoring Visits  ...................................................................... 79 
13.2  Protocol Deviations ................................................................................................ 79 
14 STUDY DISCONTINUATION/INVESTIGATIVE SITE TERMINATION  ............ 80 
14.1  Criteria for Premature Termination or Su spension of the Study ............................ 80 
14.2  Criteria for Premature Termination or Suspension of Investigational Study Sites  80 
14.3  Procedures for Premature Termination or Suspension of the Study or 
Investigational Sites  ............................................................................................... 80 
15 ETHICS  ....................................................................................................................... 80 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 8 of 98 15.1  Ethical Conduct of the Study ................................................................................. 80 
15.2  Institutional Review Board/Independent Ethics Committee  .................................. 80 
15.3  Subject Information and Consent ........................................................................... 81 
15.4  Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP .... 81 
15.5  Subject Confidentiality  ........................................................................................... 81 
16 PUBLICATION OF STUDY RESULTS  ................................................................... 82 
17 REFERENCES ............................................................................................................ 83 
APPENDIX A:  SCHEDUL E OF ACTIVITIES ................................................................... 85 
APPENDIX B: VADADUST AT DOSING AND DOSE ADJUSTMENT 
ALGORITHMS  .......................................................................................................... 89 
APPENDIX C:  DARBEPOETIN ALFA DOSING AND DOSE ADJUSTMENT 
ALGORITHMS  .......................................................................................................... 91 
APPENDIX D:  END OF TREATMENT AND  GLOBAL STUDY COMPLETION 
SUBJECT FLOW  ....................................................................................................... 93 
APPENDIX E:  HISTORY  OF AMENDMENTS TO THE PROTOCOL  ........................... 94 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 9 of 98 2 PROTOCOL SYNOPSIS  
Study Title  Phase 3, Randomized, Open -Label, Active -Controlled Study Evaluating the Efficacy 
and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects 
with Dialysis -Dependent Chronic Kidney Disease (DD -CKD)  (INNO 2VATE – 
CONVERSION)  
Protocol Number  AKB -6548 -CI-0017 
Study Phase  Phase 3  
Investigational 
Product  Vadadustat ; 150 mg tablets  
Reference Medicinal 
Product  Darbepoetin  alfa; Amgen, Inc.  
Study Population  The study population will consist of subjects ≥18 years of age  receiving chronic 
outpatient dialysis ( either  peritoneal dialysis or hemodialysis), with hemoglobin ( Hb) 
between 8.0 g/dL and 11.0 g/dL (inclusive) in the United States (US) and  between 9.0 
and 12.0 g/dL  (inclusive)  outside of the US , and who are currently treated with an 
erythropoiesis -stimulating agent (ESA) for anemia.  
Investigative Sites  Approximately 300 investigative sites  in North America, Latin America, Europe, and 
Asia Pacific . 
Planned Number o f 
Subjects  Approximately 3300  subjects .  
Primary Objective  To demonstrate the efficacy and safety of vadadustat  compared to darbepoetin  alfa for 
the maintenance treatment of anemia in subjects with DD -CKD  after conversion from 
current ESA therapy . 
Study Design 
Overview  Phase 3, randomized, open -label, active -controlled study of vadadustat vs darbepoetin  
alfa for the maintenance treatment of anemia af ter conversion from ESA therapy.  
Following a Screening period of up to 8 weeks  (56 days), subjects who meet all 
inclusion and none of the  exclusion criteria will be randomized 1:1 to vadadustat or 
darbepoetin  alfa. 
Randomization will be stratified by:  
• Geographic region (United States [US] versus European Union [EU] versus 
Rest of World [ROW]) . 
• New York Heart Association congestive heart failure (CHF) Class 0 (no CHF) 
or I versus II or III . 
• Study entry Hb (<10.0 versus ≥10.0 g/dL).  
Following randomization, there will be 3 periods during the study:  
• Conversion and Maintenance Period (Weeks 0 to 52): conversion to  study 
medication for maintaining Hb (Weeks 0 -23), primary  efficacy evaluation  
(Weeks 24 -36), and secondary efficacy evaluation  (Weeks 40 -52). 
• Long -term Treatment Period (Weeks 53 to End of Treatment [EOT]): 
continued study medication to assess long -term safety . 
• Follow -up (EOT + 4 weeks):  post- treatment visit (either in person or via 
telephone) for safety . 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 10 of 98 Study Duration  The study will be considered completed (end of trial) when approximately 631 major 
adverse cardiovascular events (MACE) have accrued over the 2 DD -CKD studies 
(Studies AKB -6548 -CI-0016 and AKB- 6548- CI-0017) , and all enrolled subjects have 
had the opportunity to have their Visit 13 (+/ - 5 days) .(.  All subjects will remain in the 
study until the global study completion ( end of trial ), at which time subjects will be 
scheduled for a final visit and the study will close.  Sites will be notified of the global 
study completion  date approximately 3  months prior to study closure (based on accrual 
of MACE acros s the 2  studies) and will have any subject that is active complete the  
EOT visit and Follow -up visit, as applicable , and confirm the End of Study ( EOS ) 
status.  
Inclusion Criteria  Subjects  must meet  the following inclusion  criteria:  
1. ≥18 years of age.  
2. Receiving chronic maintenance dialysis (either peritoneal or hemodialysis) for 
end-stage kidney disease for at least 12  weeks prior to Screening. 
3. Currently maintained on ESA therapy, with a dose received within  6 weeks 
prior to or during Screening . 
4. Mean screening Hb between 8.0 and 11.0 g/dL (inclusive) in the US and 
between 9.0 and 12.0 g/dL (inclusive ) outside of the US , as determined by the 
average of 2  Hb values measured by the central laboratory during Screening.  
5. Serum ferritin ≥100 ng/mL and  transferrin saturat ion (TSAT) ≥20% during 
Screening.  
6. Folate and vitamin B 12 measurements  ≥ lower limit of normal during  
Screening.  
7. Understands the procedures and requirements of the study and provides 
written informed consent and authorization for protected health information 
disclosure.  
Exclusion Criteria  Subjects must meet  none of the  following exclusion criteria : 
1. Anemia due to a cause other than CKD or subjects with  active bleeding or 
recent blood loss.  
2. History of  sickle cell disease, myelodysplastic syndromes, bone marrow 
fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia. 
3. Red blood  cell (RBC) transfusion within 8  weeks prior to randomization . 
4. Anticipated to recover adequate kidney function to no longer require dia lysis.  
5. Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase 
(SGOT), alanine aminotransferase (ALT)/serum glutamic pyruvic 
transaminase (SGPT), or total bilirubin >2.0  x upper limit of normal (ULN) 
during  Screening.  Subjects with a hist ory of Gilbert’s syndrome are not 
excluded.  
6. Uncontrolled hypertension (defined as confirmed predialysis systolic blood 
pressure [BP] >190  mmHg or diastolic BP >110  mmHg at rest) during  
Screening.  
7. Severe heart failure (HF) during Screening (New York Heart Association 
Class IV).  
8. Acute coronary syndrome (hospitalization for unstable angina or myocardial 
infarction), surgical or percutaneous intervention for coronary, 
cerebrovascular or peripheral artery disease (aortic or lower extremity) , 
surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for HF, or stroke within 12 weeks prior to or 
during Screening . 
9. History of active malignancy within 2 years prior to or during Screening, 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 11 of 98 except for treated  basal cell  carcinoma of skin, curatively resected squamous 
cell carcinoma of skin, or cervical carcinoma in situ .  
10. History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 
12 weeks prior to  randomization. 
11. History of hemosiderosis or hemochromatosis.  
12. History of prior organ transplantation or scheduled organ transplant (subjects 
on the kidney transplant wait -list or with a history of failed kidney transplant 
are not excluded), or prior hematopoietic stem cell or bone marrow transplant 
(corneal transplant s and stem cell therapy for knee arthritis are not excluded).  
13. Hypersensitivity to vadadustat, darbepoetin alfa, or any of their excipients.  
14. Use of an investigational medication or participation in an investigational study within 30 days or 5 half -lives of the investigational medication 
(whichever is longer), prior to  Screening.  
15. Previous participation in this study  or previous participation in a study with 
another hypoxia -inducible factor prolyl -hydroxylase inhibitor (HIF -PHI)  
other than vadadustat . 
16. Females who are pregnant or breastfeeding.  Women of childbearing potential 
who are unable or unwilling to use an acceptable method of contraception . 
17. Non-vasectomized male subjects who are unable or unwilling to use an 
acceptable method of contraception.  
18. Any other  reason, which in the opinion of the Investigator, would make the 
subject not suitable for participation in the study.   
 
Retesting/ Rescreening  Retesting is defined as repeating laboratory tests within the same Screening Period.  
Subjects who initially fail to qualify for the study based on laboratory test results may 
be retested once for each laboratory parameter within the 8 -week Screening  period, per 
Investigator discretion.   Subjects who fail to qualify for the study based on low TSAT, 
ferritin, fola te, or B 12 values may receive replacement therapy based on the 
investigative sites’ standard of care during the screening period and retest the 
laboratory parameter(s).  Subjects who receive iron replacement may retest screening 
Hb a minimum of  3 weeks aft er completion of iron replacement therapy.  
Subjects who fail to meet the qualifying criteria for Hb during a Screening period  may 
be considered for rescreening at the discretion of the Investigator if it is felt that the subject’s status has progressed and  that the subject may now qualify for the study.  
Additionally, subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B
12 values may be considered for rescreening after receiving replacement 
therapy.  Screening is limited to 3 attempts (initial Screening and 2  additional 
rescreening attempts).  
Efficacy Endpoints  Primary : 
• Mean change in Hb between Baseline (mean pretreatment Hb) and the 
primary evaluation period (mean Hb from Weeks  24 to 36). 
Key Secondary : 
• Mean change in Hb value between Baseline (mean pretreatment Hb) and the 
secondary evaluation period (Weeks  40 to 52). 
• Proportion of  subjects with Hb values within the target range during the 
primary evaluation period (Weeks 24 to 36) . 
• Proportion of subjects with Hb  values within the target range during the 
secondary evaluation period (Weeks 40 -52). 
Other Secondary : 
• Proportion of time with Hb values within the target range during the primary 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 12 of 98 evaluation period (Weeks 24 -36). 
• Proportion of time with Hb values within th e target range during the 
secondary evaluation period (Weeks 40 -52). 
• Proportion of subjects with Hb increase of >1.0 g/dL from Baseline. 
• Time to achieve Hb increase of >1.0 g/dL from Baseline . 
• Mean change in Hb between Baseline (mean pretreatment Hb) and t he 
primary evaluation period (mean Hb from Weeks 24 -36) stratified by pre -
baseline ESA exposure.  
• Proportion of subjects receiving IV iron therapy from Baseline to Week 52 . 
• Mean monthly dose of IV elemental iron administered from Baseline to Week 
52 in subj ects who have received IV iron . 
• ESA rescue . 
• Dose adjustments  from Baseline to Week 52 . 
• Proportion of subjects receiving RBC transfusion(s) from Baseline to Week 52. 
Safety Endpoints  • MACE, defined as all -cause mortality, non -fatal myocardial infarction  (MI) , 
or non -fatal stroke . 
• Individual components of MACE:  
o All-cause mortality  
o Non-fatal myocardial infarction  
o Non-fatal stroke  
• Thromboembolic events: arterial thrombosis, DVT, PE, or vascular access 
thrombosis . 
• Hospitalization for HF. 
• Expanded MACE, d efined as all -cause mortality, non -fatal myocardial 
infarction, non- fatal stroke, hospitalization for HF, or thromboembolic event.  
• Fatal/non -fatal MI . 
• Fatal/non -fatal stroke . 
• Sudden death . 
• Cardiovascular death . 
• Non-cardiovascular death . 
• Hospitalization . 
• Hb >12.0 g/dL, >13.0 g/dL, or >14.0 g/dL.  
• Hb < 8 .0 g/dL . 
• Hb increase >1.0 g/dL within any 2 -week interval or >2.0 g/dL within any 4 -
week interval.  
• Adverse events (AEs) and serious AEs (SAEs). 
• Vital sign measurements and clinical laboratory values . 
Exploratory 
Endpoints  • Biomarkers ( including, but not limited to, hepcidin and vascular endothelial 
growth factor [ VEGF ]). 
• Time to achieve stable Hb values within target range.  
• Proportion of subjects with Hb  values in the target range without evidence of 
iron overload.  
Dosage and Regimens  Subjects will be randomized 1:1 to either:  
• Vadadustat starting dose : 2 tablets once daily (300  mg/day)  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 13 of 98 • Darbepoetin alfa: initial  dose based on the Package Insert (PI) for 
investigational sites in the US an d the European Summary of Product 
Characteristics (SmPC) for all other investigational sites (non -US), for adult 
patients with CKD on dialysis . 
o For subjects already on darbepoetin  alfa, the initial dosing regimen in 
the study should be based on the prior dosing regimen.  
For all subjects, it is recommended that no additional ESA doses be administered after 
Screening visit 2 (SV2) and prior to the Randomization visit.  
Dose Adjustment Guidelines – All Treatment Groups  
Dosing will be initiated at the Baseline visit, and the first dose of study medication 
(vadadustat or darbepoetin  alfa) will be administered at the clinic/investigative site 
after other Baseline procedures have been completed.  For all subjects, it is 
recommended  that no additional ESA doses be administered after SV2 and prior to the 
Randomization visit.   The investigator may elect to postpone the initial dose of study 
medication until a subsequent visit based on the subject’s Hb level or Hb trajectory 
assessed at  the Baseline visit, or based on timing of the last ESA dose given during 
screening.  
Hemoglobin will be monitored via HemoCue® point of care device throughout the 
study to determine if the dose of study medication (vadadustat or darbepoetin alfa) 
should be adjusted , interrupted , or maintained .   
Year 1 -4 Treatment Period Visits  
From Weeks  0 to 12, Hb will be measured via HemoCue every 2  weeks  for monitoring 
for dose adjustment s.  From Week 12 to Week 52, Hb via HemoCue will be monitored 
every 4  weeks  unles s more frequent monitoring is clinically indicated or warranted 
based on dosing changes.  From Week 53 through the end of the study, Hb will 
continue to be monitored via HemoCue to determine if the dose of study medication 
should be adjusted, interrupted , or maintained .  Hemoglobin will be assessed with a 
complete blood count (CBC) through the central laboratory for efficacy and safety evaluations; however, dose adjustments should be based on the local HemoCue Hb 
value.   If the Investigator has an immediate clinical concern about a subject’s 
HemoCue value, the Investigator may use clinical judgement and repeat the HemoCue 
Hb, use local lab values or wait for central lab results. The test method utilized to 
inform the treatment decision must be recorded in the appropriate CRF and the 
subject’s source . 
Year 2 -4 Monthly Hb Monitoring 
Additionally,  after Week 52, the Hb drawn as part of the local  standard of care labs 
must be monitored monthly for dosing oversi ght.  Per the vadadustat or darbepoetin 
dosing algorithms, if the Hb value suggests a dose adjustment is needed, an unscheduled visit must be performed.  
If monthly standard of care labs are not available,  a study unscheduled visit must be 
performed.   This visit will include, at minimum, the Hb measurement via HemoCue, 
dose adjustment assessment, and adverse events assessment.     
The monthly Hb monitoring method is flexible between study visits after Week 52 to 
minimize unnecessary travel or redundant blood sampling for the subject.  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 14 of 98 The aim is to maintain a Hb level of 10.0 to 11.0 g/dL in the US and 10.0 to 12.0 g/dL 
outside the US throughout t he study.  
Dose adjustments will be guided by Hb concentration and the Dose Adjustment 
Algorithms. The Dose Adjustment Algorithm for darbepoetin alfa will follow the PI 
for investigational sites in the US and the SmPC for all other investigational sites (no n-
US) for adult patients with CKD on dialysis . 
This protocol provides guidance for the treatment of subjects with anemia associated 
with CKD in order to achieve and maintain Hb levels within the target Hb range.  Dose 
adjustment should be based on the Investigator’s clinical discretion, incorporating the 
protocol guidance,  and considering the subject’s clinical condition, Hb rate of rise, Hb 
rate of decline, Hb variability, and ESA responsiveness.  
In cases where the Investigator does not follow the dosing algorithm, the clinical 
circumstances must be documented in the subject’s source . 
Vadadustat   
Vadadustat  should be dosed according to the Dose Adjustment Algorithms in 
Appendix B . 
Darbepoetin  alfa 
Darbepoetin alfa  should  be dosed according to the Dose Adjustment Algorithm s in 
Appendix C . 
Subsequent  administration of darbepoetin alfa may occur at the clinic/investigative site 
or may be self -administered at home per regional standard of care and/or based on 
dialysis modalit y (hemodialysis or peritoneal dialysis).  Darbepoetin alfa dosing is 
independent of the study visit schedule, and the dosing schedule may shift per local 
standard of care, the patient’s dialysis schedule, and per Investigator discretion.  
Dosing Instructions  Vadadustat  
All subjects will start with 2 tablets daily (300  mg/day).  Dose levels of vadadustat 
include 150, 300, 450, and 600  mg (available tablet strength is 150  mg).  Each  subject 
will take his/her first dose of vadadustat at the investigative site at the Baseline visit.  
Thereafter,  vadadustat  will be taken  once daily , on an outpatient basis.  Subjects may 
take vadadustat with or without food.  The full dose should be taken at approximately 
the same time each  day.  The subject should be instructed to take any oral iron 
supplements (including multivitamins containing iron),  iron containing phosphate 
binders , or any medications containing iron  at least 2  hours before or 2  hours after the 
dose of vadadustat.  
Darbepoetin alfa  
Darbepoetin  alfa will be administered, stored, and dispensed based on the Dosing 
Algorithms, and PI for investigational sites in the US and the SmPC for all other investigational sites (n on-US). 
Iron Supplementation  Investigators will prescribe iron supplementation  (IV, oral, or intradialytic)  during the 
study to maintain ferritin ≥100 ng/mL or  TSAT ≥ 20%.  Subjects already receiving oral 
iron supplementation as part of their treatment plan may continue their current 
treatment regimen.  For subjects who are on peritoneal dialysis, oral iron 
supplementation is allowed as per local guidelines and routine practice.    
Important : Because of the potential for oral iron to reduce the bioavailab ility of 
vadadustat, the study medication is not to be administered concurrently with an oral 
iron supplement (including multivitamins containing iron) , iron containing phosphate 
binders , or any medications containing iron.  The subject should be instructed to take 
these medications  at least 2 hours before or 2 hours after the dose of vadadustat.  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 15 of 98 Rescue Therapy 
Guidelines  To ensure the safety of study subjects and to standardize the use of rescue in the study, 
rescue therapy guidelines are provided.  
1. Red Blood Cell (RBC) Transfusion:  Investigators will use their local institution’s 
transfusion guidelines when determining whether to transfuse a study subject.  In 
general, in the event of an acute or severe loss of blood, a RBC transfusion should 
be admi nistered as clinically indicated.  In less severe instances but where there 
may be worsening of anemia or moderate to severe symptoms of anemia, RBC transfusions are perm itted at the discretion of the I nvestigator given medical 
necessity. Reasons for RBC transfusion will be captured in the appropriate CRF.  
Study medication ( vadadustat or darbepoetin alfa) may be continued during the 
transfusion period. 
2. ESA Rescue:  Starting at Week 6, subjects in both treatment arms will be allowed 
(although will not be r equired) to have their Hb rescued with ESA therapy.  When 
possible, a subject on vadadustat should be on maximum dose of vadadustat for 
2 weeks prior to ESA rescue.  A subject on darbepoetin  alfa may be rescued with 
another ESA per the standard of care.  To qualify for ESA rescue, a subject must 
fulfill BOTH  of the following:  
• The subject has experienced worsening  of the  symptoms of anemia (eg, 
fatigue, weakness, shortness of breath, chest pain, confusion, or dizziness) 
compared to Baseline 
• The subject’s Hb  is <9. 5 g/dL  
However, in the event the subject does not meet the above criteria for ESA rescue, ESA rescue is permitted when medically necessary at the discretion of the Investigator.  
Reasons for ESA use will be captured in the appropriate CRF.  
The ESA rescue therapy should be administered using an approved local product and 
dosing as per the local institution’s guidelines and per the approved local product label.  
While receiving ESA rescue therapy, subjects must temporarily interrupt study 
medication (va dadustat or darbepoetin alfa).  Hemoglobin will be monitored 
throughout the study at scheduled visits using a HemoCue point of care device, and ESA rescue treatment should be stopped when Hb is ≥10.0 g/dL.  A minimum interval 
must be observed prior to restarting vadadustat after the last dose of rescue medication, and treatment may be resumed after the following intervals:
 
• 2 days after last dose of epoetin  rescue.  
• 7 days after last dose of darbepoetin  alfa. 
• 14 days after last dose of methoxy  polyethylene glycol -epoetin beta rescue.  
Following ESA rescue, the study medication should be resumed at the same dose as previously used or one dose higher  and adjusted according to the Dose Adjustment 
Algorithms . 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 16 of 98 Phlebotomy  If a subject’s Hb exceeds 14.0 g/dL or the rate of rise of Hb raises concern to the 
Investigator, the subject may be phlebotomized based on the Investigator’s clinical 
judgment.  The method of phlebotomy will be in accordance with the investigative site’s standard clinical  practice
. 
Study Medication 
Stopping Rules  Study medication must be permanently discontinued if a subject meets one of the 
criter ia.  
• ALT or AST >3x Upper Limit of Normal (ULN) and total bilirubin >2x ULN  
• ALT or AST >3x ULN and INR >1.5  
• ALT or AST >8x ULN  
• ALT or AST remains >5x ULN over 2 weeks* 
• ALT or AST >3x ULN with symptoms (e.g., fatigue, nausea, vomiting, right 
upper quadr ant pain, fever, rash) or eosinophilia  
*Re- challenge generally should be avoided with ALT or AST >5x ULN unless 
there are no other  good therapeutic options.  
Study Completion, 
Subject Completion, Premature 
Termination of Study 
Medication, or Withdrawal from the 
Study  Study Completion  
The study will be considered completed (end of trial) when approximately 631 MACE 
events have accrued  over the 2 DD -CKD studies (Studies AKB- 6548 -CI-0016 and 
AKB -6548- CI-0017 ), and all enrolled subjects in this study have had the opportunity to 
have their Visit 13 (+/ - 5 days) . 
Subject Completion  
A subject will be considered as having completed the study, regardless of whether the 
subject is on or off study medication, and the subject is followed until global study  
completion (end of trial) .   
Subjects who continue on the study medication up to the global study completion  will 
complete  the EOT visit , followed by the Follow -up visit, which will include recording 
the end of study ( EOS ) status .   
It is important to note that a  subject’s need for re scue therapy or the occurrence of 
MACE event(s) : 
• Does  not constitute study completion and  
• Is not criteria for subject withdrawal from the study or  
• Is not a requirement for p ermanent discontinuation of study medication 
(vadadustat or darbepoetin alfa).  
Discontinuation of Study Medication Treatment  
Subjects who discontinue study medication prior to global study completion are 
expected to continue to be followed post discontinuation of study medication.   These 
subjects are to have their EOT  visit at the ti me of discontinuing study medication, have 
the F ollow -up visit and continue to be follow ed through global study completion.  At 
the time of global study completion, each subject will have an EOS assessment  to 
complete participation in the study.    
Receipt  of rescue therapy is not a reason for permanent study medication 
discontinuation.  While receiving ESA rescue, subjects must temporarily discontinue study medication,  but are to  resume study medication  following the end of rescue 
therapy.  
During this study, it is anticipated that some subjects may permanently discontinue 
study medication (vadadustat or darbepoetin alfa) for any of the following reasons:  
• Unacceptable toxicity or drug intolerability  
• Investigator discretion  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 17 of 98 • Subject withdrawal of consent  
• Subject becomes pregnant  
• Receipt of kidney transplant  
• Lack of efficacy  
• Other reasons  
Subjects who undergo a solid organ (including kidney), hematopoietic stem cell, or 
bone marrow transplantation will have their study medication (vadadustat or 
darbepoetin  alfa) permanently discontinued.  
It is important to continue to follow subjects that permanently discontinue study 
medication  through global study completion.   Please see “Procedures to Avoid 
Withdrawal or Loss to Follow -up” for options to maintain subjects in the study .    
Complete Withdrawal from Study Visits/Assessments  
A subject has the right to withdraw consent  for participation in the study  at any time .  
Withdrawal of consent is a subject’s refusal of ALL methods of follow -up noted in the 
infor med consent form: procedures, participation in reduced procedures/study visits, 
telephone contact only or alternative contact only, source document or designated alternative contact, or access to medical records from alternative sources . 
It is important for the I nvestigator to review options  with a subject that would allow 
follow -up through global study completion before the subject withdraws consent. For 
subjects  considering withdrawal of consent , the Investigator should consult with the 
Medical Monitor to ensure all options have been explored and that there is complete 
understanding by the subject for what withdrawal of consent constitutes .   
Procedures to Avoid 
Withdrawal or Lost  to 
Follow -up Avoiding Withdr awal of Consent or Lost to Follow -up 
As part of the informed consent process, only subjects who fully understand and agree 
to full participation and long -term follow -up should be consented to participate.  
It is important that subjects understand the long -term duration and purpose of a 
cardiovascular outcome trial and that the subject (or designee) continue to allow 
follow -up through global study completion which could be several years , even  post 
subject ’s permanent discontinuation of study medication.   
In all cases of impending study medication  disco ntinuation or subject request for 
stopping  study visits , Investigator s will discuss with the subject his/her options of 
continuing in the study .  It is important to continue to follow subjects that discontinue 
study medication  through global study completion at a frequency and approach that is 
agreed to between the Investigator and subject.  Visit schedule and assessments are flexible and at the discretion of the Investigator and subject and will be clearly 
documented in the me dical chart . Optimal data collection would include the following 
assessments through global study completion. 
• EOS subject status (must collect at minimum)  
• MACE Endpoint Questionnaire  
• AE Assessment  
Alternative options to support continued follow -up include  but are not limited to the 
following : 
1. Reduce d frequency of on -site visits  
2. Telephone visits in lieu of on -site visits  
3. Telephone or any contact method  
4. Telephone or any contact method with an alternative person (family member or medical designee)  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 18 of 98 5. Study team access to medical records for reporting MACE data  or vital status  
6. Reporting of vital status at the EOS visit which will occur at global study 
completion  
In the most extreme case, the protocol will accommodate minimal contact with a 
subject  or alternat ive method to obtain  vital status  at the global study completion . The 
objective is to keep a subject’s study status active to ascertain , at a minimum , vital 
status (alive or deceased) even if study medication  is permanently discontinued 
(Section 7.5.5.2 ) or there is a significant change in a subject’s personal or medical 
situation (i .e., home move, dialysis unit/provider change, kidney transplant, long -term 
care facility admission) .  
The I nvestigator will ensure understanding and documentation of the reasons for a 
subject’s desire to stop study procedu res or stop study medication . 
Minimizing Loss to Follow -up 
The I nvestigator must make every effort to contact subjects who fail to return for 
scheduled visits so that they will not be declared “lost to follow -up” (LTFU) .  The 
actions must include, but are not limited to, the following: 
• Contact all telephone numbers for the subject and his/her listed contacts (to be collected in the source at the subject’s entry into the study).  This 
includes making phone calls after normal business hours or on holidays 
or weekends.  
• Contact the subject’s primary care physician, referring specialist, 
pharmacist, or other healthcare professional, as applicable.  
• Send email, text, and postal mail with registered (traceable or  trackable) 
letters  to all the subject’s addresses and contact persons , as applicable.   
Registered (traceable or trackable) letters need to  be returned with a copy 
of the signature from whomever signed, which can be compared to the 
ICF for vital status dat a.  If un deliver able, then send non -registered 
standard letters, which may be forwarded to a new address if the subject has moved.  
• Review available medical records/notes for details of hospitalizations, 
clinic visits, or other procedures that may indicate the status of the 
subject, as applicable.  
• Utilize the internet to search for additional contact information, as applicable.  
• Check local, regional, and national public records to locate the subject or 
search for mortality status as allowed by law, as applic able.  
It is important to obtain vital status at the global study completion for subjects that 
have been LTFU during the study.   
The Sponsor may utilize a third -party provider in accordance with all applicable 
guidelines and legislation  to assist the site in locating contact information for all  
subject s during the study or in locating the vital status for all of their randomized 
subjects in anticipation of  global study completion (end of trial). 
Study Termination/  
Individual Study Site 
Termination  The entire trial may be suspended or terminated by the Sponsor for safety or other 
unanticipated reasons or upon request of regulatory agencies.  If this occurs, prompt notification will be given to Investigators, Institutional Review Boards 
(IRBs)/Institution al Ethics Committees (IECs), and regulatory authorities in 
accordance with regulatory requirements.  
The Investigator must notify the Sponsor if the trial is terminated by the Investigator or 
the IRB/IEC at the site.  If the Investigator, IRB/IEC, or Sponso r decides to terminate 
or suspend the trial conduct at a particular investigative site for safety, non -enrollment, 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 19 of 98 non-compliance with the protocol, or other unanticipated reasons, the above parties 
will be promptly notified.  
Statistical 
Considerations  Primary Efficacy Endpoint Analysis  
The primary efficacy endpoint is defined as the mean Hb change from Baseline (mean 
pretreatment Hb) to the mean Hb from Weeks 24 to 36 (inclusive).  
The primary analysis will use an analysis of covariance (AN COVA)  with multiple 
imputation , stratified by the randomization strata and using Baseline H b as the 
covariate .  
A 2-sided, 95% confidence interval (CI) will be calculated for the difference between 
the vadadustat group and control group.  Noninferiority of vadadustat wi ll be 
established if the lower limit of this CI is ≥ -.75 g/dL.  
Analysis of MACE and Expanded MACE C omponent s 
The MACE endpoint (adjudicated result) will be analyzed as the time (days) from 
randomization date to first MACE  +1.  Subjects who have not experienced an 
adjudicated MACE by study closure will be censored as of their last assessment time.  
Major adverse cardiovascular events will be analyzed using a stratified Cox proportional hazards model with a model containing treatment group.  The 
randomization strata will be used in this analysis.  The primary MACE analysis will 
take place at study conclusion and will be based upon all subjects in the randomized  
population.  The hazard ratio (vadadustat /control) will be estimated, together with its 
95% CI.  As this individual study has not been powered to provide a stand -alone 
assessment of MACE, this interval will be considered as descriptive.  Time to first 
MACE will also be graphically presented using  Kaplan -Meier curves.  
These analyses will be repeated with censoring occurring 4 weeks following early 
discontinuation of study medication.    
The following safety endpoints will also be summarized using time to event methods as for MACE:  
1) Individual components (all -cause mortality, non -fatal myocardial infarction, 
non-fatal stroke) of MACE  
2) Thromboembolic events (defined as arterial thrombosis, DVT, PE, or vascular access thrombosis)  
3) Hospitalization for HF  
4) Expanded MACE, defined as all -cause mortality , non -fatal myocardial 
infarction, non- fatal stroke, hospitalization for HF, or thromboembolic event . 
For these endpoints the incidence ("yes"/"no") of the endpoint will be presented for each treatment arm.  Kaplan -Meier curves will be presented for each e ndpoint as the 
time of endpoint free survival (i .e., time until endpoint or death).
 
An independent statistical analysis center will perform analyses in support of the Independent Data Monitoring Committee (IDMC).  
Sample Size 
Estimation  For the primary efficacy analysis, it will be assumed that the difference in mean change 
in Hb for vadadustat will be the same as the active control, darbepoetin  alfa, and the 
common standard deviation for the mean change will be assumed to be 1.5 g/dL.  T he 
noninferiority margin of -0.75 g/dL will be used (for vadadustat minus darbepoetin 
alfa).  With these assumptions and approximately 1650 subjects per treatment group, 
the noninferiority test will have >99% power.  
The primary MACE analysis will be based upon all events that accrue over the 
2 DD-CKD studies (Studies AKB- 6548 -CI-0016  and AKB -6548 -CI-0017 ).  It has been 
calculated that 631 events will be required overall to have 80% power to establish 
noninferiority wi th a margin of 1.25  when evaluated with a 2 -sided 95% confidence 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 20 of 98 interval assuming no difference between the treatments.   With 631 events, the power is 
>90% to establish  noninferiority with a margin of 1.25 if the hazard ratio is 0.95 
favoring vadadustat.    
A MACE rate of 12% annually is anticipated in both treatment arms based on a 
comprehensive review of available epidemiology and prospective clinical trials in the 
field.   
Independent Data 
Monitoring 
Committee  (IDMC)  An IDMC will be established to revie w and discuss the available study data as subjects 
are enrolled and followed.  The team will meet approximately twice per year throughout the course of the study.  The IDMC will be unblinded and will include, at a 
minimum, a nephrologist, a cardiologist, a nd a biostatistician.  The discussions of the 
IDMC will include a review of key safety  data (ie, AEs, vital sign measurements, and  
laboratory assessments).  
Endpoint 
Adjudication Committee (EAC)  An independent safety EAC, blinded to treatment assignment, w ill be formed prior to 
study commencement to adjudicate the components of the primary safety endpoints (e.g., all-cause  mortality , non-fatal myocardial infarction, and non-fatal stroke).  
Thromboembolic events and hospitalization for HF will also be adjudicated by the 
EAC.  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 21 of 98 3 LIST OF ABBREVIATIONS 
 
AE adverse event  
ALT  alanine aminotransferase (SGPT)  
ANOVA  analysis of variance  
AST  aspartate aminotransferase (SGOT)  
β-HCG  beta human chorionic gonadotropin 
BCRP  breast cancer resistance protein  
BP blood pressure 
BUN  blood urea nitrogen 
CBC  complete blood count 
CHF  congestive heart failure  
CI confidence interval 
CKD  chronic kidney disease 
CMH  Cochran- Mantel -Haenszel  
CPK  creatine phosphokinase 
CRF  case report form  
CRO  contract research organization  
CRP  C-reactive protein  
CS clinically significant  
CV cardiovascular  
CVD  cardiovascular disease  
DD-CKD  dialysis dependent chronic kidney disease  
dL deciliter  
DNA deoxyribonucleic acid 
DVT  deep venous thrombosis 
EAC  Endpoint Adjudication Committee  
ECG  electrocardiogram  
EDC  electronic data capture  
EOS  end of study 
EOT  end of treatment 
EPO  erythropoietin  
ESA  erythropoiesis -stimulating agent  
ESC Executive Steering Committee  
ESRD  end-stage renal disease  
EU European Union 
FDA  Food and Drug Administration 
g gram  
GCP  Good C linical Practice  
GFR  glomerular filtration rate  
GMP  Good Manufacturing Practice 
HAs Health A uthorities  
HDL  high- density lipoprotein  
HF heart failure  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 22 of 98 Hb hemoglobin 
HIF hypoxia-inducible factor 
HIFPH  hypoxia-inducible factor prolyl-hydroxylase 
HIF-PHI hypoxia-inducible factor prolyl- hydroxylase inhibitor  
IC50 50% inhibitory concentration 
ICH International Council for Harmonis ation  
ID identification  
IDMC Independent D ata Monitoring C ommittee  
IEC independent ethics committee 
INR international normalized ratio  
IRB institutional review board 
IV intravenous (ly) 
IWR  interactive web response  
JSDT  Japanese Society for Dialysis Therapy  
JSN Japanese Society  of Nephrology 
KDIGO  Kidney Disease: Improving Global Outcomes 
kg kilogram 
LDH  lactate dehydrogenase  
LDL  low-density lipoprotein  
LDO  Large Dialysis Organization 
LTFU  Lost to Follow-up 
LLN  lower limit of normal 
MACE  major adverse cardiovascular events  
mcg micrograms  
MCH  mean corpuscular (cell) hemoglobin 
MCHC  mean corpuscular (cell) hemoglobin concentration 
MCV  mean corpuscular ( cell) volume  
MedDRA  Medical Dictionary for Regulatory Activities  
MI myocardial infarction  
µM micromolar 
mg milligram  
mL milliliter  
mmHG  millimeters of mercury 
mRNA  messenger ribonucleic acid   
ng nanogram 
NDD- CKD  non-dialysis -dependent chronic kidney disease 
NYHA New York Heart Association  
PD pharmacodynamics(s)  
PE pulmonary embolism 
PHD  prolyl 4-hydroxylase domain 
PI Package I nsert  
PK pharmacokinetic (s) 
PP per protocol 
PT prothrombin time 
PTT partial thromboplastin time  
RBC  red blood cell 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 23 of 98 RDW  red cell distribution width  
ROW  rest of world  
SAE  serious adverse event  
SAP Statistical Analysis Plan 
SC subcutaneous (ly) 
SGOT  serum glutamic oxaloacetic transaminase (AST)  
SGPT  serum glutamic pyruvic transaminase (ALT)  
SmPC  summary of product characteristics  
SV Screening visit  
TIBC  total iron binding capacity 
TREAT  Trial to Reduce Cardiovascular Events with Aranesp Therapy  
TSAT  transferrin saturation  
ULN  upper limit of normal 
US United States  
VEGF  vascular endothelial growth factor  
WBC  white blood cell  
WHO  World Health Organization 
 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 24 of 98 4 BACKGROUND INFORMATI ON 
Chronic kidney disease (CKD), defined as the presence of kidney damage or a decreased level of 
kidney function, is a major public health problem worldwide.  Globally, CKD is estimated to affect between 8 % to 16% of the population ( Jha et al.  2013 ; KDIGO 2013).  At the most 
advanced stages of CKD, end- stage renal disease (ESRD), patients require chronic dialysis or 
kidney transplantation to sustain life.  Chronic kidney disease is not only a cause of ESRD, but is also a significant risk factor for cardiovascular disease (CVD), infection,  cancer, and mortality 
(Iseki and Kohagura 2007). 
Renal anemia often develops during the progression of CKD and is present in almost all patients with ESRD.  Anemia is defined as a decrease in circulating red blood cell (RBC) mass that is usually detected by low hemoglobin ( Hb) concentration.  The causes of anemia in CKD include 
blood loss, shortened RBC lifespan, iron deficiency, erythropoietin (EPO) deficiency, and inflammation (Nurko 2006).  Although many factors contribute to anemia in CKD, it occurs primarily due to an inadequate synthesis of EPO by the kidneys, leading to a deficiency in the 
production of RBC progenitor cells by the bone marrow.  Also contributing to anemia in CKD 
are impaired iron homeostasis and iron loss, which often necessitate iro n supplementation 
(Nurko 2006).  Anemia in CKD patients usually occurs when the glomerular filtration rate 
(GFR) falls below 60  mL/min/1.73 m
2, and is present in >90% of the patients undergoing 
dialysis (CKD Stage  5) (Goodkin et al. 2011). 
The main impact of anemia on organ function is reduced oxygen delivery to tissues leading to a 
constellation of symptoms including fatigue, shortness of breath, and exercise intolerance (Stauffer  and Fan  2014) .  In patients with anemia related to CKD, comp ensatory changes occur 
in cardiac structure and function, including an increase in cardiac output, the development of left ventricular hypertrophy, and, eventually, the development of heart failure ( Metivier  et al.  2000).  
Risk of stroke also increases wit h anemia, which may be an underlying mechanism leading to 
stroke in CKD ( Abramson et al.,  2003;  Iseki and Kohagura  2007).  Other consequences from 
anemia in CKD patients include impaired cognitive function, sleep disorders, and depressed immune function, w hich can impact the quality of life in these patients (Iseki and 
Kohagura 2007; NICE  2011) .  Overall, anemia contributes to a poorer prognosis in patients with 
CKD (Nurko  2006; Iseki and Kohagura 2007). 
Erythropoiesis -stimulating agents (ESAs) administered  either intravenously (IV) or 
subcutaneously (SC), along with oral or IV iron therapy, are currently the cornerstones for treating anemia in patients with CKD.  Treatment with exogenous recombinant ESAs can raise Hb levels, relieve symptoms, and reduce the complications of anemia, including RBC 
transfusions which carry the risks of infection, iron overload, and impact candidacy for kidney transplantation. 
Clinical practice guidelines and prescribing information for approved ESAs and guidelines 
provided by t he United States (US) Food and Drug Administration (FDA), the European Union 
(EU), the Japanese Society of Nephrology, and the Japanese Society for Dialysis Therapy Guideline Committee differ slightly in their recommendations for treatment of renal anemia,  as 
summarized in  Table 1. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 25 of 98 Table 1 Treatment Guidelines and Prescribing Information for Renal Anemia in 
DD-CKD 
KDIGO guidelines  Treatment should be given when  Hb is between 9.0 -10.0 g/dL (Kidne y Disease: 
Improving Global Outcomes [KDIGO] 2012).   ESAs should not be used to maintain Hb 
above 11.5 g/dL  
US darbepoetin alfa 
label  Initiate treatment when the Hgb level is less than 10 g/dL.  I f Hb approaches or exceeds 
11.0 g/dL  in adults on dialysis, the dose of ESA should be reduced or interrupted  
(darbepoetin alfa [ Aranesp®) US Package Insert  2017). 
EU practice 
guidelines  Individualize dosing to achieve and maintain hemoglobin levels within the range of 100 to 
120 g/L (10.0 – 12.0 g/dL).  Hemoglobin levels should not exceed 120 g/L (12.0 g/dL).  
(Aranesp EU Label ). Detailed information on darbepoetin alfa in the EU is available on 
the European Medicines Agency web site.  
Japan practice 
guidelines  JSDT recommends that ESA treat ment be initiated when Hb is below 11.0  g/dL following 
a diagnosis of renal anemia in DD -CKD.  JSN 2013 does not provide a clear 
recommendation or maintenance range for Hb.  Both guidelines recommend that if the Hb 
exceeds 13.0  g/dL, the dose of ESA should be reduced or interrupted.  In patients with 
CVD or complications, ESA treatment should be reduced or interrupted if the Hb exceeds 
12.0 g/dL ( Tsubakihara  2010; Japanese Society of Nephrology  2014).  
Abbreviations: CVD  = cardiovascular disease; DD -CKD  = dialysis dependent chronic kidney disease;  ESA  = erythropoietin 
stimulating agent; EU  = European Union; Hb = hemoglobin; JSDT  = Japanese Society for Dialysis Therapy; JSN  = Japanese 
Society of Nephrology;  KDIGO  = Kidney Disease Improving Global Outcomes; US  = United States.  
 
The majority of patients with ESRD  currently receive interventional therapy in the form of iron 
therapy and an ESA if their Hb  levels fall below 10.0 to 11.0 g/dL, dependent upon local clinical 
practice guidelines.  
A number of large, prospective, randomized controlled trials in CKD (Stages 3 to 5) have 
explored the potential benefit of ESAs in patients with CKD with respect to overall mortality, 
cardiovascular (CV) events, and progression of CKD with higher Hb  target s (≥13.0 g/dL) 
(Besarab  et al.  1998; Drüeke et al.  2006; Singh et al.  2006 ; Pfeffer  et al.  2009a ; 
Pfeffer  et al. 2009b) .  These trials did not demonstrate the expected beneficial effects of 
correcting anemia on these outcomes, but suggested an increased risk of death and CV events when targeting higher Hb  levels (Besarab  et al.  1998; Drüeke et al.  2006 ; Singh et al.  2006; 
Pfeffer  et al. 2009a ; Pfeffer  et al.  2009b) .  Additional analyses from these trials suggest that the 
risk of death or CV events appears to be highest in CKD patients who fail to respond to ESAs, as indicated by lower achieved Hb  levels and higher average ESA dose requirements 
(Szczech  et al. 2008; Solomon et al.  2010) .  This suggests that in some subjects the ESAs 
themselves, and not the Hb level, may be causative of the increase in events.  This is supported 
by studies in CKD patients on dialysis with naturally high Hb  levels and no increase in CV 
events (Goodkin et al.  2011). 
The risks identified with ESAs from these trials have led to changes in prescribing information and practice guidelines in the US, the EU, and Japan that guide clinicians toward more cautious use of ESAs and targeting lower Hb  levels.  In the US, the mortality and CV risks associated 
with ESAs are outlined in a black-box warning in the prescribing information of ESAs with a recommendation to use the lowest dose possible to avoid transfusions.  While no similar major warnings exist in the EU Summary of Product Characteristics (SmPC) or on the approved labeling for ESAs in Japan, the EU SmPCs for ESAs do suggest caution with the use of these drugs, with a recommendation to keep Hb  levels below 12.0 g/dL, while the Japanese practice 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 26 of 98 guidelines recommend ESA treatment be reduced or interrupted if the Hb  exceeds 12.0  g/dL in 
patients with CVD or complications.   Further, recent EU clinical practice guidelines 
(Locatelli  et al. 2013) recommend that risk factors for stroke (including a past history of stroke) 
and the presence of active malignancy or a past history of malignancy should be taken into 
account when making decisions to use ESAs for the treatment of anemia. 
The risks associated with ESAs, including an increased risk of death and CV events, highlight 
the need for additional therapies that might minimize or avoid these risks when compared to currently available recombinant protein -based ESAs.  Therefore, the unmet medical need for  the 
treatment of anemia in dialysis dependent CKD (DD -CKD) patients remains high, especially 
from a CV safety perspective.  To fulfill this unme t need, the vadadustat clinical program is 
focused on developing an orally active therapeutic for the treatment of anemia in patients with CKD.  
4.1 Hypoxia- Inducible Factor Prolyl -Hydroxylase Inhibitors 
Please see the vadadustat Investigator ’s Brochure for additional discussion and information for 
the following section . 
Vadadustat is a synthetic, orally bioavailable, small molecule being developed as an inhibitor of hypoxia-inducible factor prolyl- hydroxylases (HIF -PHs) for the treatment of anemia associated 
with CKD.  Hypoxia-inducible factor prolyl- hydroxylase enzymes are also referred to as prolyl 
4-hydroxylase domains (PHDs), of which the 2 most commonly expressed are PHD2 and PHD3.  Vadadustat is a slightly more potent inhibitor of PHD3 (50% inhibitory concentration [IC
50] = 0.08 µM) than of PHD2 (IC 50 = 0.19 µM).  The inhibition of PHD3 and PHD2 stabilizes 
hypoxia- inducible factor (HIF)-2α and HIF -1α, which in turn stimulates the production of EPO.  
In vivo anim al efficacy and messenger ribonucleic acid (mRNA) data indicate that vadadustat 
induces the production of EPO from both renal and extra- renal sites (liver and brain), and  this 
increase in EPO results in an increase in RBC production in the bone marrow.  In clinical trials, vadadustat has been shown to facilitate iron homeostasis by decreasing hepcidin and increasing transferrin levels in healthy adult male volunteers and male and female CKD patients.  This enables iron transport mechanisms that should enhan ce the terminal steps of erythropoiesis.  
Vadadustat offers the potential of flexible oral dosing that provides a more gradual and reliable means of titration than injectable hormones.  Therefore, vadadustat is being developed as an alternative to the existing protein hormone ESAs. 
4.2 Summary of Clinical Experience  
Please see the vadadustat Investigator Brochure for additional discussion and information for 
the following section . 
To date, the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD)  profiles of 
vadadustat have been characterized in 9 completed Phase 1 studies in healthy volunteers 
including 1 ethno-bridging study in Caucasian & Japanese subjects, 1 completed Phase 1 study 
in subjects undergoing chronic hemodialysis, 3 completed Phase 2a studies in NDD- CKD 
subjects, 1 completed Phase 2b study in NDD-CKD subjects, and 1 completed Phase 2 study in DD-CKD subjects.  The Phase 2a studies evaluated Stages 3, 4, and 5 CKD (not on dialysis) 
subjects in a single-dose PK study, a multi- dose, 28-day, open-label, dose escalation pilot study, 
and a randomized, placebo-controlled study with 5 different dose groups dosed for 42 days.  The Phase 2b study evaluated Stages 3, 4, and 5 CKD (pre-dialysis) dosed for 20 weeks.  The phase 2 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 27 of 98 study evaluated DD-CKD subjects on chronic hemodialysis dosed for 16 weeks.  In the studies 
completed to date, a total of 548 subjects have received vadadustat, including 200 healthy volunteers and 348 subjects with CKD. 
Vadadustat has showed dose- dependent increases in  EPO concentrations in Phase 1 and Phase 2a 
studies.   The changes in EPO have been accompanied by an increase in reticulocytes as well as 
dose responsive increases in total  iron binding capacity ( TIBC ) and decreases in hepcidin and 
ferritin.  Overall, the safety profile for v adadustat has been acceptable and has supported further 
development.  Vadadustat has demonstrated dose proportional PK and dose-dependent PD 
(changes in serum EPO and/or Hb) in Phase 1 and Phase 2 studies covering the dose range of 
80 mg to 1200 mg after single administration and 500 to 900 mg after repeated daily administration.  The plasma half -life of vadadustat was about 4 to  5 hours, 7 to  8 hours, and 9 to 
10 hours in healthy subjects, NDD-CKD patients, and DD- CKD patients, respecti vely.    
Vadadustat is extensively metabolized.  Vadadustat and its metabolites are eliminated  from the 
body by dual routes of elimination (both renal  and fecal).   The urinary excretion of vadadustat 
and its metabolites has been shown to be less than 60% in healthy human volunteers.  In a clinical study conducted to evaluate the effect of hemodialysis on the exposures to vadadustat, hemodialysis did not have an effect on the exposures of vadadustat or its metabolites.   Given its 
short half-life and the dual routes of elimination, vadadustat is unlikely to accumulate in patients with CKD.  
A 16 -week, open- label, multicenter, Phase 2 trial evaluated vadadustat in 94 subjects receiving 
chronic hemodialysis previously maintained on epoetin alfa.  Subjects were assigned to one of three vadadustat dose cohorts: 300 mg daily, 450 mg daily, or 450 mg thrice weekly.  Sixty -nine 
of the 94 subjects completed the study.  The primary endpoint was the mean Hb change from pre-treatment average to mid -trial (W eek 7 -8) and end-of- trial (Week 15-16) and was analyzed 
using observed Hb values (no imputation for missing data).  No statistically significant mean change in Hb from pre- treatment average was observed for either of the two time  points for any 
of the three treatment groups.  For all three treatment groups, group mean Hb concentrations, analyzed using observed data, remained stable at mid - and end-of-trial, with one subject with an 
excursion >13.0 g/dL. 
Based on the Phase 1 and Phase  2 study results, vadadustat appears to be  a suitable candidate for 
continued development as a treatment for anemia in patients with DD-CKD.  
4.3 Potential Benefits and Risks  
Please see the vadadustat Investigator ’s Brochure for additional discussion and information for 
the following section . 
Trials of injectable erythropoiesis -stimulating agents (ESAs) in patients with anemia secondary 
to NDD- CKD or DD- CKD have demonstrated an increased risk of cardiovascular events 
associated with higher Hb targets (Besarab 1998; Singh 2006; Pfeffer 2009).  Post -hoc analyses 
performed by the FDA and others have shown an association between these adverse outcomes 
and supraphysiologic serum EPO levels and/or Hb oscillations and overshoots (McCullough 2013, Unger 2010).  In studies of to date, oral vadadustat daily increased mean Hb 
with few excursions above the target range.  In addition, serum EPO levels remained well below those reported with ESAs in the literature.  As a result, the re is the potential for the 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 28 of 98 investigational drug vadadustat to provide an effective and safe therapeutic option for the 
treatment of renal anemia.  
In addition, vadadustat may enhance iron metabolism and transport.  Phase 1 and Phase 2 trials have demonstrated a consistent dose -dependent increase in TIBC and decrease in ferritin and 
hepcidin.  Mechanistic studies have demonstrated that HIF stabilization downregulates the iron 
absorption regulator hepcidin, and upregul ates the iron -mobilizing regulators ferroportin and 
transferrin (and its receptor) (Peyssonnaux et al. 2007).  Potential clinical benefits include enhanced erythropoiesis and decreased exogenous iron requirements. 
The toxicological profile of vadadustat supports continued development in the ongoing Phase 3 
clinical trials.  Dose -limiting toxicity noted in the exploratory toxicology studies was due to 
hemoglobinuric nephropathy (rat) and emesis associated with body weight loss (dog).  Dose -limiting toxicity noted in the sub-chronic and chronic toxicology studies was due to 
exaggerated pharmacology and the sequelae of events related to polycythemia (increased RBC mass, blood hyperviscosity and fibrin thrombi); polycythemia- related toxicity was consistent 
across species, monitorable and reversible.   In the completed clinical studies, vadadustat has had 
an acceptable safety profile to support further development.  
5 STUDY OBJECTIVES AND ENDPOINTS  
5.1 Primary Objective  
The primary objective of this study is to demonstrat e the efficacy and safety of vadadustat 
compared with darbepoetin alfa for the maintenance treatment of anemia in subjects with DD -
CKD. 
5.2 Primary Efficacy Endpoint  
The primary endpoint used to assess the efficacy  objective will be the mean change in Hb  
between Baseline (mean pretreatment Hb) and the primary evaluation period (mean Hb  from 
Weeks 24 to  36). 
5.3 Secondary Efficacy  Endpoints  
Key secondary efficacy endpoints include the following: 
• Mean change in Hb value between Baseline (mean pretreatment Hb) and the secondary 
evaluation period (Weeks 40 to  52) 
• Proportion of subjects with Hb  values within the target range  during the primary 
evaluation period (Weeks 24  to 36) 
• Proportion of subjects with Hb values within the target range during the secondary 
evaluation period (Weeks 40 -52)  
Other secondary efficacy endpoints include:  
• Proportion of time with Hb values within the target range during the primary evaluation period (Weeks 24-36) 
• Proportion of time with Hb values within the target range during the secondary 
evaluation period (Weeks 40-52) 
• Proportion of subjects with Hb increase of >1.0 g/dL from Baseline 

Protocol No.  AKB -6548- CI-0017  
Amendment 5 ( Version 6 ) 
Akebia  — Company Confidential  
Page 29 of 98 •Time to achieve Hb increase of >1.0 g/dL from Baseline
•Mean change in Hb between Baseline (mean pretreatment Hb ) and the primary evaluation
period (mean Hb from Weeks 24-36) stratified by pre-baseline ESA exposure
•Proportion of subjects receiving IV iron therapy from Baseline to Week 52
•Mean monthly dose of IV elemental iron administered from Baseline to Week  52 in
subjects who have received IV iron
•Proportion of subjects receiving RBC transfusion(s) from Baseline to Week 52
•ESA rescue
•Dose adjustments from Baseline to Week 52
5.4 Safety Endpoints  
Safety endpoints in this study include the following: 
•Major adverse cardiovascular events (MACE) , defi ned as all -cause mortality, non- fatal
myocardial i nfarction, or non- fatal stroke
•Individual components of MACE:
oAll-cause mortality
oNon- fatal myocardial infarction
oNon- fatal stroke
•Thromboembolic events: arterial thrombos is, deep vein thrombosis (DVT), pulmonary
embolism (PE), or vascular access thrombosis
•Hospitalization for heart failure  (HF)
•Expanded MACE, defined as all -cause mortality, non- fatal myocardial infarction, non-
fatal stroke, hospitalization for HF, or thromboembolic event
•Fatal/non- fatal MI
•Fatal/non- fatal stroke
•Sudden death
•Cardiovascular death
•Non-cardiovascular death
•Hospitalization
•Hb >12.0 g/dL, >13.0 g/dL, or >14.0 g/dL
•Hb < 8.0 g/dL
•Hb increase >1.0  g/dL wit hin any 2-week interval or >2.0 g/dL  within any 4- week
interval
•AEs and SAEs
•Vital signs and clinical laboratory values .
5.5 Exploratory Endpoints 
•Biomarkers ( including, but not limited to, hepcidin and vascular endothelial growth
factor [VEGF])
•Time to achieve stable Hb values within target ran ge
•Proportion of subjects with Hb values in the target range without evidence of ironoverload

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 30 of 98 6 STUDY DESIGN 
6.1 Study Design 
This is a P hase 3, randomized, open- label, active -controlled study of  vadadustat versus 
darbepoetin alfa for the maintenance treatment of anemia in subjects with DD- CKD ( either 
peritoneal dialysis or hemodialysis) after conversion from erythropoiesis- stimulating agent 
(ESA)  therapy.  Target enrollment in this study is approximately  3300 subjects at approximately 
300 investigativ e sites in North America, Latin America, Europe, and Asia Pacific.  
Subjects will be randomized  at the Baseline visit using an Interactive Web Response (IWR)  
system to receive either vadadustat at a starting dose of two 150 mg tablets once daily 
(300 mg/day) or darbepoetin  alfa (based on the current PI for investigational sites in the US and 
the SmPC for all other investigational sites (non -US) for adult patients with CKD on dialysis).  
Randomization will be stratified by geographic region (US versus EU  versus rest of world 
[ROW]), by New York Heart Association  congestive heart failure (CHF) Class 0 (no CHF) or I 
versus II or III, and by study entry Hb  (<10.0 versus ≥10.0 g/dL). 
Following randomization, there will be 3 periods during the study: 
• Conversion and Mai ntenance Period (Weeks 0 to 52): conversion to study medication for 
maintaining Hb (Weeks 0 -23), primary efficacy evaluation (Weeks 24 -36), and secondary 
efficacy evaluation  (Weeks  40-52)  
• Long- term Treatment Period (Week 53 to  EOT ): continued study medication to assess 
long- term safety  
• Follow-up P eriod  (EOT  + 4 weeks): post -treatment visit for safety (either in person or via 
telephone) 
A HemoCue  point of care device will be used throughout the study to monitor Hb  to determine if 
the dose of study medication (vadadustat or darbepoetin alfa) will be adjusted  or interrupted .  
From Weeks 0 to 12, HemoCue will be used to monitor Hb  every 2  weeks for d ose adjustment.  
From Week  12 to Week  52, Hb  will be monitored via HemoCue every 4 weeks unless more 
frequent monitoring is clinically indicated or warranted based on dosing changes .  From 
Week  53 through the end of study, Hb  will continue to be monitored via HemoCue to determine 
if the dose of study medication will be adjusted, interrupted, or maintained .  Hemoglobin will 
also be assessed with a complete blood count (CBC) through the central laboratory for efficacy 
and safety  evaluations; however, dose adjustments should be based on the HemoCue Hb  value. 
The aim of the dosing strategy is to maintain Hb levels of 10.0 g/dL to 11.0 g/dL in the US 
and 10.0 g/dL to 12.0 g/dL outside of the US throughout the study.  
Subjects assigned to vadadustat will initiate dosing at 2 tablets once daily at the Baseline visit.   
Adjustments to doses for vadadustat will be guided by Hb  concentration and Dose Adjustment 
Algorithm s (Section  8.4.4.1, Vadadustat Dosing and Dose Adjustment Algorithms ). 
For subjects randomized to darbepoetin alfa, the initial dose will be based on the current PI for investigational sites in the US and the SmPC for all other investigational sites (non -US) for adult 
patients with CKD on dialysis : 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 31 of 98 • For subjects already on darbepoetin alfa , the initial dosing regimen in the study should be 
based on the prior dosing regimen. 
Following dose conversion, darbepoetin alfa  will be dosed IV/ SC with dose adjustments guided 
by the Dose Adjustment Algorithm s (Section  8.4.4.2, Darbepoetin Alfa Dosing and Dose 
Adjustment Algorithms ).  Darbepoetin alfa dosing is independent of the visit schedule, and the 
dosing schedule may shift per local standard of care and Investigator discretion . 
Investigators will prescribe iron supplementation ( IV, oral, or intradialytic) as needed during the 
study to maintain ferritin ≥100 ng/mL or TSAT ≥20%  (see Section  8.4.6, Iron Supplementation 
for details regarding iron supplementation during the study).  Subjects already receiving oral iron 
supplementation as part of their treatment plan may continue their current treatment regime n.  
For subjects who are on peritoneal dialysis, oral iron supplementation is allowed as per local 
guidelines and routine practice. 
Clinical and safety assessments (including laboratory assays,  PK evaluations [both vadadustat 
parent compound and metabolite s], MACE endpoint data, vital sign measurements, and AE s) 
will be perform ed as indicated at Screening, during the Conversion and Maintenance Period 
(Baseline [Week 0], Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52), during 
the Long- term Treatment Period  (visits approximately every 3 months, Weeks 53 to  EOT) , and 
during the Follow-up P eriod (4  weeks after the EOT).   Refer to Section  9, Study Procedures and 
Schedule of Activities  and Appendix A:  Schedule of Activities  for additional details. 
The study will be considered completed (end of trial) when approximately 631 major adverse 
cardiovascular events (MACE) have accrued over the 2  DD- CKD studies (Studies  AKB-6548-
CI-0016 and AKB-6548- CI-0017), and all enrolled subjects have had the opportunity to have 
their Visit 13 (+/- 5 days).  All subjects will remain in the study until the global study completion 
(end of trial), at which time  subjects will be scheduled for a final visit, and the study will close 
(see Section  11.1.2, Sample Size for the Primary Safety  Endpoint ). 
6.2 Rationale for Study Design 
During prior clinical trials, vadadustat has demonstrated dose proportional PK and dose-dependent PD.  Vadadustat showed dose- dependent increases in  EPO concentrations in Phase 1 
and Phase 2 studies.  The changes in EPO have been accompanied by an increase in reticulocytes as well as dose responsive increases in TIBC and decreases in  hepcidin and ferritin.  Overall, the 
safety profile for v adadustat  has been acceptable and has supported further development.  
In a clinical study conducted to evaluate the effect of hemodialysis on the exposures to vadadustat, it was determined that the hemodialysis procedure did not impact the exposures of 
vadadustat o r its metabolites.  Vadadustat is eliminated from the body by dual routes of 
elimination, both renal and fecal.  Given the dual routes of elimination, vadadustat is unlikely  to 
accumulate in patients with CKD.  Based on the Phase 1 and Phase 2 study results, continued 
development of vadadustat as a treatment for anemia in patients with CKD is warranted.  
In this study, darbepoetin alfa was chosen as an active comparator  as it is marketed and available 
globally and has an extensive safety profile.  This is pa rticularly relevant in the current medical 
and regulatory climate given the accumulating trial findings that resulted in the FDA revising the prescribing information for the currently marketed ESAs.  These trial results indicate an increased risk of death and adverse CV events, such as stroke and heart failure, particularly when using ESAs to achieve a higher Hb  concentration.  In the US, the mortality and CV risks 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 32 of 98 associated with ESAs are outlined in a black -box warning in the prescribing information of 
ESAs, with a recommendation to use the lowest dose possible to avoid transfusions.  While no 
similar major warnings exist in the EU SmPC  or on the approved labeling for ESAs in Japan, the 
EU SmPCs for ESAs do suggest caution with the use of these drugs, with a recommendation to 
keep Hb  levels below 12.0 g/dL.  Recent clinical practice guidelines ( Locatelli  et al.  2013) 
recommend that risk factors for stroke and malignancy should also be taken into account when making treatment decisions to use ESAs for the treatment of anemia.  
Given the concerns associated with marketed ESAs, a goal of this study will be to evaluate the CV events during the treatment of anemia with vadadustat.  The inclusion of a MACE endpoint in this study will allow for a statistical compa rison of the rates of CV events between vadadustat 
and darbepoetin alfa treatment groups when used to treat anemia associated with DD -CKD.  
While the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)  (Pfeffer  et 
al 2009b) compared differen t Hb targets, the present study will have similar Hb targets between 
treatment arms.  Importantly, the Hb goals for this study are lower than those used in TREAT 
and are consistent with practice guidelines and prescribing information for approved ESAs. 
This study will be performed as an open- label study.  Because Hb values are objective and will 
be measured via a central laboratory for all efficacy endpoints, efficacy assessments are not 
considered to be subject to bias with an open-label design.  Blinding of this study presented inherent practical problems, including potential dosing errors, inappropriate dose adjustments, and delays in dosing, which may also increase the safety risk to study participants.  Given the differing dosing regimens and routes for vadadustat (oral) and darbepoetin alfa (IV/SC injection), a double -dummy design would have been required, which also created ethical 
concerns and required extensive coordination to maintain the blind.  To minimize bias, the Sponsor and contract research organization (CRO) study teams will remain blinded to ‘by treatment’ aggregated analyses, except for the unblinded statistician.  In addition, the study will involve blinded adjudication of MACE, the use of an independent data monitoring committee (IDMC), a nd an identical schedule of visits, procedures, and assessments for both treatment 
groups in order to reduce the potential for bias.  However, certain personnel directly involved in medical  oversight of the study, regulatory reporting of safety information, and on- site monitoring 
activities may become unblinded to the treatment assignments of individual subjects during the course of the study.  In addition, to reduce subjectivity of dose adjustment, adjustments to doses for vadadustat and darbepoetin alfa will be guided by Hb  concentration and the Dose Adjustment 
Algorithms . 
6.3 Dose Justification 
The starting dose and the proposed dosing algorithm in this study are designed to maintain Hb  in 
a predictable and controlled manner while minimizing abrupt increases or excessive rises in Hb 
levels.  Based on plasma concentrations and PD measures from previously conducted clinical studies with vadadustat, a population PK/PD model was developed.  Using this model and the proposed dosing algorithm, simulations were carried out to evaluate the effects of different starting doses and the resulting Hb  responses to support the dosing rationale.  Results of the 
simulations indicated that a starting dose regimen of 300 mg once daily along with the proposed 
dosing algorithm are optimal to maintain Hb  levels of 10.0 to 11.0 g/dL in the US and 10.0 to 
12.0 g/dL outside of the US while minimizing excessive rises.  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 33 of 98 6.4 Executive Steering Committee and Independent Data Monitoring Committee  
6.4.1 Executive Steering Committee  
An Executive Steering Committee (ESC) will be established, which will be blinded to the 
randomization, and will oversee the study and provide expert input to assure a high scientific standard.  The ESC m ay function as the Publication Committee.  The ESC membership will 
comprise recognized academic leaders, including those from the field of nephrology and cardiology.  Details on the roles and responsibilities of the ESC will be described further in the ESC charter.  
6.4.2 Independent Data Monitoring Committee  
An IDMC will be established to review and discuss study safety data as subjects are enrolled and  
followed.  The team will meet approximately twice per year throughout the course of the study.  The IDMC will b e unblinded and will include, at a minimum, a nephrologist, a cardiologist, and 
a biostatistician.  The discussions of the IDMC will include a review of key safety data (ie, AEs, vital signs, and laboratory assessments).  Written records of the IDMC meetin gs, the materials 
reviewed, and the decisions made will be maintained.  Details on the roles and responsibilities of the IDMC and guidelines for monitoring study safety data will be described further in the IDMC charter.  
6.5 Endpoint Adjudication Committee  
An independent safety endpoint adjudication committee (EAC) will be formed prior to study 
commencement to adjudicate the primary safety endpoints ( all-cause mortality , non- fatal 
myocardial infarction, and non- fatal stroke).  Thromboembolic events and hospital ization for HF  
will also be adjudicated by the EAC.  The committee will be blinded throughout the course of the study.  The EAC will be composed of independent experts with experience and training appropriate for adjudication of MACE, thromboembolic events, and hospitalization for HF .  
Details on the responsibilities of the EAC will be described further in the EAC charter.  
7 SELECTION AND WITHDRAWAL OF SUBJECTS  
7.1 General Criteria  
To be eligible for this study, a subject or their legally acceptable representative must provide valid informed consent and must meet all of the following criteria.  No study procedures (including s creening  tests) may be performed until after  the informed consent has been legally 
signed. 
An optional Pres creen visit can be used to perform initial testing of the Hb  level using a 
HemoCue  point of care device to evaluate whether a subject should progress to full screening 
procedures.  A separate Pres creen informed consent (distinct from the full protocol informed 
consent) will be implemented for the Pre screen visit.  To be eligible for the Pre screen Hb 
measurement, a study subject or their legally acceptable representative must provide valid informed consent prior to the Prescreen procedure.  For a better understanding of the Prescreening visit, please see Section  9.3.1, Prescreening Visit.  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 34 of 98 7.2 Inclusion Criteria  
Subjects must meet all of the following inclusion criteria to be eligible:  
1. ≥18 years of age. 
2. Receiving  chronic maintenance dialysis (either peritoneal or hemodialysis) for end- stage 
kidney disease for at least 12  weeks prior to Screening . 
3. Currently maintained on ESA therapy, with a dose received within 6 weeks prior to or during 
Screening . 
4. Mean screening Hb between 8.0 and 11.0 g/dL (inclusive) in the US and between 9.0 and 
12.0 g/dL (inclusive) outside of the US, as determined by the average of 2  Hb values 
measured by the central laboratory during Screening. 
5. Serum ferritin ≥100 ng/mL and transferrin saturation (TSAT) ≥20% during S creening . 
6. Folate and vitamin B 12 measurement s ≥ lower limit of normal (LLN) during Screening. 
7. Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure. 
7.3 Exclusion Criteria  
1. Subjects presenting with any of the following will not qualify for entry into the study: Anemia 
due to a cause other than CKD or subjects with  active bleeding or recent blood loss. 
2. History of sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia. 
3. Red blood cell (RBC) transfusion within 8 weeks prior to randomization. 
4. Anticipated to recover adequate kidney function to no longer require dialysis. 
5. Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT), or total bilirubin >2.0 x upper limit of nor mal (ULN) during Screening.  Subjects with a history of Gilbert’s 
syndrome are not excluded. 
6. Uncontrolled hypertension (defined as confirmed predialysis systolic blood pressure [BP] >190 mmHg or diastolic BP >110 mmHg at rest) during Screening.  
7. Severe hea rt failure (HF) during Screening (New York Heart Association Class IV).  
8. Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, 
sustained ventricular tachycardia , hospitalization for HF, or stroke within 12 weeks prior to 
or during Screening. 
9. History of active malignancy within 2 years prior to or during Screening, except for treated  
basal cell carcinoma of skin, curatively resected squamous cell carcinoma of skin, or cervical 
carcinoma in situ .  
10. History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 12  weeks prior 
to randomizatio n. 
11. History of hemosiderosis or hemochromatosis. 
12. History of prior organ transplantation or scheduled organ transplant (subjects on the kidney transplant wait -list or with a history of failed kidney transplant are not excluded), or prior 
hematopoietic stem cell or bone marrow transplant (corneal transplants and stem cell therapy 
for knee arthritis are not excluded) . 
13. Hypersensitivity to vadadustat, darbepoetin alfa, or any of their excipients.  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 35 of 98 14. Use of an investigational medication or participation in an invest igational study within 
30 days or 5 half- lives of the investigational medication (whichever is longer), prior to 
Screening . 
15. Previous participation in this study or previous participation in a study with another hypoxia-
inducible factor prolyl -hydroxylase i nhibitor (HIF -PHI)  other than vadadustat. 
16. Females who are pregnant or breastfeeding.  Women of childbearing potential who are 
unable or unwilling to use an acceptable method of contraception ( refer to  Section  9.1.3, 
Contraception and Pregnancy Avoidance Measures ). 
17. Non-vasectomized male subjects wh o are unable or unwilling to use an acceptable method of 
contraception (r efer to  Section  9.1.3, Contraception and Pregnancy Avoidance Measures ). 
18. Any other reason, which in the opinion of the Investigator, would make the subject not suitable for participation in the study.  
7.4 Retesting and Rescreening  
Subjects who fail to qualify for the study based on certain laboratory parameters may be retested and/or rescreened at the discretion of the Investigator. 
7.4.1 Retesting  
Retesting is defined as repeating laboratory tests within the same Screening Period.  
Subjects who initially fail to qualify for the study based on laboratory test results may have any 
individual laboratory parameter  retested 1 time  within the 8 -week Screening period at the 
discretion of the Investigator.  Retesting within the 8 -week Screen ing period does not constitute 
rescreening; however, if retesting falls outside of the 8 -week Screening period, it should be 
considered a rescreen.  All screening laboratories, including any repeat measurements, must be performed within the 8 -week Screenin g window with a minimum of 4 days between the last 
qualifying repeat measurement and the Baseline visit.  
For eligibility , the average of 2 Hb values measured by the central laboratory during Screening 
(SV1, SV2 or retest) must be between 8.0 and 11.0 g/dL (inclusive) in the US and between 9.0 and 12.0 g/dL (inclusive) outside of the US.  
Subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B
12 values may 
receive replacement therapy based on the investigative sites’ standard of  care during the 
Screening Period and retest  the laboratory parameter (s).  Subjects who receive iron replacement 
therapy may retest screening Hb a minimum of 3 weeks after completion of iron replacement 
therapy. 
7.4.2 Rescreening  
Subjects who fail to meet the qu alifying criteria for Hb during a Screening period may be 
considered for rescreening at the discretion of the Investigator if it is felt that the subject’s status 
has progressed and that the subject may now qualify for the study.  Additionally, subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B
12 values may be considered 
for rescreening after receiving replacement therapy. 
Screening is limited to 3 attempts (initial Screening and 2 additional rescreening attempts). 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 36 of 98 Subjects who fail to qualify for the study at the initial Screening visit will receive a new subject 
number for each rescreening attempt .  If rescreened, the subject will also sign a new informed 
consent form and will repeat all Screening procedures for each rescreening attempt . 
7.5 Study Completion, Subject Completion, Study Discontinuation, and Withdrawal of Subjects  
7.5.1 Study Completion  
The study will be considered completed (end of trial) when approximately 631 MACE events have accrued over the 2 DD- CKD studies (Studie s AKB-6548- CI-0016 and AKB-6548- CI-0017) 
and all enrolled subjects have had the opportunity to have their Visit 13 (+/- 5 days).  These 2 
DD-CKD studies were sized based on power considerations for the primary safety analysis of 
MACE events, and thus each study is highly powered (>90%) for the primary and key secondary 
efficacy analysis.  Thus, primary efficacy analyses will be based on the randomized population 
and every subject will have completed (or had the opportunity to complete) the primary 
evaluatio n period (Weeks 24-36).   
7.5.2 Subject Completion  
A subject will be considered as having completed the study, regardless of whether they are on or off study medication (vadadustat or darbepoetin alfa), if the subject is followed until the global 
study completio n (end of trial).  The table outlines the different categories of subjects and 
handling the global study completion activities.   
Subject Status  at time of 
Global Study Completion  End of Treatment (EOT)  End of Study (EOS)   
Subject on study medication 
(includes those on temporary interruption) After announcement of global 
study completion: 
• Perform  EOT visit  
• Perform  the Follow-
up visit 4 weeks after  
EOT visit and include 
End of Study ( EOS ) 
subject status  Not applicable  
 
The EOS subject status will be captured  as part of the 
Follow-up visit  
Subject permanently 
discontinued study medication and continues to be followed in the study At time of permanent 
discontinuation of study medication : 
• Perform EOT visit 
• Perform the F ollow-
up visit 4 weeks after  
EOT  visit   Optimal data collection 
would include the following assessments: 
 
• EOS subject status 
(must collect at 
minimum)  
• MACE Endpoint 
Questionnaire 
• AE Assessment  
 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 37 of 98 Subject Lost to Follow -up  Not applicable  Work with third party vendor 
to ascertain vital status and 
complete EOS subject status  
If subject -site contact is 
reestablished and possible, 
collect available information 
for EOS subject status   
Subject Withdrawn Consent  Not applicable  Complete  the EOS  subject 
status form at time of 
withdrawal of consent , 
absolute refusal of ALL methods of MACE and health status follow -up 
Subject Death  Not applicable  Complete the  EOS subject 
status form at the time of 
death (see Section 10 
Adverse Events  for more 
details on other actions related to reporting a death)  
 
The need for rescue therapy does not constitute study completion and is not a criterion for 
subject withdrawal from the study.  Also, the occurrence of a safety end point also does not 
constitute study completion and is not a criterion for subject withdrawal from the study or study medication (vadadustat or darbepoetin alfa).  
7.5.3 Entire Study Termination 
The entire study may be suspended or terminated by the Sponsor for safety or other unanticipated reasons or upon request of regulatory agencies.  Criteria for premature study termination or suspension are detailed in Section  14.1, Criteria for Premature Termination or 
Suspension of the Study. 
7.5.4 Individual Study Site Termination 
Study participation may be suspended or terminated at an individual investigational site for 
various reasons.  Criteria and procedures for premature termination or suspension of an investigational site are detailed in Section  14.2, Criteria for Premature Termination or 
Suspension of Investigational Study Sites  and Section  14.3, Procedures for Premature 
Termination or Suspension of the Study or Investigational Sites . 
7.5.5 Individual Subject Discontinuation 
During this study, it is anticipated that some subjects may permanently discontinue study 
medication (vadadustat or darbepoetin alf a) for any of the following reasons: 
• Unacceptable toxicity or drug intolerability  
• Investigator discretion  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 38 of 98 • Subject withdrawal of consent  
• Subject becomes pregnant 
• Receipt of a kidney transplant 
• Lack of efficacy  
• Other reasons. 
Lack of efficacy is defined as inadequate response to darbepoetin alfa or vadadustat in the 
Investigator’s opinion. 
Subjects who undergo a solid organ (including kidney), hematopoietic stem cell, or bone marrow 
transplantation will have their study medication (vadadustat or darbepoetin alfa) permanently discontinued. 
See Section 9.4, Study Medication Stopping Rules  for additional details on the management of 
subjects with ALT and AST abnormalities. 
It is important to continue to follow subjects that permanently discontinue study 
medication .  Please  s ee Section  7.5.5.1, Temporary Interruption of Study Medication  and 
Section 7.5.5.2, Permanent Discontinuation of Study Medication, and Appendix A :  Schedule of 
Activities . 
Receipt of rescue therapy is not a reason for permanent study medication discontinuation.  While receiving ESA rescue, subjects must temporarily discontinue study medication (vadadustat or darbepoetin alfa), but should resume study medication once rescue therapy has ended, as detailed 
in Section  8.4.7, Rescue Therapy . 
As part of the informed consent process, only subjects who fully understand and agree to full participation and long- term follow -up should be consented to participate. 
7.5.5.1 Temporary Interruption of Study Medication  
Subjects who temporarily interrupt stud y medication (vadadustat or darbepoetin alfa) treatment 
after the first dose and prior to completion of the study will continue with study visits and assessments.  Unless con traindicated, treatment should be resumed wherever possible and 
routinely considered at every visit following study medication discontinuation.  If a subject does 
not return for a scheduled visit, every effort should be made to contact the subject.  If a s ubject ’s 
study medication has been temporarily interrupted for more than 60 days , the Investigator should 
contact the Medical Monitor before resuming study medication.   
7.5.5.2 Permanent Discontinuation of Study Medication  
Subjects who permanently discontinue study medication prior to global study completion are expected to continue to be followed post discontinuation of study medication.  These subjects are 
to have their EOT visit at the time of permanent discontinuation of study medication, have the 
Follow-up visit 4 weeks after the EOT visit and continue to be follow ed through global study 
completion.  At global study completion, each subject will have an End of Study (EOS) assessment  to complete participation in the study.  Receipt of rescue therapy is not a reason for 
permanent study medication discontinuation.  While receiving ESA rescue, subjects must 
temporarily discontinue study medication but should resume study medication following the end 
of rescue therapy. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 39 of 98 For subjects who permanently discontinue study medication, the Investigator will resume 
standard of care treatment, including ESAs and iron therapy, as deemed appropriate. 
It is important to continue to follow subjects that permanently discontinue study medication .   
7.5.5.3 Complete Withdrawal from Further Study Visits/Assessments  
A subject has the right to withdraw consent for participation in the study.  Withdrawal of consent 
is a subject’s refusal of ALL methods of follow -up noted in the informed consent form: 
procedures, participation in reduced procedur es/study visits, telephone contact only or alternative 
contact only, source document or designated alternative contact, or access to medical records 
from alternative sources . 
It is important to provide options for the subject to consider for long- term follow-up before the 
subject withdraws consent.  It is important for the Investigator to review options with a subject 
that would allow follow-up through global study completion before the subject withdraws 
consent.  For subjects considering withdrawal of consent, the Investigator should consult with 
the Medical Monitor to ensure all options have been explored and that there is complete understanding by the subject  for what constitutes withdrawal of consent. 
  
7.5.5.4 Procedures to Suppor t Continued Study Participation  
As part of the informed consent process, only subjects who fully understand and agree to full 
participation and long- term follow -up should be consented to participate.  It is important that 
subjects understand the long -term duration and purpose of a cardiovascular outcome trial 
and that the subject (or designee) continue to allow follow -up through global study 
completion which could be several years, even post subject ’s permanent discontinuation of 
study medication.   
In all cases o f impending study medication  discontinuation or subject request for stopping study 
visits , Investigators will discuss with the subject his/her options of continuing in the trial.  
 It is important to continue to follow every randomized subject, even  if discontinued study 
medication , through global study completion at a frequency and approach that is agreed to 
between the Investigator and subject.  Visit schedule and assessments are flexible and at the discretion of the Investigator and subject and wi ll be clearly documented in the medical chart .  
Optimal data collection would include the following assessments through global study completion:
 
• EOS subject status (must collect at minimum)  
• MACE Endpoint Questionnaire 
• AE Assessment  
 
The protocol allows flexibility of follow-up to maintain the subjects in active status post permanent discontinuation of study medication.  For those subjects who decline full participation in the study post discontinuation of study medication, other options for continued fol low-up on a 
subject include (but are not limited to):  
1. Reduced frequency of on- site visits  
2. Telephone visits in lieu of on- site visits  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 40 of 98 3. Telephone or any contact method (e.g., email, site staff visit subject’s home, etc.)  to 
verify vital status  
4. Telephone or any contact method with an alternative person (family member or medical 
designee) 
5. Study team access to medical records for reporting MACE data or vital status  
In the most extreme case, the protocol will accommodate minimal contact with a subject or 
altern ative method to obtain the subject’s vital status.  The objective is to keep a subject’s study 
status active to ascertain at a minimum vital status ( alive or deceased)  at the global study 
completion.   
The Investigator will ensure understanding and documentation of the reason(s) for a subject’s 
desire to stop study procedures or stop study medication . 
7.5.5.5 Procedures to Prevent “Lost to Follow -up” 
The Investigator must make every effort to contact subjects who fail to return for scheduled 
visits so that they will not be declared “lost to follow -up.”  These actions must include, but are 
not limited to, the following: 
1. Contact all numbers for the subject and their listed contacts (to be collected in source at 
the subject’s entry into the study), as applicable.  T his includes making calls after normal 
business hours or on holidays and weekends 
2. Contact the  subject’s primary care physician, referring specialist, pharmacist, and/or 
other healthcare professional (using th contacts provided by the subject at entry into the 
study), as applicable. 
3. Send email, text, and postal mail with registered (traceable or trackable) letters to all the 
subject’s addresses and contact persons, as applicable.  Registered (traceable or 
trackable) letters will be returned with a copy of the signature from whomever signed, which can be compared to the ICF for vital status data.  If undeliver able, then send non-
registered standard letters, which may be forwarded to a new address if the subject has moved. 
4. Review available medical records/notes for details of hospitalizations, clinic visits, or other procedures that may indicate the status of the subject, as applicable.  
5. Utilize the internet to search for additional contact information, as applicable.  
6. Check local, regional, and national public records to locate the subject or search for 
mortality status as allowed by law, as applicable.  
It is important to obtain at a minimum vital status  (alive or deceased) at the global study 
completion for all randomized  subjects, including those that have been LTFU during the course 
of the study.   
The Sponsor may utilize a third- party provider in accordance with all applicable guidelines and 
legislation  to assist the site in locating contact information for all subject s during the study or in 
locating the vital status for all of their randomized subjects in anticipation of the global study 
completion (end of trial).  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 41 of 98  
8 STUDY PRODUCT AND TREATMENT OF SUBJECTS  
8.1 Study Product, Supplies, and Storage  
Vadadustat for oral adminis tration and darbepoetin alfa for injection will be provided and 
shipped by the Sponsor or its designated supplier/distributor.  Both vadadustat and darbepoetin 
alfa will be supplied as open -label supplies.  All study medication supplies must be kept in a 
temperature-controlled, locked facility, accessible only to authorized study personnel. 
The Investigator or designated study personnel will be responsible for preparing study medication for dispensing to the subject ( Section  8.2, Dispensing Procedures ) and for study 
medication supply accountability ( Section  8.3, Product Accountability and Destruction ). 
8.1.1 Vadadustat  
Vadadustat will be provided as 150 mg white to off-white, round, bi-convex film- coated tablets 
for oral administration .  The tablets will be packaged in high-density polyethylene bottles with 
child -resistant closures, polypropylene liner, and induction seal.  Labeling will be in accordance 
with current Good Manufacturing Practices (GMP) and local regulatory requirements. 
Dose levels utilized in this study will include: 150  mg (1  tablet), 300 mg (2  tablets), 450  mg 
(3 tablets), and 600 mg (4  tablets) per day. 
Vadadustat should be stored per the product label.  Please consult the Pharmacy Manual for 
details on storage and managing temperature excursions. 
8.1.2   Darbepoetin  Alfa  
Darbepoetin alfa will be provided in its commercially -approved primary packaging and stored 
per the US PI for US sites or EU SmPC for non -US sites for adult patients with CKD on dialysis .  
8.2 Dispensing Procedures  
The Investigator will maintain  record of all vadadustat tablets and darbepoetin alfa injections 
dispensed to and returned from each subject during the study.  Subjects will receive either 
vadadustat or darbepoetin alfa according to the randomization assignments provided via the IWR system (see Section  8.4.2, Randomization ). 
8.2.1 Dispensing of Vadadustat  
Subjects will be provided with a supply of vadadustat at the Baseline visit according to the IWR 
system assignment.  Resupply of additional vadadustat at subsequent visits will be managed via the IWR system and will be dependent on the current dose level of vadadustat and the number of tablets remaining in the subject’s current vadadustat supply at a given study visit (Section  8.4.4.1, Vadadustat  Dosing and Dose Adjustment Algorithms .  Subject s will be 
instructed to finish 1  bottle before opening a new bottle. 
At the Baseline visit, study subjects will be provided with 1  bottle of vadadustat.  Each bottle of 
vadadustat will contain 100 tablets of vadadustat (150 mg /tablet).  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 42 of 98 Subjects should be instructed to bring unused vadadustat and empty bottles to each study visit for 
product accountability.  Empty bottles will be collected at these study visits.  Previously dispensed bottles (whether opened or unopened) with remaining tablets may be redispensed to the subject during the dosing phase of the study. 
A Vadadustat Dosing Information  Sheet will be provided to the subject at dispensing of study 
medication.   
8.2.2 Dispensing of Darbepoetin  Alfa  
Darbepoetin alfa  will be  dispensed according to the IWR system assignment.  
• For subjects already on darbepoetin alfa , the initial dosing regimen in the study should be 
based on the prior dosing regimen. 
Dispensing of additional darbepoetin alfa at subsequent dosing visits will be managed by the 
IWR sy stem ( Section  8.4.4.2, Darbepoetin Alfa Dosing and Dose Adjustment Algorithms ). 
Darbepoetin alfa doses may be self -administered or staff administered at the site facility or by 
the subject at home according to the I nvestigator’s determination and local practice.  
Subjects should be instructed to bring the darbepoetin boxes to each study visit for drug  
accountability.  There will be no physical accountability performed  with used syringes.  The 
investigative site will maintain site drug accountability records of the actual syringes dispensed and used by a subject. 
A Darbepoetin Alfa Dosing Information Sheet will be provided to the subject at dispensing of 
study medication.   
8.3 Product Accountability and Destruction  
Product accountability should be an ongoing process throughout the study.  All study medication 
(vadadustat and darbepoetin alfa) must be accounted for and any discrepancies explained.  The Investigator or designated study personnel are responsible for keeping accurate records of the clinical supplies received from the Sponsor, all supplies retained in inventory at the investigative site, and study medication dispensed to or returned from each subject.  Records wi ll be 
maintained that accurately reflect the drug accountability of vadadustat and darbepoetin alfa at 
all times.  
Proper drug accountability includes, but is not limited to: 
• Continuously monitoring expiration dates if expiry date or retest date is provided to the 
Investigator 
• Frequently verifying that actual inventory matches documented inventory 
• Verifying that the log is completed for all drug received and that all required fields are 
complete, accurate, and legible.  
If any dispensing errors or discrepancies are discovered, the Sponsor must be notified 
immediately.  
During the study, the Investigator will be notified of any expiry dates or retest date extensions of clinical study material.  If an expiry date notification is received during the study, the 
investigative site must complete all instructions outlined in the notification, including 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 43 of 98 segregation of expired clinical study material  for return to the Sponsor or its designee for 
destruction. 
Prior to investigative site closure and at appropriate interval s during the study, a representative 
from the Sponsor will perform clinical study material  accountability and reconciliation. 
At the end of the study, the Investigator will retain all original documentation regarding clinical 
study material  accountability,  return, and/or destruction, and copies will be sent to the Sponsor. 
All unused and/or partially used vadadustat or darbepoetin alfa should be returned to the Sponsor or destroyed at the investigational site, as specified by the Sponsor.  Appropriate records of the disposal will be documented and maintained.  No unused vadadustat or darbepoetin alfa may be disposed of until fully accounted for by the Sponsor’s monitor (or designee).  Empty containers may be disposed of according to local procedures. 
8.4 Treatment of Subjects  
8.4.1 Treatment  Group Assignments  
Subjects will be randomized in a 1:1 ratio via the IWR system to either:  
• Vadadustat (starting dose of 2 tablets once daily [300 mg/day]) 
• Darbepoetin alfa : (starting dose based on the PI for investigational sites in the US and the 
SmPC for all other investigational sites [non- US] for adult patients with CKD on 
dialysis). 
o For subjects already on darbepoetin alfa , the initial dosing regimen in the study 
should be based on the prior dosing regimen. 
Target enrollment for each treatment group is approximately 1650 subjects. 
8.4.2 Randomization 
This study will be open to approximately 3300 subjects with DD -CKD with Hb between 8.0 and 
11.0 g/dL (inclusive) in the US and be tween 9.0 and 12.0 g/dL  (inclusive ) outside of the US. 
Using an IWR system, eligible subjects will be assigned using permuted block randomization 
and a 1:1 ratio to either vadadustat or darbepoetin alfa during their Baseline visit.  
To maintain balance betw een vadadustat -treated and darbepoetin alfa -treated  subjects, 
randomization will be stratified with respect to: 1) geographic region (US v ersus EU v ersus 
ROW);  2) New York Heart Association CHF Class (0  [no CHF] or I v ersus II or III) ; and 3) 
study entry Hb (<10.0 versus ≥10.0 g/dL). 
8.4.3 Blinding  
This will be an open-label study.  Treatment assignment will be done through the IWR system and the Investigator, Sponsor, and CRO study teams will not be aware of which treatment will be assigned next.  Treatments wi ll be administered in an open -label fashion .  The Sponsor and CRO 
study teams will be blinded to ‘by treatment ’ aggregated analyses except for the unblinded 
statistician.  Because Hb values are objective and will be measured via a central laboratory for al l 
efficacy endpoints, efficacy assessments are not considered to be subject to bias with an open -
label design.  In addition, the study will involve blinded adjudication of MACE, the use of an IDMC, and an identical schedule of visits, procedures, and assessments for both treatment groups 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 44 of 98 in order to reduce the potential for bias.  However, certain personnel directly involved in medical  
oversight of the study, regulatory reporting of safety information, and on-site monitoring 
activities may become unblinded to the treatment assignments of individual subjects during the 
course of the study.  In addition, in order to reduce subjectivity of dose adjustment, adjustments to doses for vadadustat and darbepoetin alfa will be based on Hb concentration and Dose Adjust ment Algorithms.  
The EAC will remain blinded throughout the full course of the study. 
8.4.4 Dosing and Dose Adjustment Guidelines  
Dosing will be initiated at the Baseline visit, and the first dose of study medication (vadadustat 
or darbepoetin alfa) will be admi nistered at the investigative site after other Baseline visit 
procedures have been completed .  The Investigator may elect to postpone the initial dose of 
study medication until a subsequent visit based on the subject’s Hb level or Hb trajectory assessed at  the Baseline visit, or based on timing of the last ESA dose given during screening.  
Year 1 -4 Treatment Period Visits  
Hemoglobin will be monitored via HemoCue throughout the study to determine if the dose of 
study medication (vadadustat or darbepoetin alfa) will be  adjusted , interrupted , or maintained.  
From Weeks 0 to 12, Hb  will be obtained via HemoCue every 2 weeks for monitoring for dose 
adjustment.  From Week 12 to Week 52, Hb  will be monitored every 4 weeks via HemoCue 
unless more frequent monitoring is clinically indicated or warranted based on dosing changes.  From Week  53 through the study end, Hb  will continue to be monitored via HemoCue
 to 
determine if the dose of study medication will be adjusted , interrupted, or maintained.  Any 
unscheduled measurement taken between study visits will be recorded in the appropriate CRF 
and the subject’s source when a HemoCue value is taken .  Hemoglobin will also be assessed 
with a CBC through the central laboratory for efficacy and safety evaluations; however, dose adjustments should be based on the HemoCue Hb  value.  If the Investigator has an immediate 
clinical concern about a subject’s HemoCue value, the Investigator may use clinical judgement and repeat the HemoCue Hb, use local lab  values or wait f or central lab results.  The test method 
utilized to inform the treatment decision must be recorded in the appropriate CRF and the 
subject’s source.  
Year 2 -4 Monthly Hb Monitoring 
Additionally, after Week 52 visit, the Hb drawn as part of the local standa rd of care labs must be 
monitored monthly for dosing oversight.  Per the dosing algorithms, if the Hb value suggests a dose adjustment is needed, an unscheduled visit must be performed.  
If monthly standard of care labs are not available, a study unschedul ed visit must be 
performed.  This visit will include, at minimum, the Hb measurement via HemoCue, dose 
adjustment assessment, and adverse events assessment.  
The monthly Hb monitoring method is flexible between study visits after Week 52 to minimize unnecessary travel or redundant blood sampling for the subject. 
The aim is to maintain a Hb level of 10.0 g/dL to 11.0 g/dL in the US and 10.0 g/dL to 12.0 g/dL 
outside of the US throughout the study. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 45 of 98 Dose adjustments for vadadustat and darbepoetin alfa will be guided by Hb  concentration and the 
Dose Adjustment Algorithms.  The Dose Adjustment Algorithm for darbepoetin alfa will follow 
the PI for investigational sites in the US, and the SmPC for all other investigational sites (non -
US) for adult patients with CKD on dialysis. 
This protocol provides guidance for the treatment of subjects with anemia associated with CKD in order to achieve and maintain Hb levels within the target Hb range.  Dose adjustment should be based on the Investigator’s clinical discretion, incorporating the protocol guidance and considering the subject’s clinical condition, Hb rate of rise, Hb rate of decline, Hb variability, and ESA responsiveness.  In cases where the Investigator does not follow the dosing algori thm, 
the clinical circumstances must be documented in the subject’s  source. 
8.4.4.1 Vadadustat Dosing and Dose Adjustment Algorithms 
Subjects assigned to vadadustat will initiate dosing at 2 tablets taken orally , once daily 
(300 mg /day).  Dose levels of vadadustat utilized in this study  include 150, 300, 450, and 600 mg 
(available tablet strength is 150  mg).  
Dosing will be initiated at the Baseline visit and the first dose of vadadustat will be administered at the investigative site after other Baseline visit procedures have been completed.  The Investigator may elect to postpone the initial dose of study medication until a subsequent visit based on the subject’s Hb level or  Hb trajectory assessed at the Baseline visit, or based on timing 
of the last ESA dose given during screening.  Thereafter, vadadustat will be taken once daily on 
an outpatient basis.  Subjects may take vadadustat with or without food and should be instructed to swallow the tablet(s) whole , without chewing.  Subjects should be instructed to take 
vadadustat at roughly the same time each day. 
During the study, vadadustat should be dosed according to the Dose Adjustment Algorithms 
(Appendix B: Vadadustat Dosing and Dose Adjustment Algorithms ). 
8.4.4.2 Darbepoetin Alfa Dosing and Dose Adjustment Algorithms  
For subjects randomized to darbepoetin alfa, the initial dose will be based on the current PI for investigational sites in the US, and the SmPC for all other in vestigational sites (non -US) for adult 
patients with CKD on dialysis .  For subjects already on darbepoetin alfa, the initial dosing 
regimen in the study should be based on the prior dosing regimen.  Dosing adjustments will be 
based on Dose Adjustment Algor ithms (Appendix C:  Darbepoetin Alfa Dosing and Dose 
Adjustment Algorithms ). 
In general, darbepoetin alfa will be dosed intravenously for subjects on chronic hemodialysis and 
SC for subjects receiving peritoneal dialysis and in accordance with the approved product label.  
Each subject will receive their first dose of darbepoetin alfa at the Baseline visit.  The 
Investigator may elect to postpone the initial dose of study medication until a subsequent visit 
based on the subject’s Hb level or  Hb trajectory assessed at the Baseline visit, or based on timing 
of the last ESA dose given during screening.   
Following dose conversion, darbepoetin alfa will be dosed IV or SC, with dose adjustments 
guided by the  Dose Adjustment Algorithm ( Appendix C:  Darbepoetin Alfa Dosing and Dose 
Adjustment Algorithms ).  Subsequent administration of darbepoetin alfa may occur at the 
clinic /investigative site or may be self -administered at home per regional standard of care and/or 
based on dialysis modality (hemodialysis or peritoneal dialysis).  Darbepoetin  alfa dosing is 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 46 of 98 independent of the study visit schedule, and the dosing schedule may shift per local standard of 
care, the patient’s dialysis schedule,  and per I nvestigator discretion . 
8.4.5 Late or Missed Doses 
Subjects on vadadustat should be instructed to take the study medication at roughly the same time each  day.  If a dose is forgotten, subjects should be instructed to take the dose as soon as 
they remember during the same day.  If a forgotten dose is not remembered on the same day, the subject should skip the dose and resume the normal dosing schedule the following day.  Subjects should not double-up on missed doses. 
Subjects on darbepoetin alfa should be instructed to take the study medication, including 
handling of late or missed dosed, as described in the PI or SmPc . 
Subjects should be questioned regarding dosing compliance and whether they have questions or have experienced any problems related to the dosing of study medication (vadadustat or darbepoetin alfa). 
8.4.6 Iron Supplementation 
Investigators will pre scribe iron supplementation  (IV, oral, or intradialytic ) during the study to 
maintain ferritin ≥100 ng/mL or TSAT ≥20%.  The use of iron-based phosphate binders (eg, 
ferric citrate) is permitted.  However, the duration, dosage, and frequency of intradialytic iron 
should be documented in CRF. 
Subjects already receiving oral iron supplementation as part of their treatment plan may continue 
their current treatment regimen.  For subjects who are on peritoneal dialysis, oral iron supplementation is al lowed per local guidelines and routine practice.  
Important : Because of the potential for iron to reduce the bioavailability of vadadustat, the 
study medication is not to be administered concurrently with an oral iron supplement (including 
multivitamins containing iron), iron containing phosphate binders , or medications containing 
iron.  The subject should be instructed to take these medications at least 2 hours before or 2 
hours after the dose of vadadustat. 
8.4.7 Rescue Therapy  
To ensure the safety of study subj ects and to standardize the use of rescue in the study, rescue 
therapy guidelines are provided. 
8.4.7.1 Red Blood Cell Transfusion  (Optional)  
Investigators will use their local institution’s transfusion guidelines when determining whether to 
transfuse a study  subject.  In general, in the event of an acute or severe loss of blood, an RBC 
transfusion should be administered as clinically indicated.  In less severe instances but where 
there may be worsening of anemia or moderate to severe symptoms of anemia, RBC tr ansfusions 
are permitted at the discretion of the Investigator given the medical necessity.  Reasons for RBC 
transfusion will be captured in the appropriate CRF (e.g., worsening anemia due to CKD, blood loss, surgery, etc.).  Study medication (vadadustat or darbepoetin  alfa) may be continued during 
the RBC transfusion period. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 47 of 98 8.4.7.2 Erythropoiesis- stimulating Agent Rescue (Optional)  
Starting at Week  6, subjects in both treatment arms will be allowed (although will not be 
required) to have their Hb  rescued with ESA  therapy.  Drug product and supplies for ESA rescue 
will not be provided by the Sponsor. 
If possible, a subject on vadadustat should be on a maximum dose of vadadustat for 2 weeks 
prior to ESA rescue.  A subject on darbepoetin alfa may rescue with another ESA per the 
standard of care.  To qualify for ESA rescue, a subject must fulfill BOTH of the following: 
• The subject has experienced worsening of the symptoms of anemia (eg, fatigue, 
weakness, shortness of breath, chest pain, confusion, or dizziness) compared with Baseline  
• The subject’s Hb is <9. 5 g/dL 
However, in the event the subject does not meet the above criteria for ESA rescue, ESA rescue is permitted when medically necessary at the discretion of the Investigator.   Reasons for ESA use 
will be captured in the appropriate CRF. 
The ESA rescue therapy should be administered  using an approved local product and dosing as 
per the local institution’s guidelines and per the approved local product label.  While receiving 
ESA rescue therapy, subjects must  temporarily discontinue taking study medication (vadadustat 
or darbepoetin alfa) .  Hemoglobin will be monitored throughout the study at scheduled visits as 
defined in the Schedule of Activities ( See Appendix A :  Sched ule of Activities ) using HemoCue, 
and ESA rescue treatment should be stopped when Hb  is ≥10.0 g/dL.  A minimum interval must 
be observed prior to restarting vadadustat after the last dose o f rescue medication, and treatment 
may be resumed after the following intervals: 
• 2 days after last dose of epoetin alfa rescue. 
• 7 days after last dose of darbepoetin alfa rescue. 
• 14 days after last dose of methoxy polyethylene glycol- epoetin beta rescue.  
Following ESA rescue, the study medication should be resumed at the same dose as previously used or one dose higher and adjusted according to the Dose Adjustment Algorithms  
(Section  8.4.4, Dosing and Dose Adjustment Guidelines ).  If a subject’s study medication has 
been  temporarily  interrupted for more than 60 days, the Investigator should contact the Medical 
Monitor before resuming study medication.   
8.4.8 Phlebotomy  (Optional)  
If a subject’s Hb exceeds 14.0  g/dL or the rate of rise of Hb raises concern to the Investigator, 
the subject may be phlebotomized based on the Investigator’s judgment.  The method of 
phlebotomy will be in accordance with the local institution’s guidelines and standard clinical practice.  
8.4.9 Treatment Compliance  
Subjects will be questioned regarding dosing compliance and whether they have questions or have experienced any problems related to the dosing of study medication (vadadustat or 
darbepoetin alfa).  The Investigator will also maintain drug accountability logs itemizing all 
study medications dispensed to and returned from each subject during the study.  Treatment 
compliance will be determined from these forms along with the subject questioning and the study 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 48 of 98 medication CRFs.   Dosing compliance for vadadustat or darbepoetin alfa is defined as 80 to 
120% over the course of the Treatment Period. 
Subjects who miss doses will be counseled on the importance of compliance.  
Subjects will also be questioned regarding the timing of their last dose of vadadustat prior to the 
PK samples at the Week 4, 12, 28, and 52 study visits.  The date and time of these doses will be 
recorded on the CRF. 
8.4.10 Continuation of Treatment 
Subjects may receive study medication (vadadustat or darbepoetin alfa) up until the EOT visit.  
8.5 Prior and Concomitan t Therapy  
8.5.1 General  
All medications  (except those routinely administered as part of the dialysis procedure or flus hes 
used for routine catheter maintenance) taken during the screening period and during the study 
should be recorded on the appropriate CRF.  If  the duration of the screening period is less than 
30 days, all medications taken within 30 days prior to first dose of study medication will be recorded.  In addition, the ESA, blood transfusion, and iron treatment regimen prior to randomization and the d ate of last dose will be recorded.   To ens ure adequate collection of prior 
ESA dosing history, a minimum of 8 weeks of ESA therapy prior to start of study medication will be recorded. 
8.5.2 Erythropoiesis- stimulating Agents  
For all subjects, it is recommended that no additional ESA doses be administered after Screening 
visit 2 (SV2) and prior to the Randomization visit.    
Non-protocol ESAs are prohibited  from  Randomization until the end of the study, unless the 
subject is  receiv ing ESA rescue therapy, interrupts study medication  for other reasons, or 
permanently discontinues study medication .  Reasons for ESA use will be captured in the 
appropriate CRF  (e.g., adverse event, inadvertent administration, etc. ).  
Concomitant use of an ESA with study medication  is strictly prohibited.   
In the setting of ESA rescue therapy, the initial dose of ESA rescue therapy may be administered on the same day as the last vadadustat dose prior to vadadustat dose interruption ( see Section  
7.5.5.1, Temporary Interruption of Study Medication)  if deemed medically necessary  at the 
discretion of the Investigator.  Guidelines for ESA administration as rescue therapy are provided in Section  8.4.7.2, Erythropoiesis- stimulating Ag ent Rescue (Optional) .   
 All efforts will be made to avoid inadvertent administration of ESAs resulting from following 
routine ESA hemodialysis protocols (e.g., dialysis center ESA protocols for subjects on 
hemodialysis).  If ESA is inadvertently administered to subjects actively receiving vadadustat treatment, vadadustat treatment will be stopped and the event will be reported as a protocol deviation.   

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 49 of 98 8.5.3 Transfusions  
Documentation of transfusions will be collected.  The receipt of any transfusions for 4 weeks 
prior to Screening  will be recorded . 
8.5.4 Dialysis Treatment and Renal Replacement Therapy  
Information on dialysis treatment including dialysis vascular access type, dialysis adequacy, and 
history of and c hanges in renal replacement therapies will be collected as described in  Section  9, 
Study Procedures and Schedule of Activities  and Appendix A :  Schedule of Activities . 
8.5.5 Investigational Medications  
Study subjects should not have received any investigational medications or participated in an 
investigational study within 30 days or 5 half- lives of the investig ational medication, whichever 
is longer, prior to the Screening visit.  In addition, subjects should not have participated in a study with another HIF- PHI. 
Additionally, subjects should not take another investigational medication while participating in this study. 
8.5.6 HMG -CoA Reductase Inhibitors (Statins)  
Exposures to atorvastatin and an active metabolite (para-hydroxy atorvastatin) were mildly 
increased in the setting of vadadustat co -administration in healthy adults.  No dose adjustment of 
atorvastatin is re commended.  
Exposures to simvastatin and an active metabolite (beta-hydroxy acid) were both mildly to moderately increased with co -administration of vadadustat in healthy adults.  For subjects taking 
vadadustat who are concomitantly taking simvastatin, the recommended maximum daily dose of simvastatin is 20 mg.  Investigators should review simvastatin dosing and consider clinical guidelines and local prescribing information including specific guidance in product labels with reference to renal impairment as well as hepatic impairment, concomitant medications and other 
medical factors relevant to the management of the subject.  
Exposure to rosuvastatin was moderately increased with co-administration of vadadustat based on a study in healthy adults.  For subject s taking vadadustat who are concomitantly taking 
rosuvastatin, the recommended maximum daily dose of rosuvastatin is 10 mg.  Investigators should review rosuvastatin dosing and consider clinical guidelines and local prescribing information including specif ic guidance in product labels with reference to renal impairment as 
well as hepatic impairment, concomitant medications, and other medical factors relevant to the management of the subject. 
Exposure to pravastatin was studied in the setting of vadadustat co-administration in healthy 
adults.  There was no interaction.  No dose adjustment of pravastatin is recommended.  
Exposures to the other statins may be increased with co -administration of vadadustat.  When 
used with vadadustat, upward titration of other statins to higher doses should be carried out with 
caution. 
  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 50 of 98 A summary of results and management of concomitant administration of vadadustat with the 
various statins is provided below:    
Statin  Change in Statin Exposure 
When Dosed with Vadadustat*  Recommended Statin Dosing in Subjects 
Receiving Concomitant Vadadustat  
Atorvastatin  Mild increase  No dose adjustment  
Pravastatin  No increase  No dose adjustment  
Rosuvastatin  Moderate increase  Maximum daily dose of 10 mg  
Simvastatin  Mild -to-moderate incr ease Maximum daily dose of 20 mg  
Other statins  Not studied  Upward titration to higher doses should be 
done with caution  
* Based on FDA guidance, an increase in exposure of ≥  1.25- to < 2-fold, ≥ 2- to < 5-fold, or ≥ 5-fold is classified as a mild, 
moderate, or strong interaction, respectively (FDA 2017 ). 
8.5.7 Sulfasalazine and Other BCRP Substrate s 
Exposure to sulfasalazine was moderately increased with co -administration of vadadustat based 
on a study in healthy adults; mesalamine exposure was mildly increased, and no increase was 
observed in exposure to the metabolite sulfapyridine.  Sulfasalazine and other breast cancer 
resistant protein (BCRP ) substrates should be used with caution when taken concomitantly with 
vadadustat. 
9 STUDY PROCEDURES AND SCHEDULE OF ACTIVITIES  
Please see Appendix A :  Schedule of Activities  for a detailed table of the Schedule of Activities.  
This study includes the following visits: 
• Optional P rescreening  
• Two Screening visits (SV1 and SV2) 
• Baseline /Randomization  visit (Week 0/ Day 1) 
• Year 1 Treatment Period Study Visits/Evaluations while receiving study medication: 
Weeks 2, 4, 6, 8, 10, 12, (± 3 days ) and every 4 weeks thereafter until Week 52 ( ± 5 days ) 
• Year 2 Treatment Period Study Visits/Evaluations while receiving study medication: 
Weeks 64, 76, 88, and 104 (± 10 days) 
• Year 3 Treatment Period Study Visits/Evaluations while receiving study medication: 
Weeks 116, 128, 140, and 156 ( ± 10 days ) 
• Year 4 Treatment Period Study Visits/Evaluations while receiving study medication: 
Weeks 168, 180, 192, and 208 ( ± 10 days ) 
• EOT visit (± 7 days) 
• Follow- up visit: 4 weeks after the EOT  (± 7 days). 
• Unscheduled visit(s) 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 51 of 98 The following sections describe the procedures to be completed during the study.  Subjects are to 
be assessed by the same Investigator or investigative site personnel whenever possible. 
9.1 Administrative Procedures 
9.1.1 Informed Consent  
Informed consent must be obtained prior to the subject entering into the study and before any protocol- direct ed procedures are performed (including Screening activities).  Subjects 
participating in the optional Pre screening visit must sign an abbreviated consent form or full 
consent form prior to Prescreening and, if eligible, may proceed with the Screening visit after 
full consent has been obtained (see Section  9.3.1, Prescreening Visit  and Section  15.3 , Subject 
Information and Consent  for additional details).  Additionally, subjects may be asked to provide 
a separate, optional consent to obtain and store a blood sample(s) for future genetic analyses.  
9.1.2 Documentation of Screen Failures  
Investigators will maintain documentation of prescreening  activities, to include information on 
potential stud y candidates evaluated and reasons that subjects  considered for the study did not 
qualify. 
Investigators must account for all subjects who sign informed consent and will maintain a log of 
subjects screened and indicate who was randomized or excluded.  If t he subject is found not to be 
eligible for randomization, the reason(s) for ineligibility must be documented by the Investigator. 
Screening numbers assigned to subjects who fail Screening will not be re-used. 
9.1.3 Contraception and Pregnancy Avoidance Measures  
In nonclinical animal embryo-fetal development and fertility studies, there was no evidence of 
teratogenicity, no skeletal or visceral malformations, and no changes in male or female reproductive and fertility indices, or in sperm parameters.  In rats, dec reased fetal body weight 
and reduced skeletal ossification were noted at the highest dose tested of 160 mg/kg/day.  Peri-postnatal development studies have not yet been conducted with vadadustat, and there are 
no data on the transmission of vadadustat in breast milk or the effect of vadadustat on infants.  
Although the potential risk of vadadustat on the developing fetus is limited based on studies to date, the study requires that all subjects must agree to use adequate contraception throughout the 
study and for 30 days after the last dose of study medication.  
Adequate contraception is defined as follows: 
• Female subjects must be surgically sterile, postmenopausal (no menses for at least one year), 
or have negative pregnancy test results at Screening (serum).  
• Female subjects not surgically sterile or postmenopausal (no menses for at least one year) 
and non- vasectomized male subjects must practice at least 1  of the following methods of 
birth control: 
o Total abstinence from sexual intercourse (minimum one complete  menstrual cycle prior 
to Screening visit, throughout the study, and for 30 days after the last dose of study 
medication) 
o A vasectomized partner  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 52 of 98 o Hormonal contraceptives (oral, parenteral, or transdermal) for at least 3  months prior to 
study medication  admi nistration or intrauterine contraception/device , throughout the 
study, and for 30 days after the last dose of study medication 
o Double-barrier method (such as male condom, female condom, diaphragm, sponge, or 
cervical cap together with spermicidal foam/gel/ film/suppository) starting at Screening 
Visit 1, throughout the study, and for 30 days after the last dose of study medication. 
9.1.4 Laboratory Accreditation and Reference Ranges 
The Investigator and the Sponsor will maintain a copy of the laboratory accreditation and the reference ranges for the central laboratory used for clinical laboratory evaluations.  Additionally, other accreditation(s) will be collected as required.  
9.2 Study Procedures and Evaluations  
9.2.1 Clinical Evaluations  
The following clinical evaluations will be conducted during the course of the study.  If the 
evaluations will occur on a hemodialysis day, the clinical evaluations should be completed 
before dialysis, if applicable.  
• Medical History, Demographics, and Physical E xamination: Medical history, 
demographic information, and physical examination (including height) will be collected at SV2.  Relevant medical history (with particular emphasis on previous medical conditions that may lead to exclusion) and significant ongoing medical conditions or diseases should be documented.  After SV2, an abbreviated, symptom-directed physical examination should be performed at the discretion of the Investigator, as clinically indicated. 
• Dialysis Adequacy:  Dialysis adequacy, as available from local collection, will be 
recorded in the CRF. 
• Dialysis Treatment : Hemodialysis vascular access type use and any changes at baseline 
and monthly; and changes in renal replacement therapy (from hemodialysis to peritoneal dialysis or from in -center to home dialysis). 
• Vital S ign M easurement s: Vital signs will include  heart  rate and blood pressure.  Heart  
rate and blood pressure should be assessed in the seated position after 5  minutes of rest.  
Vital signs will be collected at SV1, SV2, Baseline, during study visits, and EOT and should be taken prior to blood draws when possible. 
• Weight : Dry weight will be collected for all subjects at SV2, at Weeks 12, 24, 36, and 52, 
yearly thereafter , and at the EOT visit.  For subjects on darbepoetin alfa, subject s will be 
weighed for dosing a s per the local standard of care.  
• 12-Lead E lectrocardiogram (ECG): A standard 12- lead ECG will be performed at 
Baseline, which may be obtained up to 3 days prior to the Baseline visit.  The ECG 
should be obtained after the subject has been resting comfortably in a supine position for approximately 5 minutes and should be taken prior to vital sign assessments and blood draws when possible.  With the subject in a supine position, obtain the 12-lead tracing.  All ECGs will be reviewed by the Investigator for the presence of rhythms of potential 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 53 of 98 clinical concern.  A record of the tracing(s) will be made and retained with other source 
documents. 
• Completion of MACE Endpoint Questionnaire : At each post-randomization study visit, 
the subject must specifically be que stioned regarding the occurrence of any potential 
MACE endpoint event since the last study visit.  IMPORTANT: The endpoint 
questionnaire electronic CRF must be completed in full at each visit even if no 
potential MACE endpoints have occurred.   If a potential endpoint event is reported, 
the date of the event should be recorded and the appropriate source documents should be 
collected according to the endpoint packet checklist.  
• AE Assessments: AE collection will begin from time of randomization  through global 
study completion.  The Investigator and study personnel will review each subject’s 
laboratory and clinical evaluation findings and query the subject directly regarding AEs (see Section  
10, Adverse Events ).  Subjects must be followed for AEs until the final 
required protocol visit or until all drug -related toxicities and SA Es have resolved (or are 
considered chronic/stable), whichever is later. 
• Concomitant Medication Recording: All medications (both prescription and 
non-prescription, and including vitamins, herbals, topicals, inhaled, and intranasal), taken 
during the screening period and throughout the study, ending at the final protocol  
required visit , should be recorded on the appropriate CRF.  If the duration of the 
screening period is less than 30 days, all medications taken within 30 days prior to the start of study medication (vadadustat or darbepoetin alfa), will be recorded.  At each 
study visit, subjects will be asked whether they have started or discontinued any medication  since their previous study visit.  This includes single- use or as -needed 
medi cation use.  All medications and treatments , including vitamin supplements, over-
the-counter medications and oral herbal preparations must be recorded in the CRFs.      
Routine medications and treatments used during each hemodialysis session, such as 
heparin injections or saline flushes, are not required to be recorded unless relevant for an AE or SAE .  In addition, the ESA, blood transfusion, and iron treatment regimen  prior to 
randomization and date of  last dose will be recorded.  
9.2.2 Laboratory Evaluations 
Samples for laboratory assays will be sent to a central laboratory for analysis.  Detailed instructions for the collection, processing, and shipment of laboratory samples will be provided by the Sponsor and the central laboratory.  If blood is collected on a hemo dialysis day, blood 
draws should be done prior to dialysis, if applicable .  The Investigator is responsible for 
reviewing laboratory results for clinical significance.  
The following laboratory evaluations will be conducted during the course of the study: 
• Pregnancy T est: A serum pregnancy test will be performed at SV2 for females of 
childbearing potential.  Additional serum or local urine (if possible) pregnancy tests may 
be conducted throughout the study in sufficient number, as determined by the Investigator or required by local regulations, to establish the absence of pregnancy during the study.  The SV2 results must be available and must be negative before the subject takes the first dose of study medication. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 54 of 98 • Complete Blood Count (CBC) : A CBC with differential will be performed at Baseline 
and twice annually at Weeks 28, 52, 76, 104, 128, 156, 180, and 208.  At all other noted 
visits in  Appendix A :  Schedule of Activities , including SV1 and SV2, a CBC without 
differential will be performed.  The CBC with differential will include: Hb, hematocrit, 
RBCs, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), and platelets. 
Hemoglobin assessed by central laborat ory CBC will be used for evaluations of efficacy 
and safety.  Hemoglobin levels assessed by HemoCue should be used for dose 
adjustments, as described in Section  8.4.4, Dosing and Dose Adjustment Guidelines .  If 
the Investigator has an immediate clinical concern about a subject’s HemoCue value, the Investigator may use  clinical judgement and repeat the HemoCue Hb, use local lab  values 
or wait for central lab results.  The test method utilized to inform the treatment decision 
must be recorded in the appropriate CRF and the subject’s source.  
For eligibility  purposes, one retest for Hb may be performed during the screening 
window.  The average of 2 Hb values measured by the central laboratory during Screening (SV1, SV2 or retest) must be between 8.0 and 11.0 g/dL (inclusive) in the US 
and between 9 .0 and 12.0 g/dL (inclusive) outside of the US.  Refer to Section  7.4.1, 
Retesting  and Section 7.4.2, Rescreening  for further details regarding repeating 
laboratory measurements during the Screening period. 
• Point of C are Hb: Using HemoCue, Hb will be monitored throughout the study to 
determine if the dose of study medication (vadadustat or darbepoetin alfa) will be adjusted , interrupted, or maintained as described in Section  
8.4.4, Dosing and Dose 
Adjustment Guidelines . 
• Reticulocyte C ount: An automated reticulocyte count (both absolute and percent) will be 
performed at Baseline and at Weeks 4, 12, 28, and 52. 
• Coagulation T ests: Blood samples will be drawn at Baseline to assess the prothrombin 
time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR).  
• Folate and Vitamin B 12: A blood sample will be drawn at SV1  to assess the folate and 
Vitamin  B12 levels.  
• C-reactive P rotein  (CRP) : A blood sample for CRP  will be collected at the Baseline visit, 
Weeks 28, 52, 104, 156, and EOT.  
• Serum Chemistry : Blood samples to assess serum chemistry will be collected at SV1, 
Baseline, and twice annually at Weeks 28, 52, 76, 104, 128, 156, 180, and 208, and EOT.  The serum chemistry will  include the following assays: sodium, potassium, bicarbonate, 
chloride, calcium, magnesium, phosphorus, glucose, creatinine, blood urea nitrogen 
(BUN), creatine phosphokinase (CPK), uric acid, albumin, and total protein. 
• Liver Function Tests : Blood samples to assess liver f unction will be collected at SV 1, 
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 44, 52, 64, 76, 88, 104, 116, 128, 140, 156, 168, 180, 192, 208, and EOT .  Liver function tests will include: total bilirubin, alkaline 
phosphatase, ALT/SGPT, AST/SGOT, and lactate dehydrogenase (LDH). 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 55 of 98 • Iron I ndices : Blood samples to assess the iron indices will be collected at SV1, Baseline, 
Weeks 4, 8, 12, 20, 28, 36, 44, 52, 64, 76, 88, 104, 116, 128, 140, 156, 168, 180, 192, 
208, and EOT.  Assessments will include the following indices: ferritin, iron, TIBC, and 
TSAT.  
• Lipid Profile: Blood samples will be collected at the Baseline, Week 28, and Week 52 
visits to assess the cholesterol levels and will be tested for the following types of lipids: 
total cholesterol, low -density lipoprotein (LDL), high-density l ipoprotein (HDL), and 
triglycerides.  
• Biomarkers ( including, but not limited to, hepcidin, vascular endothelial growth factor 
[VEGF] ): Samples for biomarker analysis will be drawn at the Baseline, Week s 12, 28, 
52, 104, 156 and EOT visits. 
• Erythropoietin : Blood samples for EPO analysis will be obtained at Baseline and at 
Weeks 4, 12, 28, and 52. 
• PK Evaluations (samples to be drawn only for subjects randomized to vadadustat) : 
Plasma samples for PK evaluation will be collected to analyze for both the parent compound (vadadustat) and its metabolites.  Collection time points for PK will include Study Day 1 ( Baseline), Weeks 4, 12, 28, and 52. 
The modality of dialysis (hemodialysis vs peritoneal dialysis) that the subject is receiving 
will determine the timing of  the PK samples. 
For subjects receiving hemodialysis : 
Study Day 1 (Baseline visit): 
Ideally, vadadustat will be administered on Study Day 1 after the Baseline 
procedures, and the PK sample will be collected between 15 minutes to 1.0 hour 
after vadadustat  administration  but prior to start of the hemodialysis session.   
If it is not possible to administer vadadustat prior to start of the hemodialysis session, then the next preferred time would be to administer vadadustat just after completion of the hemodia lysis session with the PK sample collected  between 
15 minutes to 1.0 hour after vadadustat  administration .   
Otherwise, the first dose of vadadustat may be administered during the hemodialysis session and the PK sample will be collected  between 15 minutes to  1.0 hour after 
vadadustat administration .  The times of the vadadustat dose, the PK sample, and the 
start and stop of the hemodialysis session will be documented. 
Weeks 4, 12, 28, and 52: 
Pharmacokinetic samples will be collected pre -dialysis at the same time as the other 
study laboratory samples at the  Weeks 4, 12, 28, and 52 study visits.  T he date and 
time of the last dose of vadadustat prior to the PK sampling, as well as the timing of 
the PK sample collection,  will be documented. 
For subjects receiving peritoneal dialysis  (or subjects receiving in -home hemodialysis 
whose study visits are independent of their dialysis sessions) : 
Study Day 1 (Baseline visit): 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 56 of 98 Vadadustat will be administered on Study Day 1 in the clinic after the Baseline 
procedures, and the PK sample will be collected between 15 minutes to 1.0 hour 
after vadadustat  administration .  The times of the vadadustat dose and the PK sample 
will be documented. 
Weeks 4, 12, 28, and 52: 
Pharmacokinetic sampling will be collected along with the other study laboratory 
samples at  the Weeks 4, 12, 28, and 52 study visits.  The date and times of 
vadadustat administration and PK sampling will be documented. 
• Exploratory Samples : Additional blood samples will be collected at Baseline , Weeks 28, 
52, 104, 156, and EOT which may be used for exploratory measurement of biomarkers 
(eg, factors relating to the activation of the HIF pathway).  Subjects will also be asked to provide optional consent to obtain a blood sample at Baseline and EOT to be stored  for 
future genetic analyses (eg, DNA and mRNA).  
9.3 Schedule of Activities  
The Schedule of Activities  (see Appendix A:  Schedule of Activities ) shows the timing of 
planned study procedures.  Every effort should be made to adhere to this procedure schedule and 
all assessments should be completed at each study visit.  Where possible, study visits should be 
performed and scheduled as part of a patients regularly scheduled dialysis session.  
9.3.1 Prescreening Visit  
To minimize screen failures, there will be an optional Pre screening visit which will enable the 
subject to have a HemoCue Hb  prior to proceeding with full Screening.  Subjects will need to 
sign an abbreviated Prescreening informed consent form or full consent form prior to 
Prescreening.  If the Pre screen HemoCue Hb is between 8.0 and 11.0 g/dL (inclusive) within the 
US or betwe en 9.0 and 12.0 g/dL (inclusive) outside of the US, the investigative site may 
proceed with SV1, which preferably will occur o n the same day as Prescreening. 
9.3.2 Screening Visit s 
Subjects will need to sign a full consent form prior to SV1  procedures.  The cons ent form may be 
signed in advance of the SV1 procedures.  The Screening period starts at the time the informed 
consent is signed and will be a maximum of  8 weeks in duration.  Two Screening visits (SV1 and 
SV2) must be performed within 8 weeks prior to d osing (Baseline visit/Day 1).  There must be a 
minimum of 4  days between the 2 Screening visits and a minimum of 4 days between SV2  or last 
retest  and the Baseline visit.  
The Investigator will maintain a log of  subjects (both Prescreened and Screened) and indicate 
who of the pres creened  subj ects were  brought in for informed consent and Screening and who of 
the Screened  subj ects were enrolled or excluded and the reason for exclusion. 
After obtaining informed consent, subjects will undergo a number of s creeni ng activities.  
9.3.2.1 Screening Visit 1 (SV1)  
At SV1, the following activities/procedures will be performed: 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 57 of 98 • Informed consent (including an additional optional consent for blood samples for future 
genetic analyses). 
• Review of eligibility criteria  
• Vital signs including heart  rate and blood pressure (assessed in seated position after 
5 minutes of rest and prior to blood draws) 
• Laboratory procedures:  
o CBC (without differential).  
o Iron indices  
o Folate and vitamin B 12 levels  
o Serum Chemistry  
o Liver Function Tests  
• Visit registration in IWR  
Refer to  Section  7.4.1, Retesting  and Section 7.4.2, Rescreening  for further details regarding 
repeating laboratory measurements during the Screening period.  
9.3.2.2 Screening Visit 2 (SV2)  
At SV2, the following activities/procedures will be performed: 
• Review of eligibility criteria  
• Physical examination 
• Demographics and medical history 
• Vital signs including heart rate and blood pressure (assessed in seated position after 
5 minutes of rest and prior to blood draws), as well as height and dry weight 
• Laboratory procedures:  
o CBC ( without differential)  
o Serum pregnancy test for females of childbearing potential (eligible subjects will be 
advised to use an adequate contraceptive method)  
• Prior and current medication use.  
The mean of 2 Hb  values from the central laboratory must be between 8.0 and 11.0 g/dL 
(inclusive) in the US or between 9.0 and 12.0 g/dL (inclusive) outside the US to qualify for inclusion into the trial.  If the subject’s Hb does not qualify after SV1, SV2 , or retest Hb, the 
subject should be considered a Screen f ailure.  
9.3.2.3 Subject Retesting  
Subjects who initially fail to qualify for the study based on laboratory test results may be retested once within the 8-week  Screening period, per Investigator discretion (Section  7.4.1, Retesting ).  
9.3.2.4 Subject Rescreen ing 
Subjects who fail to meet the qualifying criteria for Hb during the Screening period may be 
considered for rescreening at the discretion of the Investigator if it is fe lt that the subject’s status 
has progressed and that the subject may now qualify for the study.  Additionally, subjects who fail to qualify for the study based on low TSAT, ferritin, folate, or B
12 values may be considered 
for rescreening after receiving replacement therapy.  Screening is limited to 3  attempts ( initial 
Screening and 2 additional rescreening attempts) ( Section  7.4.2, Rescreening ).  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 58 of 98 9.3.3 Baseline Visit (Day 1)  
The Baseline visit must be performed at a minim um of 4  days from  the last Screening visit (SV2) 
procedure, including retests . 
At the Baseline visit, the following activities/procedures will be performed: 
• Randomization 
• 12-lead ECG (prior to vital sign assessments and blood draws) 
• Vital signs including heart rate and blood pressure (assessed in seated position after 
5 minutes of rest and prior to blood draws) 
• Laboratory Procedures:  
o Coagulation Tests 
o CRP 
o CBC (including differential) 
o Reticulocyte count 
o Serum chemistry   
o Liver function tests 
o Iron indices 
o Lipid profile 
o EPO  
o Biomarkers  
o PK (see 9.2.2, Laboratory Evaluations ; samples to be drawn only for subjects 
randomized to vadadust at) 
o Exploratory samples  
• Review of medical history for new conditions since Screening visit 
• Medication use since Screening visit  
• Study medication assessments and procedures:  
o Subject will take their first dose of study medication at the investigative site du ring 
the Baseline visit  
o Hb by HemoCue  
o Assess:  
 Hemodialysis vascular access type use changes  
 Renal replacement therapy changes  
o Dialysis adequacy, as available from local collection  
o Vadadustat dispensing  
o Darbepoetin alfa dispensing  
o Iron supplementation as needed to maintain ferritin ≥100 ng/mL or TSAT  ≥20% (per 
local product label; see Section  8.4.6, Iron Supplementation)  
o Visit r egistration in IW R 
• Safety assessments:  
o AE assessment as needed (after receiving the first dose of study medication) . 
9.3.4 Year 1 Treatment Period Visits (Da y 2 through Week 52) 
During the Year  1 Treatment Period visits  at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 
44, 48, and 52, the following activities/procedures will be performed: 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 59 of 98 • Vital signs including heart rate and blood pressure (assessed in seated position after 
5 minutes of rest and prior to blood draws) 
• Dry weight (Weeks 12, 24, 36, and 52) 
• Laboratory procedures:  
o CBC (Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52; differential at Weeks 28 and 52) 
o Reticulocyte count (Weeks 4, 12, 28, and 52) 
o Serum ch emistry (Weeks 28 and 52) 
o Liver function tests (Weeks 4, 8, 12, 16, 20, 24, 28, 36, 44, and 52) 
o Iron indices (Weeks 4, 8, 12, 20, 28, 36, 44, and 52) 
o Lipid profile (Weeks 28 and 52) 
o EPO (Weeks 4, 12, 28, and 52) 
o CRP (Weeks 28 and 52) 
o Biomarkers (Weeks 12 , 28, and 52) 
o PK (Weeks 4, 12, 28, and 52; see Section  9.2.2, Laboratory Evaluations ; samples to 
be drawn only for subjects randomized to vadadust at) 
o Exploratory samples (Week s 28 and 52) 
• Record date and time of subject’s last dose of vadadustat prior to the PK sample (Weeks 4, 12, 28, and 52) 
• Safety assessments:  
o AE assessment  
o RBC transfusions and ESA rescue  
o Therapeutic phlebotomy  
o MACE endpoint questionnaire 
• Medication assessments and procedures:  
o Review of concomitant medications 
o Hb by HemoCue
 for dose adjustment 
o Assess:  
 Hemodialysis vascular access type use changes  
 Renal replacement therapy changes  
o Dialysis adequacy, as available from local col lection  
o Drug reconciliation: Study medication (vadadustat or darbepoetin alfa) reconciliation 
will be conducted per the pharmacy manual instructions. 
o Visit r egistration in IWR  
o Vadadustat dispensing as needed per  Section  8.2.1, Dispensing of Vadadustat  
o Darbepoetin alfa dispensing  
o Iron supplementation as needed to maintain ferritin ≥100 ng/mL or TSAT ≥20% (per 
local product label; see  Section  8.4.6, Iron Supplementation)  
o Question subject regarding dosing compliance and whether they have questions or have experienced any problems related to the dosing of study medication (vadadustat or darbepoetin alfa) . 
9.3.5 Year 2 -4 Monthly Hb Monitoring  
Monthly monitoring of Hb as part of local standard of care labs or at unscheduled visits for dose adjustment. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 60 of 98 9.3.6 Year 2 Treatment Period Visits (Weeks 53 through 104) 
During the Year 2 Treatment Period visits  at Weeks 64, 76, 88, and 104, the following 
activities/procedures will be performed: 
• Vital signs including heart rate and blood pressure (assessed in seated position after 
5 minutes of rest and prior to blood draws)  
• Dry weight (Week 104) 
• Laboratory Procedures:  
o CBC (Weeks 64, 76, 88, and 104; differential at Weeks 76 and 104) 
o Serum chemistry (Weeks 76 and 104) 
o Liver function tests (Weeks 64, 76, 88, and 104) 
o Iron indices (Weeks 64, 76, 88, and 104)  
o CRP (Week 104) 
o Biomarker s (Week 104) 
o Exploratory samples (Week 104) 
• Safety assessments:  
o AE assessment  
o RBC transfusions and ESA rescue  
o Therapeutic phlebotomy  
o MACE endpoint questionnaire 
• Medication assessments and procedures:  
o Review of concomitant medications 
o Hb by HemoCue for dose adjustment 
o Assess:  
 Hemodialysis vascular access type use changes  
 Renal replacement therapy changes  
o Dialysis adequacy, as available from local collection  
o Drug reconciliation: Study medication (vadadustat or darbepoetin alfa) reconciliation 
will be conducted per the pharmacy manual instructions. 
o Visit r egistration in IWR  
o Vadadustat dispensing as needed pe r Section  8.2.1, Dispensing of Vadadustat  
o Darbepoetin alfa dispensing  
o Iron supplem entation to maintain ferritin ≥ 100 ng/mL  or TSAT ≥ 20% (per local 
product label; see Section  8.4.6, Iron Supplementation ) 
o Question subject regarding dosing compliance and whether they have questions or have experienced any problems related to the dosing of study medication (vadadustat or darbepoetin alfa) . 
9.3.7 Year  3/4 Treatment Period Visits  (Weeks 116 through 208) 
During the Year 3/4 Treatment Period visits  at Weeks 116, 128, 140, 156, 168, 180, 192, 
and 208, the following activities/procedures will be performed: 
• Vital signs including heart rate and blood pressure (assessed in seated position after 5 minutes of rest and prior to blood draws) 
• Dry weight (Weeks 156 and 208) 
• Laboratory Procedures:  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 61 of 98 o CBC (Weeks 116, 128, 140, 156, 168, 180, 192, and 208; differential at Weeks 128, 
156, 180, and 208) 
o Serum chemistry (Week s 128, 156, 180, and 208) 
o Liver function tests (Weeks 116, 128, 140, 156, 168, 180, 192, and 208) 
o Iron indices (Weeks 116, 128, 140, 156, 168, 180, 192, and 208)  
o CRP (Week 156) 
o Biomarkers (Week 156)  
o Exploratory samples (Week 156) 
• Safety assessments:  
o AE assessment  
o RBC transfusions and ESA rescue  
o Therapeutic phlebotomy  
o MACE endpoint questionnaire 
• Medication assessments and procedures:  
o Review of concomitant medications 
o Hb by HemoCue for dose adjustment 
o Assess:  
 Hemodialysis vascular access type use changes 
 Renal replacement therapy changes  
o Dialysis adequacy, as available from local collection  
o Drug reconciliation: Study medication (vadadustat or darbepoetin alfa) reconciliation 
will be conducted per the pharmacy manual instructions. 
o Visit registration  in IWR  
o Vadadustat dispensing as needed per Section  8.2.1, Dispensing of Vadadustat  
o Darbepoetin alfa dispensing  
o Iron supplementation to maintain ferritin ≥ 100 ng/mL  or TSAT  ≥20% (per local 
product label; see Section  8.4.6, Iron Supplementation ) 
o Question subject regarding dosing compliance and whether they have questions or have experienced any problems related to the dosing of study medication (vadadustat or darbepoetin alfa) . 
9.3.8 End of Treatment  (EOT)  Visit  
The EOT visit will be performed at the time a subject permanently discontinues study medication  
or for subjects on study medication at the time of notification of global study completion.
  (See 
Appendix A :  Schedule of Activities ). 
At the EOT visit, the  following activities/procedures will be performed: 
• Vital signs including heart rate and blood pressure (assessed in seated position after 5 minutes of rest and prior to blood draws), as well as dry weight 
• Laboratory Procedures:  
o CBC (without differential)  
o Serum  chemistry  
o Liver function tests 
o Iron indices  
o Biomarkers  
o CRP  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 62 of 98 o Exploratory samples 
• Safety assessments:  
o AE assessment  
o RBC transfusions and ESA rescue  
o Therapeutic phlebotomy  
o MACE endpoint questionnaire 
• Recording of concomitant medications 
• Assess:  
o Hemodialysis vascular access type use changes  
o Renal replacement therapy changes  
• Dialysis adequacy, as available from local collection  
• Drug reconciliation: Study medication (vadadustat or darbepoetin alfa) reconciliation will 
be conducted per the pharmacy manual instructions. 
• Visit r egistration in IWR  
• Question subject regarding dosing compliance and whether they have experienced any 
problems related to the dosing of study medication (vadadustat or darbepoetin alfa) . 
9.3.9 Follow-u p Visit  
The Follow- up visit will be conducted in person or via the telephone 4 weeks after the EOT visit.  
The following activities/procedures will be performed: 
• AE assessment  
• RBC transfusions and ESA rescue  
• Therapeutic phlebotomy  
• MACE endpoint questionnaire 
• Recording of concomitant medications 
• Dialysis adequacy, as available from local collection  
9.3.10 Unscheduled Visits 
Unscheduled assessments may be conducted at any time as medically warranted.  The following 
activities/procedures will be performed .  At minimum,  
• MACE Endpoint Questionna ire 
• AE assessments  
• Any other procedures that are medically warranted at the discretion of the Investigator. 
9.3.11 End of Study Subject Status  
The End of Study (EOS) assessment  documents the subject status at the global study completion  
or at the  time of subject withdrawal of consent  or when subject is deemed LTFU  or upon death.  
The table below outlines how to handle each subject based on their status.   
The following activities/procedures will be performed .  At minimum,  
• EOS subject status  
Subject Status  Global Study Completion   

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 63 of 98 Subject on Study Medication (includes those 
on temporary interruption) at time of global 
study completion • Perform  EOT visit  
• Perform  the F ollow-up visit 4 weeks after 
EOT and include EOS subject status  
Subject permanently discontinued study 
medication and continues to be followed in 
the study Optimal data collection would include the 
following assessments:  
• EOS subject status (must collect at 
minimum)  
• MACE Endpoint Questionnaire 
• AE Assessment  
NOTE: EOT and the F ollow -up visit 4 weeks 
after EOT visit to be performed at time study 
medication is permanently discontinued. 
Subject Lost to Follow -up  Work with third party vendor to ascertain 
vital status and complete EOS subject status.  
If subject site -site contact is reestablished and 
possible, collect available information for 
EOS subject status.  
Subject Withdrawn Consent  Complete  the EOS subject status form at the 
time of withdrawal of consent , absolute 
refusal of ALL methods of MACE and health status follow -up 
Subject Death  Complete  the EOS subject status form at the 
time of death ( see Section 10 Adverse Events  
for more details on other actions related to reporting a death).   
9.4 Study Medication Stopping Rules  
Study medication must be permanently di scontinued if a subject meets one of the criteria in 
Table 2 below  
Table 2. Study Medication Stopping Rules  
ALT or AST >3x ULN and total bilirubin >2x ULN  Permanently Discontinue Treatment  
ALT or AST >3x ULN and INR >1.5  Permanently Discontinue Treatment  
ALT or AST >8x ULN  Permanently Discontinue Treatment  
ALT or AST remains >5x ULN over 2 weeks* Permanently Discontinue Treatment  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 64 of 98 ALT or AST >3x ULN with symptoms including e.g., 
fatigue, nausea, vomiting, right upper quadrant pain, 
fever, rash or eosinophilia Permanently Discontinue Treatment  
* Re-challenge generally should be avoided with ALT or AST >5 times ULN unless there are no other good 
therapeutic options . 
ALT: alanine transferase; AST:  asparagine  transferase; INR:  international normalized ratio; ULN:  upper limit of 
normal   
See Section 10.1.1, Adverse Events for reporting requirements related to a subject being 
permanently discontinued based on meeting the laboratory abnormalities list above in Table 2. 
10 ADVERSE EVENTS  
10.1 Definitions  
10.1.1 Adverse Events  
For the purposes of this study, an AE is any untoward medical occurrence (including a n 
abnormal laboratory finding) that occurs in the protocol- specified AE reporting period; the event 
does not necessarily have a causal relationship with that treatment or usage.  
An AE includes medical conditions, signs, and symptoms not previously observed in the subject that emerge during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. 
• Adverse events therefore include the following:  
• All AEs, whether suspected to be causally related to study medication  or otherwise  
• All AEs secondary to any medication overdose, medication error, abuse, withdrawa l, 
sensitivity, or toxicity  
• Illnesses apparently unrelated to study medication , including the worsening of a pre-
existing illness (see paragraph below on Pre-existing Conditions) 
• Injury or accidents.  Note that if a medical condition is known to have cause d the injury 
or accident (eg, a fall secondary to dizziness), the medical condition (dizziness) and the accident (fall) should be reported as 2 separate AEs. 
• Abnormalities in physiological testing or physical examination findings that require clinical inte rvention or further investigation (beyond ordering a repeat [confirmatory] 
test) 
• Laboratory abnormalities that require clinical intervention or further investigation 
(beyond ordering a repeat [confirmatory] test) unless they are associated with an already 
reported clinical event.  Laboratory abnormalities associated with a clinical event reported as an AE (eg, elevated liver enzymes in a subject with jaundice) should be described under ‘Comments’ on the report of the clinical event rather than reported as 
separate AEs.  
The following guidelines are to be used when reporting AEs for this study: 
Medical Diagnoses – Whenever possible, a medical diagnosis term should be used to report AEs 
instead of signs and symptoms due to a common etiology, as determined by qualified medical 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 65 of 98 study staff.  For example, pneumonia should be the reported AE term, instead of fever and 
dyspnea, when the diagnosis has been established.  Signs and symptoms should be reported as event terms only when the medical diagnosis remains unknown, and revised to a medical diagnosis term once it has been established.  
Procedures – Diagnostic and therapeutic non-invasive and invasive procedures, such as surgery, should not be reported as AEs.  However, the medical condition for which the procedure w as 
performed should be reported if it meets the definition of an AE.  For example, an acute appendicitis that begins during the AE reporting period should be reported as the AE and the resulting appendectomy noted under ‘ Comments ’. 
Pre-planned therapeutic procedures not associated with a new medical condition or worsening 
pre-existing condition should not be reported as AEs. 
Pre-existing Conditions  – In this study, a pre-existing condition (ie, a disorder present before 
the AE reporting period started and noted on the pretreatment medical history/physical 
examination form) should not be reported as an AE unless the condition worsens or episodes increase in frequency during the AE reporting period. 
Abnormal Test Findings – All laboratory test results will be reviewed by the Investigator.  The 
Investigator will utilize his/her judgment in determining if out-of- range laboratory values are 
clinically significant and will denote this using the abbreviation “CS” on the laboratory report for 
source documentation.  L aboratory tests that are labeled as clinically significant  should be 
reported as AEs, either separately or as part of a description of a symptomatic AE.  If there are significant changes in a laboratory report from a previous visit that are determined to b e 
clinically significant, these should also be reported as AEs.  Any abnormal laboratory value which requires treatment or further diagnostic testing and/or results in discontinuation from study should be reported as an AE .  An expected laboratory abnormal ity from a condition that is part of 
the medical history is not considered clinically significant for the purposes of the study unless it represents a worsening of the condition. 
Abnormalities in ALT, AST, and Total Bilirubin  – Abnormalities in ALT, AST , and total 
bilirubin should be reported to the Sponsor’s Medical Monitor or CRO designee within 24 hours 
of awareness as an SAE with ‘other medically important event’ criteria selected, if the following 
conditions are met: 
• New elevation in ALT or AST > 3 time s ULN, with or without an elevation of total serum 
bilirubin > 2 times ULN, AND  
If new elevations in ALT or AST > 3 times ULN, without  an eleva tion of total serum bilirubin 
>2 times ULN are identified, the following steps are to be taken: • Temporary discontinuation of study medication; 
• Repeat testing of ALT, AST, ALP, and total bilirubin, should be completed within 48 to 
72 hours to confirm the abnormalities and to determine trend; 
• Study medication should not be resumed until monitoring indicates abnormalities have 
resolved  or are stable. 
Details on the management of subjects with other ALT and AST abnorma lities are further 
described in Section 9.4, Study Medication Stopping Rules .   

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 66 of 98 Worsening of Anemia – In this study, it is possible that so me subjects may experience a 
worsening o f anemia.  As the primary endpoint of this study assesses Hb  response, worsening of 
anemia is captured as part of this efficacy parameter.  Worsening of anemia should not be 
considered an AE unless the worsening of a nemia is associated with a cause other than the 
subject’s CKD.  
Transplantation – During this long- term study, it is anticipated  that some subjects may receive 
a kidney transplant.  These events will not be recorded as AEs.  Subjects will discontinue study 
medication for receipt of a kidney, other solid organ, hematopoietic stem cell or bone marrow 
transplant and should continue with the Sc hedule of Activities and safety assessments as 
described in Section 7.5.5.2, Permanent Discontinuation of Study Medication.  
 Malignancy – During this long-term study, some subjects may develop a newly diagnosed malignancy or a recurrence of a malignancy.  At the discretion of the Investigator, these subjects 
may continue study medication (vadadustat or darbepoetin alfa).  For reporting of adverse events of malignancy, s ee Section 10.1.2, Serious Adverse Events . 
10.1.2 Serious Adverse Events 
Each AE is to be classified by the Investigator as SERIOUS or NONSERIOUS.  An AE that 
meets 1 or more of the following criteria/outcomes is classified as serious:  
• Death  
• Life-threatening (see paragraph below on life -threatening) 
• In-patient hospitalization or prolongation of existing hospitalization (see paragraph below 
on hospitalization) 
• Persistent or significant disability/incapacity (see paragraph below on disability)  
• Congenital anomaly/birth defect  
• Is considered a medically important event not meeting the above criteria, but which may 
jeopardize a subject, or may require medical or surgical intervention to prevent one of the 
criteria listed in this definition.  
In addition to the above criteria for classifying AEs as serious, the following situation will also be classified as serious fo r purposes of this study:  
• Malignancies – Newly diagnosed malignancies or a recurrence of a malignancy should be 
reported as an SAE with the seriousness criterion “medically important” if no other 
seriousness criteria are met.  If a subject  develops basal cell carcinoma of skin, squamous 
cell carcinoma of skin, or cervical carcinoma in situ during the study, or has worsening of these events from Baseline, the Investigator will determine if the event is reported as an 
AE or SAE.    
• Designated Medical Events - The sponsor maintains a list of designated medical 
events  (DME) that they will always classify as serious adverse events.   If an event on the 
DME list is reported as an AE additional information on the event (e.g. investigator 
confirmation of seriousness, causality) will be requested from the Investigator. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 67 of 98 Serious also include s any other event that the Investigator or Sponsor judges to be serious.  If 
there is any doubt whether the information constitutes an AE or SAE, the information is to be 
treated as an SAE.  
The Sponsor has a list of events that they classify as “always serious” events.   If an AE is 
reported that is considered to be an event per this classification as “always serious”, additional information on the event may be requested. 
Life-threatening – Any event in which the subject was at risk of death at the time of the event; 
‘life-threatening’ does not refer to an event which hypothetically might have caus ed death if it 
were more severe.  For example, drug- induced hepatitis tha t resolved without evidence of 
hepatic failure would not be considered life threatening, even though drug-induced hepatitis of a 
more severe nature can be fatal.  
Hospitalization – Hospitalization is defined as an overnight admission with observation of a 
minimum of 24 hours.  A hospitalization planned before the start of the study for a pre-existing condition that has not worsened during the AE reporting period does not constitute an SAE unless an untoward event occurs related to the procedure (eg, elective  hospitalization for a total 
knee replacement due to a preexisting condition of osteoarthritis of the knee that has not worsened during the course of the study). 
Disability  – Defined as a substantial disruption in a person’s ability to conduct normal life 
functions. 
10.2 Eliciting Adverse Event Information  
The Investigator is to report all directly observed AEs and all AEs spontaneously reported by the 
study subject.  In addition, each study subject will be questioned about AEs at each visit following the initiation of treatment.  
10.3 Reporting  
Each AE is to be classified by the Investigator as SERIOUS or NONSERIOUS.  
All AEs that occur in study subjects during the AE reporting period specified in this protocol must be reported, whether or not the event is considered related to study medication (vadadustat or darbepoetin alfa).  
10.3.1 Reporting Period  
The AE reporting period for this study begins from time of randomization through global study 
completion. 
In addition, any AE that occurs subsequent to the AE reporting period that the Investigator 
assesses as related to the study medication should also be reported as an AE.  
10.3.2 Reporting AEs  
NONSERIOUS AEs are to be reported on the AE CRFs.  
10.3.3 Reporting SAEs  
Any SAE, regardless of causal relationship, must be reported to the Sponsor’s M edical Monitor 
or CRO designee within 24 hours after the Investigator becomes aware of the SAE.  Compliance 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 68 of 98 with this time requirement is essential so that the Sponsor may comply with its regulatory 
obligations. 
The initial SAE report should be completed as fully as possible but should contain, at a minimum:  
• Subject number/ID, sex, and age/date of birth 
• The date of report 
• Name of the reporter 
• Name of the suspected medicinal product 
• A description of the event, including event term(s), seriousness criteria, and a clinical 
summary of the event 
• Causality assessment . 
Information about all SAEs (either initial or follow -up information) should be collected and 
recorded in English on the electronic SAE Report Form within the electronic data capture (EDC) 
system.  The Investigator must assess the relationship to each specific component of the study medication.  If the event meets serious criteria and it is not possible to access the EDC system , a 
paper SAE Report Form should be sent to the CRO via email or fax, or th e Investigator will call 
the CRO SAE hotline within 24 hours of being made aware of the SAE (reference the site manual for contact information).  When the EDC system becomes available, the SAE information must be entered within 24 hours of the system becoming available. 
The Investigator must report f ollow-up information relating to an SAE to the Sponsor’s Medical 
Monitor or CRO designee within 24 hours of awareness updating the electronic CRF with the 
new information or by submitting a paper SAE Report Form in the event that the EDC is not available.  When the EDC system becomes available, the SAE information must be entered within 24 hours.  The subject should be observed and monitored carefully until the condition resolves or stabilizes.  
All deaths are to be thoroughly investigated and reported.  Autopsy reports and death certificates 
are to be obtained, if possible. 
The Sponsor and/or its designee are responsible for reporting SAEs to all applicable regulatory 
agencies and the central ethics committees wit hin the required timeline.  
The Investigators are responsible for submitting required safety information to their local Institutional Review Board (IRB) or Independent Ethics Committee (IEC)  as per local 
regulations.  This information includes, but is not limited to, any safety alert letter received from the Sponsor and any SAEs occurring at their investigative site. 
10.3.4 Reporting Study Endpoints  
Investigators will be counseled to report any event that they assess as potentially being a study 
endpoint requiring adjudication (death, myocardial infarction, stroke, thromboembolic events, and hospitalization for HF ).  All study endpoint events will be submitted in a blinded fashion to 
the EAC for adjudication.  To protect the integrity of the trial, already  adjudica ted events will not 
be unblinded or reported to either Health Authorities (HAs) or Investigator s as safety reports 
unless otherwise requested by HAs or Ethics Committees.  After study completion, these events 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 69 of 98 will be included in the final analysis which will be unblinded and submitted to HAs with the 
study report. 
10.3.5 Relationship to Study Medication  
The causal relationship of the AE to study medication (vadadustat or darbepoetin alfa) will be 
assessed by both the Investigator and the Sponsor.   
The assessment of causal relationship to study medication  should be evidence-based, and not 
based on the premise that all AEs are possibly causally related to study medication  until proven 
otherwise.   Examples of evidence that would suggest a causal relationship between  the study medication  and 
the AE include the occurrence of an AE that is uncommon and known to be strongly associated 
with drug exposure (eg, angioedema, hepatic injury, and Stevens-Johnson syndrome) or an AE that is uncommon in the population exposed to the drug. 
The causal relationship of the AE is assessed using a binary system, and AEs are classified as 
either ‘related’ or ‘unrelated;  
Related : There is ‘reasonable possibility’ that the drug caused the AE.  The AE follows a 
reasonable temporal sequence f rom the time of drug administration.  There is supportive 
evidence (facts) to suggest a possible causal relationship, irrespective of the degree of certainty between the observed AE and the drug. 
Unrelated : An AE does not follow a reasonable temporal sequence from administration of the 
product and/or there is no reasonable possibility that the drug caused the AE.  This assessment includes situations where the AE is related to other factors such as the subject’s clinical state, other therapeutic intervention s, or concomitant drugs administered to the subject. 
Default assessments using the ‘related ’ category without supportive evidence for a causal 
relationship to study medication  is generally uninformative and do not contribute meaningfully 
to the development of the safety profile of the drug or to subject protection. 
Investigators are encouraged to choose the most plausible cause for the event(s) from the 
following list: medical history, lack of efficacy/worsening of treated condition, study medication , 
other treatment (concomitant, or previous), withdrawal of study medication , administration error, 
protocol- related procedure, others (specify).  
10.3.6 Severity  
The Investigator will assess each AE as either MILD, MODERATE, or SEVERE using the following guidelines to describe the maximum severity of the AE:  
MILD: Does not interfere with subject's usual function 
MODERATE: Interferes to some extent with subject's usual function  
SEVERE:  Interferes significantly with subject's usual function 
Note that a severe AE is not necessarily a serious  AE.  For example, a headache may be severe 
in intensity, but would not be class ified as serious unless it met 1  of the criteria for serious events 
listed above. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 70 of 98 10.3.7 Follow-u p of Unresolved Events  
All AEs should be followed unti l they are resolved or the Investigator assesses t hem as chronic 
or stable or the subject’s participation in the trial ends (ie, until a final report is completed for 
that subject).  
In addition, all SAEs and those nonserious events assessed by the Investigator as related to the 
study medication should continue to be followed even after the subject's participation in the trial 
is over.  Such events should be followed until they resolve or until the Investigator assesses them as “chronic” or “stable”.  Resolu tion of such events is to be documented on the appropriate CRF. 
10.4 Exposure In Utero  
A pregnancy in a female subject must be confirmed by a positive serum β human chorionic 
gonadotropin (β -HCG)  test.  
The study medication should be immediately discontinued onc e the pregnancy of a female study 
participant has been confirmed.  
If any study participant becomes or is found to be pregnant while receiving a study medication (vadadustat or darbepoetin alfa) or within 30  days of discontinuing the study medication, the 
pregnancy must be recorded on the Pregnancy Reporting Form/Exposure in Utero Form in EDC within 24 hours of awareness of the pregnancy or the Investigator will call the CRO SAE hotline within 24 hours of being made aware of the pregnancy. 
Pregnancy during t his time frame of the female partner of a male subject should also be reported. 
The Pregnancy Reporting Form/Exposure in Utero Form must be completed with all known 
information regarding the pregnancy at the time of reporting.  Investigative site personnel  will 
update the form with additional information regarding the pregnancy and the outcome of the pregnancy as it becomes available until the outcome of the pregnancy is reported. 
The Investigator will follow the  subject (or female partner of a male  subject ) until completion of 
the pregnancy.  If the outcome of the pregnancy meets the criteria for classification as an SAE 
(ie, spontaneous abortion, stillbirth, neonatal death within 1 month of birth, or congenital anomaly [including that in an aborted fetus]), the Investigator will also follow the procedures for reporting an SAE within 24 hours of awareness.  A pregnancy in and of itself is not considered an AE; however, unexpected complications are considered AEs. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 71 of 98 Additional information about pregnancy outcom es follows:  
• Note that “spontaneous abortion” includes miscarriage and missed abortion. 
• All neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality, as SAEs.  In addition, any infant death after 1 month that the Investigator 
assesses as related  or unrelated to the in utero exposure to the study medication should 
also be reported.  
• In the case of a live birth, the “normality” of the newborn can be assessed at time of birth.  
• The “normality” of an aborted fetus can be a ssessed by gross visual inspection unless 
there are pre -abortion laboratory findings suggestive of a congenital anomaly. 
10.5 Special Situations  
Certain safety events, called ‘Special Situations’, that occur in association with study medication(s) may require r eporting.  These Special Situations include, but are not limited to, the 
following: 
• Overdose of the medicinal product 
o Darbepoetin alfa overdose  – The PI or SmPC should be referenced for information 
on darbepoetin alfa overdosing.   
o Vadadustat overdose - There is no known antidote for vadadustat.  In cases of 
suspected overdose, Subjects should be treated per standard medical practice based on the Investigator’s judgment and dose delays and reductions may be implemented as necessary.  
Chronic overdosage with vadadustat may result in excessive production of red blood cells and polycythemia.  Polycythemia can be potentially life threatening and may result in severe thrombosis and death (known as hyperviscosity syndrome).  If hyperviscosity syndrome is observed, vadadustat should be discontinued and standard treatment for polycythemic hyperviscosity syndrome should be initiated (i.e., phlebotomy). 
• Suspected abuse/misuse of the medicinal product 
• Inadvertent or accidental exposure to the medicinal product 
• Medi cation error involving the medicinal product (with or without subject exposure to the 
Sponsor ’s medicinal product [eg, name confusion]) 
• Drug -drug interaction. 
Special situations should be reported on the Special Situations CRF whether they result in an AE/SAE or not.  Special situations with associated AE/SAE should also be reported on the 
corresponding AE/SAE forms, following applicable AE or SAE process. 
11 DATA ANALYSIS  
Data collected throughout the study will be summarized using descriptive statistics and listed in 
by-subject listings.  Continuous variables will be summarized using number of subjects with 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 72 of 98 data, mean, standard deviation, median, minimum, and maximum.  For categorical variables, the 
number and percentage of subjects in each category will be tabulated.  Summaries will be provided by treatment group within appropriate analysis populations (as defined in Section  11.2, 
Study Analysis Populations ) and by time poi nt/time period , as appropriate.  
For Hb, Baseline will be calculated as the average of the central laboratory Hb measurements of 
samples taken at the screening visit closest to the date of randomization and the measurement taken at randomization.   For other parameters, unless otherwise specified, Baseline will be 
defined as the last available value prior to the first dose of study medication.  
Hemoglobin values as assessed through the central laboratory will be used for efficacy and safety evaluations; local HemoCue Hb  values will be used only for dose adjustments.  
11.1 Sample Size Determination  
The goal of this study is to demonstrate the efficacy and safety of vadadustat compared with darbepoetin alfa for the maintenance treatment  of anemia in subjects with DD -CKD.   The sample 
size is calculated to ensu re sufficient power for testing both efficacy in this trial and the primary 
safety endpoints as part of a pooled analysis.  
11.1.1 Sample Size for the Primary Efficacy Endpoint 
The primary efficacy endpoint is defined as the mean change in Hb  from Baseline (mean 
pretreatment Hb) to the average Hb  over the primary evaluation period (mean Hb from Weeks 24  
to 36, inclusive ).
 
The primary efficacy objective of this study is to show that vadadustat is noninferior to darbepoetin alfa within the noninferiority margin.  Noninferiority will be established based on a 
margin of -0.75 g/dL (for vadadustat minus darbepoetin alfa).  
For the primary efficacy analysis in this study, it is assumed that the mean change from Baseline 
in Hb  for vadadustat will be the same as for darbepoetin alfa, and the common standard deviation 
for the mean change from Baseline is assumed to be 1.5 g/dL.  Noninferiority will be established based on a 2-sided 95% confidence interval (CI) for the difference between the vadadustat  group 
and darbepoetin alfa  and using a noninferiority margin of -0.75 g/dL.  With these assumptions 
and approximately 1650 subjects per treatment group for the primary efficacy analysis, the noninferiority assessment will have > 99% power.   
11.1.2 Sample Size for the Prima ry Safety Endpoint  
The primary safety endpoint is the time from  randomization date  to the first (adjudicated) MACE  
+1.  
The primary safety analysis will be based upon all events that accrue over the 2 DD- CKD studies 
(Studies AKB -6548- CI-0016 and AKB-6548-CI-0017).  The sample size with respect to the 
MACE endpoint has been determined based on the number of events needed to demonstrate noninferiority of the 2-sided 95% CI  for the hazard ratio (vadadustat/darbepoetin alfa).  It has 
been calculated that 631 events will be required overall to have 80% power to establish 
noninferiority with a margin of 1.25, and 90% to establish noninferiority with a margin of 1.3, assuming no difference between treatment groups.   The power is >90% to establish a 
noninferiority margin  of 1.25 if the hazard ratio is 0.95 favoring vadadustat.  A MACE rate of 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 73 of 98 12% annually is anticipated in both treatment arms based on a comprehensive review of 
available epidemiology and prospective clinical studies in the field.  T he number of MACE  in 
each study will be a function of the actual pattern and size of enrollment as well as the duration 
of follow -up. 
11.2 Study Analysis Populations  
The following analysis populations will be used in this study: 
• Randomized population: def ined as all randomized subjects. 
• Full analysis population: defined as randomized subjects receiving 1 or more doses of 
study medication and had at least one Hb assessment during the primary efficacy evaluation period.  This population will be analyzed based upon the randomized treatment.  
• Per protocol (PP) population: defined as all randomized subjects who received study 
medication (vadadustat or darbepoetin alfa) during the primary evaluation period, had at 
least 2 Hb assessments during the primary evaluation period, received no rescue therapy 
(ESA or RBC transfusion) in the 8  weeks prior to the evaluation period, and have no 
protocol deviations affecting the primary endpoint analyses.  Protocol deviations leading to exclusion from the per protocol population will be s pecified prior to database lock on a 
blinded basis and recorded in a separate document . 
• Safety population: defined as all  subjects who received at least 1 dose of study 
medication .  This population will be analyzed based upon the actual  treatment  received . 
Efficacy analyses will utilize the randomized, full analysis, and PP populations while safety 
analyses (including MACE) will utilize the randomized population. 
11.3 Analysis of Demographic and Pretreatment Variables  
Descriptive statistics will b e generated for  demo graphic and pretreatment variables for each 
analysis population defined in Section  11.2, Study Analysis Populations . 
Medical history terms will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by System Organ Class and Preferred Term for each treatment group based on the safety population. 
11.4 Disposition of Subjects  
The number and percentage of subjects randomized and included in each analysis population will 
be summarized by treatment and overall.  Reasons for excluding subjects from the analysis populations will be presented in a by- subject listing.  
The number of randomized subjects who completed each period of study medication treatment (Conversion and Maintenance, and Long- term T reatment), discontinued from study medication 
early, and completed or discontinued from the study and reasons for discontinuation will be summarized by treatment group and overall. 
11.5 Missing Data  
Subjects who stop study medication treatment after randomization and prior to completion of the 
study should continue with planned study visits and assessments  unless they withdraw consent 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 74 of 98 for participation in the study.  Similarly, subj ects will continue with study medication and study 
procedures following the initiation of rescue therapy , with the exception that the subjects must 
discontinue taking study medication while receiving an ESA rescue therapy.  Treatment with 
study medication should be resumed after an  appropriate interval  following the ESA rescue 
therapy as described in Section  8.4.7, Rescue Therapy .  Data will continue to be collected 
following initiation of the rescue therapy as per the study Schedule of Activities (See Appendix 
A:  Schedule of Activities ). 
All data collected during the study, including at any point after the initiation of r escue therapy as 
well as after early discontinuation of study medication treatment, will be used for the primary 
analysis as well as main analyses of all efficacy endpoints.  Sensitivity analyses will be performed to assess an impact of rescue therapy on study conclusions. 
In the primary analysis of the primary efficacy endpoint, all available qualifying Hb  
measurements during the pretreatment period and during the primary evaluation period 
(Weeks 24 to  36) will be used to calculate an average Hb during each period, respectively , for 
each subject .  For any subj ect with no available Hb measurements during the primary evaluation 
period, multiple imputation s will be used to impute the change from Baseline value (detai ls are 
in the SAP) .  In an analogous manner, an average Hb will be calculated for the secondary 
evaluation period (Weeks 40 to 52) for each subject.   Given the design of this study where the 
subjects will continue to be assessed after early study medication discontinuation, i t is expected 
that there will be only a minimal amount of missing data and the primary analysis should not be 
substantially affected by the imputation. 
All data pertaining to the MACE endpoint collected at any point during the study, both during 
study medicat ion treatment and post-study medication treatment discontinuation, and regardless 
of the rescue therapy, will be used for the primary analysis of the MACE endpoint and its individual components. 
Unless stated otherwise in the SAP , missing data for all othe r secondary efficacy and safety 
endpoints will not be imputed and the analysis will be based on observed data.  For certain 
responder-type binary endpoints, subjects with no available data will be classified into one of the categories as described in the r elevant sections of the SAP . 
11.6 Efficacy Analyses 
The primary efficacy endpoint as well as all key and other secondary endpoints will be summarized using descriptive statistics by treatment group, as well as by study visit and/or analysis period as appropriat e.  Mean values of Hb as well as selected other efficacy parameters 
will be plotted across study visits/periods by treatment group. 
11.6.1 Analysis of Primary Efficacy Endpoint  
The primary efficacy endpoint is defined as the mean Hb change from Baseline (mean 
pretreatment Hb) to the mean  Hb from Weeks 24  to 36 (inclusive).  
11.6.1.1 Primary Analysis of Primary Efficacy Endpoint 
The primary analysis will use an analysis of covariance (ANCOVA) with multiple imputation, 
stratified by the randomization strata and using Baseline Hb as the covariate.    

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 75 of 98 A 2-sided 95% confidence interval ( CI) will be calculated for the difference between  treatment 
groups (vadadustat minus  darbepoetin alf a).  Noninferiority of vadadustat will be established if 
the lower limit of this CI is ≥-0.75 g/ dL. 
The primary analysis will be performed using the randomized population and the assigned 
treatment as described in Section  11.2 , Study Analysis Populations .  All data collected during the 
study for subjects included in the randomized  population at the time of analysis, including data 
collected at any point after the initiation of rescue therapy as well as after early discontinuation of study medication treatment , will be used for the primary analysis.  Mis sing data will be 
handled by using multiple imputation methodology as described in the SAP. 
11.6.1.2 Sensitivity Analyses of Primary Efficacy Endpoint  
The following sensitivity analyses will be conducted:  
• Primary analysis will be repeated using the full analysis population. 
• Primary analysis will be repeated using only subjects with available Hb data during the 
primary evaluation period, ie, excluding subjects with no available data during the 
primary evaluation period. 
• Primary analysis will be repeated using the PP population with the actual treatment 
received.  
• Primary analysis will be repeated with alternate approaches to imputation of missing data 
as described in the SAP.  
• Primary analysis will be repeated with imputation of data which may have been affected by a subject’s ha ving received any form of rescue (transfusion or ESA).  Details are 
provided in the SAP.   
11.6.2 Secondary Efficacy Analyses  
Secondary efficacy endpoints analyses will be performed using the randomized and full analysis populations and the assigned treatment as described i n Section  11.2, Study Analysis Populations .  
Analysis for the key secondary efficacy endpoints will be repeated using the PP population with the actual treatment received.  
11.6.2.1 Key Secondary Efficacy Analyse s  
Mean change in Hb value between Baseline and the secondary evaluation period (Weeks 40-52) will be analyzed using the same methodology as specified for the primary efficacy endpoint.  Sensitivity analyses similar to those of the primary efficacy endpoint will be performed and details will be provided in the SAP. 
11.6.3 Subgroups  
Analyses of the primary efficacy endpoint and key secondary efficacy endpoints will also be performed using the randomized and full analysis populations, using the assigned treatment, for subgroups based on the following: 
• Hb stratification level  
• NYHA CHF stratification level  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 76 of 98 • Due to use of different target Hb levels in the U S vs. non- US, the endpoints will also be 
analyzed for subsets based on the target Hb level:  
o The US subset will be assessed due to the target Hb ran ge being 10.0-11.0  g/dL in the 
US 
o The combined EU and ROW (non- US) subset will be assessed since the target Hb 
range is 10.0 -12.0 g/dL in these two Regions  
• Geographic region (US, EU, ROW)  
• Age 
• Gender 
• Race 
11.7 Safety Analyses 
All analyses of safety data will use the randomized population. 
11.7.1 Analysis of MACE and Expanded MACE Components  
The primary safety endpoint, time to the first adjudicated MACE, will be analyzed as [date of the 
first MACE minus the date of randomization +1].  A MACE is defined as all -cause mortality, 
non-fatal myocardial infarction, or non-fatal stroke.  Subjects who have not experienced a MACE by study closure will be censored on the date of their last study assessment.  The hazard ratio (vadadustat/darbepoet in alfa) and its 95% CI will be obtained from a stratified Cox 
proportional hazards model.  As this study has not been designed to provide a stand-alone assessment of MACE, this analysis will be considered a descriptive analysis.  A similar analysis as described for the primary analysis of the MACE endpoint will be performed with censoring of subjects 4  weeks following discontinuation of study medication  if they did not have a MACE 
prior to that time.  
The following safety endpoints will also be summarized using time to event methods as for MACE:  
1. Individual components (all-cause mortality, non-fatal myocardial infarction, non- fatal 
stroke) of MACE 
2. Thromboembolic events (defined as arterial thrombosis, DVT, PE, or vascular access thrombosis) 
3. Hospitalization for heart failure  
4. Expanded MACE, defined as all-cause mortality, non- fatal myocardial infarction, non-
fatal stroke, hospitalization for HF, or thromboembolic event 
For these endpoints the incidence ("yes"/"no") of the endpoint will be presented for each treatment arm.  Kaplan -Meier curves will be presented for each endpoint as the time of endpoint 
free survival (ie, time until endpoint or death).  
The primary MACE analysis will be based upon all events that accrue over the 2 DD- CKD 
studies (Studies AKB -6548-CI-0016 and AKB-6548- CI-0017) (see Section  11.1.2, Sample Size 
for the Primary Safety Endpoint ). 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 77 of 98 The SAP for this pooled MACE assessment in DD -CKD subjects provides details of the primary 
analyses for MACE, for individual components of MACE, and for an expanded version of 
MACE.  Detail s of sensitivity analyses and subgroup analyses are also provided in the MACE 
SAP.  
11.7.2 Analysis of Adverse Events  
Adverse events will be summarized using the number and percentage of subjects with AEs for all subjects in the safety population.  Summaries will also be provided for subgroups including 
Region, Age, Gender, and Race.  
All AEs will be coded using MedDRA.  Treatment- emergent and post -treatment AEs will be 
summarized by System Organ Class and Preferred Term for each treatment group.  Adverse events wil l also be summarized by their maximum severity.  
Summaries will also be provided for the following types of AEs: 
• SAEs  
• Related AEs (including all categories for relationship to study medication other than 
“Unrelated”, as determined by the Investigator)  
• AEs leading to early discontinuation of study medication. 
11.7.3 Remaining Safety Endpoints  
The analysis of the following safety endpoints will be detailed in the SAP: 
The analysis of proportion of subjects with Hb >12.0 g/dL, >13.0 g/dL, or >14.0 g/dL 
post- Baseline will classify a  subject as a “yes” if:  
• Any value Hb  >12.0 g/dL at any time after  Day 1  
• Any confirmed value Hb  >12.0 g/dL at any time after  Day 1  
• Any value Hb  >13.0 g/dL at any time after  Day 1  
• Any confirmed value Hb  >13.0 g/dL at any time after  Day 1  
• Any value Hb >14.0 g/dL at any time after  Day 1  
• Any confirmed value Hb  >14.0 g/dL at any time after  Day 1 . 
A Hb  value above a set threshold will be considered as confirmed if there are 2 consecutive 
values above that threshold.  The second of the 2 consecutive assessments should be done at 
most 12 weeks after the first assessment.  Subjects with no available data post -Baseline will be 
excluded from this analysis.  All other subjects will be classified to the “no” category.  
The analysis of proportion of subjects with any Hb  increase >1.0  g/dL within any 2- week 
interval or >2.0  g/dL within any 4- week interval post -Baseline will classify a  subject as a “yes” 
if at least 1 of the following criteria at any point after Day 1 is met:  
• Hb increase >1.0  g/dL within any 2-w eek interval  
• Hb increase >2.0  g/dL within any 4- week interval . 
Subjects with no available data post -Baseline will be excluded from this analysis.  All 
other subjects will be classified to the “no” category.  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 78 of 98 Observed values of continuous and categorical parameters and changes from Baseline for 
continuous parameters to each study visit will be summarized descriptively for vital signs and clinical laboratory results.  Graphical displays of selected laboratory parameters will also be provided. 
11.8 Additional Ass essments 
11.8.1 Concomitant Medications  
Prior and concomitant medications will be coded using World Health Organization (WHO) Drug 
dictionary. 
Prior medications will be defined as any medications that were taken before the date of the first 
dose of study medication.  Concomitant medications will be defined as any medications taken at any time from the date of the first dose of study medication through the date of the last dose of the study medication. 
11.8.2 Biomarkers  
Biomarkers ( including, but not limited to, hepcidin and VEGF) will be summarized descriptively 
at Baseline and by visit post- Baseline.  
11.8.3 Pharmacokinetics  
Descriptive and graphical summaries will be generated for PK measurements.  
12 DATA HANDLING AND RECORD KEEPING  
12.1 Case Report Forms/Electronic Data Capture  
This study will utilize an EDC system to manage data collection during this trial.  The system is 
fully Code of F ederal Regulations 21 part 11 compliant.  An EDC system contains certain 
functionality including, but not limited to, a graphical user interface to  help facilitate data entry, 
a data validation element to check user data, and a reporting function to assist with the review 
and analysis of data.  Case report forms available through this system are required and should be completed for each randomized subject.  
Any form of data from the electronic system are the sole property of the Sponsor and should not be made available in any form to third parties, except for authorized representatives of the Sponsor or appropriate regulatory authorities, without written permission from the Sponsor. 
The Investigator has ultimate responsibility for the accuracy, authenticity, and timely collection 
and reporting of all clinical, safety, and laboratory data entered in the EDC or any other data collection forms.  The CRFs m ust be signed electronically by the Investigator to attest that the 
data contained on the CRFs is true.  
In most cases, the source documents are contained in the subject’s chart at the hospital or the physician's office.  In these cases, data collected on the CRFs must match the data in those charts.  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 79 of 98 12.2 Record Retention  
To enable evaluations and/or audits from regulatory authorities or the Sponsor, the Investigator 
agrees to keep records, including the identity of all participating subjects (sufficient informat ion 
to link records, eg, CRFs and hospital records), all original signed informed consent forms, copies of all CRFs, SAE forms, source documents, detailed records of drug disposition, and adequate documentation of relevant correspondence (eg, letters, meet ing minutes, and telephone 
calls reports).  The records should be retained by the Investigator according to the International Council for Harmonis ation  (ICH) , local regulations, or as specified in the Clinical Study 
Agreement, whichever is longer. 
If the Investigator becomes unable for any reason to continue to retain study records for the 
required period (eg, retirement and relocation), the Sponsor should be prospectively notified.  The study records must be transferred to a designee acceptable to the Sponsor, such as another Investigator, another institution, or to the Sponsor.  The Investigator must obtain Sponsor’s written permission before disposing of any records, even if retention requirements have been met. 
13 QUALITY CONTROL AND QUALITY ASSURANCE  
13.1 Investigative  Site Monitoring Visits  
During study conduct, the Sponsor or its agent will conduct periodic monitoring visits to ensure that the protocol and Good C linical Practice (GCP) are being followed.  The monitors will 
review source documents to confirm that the data recorded on the CRFs is accurate.  The Investigator/institution will allow the Sponsor’s monitors or designees and appropriate regulatory authorities direct access to source documents to perform this verification.  
The investigative site may also be subject to Quality Assurance audits performed by the Sponsor 
or companies working with or on behalf of the Sponsor, and/or review by the IRB/IEC, and/or to inspection by appropriate regulatory authorities. 
It is important that the Investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.  
13.2 Protocol Deviations 
The Investigator will  not deviate from the protocol, except where necessary to el iminate an 
immediate hazard to study  subjects.  Should other unexpected circumstances arise that will 
require deviation from protocol- specified procedures, the Investigator will consult with the 
Sponsor or designee (and IRB or IEC, as required) to determine the appropriate course of action.  
The investigative site will document all protocol deviations in the subject’s source documents.  
In the event of a significant deviation, the investigative site will notify the Sponsor or its 
designee (and IRB or IEC, as required).  Significant deviations include, but are not limited to, those that involve fraud or misconduct, increase the health risk to the subject, or confound interpretation of primary study assessments.  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 80 of 98 14 STUDY DISCONTINUATIO N/INVESTIGATIVE SITE TERMINATION  
The Sponsor reserves the right to discontinue the study prior to inclusion of the intended number 
of subjects, but intends only to exercise this right for valid scientific or administrative reasons.  After such a decision, the Investigator must contact all participating subjects within a time period specified by the Sponsor to inform them of the decision to discontinue the study. 
14.1 Criteria for Premature Termination or Suspension of the Study  
The following criteria may result in either temporary suspension or early termination of the 
study: 
New information regarding the safety or efficacy of the study medication that indicates a change 
in the known risk/benefit profile for the compound, such that the risk/benefit is no longer acceptable for  subj ects participating in the study 
Significant violation of GCP that compromises the ability to achieve the primary study objectives or compromises subj ect safety.  
The Sponsor reserves the right to discontinue the study for other valid administrative reasons. 
14.2 Criteria for Premature Termination or Suspension of Investigational Study Sites  
A study site may be terminated prematurely or suspended if the study site (including the 
Investigator) is found to be in significant violation of GCP, protocol, contractual agreement, or is unable to ensure adequate performance of the study.  
14.3 Procedures for Premature Termination or Suspension of th e Study or Investigational 
Sites 
In the event that the Sponsor elects to terminate or suspend the study or the participation of an investigational study site, a study- specific procedure for early termination or suspension will be 
provided by the Sponsor; the procedure will be followed by applicable investigational study sites during the course of termination or study suspension. 
15 ETHICS  
15.1 Ethic al Conduct of the Study  
The study will be conducted in accordance with the Declaration of Helsinki on Ethical Principles 
for Medical Research Involving Human Subjects, adopted by the General Assembly of the World Medical Association ( 2013).  
In addition, the study will be conducted in accordance with the protocol, the ICH E6 guideline on 
GCP, and applicable local regulatory requirements and laws.  
15.2 Institutional Review Board /Independent Ethics Committee  
It is the responsibility of the Investigator to have prospective approval of the study protocol, protocol amendments, informed consent forms, and other relevant documents, (eg, recruitment advertisements, if applicable) from the IRB/IEC.  All correspondence with the IRB/IEC should be retained in the Investigator File.  Copies of IRB/IEC approvals should be forwarded to the Sponsor or its designee. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 81 of 98 In case of substantial protocol amendment, the sponsor will obtain approval from responsible 
Regulatory Authorities before implementation. 
The only circumstance in which an amendment may be initiated prior to IRB/IEC approval is 
where the change is necessary to eliminate apparent immediate hazards to the subjects.  In that event, the Investigator must notify the IRB/IEC and the Sponsor in writing immediate ly after the 
implementation.  
15.3 Subject Information and Consent  
It is the responsibility of the Investigator to give each  subject (or the subject’s acceptable 
representative), prior to inclusion in the study, full and adequate verbal and written information regarding the objective and procedures of the study and the possible risks involved.  The subjects must be informed about their right to withdraw from the study at any time. 
Furthermore, it is the responsibility of the Investigator, or a person designated by the 
Investigator, to obtain signed informed consent from each subject or the  subject’s legally 
acceptable representative prior to inclusion in the study.  The Investigator will retain the original of each  subject's signed consent form. 
The informed conse nt forms will be in compliance with ICH GCP, local regulatory requirements, 
and legal requirements.  The informed consent forms used in this study, and any changes made during the course of the study, must be prospectively approved by both the IRB/IEC and the Sponsor before use. 
15.4 Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP  
In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable 
Competent Authority, or if the Investigator is aware of any new information which might influence the evaluation of the benefits and risks of the investigational product, the Sponsor should be informed immediately. 
In addition, the Investigator will inform the Sponsor immediately of any urgent safety measures 
taken by the Investigator to protect the study subjects against any immediate hazard, and of any serious breaches of this protocol or of ICH GCP, defined as a breach that will likely affect the safety or physical or mental integrity of subjects or the scientific value of the trial, that comes to the attention of the Investigator. 
15.5 Subject Confidentiality  
All parties will ensure protection of  subject personal data and will not include subject names on 
any Sponsor forms, reports, publications, or in any other disclosures, except where required by 
law.  In case of data transfer, the Sponsor will maintain high standards of confidentiality and protection of subject personal data. 
The Sponsor and designees affirm and uphold the principle of the subject’s right to protection 
against invasion of privacy.  Throughout this study, a subject’s source data will only be linked to the Sponsor’s clinical study database or documentation via a unique identification number.  As permitted by all applicable laws and regulations, limited  subject attributes, such as sex, age, or 
date of birth, and subject initials may be used to verify the subject and accuracy of the subject’s 
unique identification number. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 82 of 98 To comply with ICH guidelines for GCP and to verify compliance with this protocol, the 
Sponsor requires the Investigator to permit its monitor or designee’s monitor, representatives 
from any regulatory authority (eg, FDA), the Sponsor’s designated auditors, and the appropriate IRBs and IECs to review the subject’s original medical records (source data or documents), including, but not limited to, laboratory test result reports, ECG reports, admission and discharge summaries for hospital admissions occurring during a subject’s study participation, and autopsy reports.  Access to a subject’s original medical records requires the specific authorization of 
the subject as part of the informed consent process. 
Copies of any subject source documents that are provided to the Sponsor must have certain 
personally identifiable information removed (ie, subject name, address, and other identifier fields not collected on the subject’s CRF).  
16 PUBLICATION OF STUDY RESULTS  
No publication or disclosure of study results will be permitted, except under the terms and conditions of a separate, written agreement bet ween Sponsor and the Investigator and/or the 
Investigator’s institution.  The Sponsor must have the opportunity to review and approve all proposed abstracts, manuscripts, or presentations regarding this study prior to submission for publication/presentation.  Any information identified by the Sponsor as confidential must be deleted prior to submission. 
For all publications relating to the study, the institution will comply with recognized ethical 
standards concerning publications and authorship, including: Section II - “Ethical Considerations 
in the Conduct and Reporting of Research” of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, established by 
the International Committee of Medical Journal Editors.  
  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 83 of 98 17 REFERENCES  
Abramson JL, Jurkovitz CT, Vaccarino V et al. Chronic kidney disease, anemia, and incident 
stroke in a middle -aged, community-based population: the ARIC study.  Kidney Int (2003) 
64(2): 610-615. 
Aranesp (package insert). Thousand Oaks, CA: Amgen, Inc.; 2017. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al.  The effects 
of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.  N Engl J Med (1998) 339(9):584-590. 
Darbepoetin alfa: Information on darbepoetin alfa in the US is available in the package insert for Aranesp ( Amgen, Thousand Oaks, CA; 2017); and detailed information on darbepoetin alfa in 
the EU  is available on the Eur opean Medicines Agency website ). 
Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al.  Normalization 
of hemoglobin level in patients with chronic kidney disease and anemia.  N Engl J Med (2006) 
355(20):2071-2084. 
FDA Guidance: Clinical Drug Interaction Studies 2017.  Available at: 
https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf . 
Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, et a l.  Naturally 
occurring higher hemoglobin concentration does not increase mortality among hemodialysis 
patients.  J Am Soc Nephrol (2011) 22(2):358-365. 
Iseki K and Kohagura K.  Anemia as a risk factor for chronic kidney disease.  Kidney Int (2007) 
Suppl 72:S4 -9. 
Japanese Society of Nephrology.  Evidence-based clinical practice guideline for CKD 2013. Clin Exp Nephrol (2014) 18(3):346-423. 
Jha V, Garcia- Garcia G, Iseki K , et al. Chronic kidney disease: global dimension and 
perspectives. Lancet (2013) 382(9888): 260-272.  
KDIGO CKD Working Group. KDIGO clinical practice guideline for the evaluation and 
management of chronic kidney disease. Kidney Int Suppl (2013) 3(1): 1-150. 
KDIGO.  KDIGO clinical practice guideline for anemia in chronic kidney disease.  Kidney Int 
(2012) 2(4):1-64.  Available at: http://www2.kidney.org/professionals/kdoqi/guidelines_ckd/p4_class_g1.htm 
Levey AS, Stevens LA, Schmid CH, et al.  A new equation to est imate glomerular filtration rate.  
Ann Intern Med (2009) 150(9):604-612. Locatelli F, B árány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al.  Kidney 
Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney 
disease: a European Renal Best Practice position statement.  Nephrol Dial Transplant (2013) 28(6):1346-1359. 
McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, 
Califf RM. Cardiovascular toxicity of epoetin -alfa in patients wi th chronic kidney disease.  2013; 
37 (6): 549-58. Doi:10.1159/000351175. Epub 2013 May 25. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 ( Version 6 ) 
 
Akebia  — Company Confidential  
Page 84 of 98 Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM.  Pathophysiology of anaemia: 
focus on the heart and blood vessels.  Nephrol Dial Transplant (2000) 15 Suppl 3: 14-18. 
National Institute for Health and Care Excellence (NICE).  Chronic kidney disease: managing 
anaemia. NICE clinical guideline. Published: 3 June 2015. http://nice.org.uk/guidance/ng8  
Nurko S.  Anemia in chronic kidney disease: causes, diagnosis, treatment.  Cleve Clin J Med 
(2006) 73(3):289-297. 
Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, and 
Johnson RS.  Regulation of iron homeostasis by the hypoxia- inducible transcription factors 
(HIFs).  J Clin Invest (2007) 117(7):1926-1932. 
Pfeffer MA, Burdmann EA, Chen CY, et al.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.  N Engl J M ed (2009a) 361(21):2019-2032. 
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al.  Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).  Am J Kidney Dis (2009b) 54(1):59-69. 
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al.  Correction of anemia 
with epoetin alfa in chronic kidney disease.  N Engl J Med (2006) 355(20):2085-2098. 
Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al.  Erythropoietic 
response and outcomes in kidney disease and type 2 diabetes.  N Engl J Med (2010) 363(12): 1146-1155. 
Stauffer ME  and Fan T.  Prevalence of anemia in chronic kidney disease in the United States.  
PLoS One (2014) 9(1): e84943. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al.  Secondary analysis 
of the CHOIR trial epoetin -alpha dose and achieved hemoglobin outcomes.  Kidney Int (2008) 
74(6):791-798. 
Tsubakihara Y, Nishi S, Akiba T, et al.  2008 Japanese Society for Dialysis Therapy:  Guidelines 
for renal anemia in chronic k idney disease.  Ther Apher and Dial (2010) 14(3):240-275. 
Unger EF.  FDA perspectives on erythropoiesis- stimulating agents (ESAs) for anemia of chronic 
renal failure: Hemoglobin target and dose optimization (Slide presentation from the Sep 11, 2007 Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee).  Retrieved from http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4315s1-10- FDA-Unger.ppt. 
Unger EF, Thompson AM, Blank MJ, and Te mple R.  Erythropoiesis- stimulating agents - Time 
for a reevaluation.  N Engl J Med  (2010) 362(3):189-92. 

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
Akebia  — Company Confidential  
Page 85 of 98 APPENDIX A:  SCHEDULE OF ACTIVITIES  
Study Period  Optional  
Pre-
screen Screening  Treatment Period 
Post  
Treatment BL/ 
rand.  
[a] Year 1 Year 2 Year 3/Year 4 
Visit  PS SV1 SV2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22/ 
26 23/ 
27 24/ 
28 25/ 
29 End of 
Trtmt Follow
-up [b] 
Week   -8 to 0  0 2 4 6 8 10 12 16 20 24 28 32 36 40 44 48 52 64 76 88 104 116/ 
168 128/ 
180 140/ 
192 156/ 
208  EOT 
[c] EOT 
+4 
wks 
[dd] 
Visit Window (Days)     ±3 ±3 ±3 ±3 ±3 ±3 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±7 ±7 
Procedures/Assessments  
Informed Consent  X [d] X [d]                             
Prescreening Local Hb 
[e] X                              
I/E Criteria [f ] X X X                            
Vital Signs [g ]  X X X X X X X X X X X X X X X X X X X X X X X X X X X X  
Demographics, Med ical 
History    X                            
Physical Exam [h ]   X                            
12-Lead ECG [i ]    X                           
Randomization     X                           
Laboratory Procedures  
Pregnancy Test [ j]   X                            
Folate and Vitamin B 12  X [k]                             
Coagulation Tests [l ]    X                           
C-Reactive Protein    X          X      X    X    X X  
CBC [m ] with periodic 
diff  X [k] X 
[k,n] X X X X X X X X X X X X X X X X X X X X X X X X X X  
Iron Indices [o ]  X [k]  X  X  X  X  X  X  X  X  X X X X X X X X X X  
Serum Chemistry [p ]  X [k]  X          X      X  X  X  X  X X  
Liver Function Tests [q ]  X [k]  X  X  X  X X X X X  X  X  X X X X X X X X X X  
Lipid Panel [r ]    X          X      X           

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
Akebia  — Company Confidential  
Page 86 of 98 Study Period  Optional  
Pre-
screen Screening  Treatment Period 
Post  
Treatment BL/ 
rand.  
[a] Year 1 Year 2 Year 3/Year 4 
Visit  PS SV1 SV2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22/ 
26 23/ 
27 24/ 
28 25/ 
29 End of 
Trtmt Follow
-up [b] 
Week   -8 to 0  0 2 4 6 8 10 12 16 20 24 28 32 36 40 44 48 52 64 76 88 104 116/ 
168 128/ 
180 140/ 
192 156/ 
208  EOT 
[c] EOT 
+4 
wks 
[dd] 
Visit Window (Days)     ±3 ±3 ±3 ±3 ±3 ±3 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±7 ±7 
Biomarkers [s ]    X      X    X      X    X    X X  
Reticulocyte Count     X  X    X    X      X           
Erythropoietin     X  X    X    X      X           
PK [t]     X  X    X    X      X           
Dialysis adequacy     To be reported every 3 months during Year 1  To be reported every 6 months until end of study 
Dialysis Treatment Type 
and Prescription     X  X  X  X X X X X X X X X X X X X X X X X X X X  
Exploratory Samples [u]     X          X      X    X    X X  
Safety Assessments  
MACE Endpoint 
Questionnaire [v ]     X X X X X X X X X X X X X X X X X X X X X X X X X X 
AE Assessment [w ]    X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Transfusions and ESA 
Rescue      X X X X X X X X X X X X X X X X X X X X X X X X X X 
Therapeutic Phlebotomy       X X X X X X X X X X X X X X X X X X X X X X X X X X 
Medication  Assessments and Procedures  
Concomitant Medicine 
Review [ x]  X X X X X Only changes in medication (started or discontinued) will be recorded X X 
Vadadustat Medication 
Dispensing [y ]    X X X X X X X X X X X X X X X X X X X X X X X X X   
Drug Reconciliation      X X X X X X X X X X X X X X X X X X X X X X X X X  
Visit Registration in 
IWR  X  X X X X X X X X X X X X X X X X X X X X X X X X X X  
Hb via HemoCue for 
Dose Adjustment [ z]    X X X X X X X X X X X X X X X X X X X X X X X X X   
Monthly Hb Monitoring 
[z]                     x x x x x x x x   

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
Akebia  — Company Confidential  
Page 87 of 98 Study Period  Optional  
Pre-
screen Screening  Treatment Period 
Post  
Treatment BL/ 
rand.  
[a] Year 1 Year 2 Year 3/Year 4 
Visit  PS SV1 SV2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22/ 
26 23/ 
27 24/ 
28 25/ 
29 End of 
Trtmt Follow
-up [b]  
Week   -8 to 0  0 2 4 6 8 10 12 16 20 24 28 32 36 40 44 48 52 64 76 88 104 116/ 
168 128/ 
180 140/ 
192 156/ 
208  EOT 
[c] EOT 
+4 
wks 
[dd] 
Visit Window (Days)     ±3 ±3 ±3 ±3 ±3 ±3 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±7 ±7 
Darbepoetin alfa     Dosing according to Algorithms [aa]   
Vadadustat  Dose 
Adjustments [ bb]    Start at 300 mg once daily, then adjust dose as per Dose Adjustment Algorithms   
Iron Supplementation 
[cc]    As needed to maintain ferritin ≥100 ng/mL or TSAT ≥20%   
 
Abbreviations: AE  = adverse event; ALT/SGPT  = alanine transaminase/serum glutamic- pyruvic transaminase; AST/SGOT  = aspartate aminotransaminase/serum glutamic oxaloacetic transaminase; 
BL = baseline; BUN = blood urea nitrogen; CBC = complete blood count; CPK = creatine phosphokinase; diff = differential; ECG = electrocardiogram; EOT = end of treatment; ESA = erythropoiesis -
stimulating agent; HDL = high density lipoprotein; Hb  = hemoglobin; HIF = hypoxia inducible factor; ICF = informed consent form; I/E  = inclusion/exclusion; INR  = international normalized ratio; 
IWR  = interactive web response; LDH = lactate dehydrogenase; LDL  = low density lipoprotein; MACE  = major adverse cardiovascular event; MCH = mean corpuscular hemoglobin; MCHC  = mean 
corpuscular hemoglobin concentration; MCV  = mean corpuscular volume; med = medication; PK = pharmacokinetic; PS = Prescreening; PT  = prothrombin time; PTT  = partial thromboplastin time; 
RBC  = red blood cell; RDW  = red cell distribution width; SV1  = Screening visit 1; SV2  = Screening visit 2; TIBC  = total iron binding capacity; Trtmt = treatment; TSAT  = transferrin saturation; 
VEGF  = vascular endothelial growth factor; WBC  = white blood cell; wks = weeks.  
[a] The Screening period is a maximum of  8 weeks  in duration.  The Baseline visit must be performed at a minimum of 4  days from  the last Screening visit (SV2) or date of  last retest. 
[b] The Follow- up visit can be performed either in person OR via the telephone.  
[c] The EOT visit will be performed at the time a subject permanently discontinues study medication (vadadustat or darbepoetin alfa) or for subjects on study medication at the time of notification of 
global study completion .  It is important to continue to follow subjects that discontinue  study medication through global study completion at a frequency  and approach that is agreed to between the 
Investigator and subject.  Visit schedule and assessments are flexible and at the discretion of the Investigator and subject and will be clearly documented in the medical chart . 
[d] An abbreviated ICF will be used for Prescreening.  If the subject is eligible for Screening, a  separate full ICF will be used, which may be signed  in advance of the SV1 procedures.  The Screening 
period starts at the time the informed consent is signed and will be a maximum of 8 weeks in duration.   An additional optional consent form for collection of blood samples for future genetic 
analys is will be provided at SV1.  
[e] If the Pre- Screen HemoCue Hb is between 8.0 and 11.0  g/dL (inclusive) within the US or between 9.0 and 12.0  g/dL (inclusive) outside of the US, the investigative site may proceed with Screening 
Visit 1 (SV1), preferably on the same day as Pre -Screening. 
[f] Inclusion/Exclusion criteria will be reviewed at the Prescreening and Screening visits (SV1 and SV2).  Final eligibility determination will occur following the Screening visits when all data are 
available. 
[g] Vital sign measurements: Heart rate and blood pressure to be assessed in the seated position after 5 minutes of rest.  Height (SV2 only) and dry weight (SV2, Weeks 12, 24, 36, and 52, and yearly 
thereafter) will also be measured.  For hemodialysis patients, the clinical evaluations should be completed before dialysis, if applicable.  
[h] Physical exam: a physical examination is required at SV2 as outlined in the protocol.  Thereafter, an abbreviated symptom -directed physical exam should be performed at the discretion of the 
Investigator as clinically indicated.  
[i] An ECG should be performed prior to blood draws when possible and obtained after the  subject has been resting comfortably in a supine position for approximately 5 minutes.  For hemodialysis 
patients, the clinical evaluations should be completed before dialysis, if applicable.  ECGs may be measured up to 3 days before Day 1.  
[j]  Serum pregnancy will be tested in women of childbearing potential at SV2 .  (Eligible subjects will be advised to use an adequate contraceptive method.)  Additional serum or local urine pregnancy 
tests should be conducted throughout the study in sufficient number, as determined by the Investigator or required by local r egulations, to establish the absence of pregnancy during the stu dy.  If 

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
Akebia  — Company Confidential  
Page 88 of 98 positive at SV2, the subject is not eligible to enter the study.  If a subject becomes pregnant during the study, the subject must permanently dis continue study medication and should  attend all 
subsequent study visits and be continually monitored a ccording to the Schedule of Activities for the duration of the study.  
[k] Subjects may be retested and/or rescreened.  
[l]  Coagulation tests: prothrombin time, partial thromboplastin time, and international normalized ratio.  
[m] For eligibility, the average of 2 Hb values measured by the central laboratory during Screening (SV1, SV2 or retest) must be between 8.0 and 11.0 g/dL (inclusive) in the US and between 9.0 and 
12.0 g/dL (inclusive) outside of the US.  If the subject’s Hb does not qualify, the subject is a screen  failure. 
[n] A CBC with differential will be performed at Baseline and twice annually at Weeks 28, 52, 76, 104, 128, 156, 180, 208.  At all other noted visits, a CBC without differential will be performed.  
CBC:  hemoglobin, hematocrit, red blood cells (RBC), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell 
distribution width (RDW), white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), and platelets.  
[o] Iron indices: ferritin, iron, total iron binding capacity (TIBC), and transferrin saturation (TSAT).  Blood samples to assess the iron indices will be collected at SV1, Baseline,  Weeks 4, 8, 12, 20,  
28, 36, 44, 52, 64, 76, 88, 104,  116, 128, 140, 156, 168, 180, 192, 208, and EOT.  
[p] A full serum chemistry panel will be performed at SV1 , Baseline and twice annually at Weeks 28, 52, 76, 104, 128, 156, 180, 208, and EOT.  If blood is collected on a hemodialysis  day, t he blood 
draw should be completed before dialysis, if applicable.  Serum chemistry: sodium, potassium, bicarbonate, chloride, calcium,  magnesium, phosphorus, glucose, creatinine, blood urea nitrogen 
(BUN)/urea, creatine phosphokinase (CPK), uric acid, albumin, and total protein.  
[q] Liver function tests: total bilirubin, alkaline phosphatase, alanine aminotransaminase (ALT/SGPT), aspartate aminotransferase (AST/SGOT), and lactate dehydrogenase (LDH).  
[r] Lipids: total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), and triglycerides.  
[s] The biomarkers include, but are not limited to hepcidin and VEGF.  
[t]  PK samples are to be drawn only for subjects randomized to vadadustat.  Subjects will be questioned regarding the timing of their last dose of vadadustat. Refer to protocol for specified timing of 
PK samples.  
[u]  Additional blood samples will be collected at Baseline and Week s 28, 52, 104, 156, EOT,  which may be used for exploratory measurement of biomarkers (eg, factors relati ng to the activation of the 
HIF pathway).  Subjects will also be asked to provide optional consent to obtain a blood sample at Baseline and EOT to be  store d for future genetic analyses (DNA and mRNA).  
[v]  At each study visit, the subject must specifically  be questioned regarding the occurrence of any potential MACE endpoint events since the last study visit.  If a potential endpoint event is reported, 
the date of the event should be recorded and the appropriate source documents should be collected according to the endpoint packet checklist.  
[w] Adverse events should be documented and recorded at each visit.  The AE reporting period for this study begins upon randomization through global study completion .  All adverse events (serious 
and non- serious, and related and non -related) will be documented and recorded through the follow- up visit.  Subjects must be followed for adverse events until the final required protocol visit or 
until all drug -related toxicities and serious adverse events have resolved (or are considered chronic/stable). 
[x] Concomitant medications should be collected and recorded at each visit as noted.  All concomitant medications received during the screen ing window  (minimum of 30 days prior to the start of 
study medication ) through to the final protocol visit will be recorded.  
[y] Subjects will be provided with a supply of vadadustat at the Baseline visit and will be resupplied at subsequent visits as needed.  Subjects will be instructed to  complete 1 bottle prior to opening the 
next bottle.  The dose should be taken at approximately the same time each  day. 
[z] Hemoglobin will be monitored via local HemoCue throughout the study to determine if the dose of study medication will be adju sted, interrupted or maintained.   From Week 53, Hb will be 
monitored monthly as part of local standard of care labs or at an unscheduled visit  for dose adjustment. 
[aa]  Refer to the Dosing Algorithms .  Darbepoetin alfa dosing is independent of the visit schedule; thus, the dosing schedule may shift per local standard of care and Investigator discretion . Vital signs 
and dry weight should be obtained prior to dosing.  
[bb] The dose will be adjusted in accordance with the Dose Adjustment Algorithms .  Changes to dose will be accomplished by changing the number of tablets to be taken per  day. 
[cc] Iron supplementation (IV, oral, or intradialytic) will be prescribed during the study to maintain ferritin ≥100 ng/mL or  TSAT ≥20%.  Subjects who fail to qualify for the study based on low TSAT, 
ferritin, folate, or B 12 values may receive replacement therapy based on the investigative sites’ standard of care during the screening period and retest the laboratory parameter(s).  Subjects who receive 
iron replacement therapy may retest screening Hb a minimum of 3 weeks after completion of iron replacement therapy.  Vadadustat is not to be administered concurrently with oral iron supplement 
(including multivitamins containing iron) , iron containing phosphate binders or any medications containing iron .  Oral iron supplement should be taken at least 2 hours before or 2 hours after the dose of 
study medication.  
[dd] End of Study  (EOS) status will be done to capture subject status at the global completion of the study  or at the time of withdrawal of consent or when subject deemed LTFU  or death . Subjects 
active on the study ( including those permanently discontinued from study medication and are being followed) will complete the Follow- up vi sit.  For s ubjects active on the study medication at global 
study completion,  the EOS status will be collected at the at the Follow- up visit.  For s ubjects that have permanently discontinued study medication and are being  followed until global study completion, 
the EOS status will be collected, which includes activities outlined at the Follow- up visit.   

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
Akebia  — Company Confidential  
Page 89 of 98 APPENDIX B: VADADUSTAT DOSING AND DOSE ADJUSTMENT ALGORITHM S 

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
Akebia  — Company Confidential  
Page 90 of 98  

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
Akebia  — Company Confidential  
Page 91 of 98 APPENDIX C:  DARBEPOETIN ALFA DOSING AND DOSE ADJUSTMENT ALGORITHM S 

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
Akebia  — Company Confidential  
Page 92 of 98  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 (Version 6) 
 
Akebia  — Company Confidential  
Page 93 of 98 APPENDIX D:  END OF TREATMENT AND GLOBAL STUDY COMPLETION 
SUBJECT FLOW  
  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 (Version 6) 
 
Akebia  — Company Confidential  
Page 94 of 98 APPENDIX E:  HISTORY OF AMENDMENTS TO THE PROTOCOL 
Amendment 1 (Version 2 .0; ) 
Amendment 1 was issued based on a Clinical Expert Advisory Board, and requests from study 
sites for additional clarification.   
The major changes introduced in the amendment are summarized below : 
• To update the study design from the current screening period of up to 4 weeks to up to 8 weeks and allow iron, vitamin B12, and folate supplementation as needed during the screening period. 
o Screening period changed from up to 4 weeks to up to 8 weeks.  
o One retest will be allowed for each laboratory parameter, within the screening period.  
o Subjects who receive iron replacement therapy may retest screening Hb a minimum of 3 weeks after completion of iron replacement therapy. 
• Inclusion Criterion 3: Adjusted due to increase of screening period from up to 4 weeks to 
up to 8 weeks.  
• To update the following exclusion criteria: 
o Exclusion Criterion 3: Adjusted due to increase of screening period from up to 4 
weeks to up to 8 weeks.  
o Exclusion Criterion 10: To clarify that benign colonic polyps is not a malignancy, therefore removed to correct the error.  
o Exclusion Criterion 11: Adjusted due to increase of screening period from up to 4 weeks to up to 8 weeks, and to clarify that chronic treatment with anticoagulants for a history of DVT or PE over 12 weeks prior to randomization is not exclusionary. 
• Vadadustat dosing and dose adjustment guidelines were updated to clarify that patients 
receiving 1 tablet of dosing prior to interruption wil l resume treatment with 1 tablet after 
interruption.   
• Section 4.2 Summary of Clinical Experiences was updated to reflect information from 
recently completed trials.  
• Section 6.4.1 Executive Steering Committee has been added.  
• To clarify darbepoetin alfa a dministration and accountability:  
o Darbepoetin alfa should be administered per the label.  
o Darbepoetin alfa doses may be self -administered or administered by health care 
professional at the clinics, site facility or at subject’s home according to the invest igator’s determination and local practice.  
o Added additional information on return of darbepoetin alfa for drug accountability 
and compliance assessment.  
• 9.2.2 Laboratory Evaluations was revised to reflect the following:  
o Modification to the frequency of protocol specified Biomarker sample collection  
o Additional Exploratory sample collection.  

Protocol No.  AKB -6548- CI-0017   
Amendment 5 (Version 6) 
 
Akebia  — Company Confidential  
Page 95 of 98 • Section 11.2 Study Analysis Populations clarified the study analysis populations. 
 
Amendment 2 (Version 3 .0; ) 
Amendment 2 was issued based on  sponsor internal assessment,  external input from nephrology 
experts, and investigative sites.   
The major changes introduced in the amendment are summarized below:  
• Section s 4.2 Summary of Clinical Experiences and 6.2 Rationale for Study Design were 
updated to reflect information from recently completed trials and for alignment 
with vadadustat Investigator’s Brochure.  
• Section 5.3 Secondary Efficacy Endpoints was updated to reflect addition of several key 
secondary, other secondary efficacy endpoints and safety endpoints in alignment with the 
Statistical Analysis Plan (SAP).  
• Section  6.1 Study Design was updated with an increase in enrollment number from 2200 
to approximately 2800 subjects to achieve the number of required MACE. 
• Section 7.4.1 Retesting was updated for simplification.  
• Section 7.5.5 Individual Subject Discontinuation was updated to add Lack of Efficacy as 
a reason for permanent discontinuation of study medication or study participation for 
accurate data capture.  
• Section 7.5.1 Study Completion was clarified  that all enrolled subjects in this study will 
have completed (at least) the Week 36 visit.  
• Section 8.4.4 Dosing and Dose Adjustment Guidelines was revised to guide Investigators 
to follow printed dose adjustment algorithms in the protoco l Appendices in lieu of IWRS-
programmed dosing recommendations due to some aspects of IWRS-programmed dosing 
instructions did not operate as planned. Updated guidance to Investigators to use clinical 
judgement and other Hb data to appropriately dose subjec ts in cases of clinical concern 
regarding HemoCue value. C larification was added that after a subject completes ESA 
rescue, the Investigator has the option to resume study medication  at the same dose as 
previously used or with one dose higher. Monthly Hb monitoring for dosing oversight in Year 2 -4 was also added to this section.  
• Section 8.4.6 Iron Supplementation was updated to align with published guidelines to 
prescribe iron supplementation during the study when serum ferritin is less than 100 
mcg/L or when serum transferrin saturation is less than 20%.  
• Section 8.4.7.1 ESA Rescue (Optional) was updated to align with published guidelines 
raising the threshold of Hb to 9.5 g/dL for initiation of ESA rescue and to permit 
Investigator initiat ion of rescue when medically necessary even if protocol defined 
criteria is not met.  
• Section 8.4.9 Dosing Compliance was updated to specify a range of 80-120%, which is 
commonly used in clinical trials with oral study medications . 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 (Version 6) 
 
Akebia  — Company Confidential  
Page 96 of 98 • Section 8.5 Prior and Concomitant Therapy was updated to clarify if the duration of 
the screening period is less than 30 days, all medications taken within 30 days prior to first dose of study medication will be recorded. 
• Section 9.3.6 Year 2- 4 Monthly Hb M onitoring was adde d with the requirement for 
monthly monitoring of Hb drawn as part of local standard of care labs or via an unscheduled visit. 
• Section 10.1.2 Serious Adverse Events was updated to require all new and recurrent 
malignancies (with a few exceptions) to be reported as a Serious Adverse Events (SAEs) 
to standardize reporting. If a subject develops basal cell carcinoma of skin, squamous cell 
carcinoma, or cervical carcinoma in situ during the study, or has worsening of these events from Baseline, the Investigator will determine if the e vent is reported as an AE or 
SAE.  
• Section 10.5 Special Situations was updated to define overdose of study medications. 
• Section 11.1.1 Sample Size for Primary Efficacy Endpoint was updated to a change in the 
non-inferiority margin from -0.5 g/dL to -1.0 g/d L. 
• Section 11.1.2 Sample Size for the Primary Efficacy Endpoint was updated with enrollment projections and median study medication  exposure times.  
• Section 11.5 Missing Data was updated to align with Statistical Analysis Plan (SAP). 
• Section 11.6.3 Subgroups was updated to pre-specify key subgroups for subsequent 
analysis. 
• Section 11.7.2 Analysis of Adverse Events was updated to  provide AE summaries for 
specific sub groups.  
 
Amendment 3 (Version 4.0; ) 
Amendment 3 was issued based on  sponsor assessment,  external input, regulatory authority 
engagement and investigative sites feedback .  
The major changes introduced in the amendment are summarized below:  
• Section 6.1 Study Design was updated with revised subject number. 
• Section 7.5.1 Study completion was updated to clarify that all enrolled subjects will be 
allowed to complete the primary evaluation period (Weeks 24 -36) prior to global study 
completion.  
• Section 7.5.2 Subject Completion was updated to clarify procedures at time of global 
study completion. 
• Section 7.5.5 Individual Subject Discontinuation was updated to emphasize the importance of continuing to follow subjects through global study completion. 
• Section 7.5.5.1 Temporary Interruption of Study Medication was updated to state that if 
study medication is temporarily interrupted for more than 60 days, Medical Monitor should be contacted before resuming study medication. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 (Version 6) 
 
Akebia  — Company Confidential  
Page 97 of 98 • Section 7.5.5.2 Permanent Discontinuation of Study Medication was updated to have the 
EOT visit and Follow up visit performed at the time of permanent discontinuation of study medication. Emphasized importance of continuing to follow subjects through global study completion. 
• Section 7.5.5.3 Complete Withdrawal from Further Study Visits/Assessments is updated 
to ref lect all options that must be considered by the Investigator before a subject 
withdraws consent. 
• Section 7.5.5.4 Procedures to Support Continued Study Participation is updated to include all options available to the Investigator to follow subjects that per manently 
discontinue study medication.  
• Section 7.5.5.5 Procedures to Prevent “Lost to Follow-up” details steps to support sites in 
efforts to identify  subjects lost to follow-up. 
• Section 8.4.3 Blinding w as updated to reflect information for which the Sponsor and 
CRO study teams will remain blinded . 
• Section 8.4.7 Rescue Therapy was clarified reflect restarting of study medication after 
ESA Rescue and RBC Transfusion
. 
• Section 8.5.2 Erythropoiesis-stimulating Agents was updated to provide clarity on study 
medi cation  dosing following ESA administration . 
• Section 8.5.6 Rosuvastatin, Pravastatin, and Other HMG-CoA Reductase Inhibitors (Statins) was added to provide guidance on how to manage the concomitant use of statins 
with vadadustat.  
• Section 9.2.1 Clinical Evaluations was updated to include collection of AEs from the 
time of randomization through global study completion. 
• Section 9.3.8 EOT Visit was updated to include detail on managing subjects that 
permanently stop study medication during the study and managing subjects on study medication at global study completion. 
• Section 9.3.11 End of Study Subject Status is added to define the end of study assessments that document subject status at the global study completion or at the time of subject withdrawal or whe n subject is deemed LTFU or upon death. 
• Section 10.1.1 Adverse Events is updated by adding guidance on managing subjects who 
develop malignancy while on study medication. 
• Section 10.1.2 Serious Adverse Events is updated to indicate that Sponsor has defined events that will be classified as serious regardless of their assessment.  
• Section 10.3.1 Reporting Period is updated to clarify that the AE reporting period begins 
at the time of randomization and continues through global study completion. 
• Section 11 Data  Analysis was updated to reflect how Baseline will be calculated for Hb.  
• Section 11.1.1 Sample Size for Primary Efficacy Endpoint was updated to reflect a 
change in the non- inferiority margin from -1.0 g/dL to -0.75g/dL and to indicate 
approximately 150 subjects per treatment group. 

Protocol No.  AKB -6548- CI-0017   
Amendment 5 (Version 6) 
 
Akebia  — Company Confidential  
Page 98 of 98 • Section 11.1.2 Sample Size for the Primary Safety  Endpoint was modified to include 
updated definition for primary safety endpoint and how noninferiority is established 
between treatment groups. 
• Section 11.2 Study Analysis Populations is updated with definition of full analysis 
population. 
• Section 11.6.1.1 Primary Analysis of Primary Efficacy Endpoint is updated with use of ANCOVA with multiple imputation, stratified by the randomization strata and using 
Baseline Hb  as the covariate.  
 
Amendment 4 (Version 5.0; ) 
Amendment 4 was issued based on preliminary results of a drug -drug interaction study. 
The major changes are summarized below:  
• Section 8.1.1 Vadadustat was updated to include reference to the Pharmacy Manual which provides further details on storage and managing temperature excursions.  
• Section 8.5.6 HMG-CoA Reductase Inhibitors (Statins) was updated to provide further 
guidance regarding concomitant use of simvastatin drug interactions with vadadustat. 
• Section 8.5.7 Sulfasalazine and Other BCRP Substrates was added to provide guidance regarding concomitant use of BCRP substrates with vadadustat.  
• Section 10.5 Special Situations was updated to reflect recen t results of investigative 
toxicology studies.  
• Liver function tests were increased in Year 2, 3, and 4 to include Week 64, 88, 116, 140, 168, and 192 for gathering data to better understand the hepatic profile of vadadustat.  
This change is reflected in S ection 9.2.2 Laboratory Evaluations, Section 9.3.6 Year 2 
Treatment Period Vis its (Weeks 53 through 104), Section 9.3.7 Year 3/4 Treatment 
Period Visits (Weeks 116 through 208), and Appendix A: Schedule of Activities. 
 
Amendment 5 (Version 6.0; ) 
Amendment 5 was issued based on FDA guidance regarding potential drug- induced liver injury.  
• Section 7.5.5 Individual Subject Discontinuation was updated to include a reference to 
Study Medication Stopping Rules for management of subjects with ALT and AST 
abnormalities.  
• Section 9.4 Study Medication Stopping Rules was added to include a table of liver 
function test results that would require permanent discontinuation of vadadustat. 
• Section 10.1.1 Adverse events was updated to exclude elevations in ALT or AST 
>3 times ULN with an elevation of total serum bilirubin >2  times ULN from conditions 
of temporary discontinuation, as this is now a condition for permanent discontinuation. 
• Section 10.1.2 Serious adverse events was updated to include information defining 
designated medical events.   

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
 
Akebia  — Company Confidential  
Page 1 of 5  
 
 
1. IDENTIYFING INFORMATION FOR AMENDMENT  
 
Protocol Title:  Phase 3, Randomized, Open -Label, Active -Controlled Study 
Evaluating the Efficacy and Safety of Oral Vadadustat for the 
Correction or Maintenance Treatment of Anemia in Subjects 
with Incident Dialysis -Dependent Chronic Kidney Disease 
(DD-CKD) (INNO 2VATE – 
CORRECTION/CONVERSION)  
Protocol Number:  AKB -6548-CI-0017 
Compound:  Vadadustat (AKB -6548)  
Status / Date:  Amendment 5 (Version 6.0 ) 
Amendment 4 (Version 5.0 ) 
Amendment 3 (Version 4.0 ) 
Amendment 2 (Version 3.0 ) 
Amendment 1 (Version 2.0 ) 
Original, Version 1.0  
 
  

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
 
Akebia  — Company Confidential  
Page 2 of 5 2. PROTOCOL CHANGES DETAILS  
Amendments to the protocol are detailed below, except for editorial changes and minor clarification changes. If it is necessa ry to clarify 
the edits, newly added text is identified using red  and deleted text is identified by s trikethrough, blue font. 
Protocol Section  Text in Version 4.0 (Amendment 3) Changes through Version 5.0 (Amendment 4) Rationale for Change  
Section 7.5.5  (Paragraph 3) 
Subjects who undergo a solid organ 
(including kidney), hematopoietic stem 
cell, or bone marrow transplantation will 
have their study medication (vadadustat or darbepoetin alfa) permanently 
discontinued. (Paragraph 3) 
Subjects who undergo a solid organ (including kidney), 
hematopoietic stem cell, or bone marrow transplantation 
will have their study medication (vadadustat or darbepoetin 
alfa) permanently discontinued.  
See Section 9.4, Study Medication Stopping Rules  for 
additional details on the management of subjects with ALT and AST abnormalities.  To include a reference to 
Study Medication 
Stopping Rules for management of subjects with ALT and AST abnormalities.  
Section 9.4 
(added)   Study Medication Stopping Rules  
Study medication must be permanently discontinued if a 
subject meets one of the criteria in Table 2 below 
Table 1.  Study Medication Stopping Rules  
See Section 10.1.1, Adverse Events  for reporting 
requirements related to a subject being permanently discontinued  based on meeting the laboratory abnormalities 
list above in Table 2. To include a table of liver 
function test results that 
would require permanent 
discontinuation of vadadustat.  

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
 
Akebia  — Company Confidential  
Page 3 of 5 ALT or AST >3x ULN and 
total bilirubin >2x ULN  Permanently 
Discontinue 
Treatment  
ALT or AST >3x ULN and 
INR >1.5  Permanently 
Discontinue 
Treatment  
ALT or AST >8x ULN  Permanently 
Discontinue Treatment  
ALT or AST remains >5x 
ULN over 2 wee ks* Permanently 
Discontinue Treatment  
ALT or AST >3x ULN with 
symptoms including e.g., 
fatigue, nausea, vomiting, 
right upper quadrant pain, fever, rash or eosinophilia  Permanently 
Discontinue 
Treatment  
*Re-challenge generally should be avoided with ALT 
or AST >5 times ULN unless there are no other good 
therapeutic options.  
ALT: alanine transferase; AST:  asparagine transferase; 
INR:  international normalized ratio; ULN: upper limit 
of normal  
Section 10.1.1  (paragraph 8)  
Abnormalities in ALT, AST, and Total 
Bilirubin  – Abnormalities in ALT, AST, 
and total bilirubin should be reported to the 
Sponsor’s Medical Monitor or CRO 
designee within 24 hours of awareness as an SAE with ‘other medically important 
event’ criteria selected, if the following 
conditions are met:  
• New elevation in ALT or AST >3 
times ULN, with or without an (paragraph 8)  
Abnormalities in ALT, AST, and Total Bilirubin  – 
Abnormalities in ALT, AST, and total bilirubin should be reported to the Sponsor’s Medical Monitor or CRO 
designee within 24 hours of awareness as an SAE with 
‘other medically important event’ criteria selected, if the following conditions are met:  
• New elevation in ALT or AST >3 times ULN, with or without an elevation of total serum bilirubin >2 times ULN, AND  To include language for 
elevations in ALT or AST 
>3 times ULN.  

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
 
Akebia  — Company Confidential  
Page 4 of 5 elevation of total serum bilirubin >2 
times ULN, AND  
• No other reason was identified that 
explains the increased ALT/AST with 
or without an increased bilirubin (eg, 
viral hepatitis, acute liver diseas e). 
If new elevations in ALT or AST >3 times ULN, with or without  an elevation of total 
serum bilirubin >2  times ULN are 
identified, the following steps are to be taken:  
• Temporary discontinuation of study 
medication; 
• Repeat testing of ALT, AST, ALP, 
and to tal bilirubin, to be completed 
within 48 to 72 hours to confirm the abnormalities and to determine trend;  
• Study medication should not be 
resumed until monitoring indicates 
abnormalities have resolved or are 
stable.  • No other reason was identified that explains the 
increased ALT/AST with or without an increased 
bilirubin (eg, viral hepatitis, acute liver disease).  
If new elevations in ALT or AST >3 times ULN, with or  
without  an elevation of total serum bilirubin >2  times ULN 
are identified, the following steps are to be taken:  
• Temporary discontinuation of study medication;  
• Repeat tes ting of ALT, AST, ALP, and total bilirubin, 
to should  be completed within 48 to 72 hours to 
confirm the abnormalities and to determine trend;  
• Study medication should not be resumed until 
monitoring indicates abnormalities have resolved or are 
stable.  
Detai ls on the management of subjects with other ALT and 
AST abnormalities are further described in Section 9.4, 
Study Medi cation Stopping Rules .   
Section 10.1.2  (paragraph 2)  
In addition to the above criteria for 
classifying AEs as serious, the following 
situation will also be classified as serious 
for purposes of this study:  
• Malignancies – Newly diagnosed 
malignancies or a recurrence of a 
malignancy should be reported as an SAE with the seriousness criterion “medically important” if no other seriousness criteria are met.  If a subject develops basal 
cell carcinoma of skin, squ amous (paragraph 2)  
In addition to the above criteria for c lassifying AEs as 
serious, the following situation will also be classified as 
serious for purposes of this study:  
• Malignancies – Newly diagnosed malignancies or a 
recurrence of a malignancy should be reported as an 
SAE with the seriousness criterion “medi cally 
important” if no other seriousness criteria are met.  If a subject develops basal cell carcinoma of skin, squamous cell carcinoma of skin, or cervical 
carcinoma in situ during the study, or has worsening 
of these events from Baseline, the Investigator will determine if the event is reported as an AE or SAE.    To define a list of 
designated medical events 
that shall always be classified as serious adverse events (SAEs).   

Protocol No.  AKB -6548- CI-0017    
Amendment 5 (Version 6) 
 
Akebia  — Company Confidential  
Page 5 of 5 cell carcinoma of skin, or cervical 
carcinoma in situ during the study, 
or has worsening of these events from Baseline, the Investigator will determine if the event is reported as an AE or SAE.    
 • Designated Medical Events - The sponsor maintains 
a list of designated medical events  (DME) that they 
will always classify as serious adverse events.   If 
an event on the DME list is reported as  an AE 
additional information on the event (e.g. 
investigator confirmation of seriousness, causality) 
will be requested from the Investigator.  
 
